<SUBMISSION>
<ACCESSION-NUMBER>0000912057-02-002731
<TYPE>SC TO-I
<PUBLIC-DOCUMENT-COUNT>17
<FILING-DATE>20020125
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>INHALE THERAPEUTIC SYSTEMS INC
<CIK>0000906709
<ASSIGNED-SIC>2834
<IRS-NUMBER>943134940
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC TO-I
<ACT>34
<FILE-NUMBER>005-47414
<FILM-NUMBER>02517698
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>150 INDUSTRIAL RD.
<CITY>SAN CARLOS
<STATE>CA
<ZIP>94070
<PHONE>6506313100
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>150 INDUSTRIAL ROAD
<CITY>SAN CARLOS
<STATE>CA
<ZIP>94070
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>INHALE THERAPEUTIC SYSTEMS
<DATE-CHANGED>19940303
</FORMER-COMPANY>
</SUBJECT-COMPANY>
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>INHALE THERAPEUTIC SYSTEMS INC
<CIK>0000906709
<ASSIGNED-SIC>2834
<IRS-NUMBER>943134940
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC TO-I
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>150 INDUSTRIAL RD.
<CITY>SAN CARLOS
<STATE>CA
<ZIP>94070
<PHONE>6506313100
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>150 INDUSTRIAL ROAD
<CITY>SAN CARLOS
<STATE>CA
<ZIP>94070
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>INHALE THERAPEUTIC SYSTEMS
<DATE-CHANGED>19940303
</FORMER-COMPANY>
</FILED-BY>
<DOCUMENT>
<TYPE>SC TO-I
<SEQUENCE>1
<FILENAME>a2068683zscto-i.htm
<DESCRIPTION>SCHEDULE TO-I
<TEXT>
<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#02PAL1091_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="RIGHT"><FONT SIZE=2>
As filed with the Securities and Exchange Commission on January&nbsp;25, 2002 </FONT></P>

<HR NOSHADE>
<HR NOSHADE>
<P ALIGN="CENTER"><FONT SIZE=5><B>SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2>Washington, D.C. 20549 </FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=5><B>SCHEDULE TO<BR>  </B></FONT><FONT SIZE=2>Tender Offer Statement under Section&nbsp;14(d)(1) or 13(e)(1)<BR>
of the Securities Exchange Act of 1934 </FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=4><B>INHALE THERAPEUTIC SYSTEMS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2>(Name of Subject Company&#151;Issuer and Filing Person&#151;Offeror) </FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=4><B>OPTIONS TO PURCHASE COMMON STOCK,<BR>  </B></FONT><FONT SIZE=2><B>par value $0.0001 per share<BR>  </B></FONT><FONT SIZE=2>(Title of Class of Securities) </FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=2><B>457191-10-4<BR>  </B></FONT><FONT SIZE=2>(CUSIP Number of Class of Securities) </FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=2><B>Ajit S. Gill<BR>
Chief Executive Officer and President<BR>
INHALE THERAPEUTIC SYSTEMS,&nbsp;INC.<BR>
150 Industrial Road<BR>
San Carlos, California 94070<BR>
Telephone: (650)&nbsp;631-3100<BR>  </B></FONT><FONT SIZE=2>(Name, address and telephone number of person authorized to receive<BR>
notices and communications on behalf of Filing Person) </FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=2>Copies
to:<BR></FONT> <FONT SIZE=2><B>Mark P. Tanoury<BR>
Thomas Z. Reicher<BR>
John M. Geschke<BR>
COOLEY GODWARD LLP<BR>
3175 Hanover Street<BR>
Palo Alto, California 94304-1130<BR>
Telephone: (650) 843-5000  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> CALCULATION OF FILING FEE  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER"><HR NOSHADE></TD>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="49%" ALIGN="CENTER"><FONT SIZE=1><B>Transaction Valuation*</B></FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="49%" ALIGN="CENTER"><FONT SIZE=1><B>Amount of Filing Fee**</B></FONT><BR></TH>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER"><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>$33,906,010.70</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2>$3,119.35</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER"><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD><FONT SIZE=2>Calculated
solely for purposes of determining the filing fee. This amount assumes that options to purchase 3,653,680 shares of Common Stock of Inhale Therapeutic Systems,&nbsp;Inc.
having an aggregate value of $33,906,010.70 will be exchanged pursuant to this offer. The aggregate value of such options was calculated based on the Black-Scholes option pricing model as of
January&nbsp;23, 2002.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>**</FONT></DT><DD><FONT SIZE=2>$92
per $1,000,000 of the aggregate offering amount (or .000092 of the aggregate transaction valuation), pursuant to Rule&nbsp;0-11 of the Securities Exchange Act of
1934, as amended by Fee Advisory&nbsp;#8, effective January&nbsp;16, 2002. </FONT></DD></DL>
<BR>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>/&nbsp;/</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><B>Check box if any part of the fee is offset as provided by Rule&nbsp;0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or
the Form or Schedule and the date of its filing.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="47%"><BR><FONT SIZE=2><B>Amount Previously Paid: </B></FONT><FONT SIZE=2>Not applicable.</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="47%"><BR><FONT SIZE=2><B>Filing Party: </B></FONT><FONT SIZE=2>Not applicable.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="47%"><FONT SIZE=2><B>Form or Registration No.: </B></FONT><FONT SIZE=2>Not applicable.</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="47%"><FONT SIZE=2><B>Date Filed: </B></FONT><FONT SIZE=2>Not applicable.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
/&nbsp;/</FONT></TD>
<TD COLSPAN=3><BR><FONT SIZE=2><B>Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.</B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><BR><FONT SIZE=2><B>Check the appropriate boxes below to designate any transactions to which the statement relates:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>/&nbsp;/</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Third-party tender offer subject to Rule&nbsp;14d-1.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>/x/</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Issuer tender offer subject to Rule&nbsp;13e-4.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>/&nbsp;/</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Going-private transaction subject to Rule&nbsp;13e-3.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>/&nbsp;/</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Amendment to Schedule&nbsp;13D under Rule&nbsp;13d-2.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><BR><FONT SIZE=2><B>Check the following box if the filing is a final amendment reporting the results of the tender offer: </B></FONT><FONT SIZE=2>/&nbsp;/</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<HR NOSHADE>
<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="1",CHK=749310,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]BA1091A.;7',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->

<P><FONT SIZE=2><B>CUSIP NO. 457191-10-4  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>SCHEDULE TO  </B></FONT></P>

<P><FONT SIZE=2><B>ITEM 1. SUMMARY TERM SHEET.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information set forth in the Offer to Exchange under the "Summary of Terms" section is incorporated herein by reference. </FONT></P>


<P><FONT SIZE=2><B>ITEM 2. SUBJECT COMPANY INFORMATION.  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>Name
and Address. The name of the issuer is Inhale Therapeutic Systems,&nbsp;Inc., a Delaware corporation (the "Company"), the address of its principal executive office is 150
Industrial Road, San Carlos, CA 94070 and the telephone number of its principal executive office is (650)&nbsp;631-3100. The information set forth in the Offer to Exchange under
Section&nbsp;16 ("Information About Inhale") is incorporated herein by reference.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>Securities.
This Tender Offer Statement on Schedule TO relates to an offer by the Company to exchange certain options granted prior to July&nbsp;24, 2001 with exercise prices per
share greater than or equal to $25.00 per share currently outstanding under the Company's 2000 Non-Officer Equity Incentive Plan, as amended (the "Option Plan"), to purchase shares of the
Company's Common Stock, par value $0.0001 per share (the "Common Stock") held by optionholders as of January&nbsp;25, 2002 (the "Eligible Options") for replacement options (the "Replacement
Options") to purchase shares of the Common Stock to be granted under the Option Plan, upon the terms and subject to the conditions set forth in the Offer to Exchange. The Company is conducting the
exchange with respect to Eligible Options on a one-for-two (1:2) basis. Thus, for an employee who elects to participate in the Offer, on August&nbsp;26, 2002 (or a later date
if the Company extends the Offer), the Company will grant such employee a Replacement Option covering fifty percent (50%) of the number of shares subject to the Eligible Options that were cancelled.
If an employee accepts this offer with respect to any Eligible Option, such employee must exchange all options to acquire Common Stock of the Company granted to such employee on or after
July&nbsp;24, 2001 (the "Mandatory Exchange Options"). The Company is conducting the exchange with respect to Mandatory Exchange Options on a one-for-one (1:1) basis. Thus,
for an employee that elects to exchange any Eligible Options, on August&nbsp;26, 2002 (or a later date if the Company extends the Offer), the Company will grant such employee a Replacement Option
covering
one hundred percent (100%) of the number of shares subject to such employee's Mandatory Exchange Options that were cancelled. The information set forth in the Offer to Exchange under the "Summary of
Terms" section, Section&nbsp;1 ("Number of Options; Expiration Date"), Section&nbsp;5 ("Acceptance of Options for Exchange and Cancellation and Issuance of Replacement Options") and
Section&nbsp;8 ("Source and Amount of Consideration; Terms of Replacement Options") is incorporated herein by reference.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>Trading
Market and Price. The information set forth in the Offer to Exchange under Section&nbsp;7 ("Price Range of Common Stock") is incorporated herein by reference. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2><B>ITEM 3. IDENTITY AND BACKGROUND OF THE FILING PERSON.  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>Name
and Address. The information set forth under Item 2(a) above is incorporated herein by reference. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2><B>ITEM 4. TERMS OF THE TRANSACTION.  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>Material
Terms. The information set forth in the Offer to Exchange under the "Summary of Terms" section, Section&nbsp;1 ("Number of Options; Expiration Date"), Section&nbsp;3
("Procedures"), Section&nbsp;4 ("Change in Election"), Section&nbsp;5 ("Acceptance of Options for Exchange and Cancellation and Issuance of Replacement Options"), Section&nbsp;6 ("Conditions of
the Offer"), </FONT></DD></DL>
</UL>
<HR NOSHADE>
<!-- ZEQ.=1,SEQ=2,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="1",CHK=222973,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]DE1091A.;11',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<UL>
<UL>

<P><FONT SIZE=2>Section&nbsp;8
("Source and Amount of Consideration; Terms of Replacement Options"), Section&nbsp;10 ("Status of Options Acquired by Us in the Offer"), Section&nbsp;11 ("Legal Matters;
Regulatory Approvals"), Section&nbsp;12 ("Material U.S. Federal Income Tax Consequences"), Section&nbsp;13 ("Terms of the Offer Specific to Non-U.S. Employees") and Section&nbsp;14
("Extension of Offer; Termination; Amendment") is incorporated herein by reference. </FONT></P>

</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>Purchases.
The information set forth in the Offer to Exchange under Section&nbsp;9 ("Interests of Directors and Officers; Transactions and Arrangements Involving the Options") is
incorporated herein by reference. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2><B>ITEM 5. PAST CONTACTS, TRANSACTIONS, NEGOTIATIONS AND AGREEMENTS.  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>Agreements
Involving the Subject Company's Securities. The information set forth in the Offer to Exchange under Section&nbsp;9 ("Interests of Directors and Officers; Transactions
and Arrangements Involving the Options") is incorporated herein by reference. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2><B>ITEM 6. PURPOSES OF THE TRANSACTION AND PLANS OR PROPOSALS.  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>Purposes.
The information set forth in the Offer to Exchange under Section&nbsp;2 ("Purpose of the Offer") is incorporated herein by reference.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>Use
of Securities Acquired. The information set forth in the Offer to Exchange under Section&nbsp;5 ("Acceptance of Options for Exchange and Cancellation and Issuance of Replacement
Options") and Section&nbsp;10 ("Status of Options Acquired in the Offer; Accounting Consequences of the Offer") is incorporated herein by reference.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>Plans.
At present, the board of directors is composed of seven (7)&nbsp;members. The Company from time to time evaluates strategic acquisitions and will continue to do so in the
future. The Company may issue its stock or pay cash in connection with such acquisitions. The Company may obtain cash for such acquisitions through a variety of means, including, without limitation,
through the issuance of additional stock. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2><B>ITEM 7. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>Source
of Funds. The information set forth in the Offer to Exchange under Section&nbsp;8 ("Source and Amount of Consideration; Terms of Replacement Options") and Section&nbsp;15
("Fees and Expenses") is incorporated herein by reference.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>Conditions.
The information set forth in the Offer to Exchange under Section&nbsp;6 ("Conditions of the Offer") is incorporated herein by reference.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD><FONT SIZE=2>Borrowed
Funds. Not applicable. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2><B>ITEM 8. INTEREST IN THE SECURITIES OF THE SUBJECT COMPANY.  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>Securities
Ownership. Not applicable.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>Securities
Transactions. The information set forth in the Offer to Exchange under Section&nbsp;9 ("Interests of Directors and Officers; Transactions and Arrangements Involving the
Options") is incorporated herein by reference. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2><B>ITEM 9. PERSONS/ASSETS, RETAINED, EMPLOYED, COMPENSATED OR USED.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. </FONT></P>

<P><FONT SIZE=2><B>ITEM 10. FINANCIAL STATEMENTS.  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>Financial
Information. Item 8 ("Financial Statements and Supplementary Data") of Inhale Therapeutic Systems,&nbsp;Inc.'s Annual Report on Form&nbsp;10-K for the fiscal
year ended December&nbsp;31, 2000, filed on March&nbsp;1, 2001, including all material incorporated by reference </FONT></DD></DL>
</UL>
<HR NOSHADE>
<!-- ZEQ.=2,SEQ=3,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="1",CHK=258767,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]DE1091A.;11',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<UL>
<UL>

<P><FONT SIZE=2>therein,
as amended by our Amendment No.&nbsp;2 to Annual Report on Form&nbsp;10-K/A for the fiscal year ended December&nbsp;31, 2000, filed on October&nbsp;4, 2001, including all
material incorporated by reference therein, is incorporated herein by reference. Item 7 ("Financial Statements, Pro Forma Financial Information and Exhibits") of Inhale Therapeutic
Systems,&nbsp;Inc.'s Current Report on Form&nbsp;8-K/A, filed on August&nbsp;10, 2001, as amended, is incorporated herein by reference. Item 7 ("Financial Statements, Pro Forma
Financial Information and Exhibits") of Inhale Therapeutic Systems,&nbsp;Inc.'s Current Report on Form&nbsp;8-K/A, filed on October&nbsp;4, 2001, is incorporated herein by reference.
The information set forth in
the Offer to Exchange under Section&nbsp;16 ("Information About Inhale") and Section&nbsp;18 ("Additional Information") is incorporated herein by reference. </FONT></P>

</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>Pro
Forma Financial Information. Not applicable. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2><B>ITEM 11. ADDITIONAL INFORMATION.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Remainder
of this page intentionally left blank.] </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=4,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="1",CHK=327250,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]DE1091A.;11',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<P ALIGN="CENTER"><FONT SIZE=2><B>SCHEDULE TO  </B></FONT></P>

<P><FONT SIZE=2><B>ITEM 12. EXHIBITS</B></FONT><FONT SIZE=2>. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="14%" ALIGN="LEFT"><FONT SIZE=1><B>Exhibit<BR>
Number<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="83%" ALIGN="CENTER"><FONT SIZE=1><B>Description</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(A)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Offer to Exchange, dated January 25, 2002.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(B)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Form of Electronic Letter of Transmittal.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(C)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Form of Summary of Terms.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(D)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Form of Election Form.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(E)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Form of Notice of Change in Election from Accept to Reject.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(F)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Form of Notice of Change in Election from Reject to Accept.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(G)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Powerpoint slide presentation to holders of Eligible Options.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(H)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Form of Confirmation of Participation in the Offer to Exchange.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(I)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Inhale Therapeutic Systems, Inc. Annual Report on Form 10-K, for its fiscal year ended December 31, 2000, filed with the Securities and Exchange Commission on March 1, 2001, and as amended by Amendment No.&nbsp;2 to Annual Report on Form&nbsp;10-K/A,
filed on October&nbsp;4, 2001, and incorporated herein by reference.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(J)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Inhale Therapeutic Systems, Inc. Current Report on Form 8-K/A, filed with the Securities and Exchange Commission on August 10, 2001, as amended, and incorporated herein by reference.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(K)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Inhale Therapeutic Systems, Inc. Current Report on Form 8-K/A, filed with the Securities and Exchange Commission on October 4, 2001 and incorporated herein by reference.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(b)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Not applicable.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(d)(1)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Inhale Therapeutic Systems, Inc.'s 2000 Non-Officer Equity Incentive Plan, as amended, (incorporated herein by reference to the indicated exhibit in Inhale's Registration Statement on Form S-8/A (No. 333-71936), filed on January 15, 2002.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(g)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Not applicable.</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2><B>ITEM 13. INFORMATION REQUIRED BY SCHEDULE 13E-3.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>[Remainder
of this page intentionally left blank.] </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=5,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="1",CHK=515125,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]DE1091A.;11',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<!-- TOC_END -->

<P><FONT SIZE=2><B>CUSIP NO. 457191-10-4  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>SCHEDULE TO  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> <A NAME="jc1091_signature"> </A>
<A NAME="toc_jc1091_1"> </A>
<BR>    </B></FONT><FONT SIZE=2><B>SIGNATURE    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. </FONT></P>

<P><FONT SIZE=2>Dated:
January&nbsp;25, 2002 </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2><FONT SIZE=2><B>INHALE THERAPEUTIC SYSTEMS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="46%"><FONT SIZE=2><BR>
/s/ Ajit S. Gill </FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Name:</FONT></TD>
<TD WIDTH="46%"><FONT SIZE=2>Ajit S. Gill</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="46%"><FONT SIZE=2>Chief Executive Officer and President</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=6,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="1",CHK=40449,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]JC1091A.;5',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<!-- TOC_END -->


<P><FONT SIZE=2><B>CUSIP NO. 457191-10-4  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>SCHEDULE TO  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> <A NAME="ka1091_index_of_exhibits"> </A>
<A NAME="toc_ka1091_1"> </A>
<BR>    </B></FONT><FONT SIZE=2><B>INDEX OF EXHIBITS    <BR>  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="14%" ALIGN="LEFT"><FONT SIZE=1><B>Exhibit<BR>
Number<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="83%" ALIGN="CENTER"><FONT SIZE=1><B>Description</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(A)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Offer to Exchange, dated January 25, 2002.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(B)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Form of Electronic Letter of Transmittal.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(C)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Form of Summary of Terms.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(D)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Form of Election Form.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(E)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Form of Notice of Change in Election from Accept to Reject.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(F)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Form of Notice of Change in Election from Reject to Accept.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(G)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Powerpoint slide presentation to holders of Eligible Options.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(H)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Form of Confirmation of Participation in the Offer to Exchange.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(I)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Inhale Therapeutic Systems, Inc. Annual Report on Form 10-K, for its fiscal year ended December 31, 2000, filed with the Securities and Exchange Commission on March 1, 2001, and as amended by Amendment No. 2 to Annual Report on Form&nbsp;10-K/A,
filed on October&nbsp;4, 2001, and incorporated herein by reference.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(J)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Inhale Therapeutic Systems, Inc. Current Report on Form 8-K/A, filed with the Securities and Exchange Commission on August 10, 2001, as amended, and incorporated herein by reference.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(a)(1)(K)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Inhale Therapeutic Systems, Inc. Current Report on Form 8-K/A, filed with the Securities and Exchange Commission on October 4, 2001 and incorporated herein by reference.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(b)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Not applicable.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(d)(1)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Inhale Therapeutic Systems, Inc.'s 2000 Non-Officer Equity Incentive Plan, as amended, (incorporated herein by reference to the indicated exhibit in Inhale's Registration Statement on Form S-8/A (No. 333-71936), filed on January 15, 2002.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="14%"><FONT SIZE=2><BR>
99.(g)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Not applicable.</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=7,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="1",CHK=581257,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]KA1091A.;6',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<P><br><A NAME="02PAL1091_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_jc1091_1">SIGNATURE</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_ka1091_1">INDEX OF EXHIBITS</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DNICHOL,SEQ=,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A)(1)(A)
<SEQUENCE>3
<FILENAME>a2068683zex-99_a1a.htm
<DESCRIPTION>EXHIBIT 99(A)(1)(A)
<TEXT>
<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#02PAL1091_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><B>Exhibit 99(a)(1)(A)  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>INHALE THERAPEUTIC SYSTEMS,&nbsp;INC.<BR>
150 INDUSTRIAL ROAD<BR>
SAN CARLOS, CA 94070<BR>
(650)&nbsp;631-3100  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>OFFER TO EXCHANGE<BR>
OUTSTANDING OPTIONS<BR>
TO PURCHASE COMMON STOCK<BR>
JANUARY&nbsp;25, 2002  </B></FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=743191,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]NA1091A.;7',USER='DNICHOL',CD='25-JAN-2002;13:49' -->
<P ALIGN="CENTER"><FONT SIZE=2><B>INHALE THERAPEUTIC SYSTEMS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> OFFER TO EXCHANGE OUTSTANDING OPTIONS  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> THE OFFER EXPIRES AT MIDNIGHT, PACIFIC STANDARD TIME,<BR>
ON MONDAY, FEBRUARY 25, 2002, UNLESS THE OFFER IS EXTENDED  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inhale Therapeutic Systems,&nbsp;Inc. ("Inhale" or the "Company") is offering employees of the Company and its wholly-owned subsidiaries who are not executive
officers of the Company (each an "Eligible Participant") the opportunity to exchange all outstanding stock options granted to you prior to July&nbsp;24,
2001, other than Evergreen Options (as defined below), with exercise prices per share greater than or equal to $25.00 per share (the "Eligible Options") granted under the Company's 2000
Non-Officer Equity Incentive Plan, as amended (the "Plan"), for replacement options (the "Replacement Options") to purchase shares of the Company's Common Stock ("Common Stock").
"Evergreen Options" are options to purchase shares of Common Stock granted under the Plan to employees that vest at the rate of 1/12<SUP>th</SUP> of the entire grant per month over twelve months,
beginning at the end of the vesting period of a previously-granted option. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is conducting the exchange with respect to Eligible Options on a one-for-two (1:2) basis. For those employees who elect to participate in this offer
pursuant to the terms described herein, on August&nbsp;26, 2002 (or a later date if Inhale extends the Offer), the Company will grant you a Replacement Option covering fifty percent (50%) of the
number of shares of Common Stock subject to your Eligible Options that were cancelled (so long as your employment or service with the Company or its subsidiaries continues through that date).
THEREFORE, FOR EVERY TWO SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF ELIGIBLE OPTIONS THAT YOU EXCHANGE, THE COMPANY WILL GRANT YOU ONE REPLACEMENT OPTION TO ACQUIRE ONE SHARE OF COMMON STOCK. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you wish to accept this offer with respect to any Eligible Option, you must exchange all options to acquire Common Stock of the Company that were granted to you on or after
July&nbsp;24, 2001, including, without limitation, options with an exercise price of less than $25.00 per share, Evergreen Options, and options granted under plans other than the 2000
Non-Officer Equity Incentive Plan (the "Mandatory Exchange Options"). The Company is conducting the exchange with respect to Mandatory Exchange Options on a
one-for-one (1:1) basis. For those employees who elect to exchange Eligible Options pursuant to the terms described herein, on August&nbsp;26, 2002 (or a later date if Inhale
extends the Offer) the Company will grant you a Replacement Option covering 100% of the number of shares of Common Stock subject to your Mandatory Exchange Options that were cancelled (so long as your
employment or service with the Company or its subsidiaries continues through that date). Should you choose to accept this offer, you are not obligated to tender each Eligible Option and are free to
elect to tender as many or as few of the Eligible Options as you wish. If you do not elect to tender any Eligible Options, no Mandatory Exchange Options will be exchanged. Please note that you must
tender all outstanding shares under each particular Eligible Option you wish to tender. You may tender a partially exercised Eligible Option so long as you tender all unexercised shares subject to the
Eligible Option. (See Section&nbsp;1 of this Offer to Exchange). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are making this offer upon the terms and subject to the conditions described in this Offer to Exchange Outstanding Options (the "Offer to Exchange," which, as it may be amended from
time to time, constitutes the "Offer"). This Offer is not conditioned upon a minimum number of options being exchanged. This Offer is subject to conditions that we describe in Section&nbsp;6 of this
Offer to Exchange. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ALTHOUGH
OUR BOARD OF DIRECTORS HAS APPROVED THIS OFFER, NEITHER WE NOR OUR BOARD OF DIRECTORS MAKES ANY RECOMMENDATION AS TO WHETHER OR NOT YOU SHOULD TENDER YOUR ELIGIBLE OPTIONS FOR
EXCHANGE. YOU MUST MAKE YOUR OWN DECISION WHETHER TO TENDER YOUR ELIGIBLE OPTIONS. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
of our Common Stock are quoted on the Nasdaq National Market under the symbol "INHL." On January&nbsp;23, 2002, the closing price of our Common Stock as reported on the Nasdaq </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=222045,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]NA1091A.;7',USER='DNICHOL',CD='25-JAN-2002;13:49' -->

<P><FONT SIZE=2>
National Market was $15.85 per share. We recommend that you obtain current market quotations for our Common Stock before deciding whether to elect to exchange your options. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should direct questions about this Offer, requests for assistance in completing the related documentation and requests for additional copies of the Offer to Exchange or related
documents to Steve Hurst or Bob Harper via e-mail at </FONT><FONT SIZE=2><I>exchange@inhale.com</I></FONT><FONT SIZE=2>. Alternatively, you may reach Steve Hurst via telephone at
(650)&nbsp;631-3118 or Bob Harper at (650)&nbsp;631-3222. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS
TRANSACTION HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC"). NOR HAS THE SEC PASSED UPON THE FAIRNESS OR MERITS OF SUCH TRANSACTION OR
UPON THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED IN THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. IN THE EVENT OF ANY CONFLICT BETWEEN THIS DOCUMENTATION AND THE
RULES OF THE PLAN OR ANY APPLICABLE LEGISLATION, THE RULES OR LEGISLATION (AS THE CASE MAY BE) WILL TAKE PRECEDENCE. ALL REFERENCES TO TAXATION CONSEQUENCES ARE FOR GUIDANCE ONLY. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=3,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=932143,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]NA1091A.;7',USER='DNICHOL',CD='25-JAN-2002;13:49' -->
<P ALIGN="CENTER"><FONT SIZE=2><B>IMPORTANT  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regardless of whether you accept or reject this Offer, </FONT><FONT SIZE=2><B><I>you must complete and sign the Election Form and return it to Steve Hurst or Bob
Harper at Inhale before midnight, Pacific Standard Time, on Monday, February&nbsp;25, 2002</I></B></FONT><FONT SIZE=2> (or a later expiration date if Inhale extends the Offer). You do not need to return
your stock option agreements for your Eligible Options to effectively elect to accept the Offer as they (and your option agreements with respect to Mandatory Exchange Options) will be cancelled
automatically if Inhale accepts your Eligible Options for exchange. However, you will be required to return such stock option agreements upon Inhale's request. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot guarantee that the Replacement Options will have a lower exercise price than the Eligible Options or Mandatory Exchange Options. The Board of Directors recognizes that the
decision to accept or reject the Offer is an individual one that should be based on a variety of factors, and you should consult your personal advisors if you have questions about your financial or
tax situation. The information about this Offer from Inhale is limited to this document. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WE
HAVE NOT AUTHORIZED ANY PERSON TO MAKE ANY RECOMMENDATION ON THE COMPANY'S BEHALF AS TO WHETHER OR NOT YOU SHOULD TENDER YOUR ELIGIBLE OPTIONS PURSUANT TO THE OFFER. WE HAVE NOT
AUTHORIZED ANYONE TO GIVE YOU ANY INFORMATION OR TO MAKE ANY REPRESENTATION IN CONNECTION WITH THIS OFFER OTHER THAN THE INFORMATION AND REPRESENTATIONS CONTAINED IN THIS DOCUMENT AND THE TENDER OFFER
STATEMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 25, 2002. IF ANYONE MAKES ANY SUCH RECOMMENDATION OR REPRESENTATION TO YOU OR GIVES YOU ANY SUCH INFORMATION, YOU MUST NOT RELY
UPON THAT RECOMMENDATION, REPRESENTATION OR INFORMATION AS HAVING BEEN AUTHORIZED BY US. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=4,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=781883,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]NA1091A.;7',USER='DNICHOL',CD='25-JAN-2002;13:49' -->
<A NAME="page_na1091_1_1"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="na1091_table_of_contents"> </A>
<A NAME="toc_na1091_1"> </A>
<BR></FONT><FONT SIZE=2><B>TABLE OF CONTENTS    <BR>  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="4%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH WIDTH="85%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="5%" ALIGN="CENTER"><FONT SIZE=1><B>Page</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>SUMMARY OF TERMS</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>1</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2><BR>
THE OFFER</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2><BR>
7</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2><BR>
1.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2><BR>
Number of Options; Expiration Date</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2><BR>
7</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>2.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Purpose of the Offer</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>8</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>3.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Procedures</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>8</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>4.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Change in Election</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>9</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>5.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Acceptance of Options for Exchange and Cancellation and Issuance of Replacement Options</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>9</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>6.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Conditions of the Offer</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>9</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>7.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Price Range of Common Stock</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>11</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>8.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Source and Amount of Consideration; Terms of Replacement Options</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>11</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>9.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Interests of Directors and Officers; Transactions and Arrangements Involving the Options</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>13</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>10.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Status of Options Acquired by Us in the Offer; Accounting Consequences of the Offer</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>14</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>11.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Legal Matters; Regulatory Approvals</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>14</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>12.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Material U.S. Federal Income Tax Consequences</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>14</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>13.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Terms of the Offer Specific to Non-U.S. Employees</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>15</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>14.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Extension of Offer; Termination; Amendment</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>15</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>15.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Fees and Expenses</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>16</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>16.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Information About Inhale</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>16</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>17.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Risk Factors</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>18</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>18.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Additional Information</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>18</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=2>19.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="85%"><FONT SIZE=2>Forward-Looking Statements; Miscellaneous</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT" VALIGN="BOTTOM"><FONT SIZE=2>20</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>SCHEDULE
A&#151;Information about the Directors and Executive Officers of Inhale </FONT></P>

<P><FONT SIZE=2>APPENDIX
A&#151;U.K. Tax Consequences </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=5,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=645076,FOLIO='1',FILE='DISK040:[02PAL1.02PAL1091]NA1091A.;7',USER='DNICHOL',CD='25-JAN-2002;13:49' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_nc1091_1_1"> </A> </FONT> <FONT SIZE=2><B>SUMMARY OF TERMS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of terms about the Offer presented in a question and answer format. We urge you to read carefully the remainder of the Offer to
Exchange and the accompanying documents because the information in this summary is not complete. We have included references to the relevant sections of the Offer to Exchange where you can find a more
complete description of the topics in this Summary of Terms. </FONT></P>

<P><FONT SIZE=2><B>Q1. WHAT SECURITIES ARE WE OFFERING TO EXCHANGE?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are offering to exchange all outstanding stock options granted prior to July&nbsp;24, 2001, other than Evergreen Options (except as required to be
exchanged), that are currently outstanding under the Inhale 2000 Non-Officer Equity Incentive Plan with exercise prices per share greater than or equal to $25.00 per share that are held by
employees of the Company or one of its wholly-owned subsidiaries. </FONT></P>


<P><FONT SIZE=2><B>Q2. WHY ARE WE MAKING THE OFFER?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A cornerstone of our success has been the retention and motivation of our employees. Accordingly, since many of our outstanding options have exercise prices that
are significantly higher than the current market price of our Common Stock, we felt it appropriate to offer this exchange program. (See Section&nbsp;2 of the Offer to Exchange.) </FONT></P>

<P><FONT SIZE=2><B>Q3. ARE THERE CONDITIONS TO THE OFFER?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Offer is subject to a number of conditions, including the conditions described in Section&nbsp;6 of the Offer to Exchange. However, the Offer is not
conditioned on a minimum number of optionholders accepting the Offer or a minimum number of options being exchanged. If you elect to participate, however, you will be required to exchange all
Mandatory Exchange Options. Mandatory Exchange Options are all options to acquire Common Stock of the Company granted to you on or after July&nbsp;24, 2001, including, without limitation, options
with an exercise price of less than $25.00 per share,
Evergreen Options, and options granted pursuant to plans other than the 2000 Non-Officer Equity Incentive Plan. </FONT></P>

<P><FONT SIZE=2><B>Q4. WHO CAN PARTICIPATE IN THE EXCHANGE?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You can elect to surrender for cancellation any Eligible Options if you are an Eligible Participant on February&nbsp;25, 2002. Termination of your employment or
service with the Company or one of its wholly-owned subsidiaries on or before February&nbsp;25, 2002 will automatically revoke any election that you make to participate in this program and you will
not receive any Replacement Options for your Eligible Options or Mandatory Exchange Options that have been cancelled, nor will the Company return any Eligible Options or Mandatory Exchange Options
that you exchanged. (See Question 6 of the Offer to Exchange) </FONT></P>

<P><FONT SIZE=2><B>Q5. HOW MANY OPTION SHARES WILL I RECEIVE IN EXCHANGE FOR THE OPTION SHARES EXCHANGED?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is conducting the exchange with respect to Eligible Options on a one-for-two (1:2) basis. Thus, for those employees who elect
to participate in the Offer, on August&nbsp;26, 2002 (or a later date if Inhale extends the Offer), the Company will grant you a Replacement Option covering fifty percent (50%) of the number of
shares subject to your Eligible Options that were cancelled (so long as your employment or service with the Company or one of its subsidiaries continues through that date). THEREFORE, FOR EVERY TWO
SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF ELIGIBLE OPTIONS THAT YOU EXCHANGE, THE COMPANY WILL GRANT YOU A REPLACEMENT OPTION TO ACQUIRE ONE SHARE OF COMMON STOCK. In the </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=6,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=512058,FOLIO='1',FILE='DISK040:[02PAL1.02PAL1091]NC1091A.;13',USER='DNICHOL',CD='25-JAN-2002;14:13' -->
<A NAME="page_nc1091_1_2"> </A>
<BR>

<P><FONT SIZE=2>
event that this would result in the issuance of any fractional shares of Common Stock, the number of shares subject to the Replacement Option will be rounded down to the nearest whole number of
shares. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is conducting the exchange with respect to Mandatory Exchange Options on a one-for-one (1:1) basis. Thus, for employees that elect to exchange any
Eligible Options, on August&nbsp;26, 2002 (or a later date if Inhale extends the Offer), the Company will grant you a Replacement Option covering one hundred percent (100%) of the number of shares
subject to your Mandatory Exchange Options that were cancelled (so long as your employment or service with the Company or one of its subsidiaries continues through that date). If you do not elect to
exchange any Eligible Options, no Mandatory Exchange Options will be exchanged. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of option shares to be represented by the Replacement Options will be adjusted for any stock splits, stock dividends, recapitalizations or similar transactions that may occur
between February&nbsp;25, 2002 (or a later date if Inhale extends the Offer) and the date the Replacement Options
are granted. Replacement Options issued in exchange for options granted under the Plan will be issued under the Plan. (See Section&nbsp;8 of the Offer to Exchange.) </FONT></P>

<P><FONT SIZE=2><B>Q6. WHAT HAPPENS IF I ACCEPT THE OFFER AND TENDER ONE OR MORE OF MY ELIGIBLE OPTIONS BUT I AM NO LONGER EMPLOYED BY THE COMPANY ON THE GRANT DATE OF THE REPLACEMENT OPTIONS?  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you accept the Offer to exchange any of your Eligible Options and are subsequently, for any reason, no longer employed by us on the grant date for the
Replacement Options, you will not receive any Replacement Options for your Eligible Options or Mandatory Exchange Options that have been cancelled, nor will the Company return any Eligible Options or
Mandatory Exchange Options that you exchanged. Participation in the Offer does not confer upon you the right to remain employed by us. THEREFORE, IF YOU ARE NOT AN EMPLOYEE OF INHALE OR ONE OF ITS
SUBSIDIARIES FROM THE DATE YOUR ELIGIBLE OPTIONS ARE CANCELLED THROUGH THE GRANT DATE OF THE REPLACEMENT OPTIONS, YOU WILL NOT RECEIVE ANY REPLACEMENT OPTIONS IN EXCHANGE FOR YOUR ELIGIBLE OPTIONS OR
MANDATORY EXCHANGE OPTIONS THAT WERE CANCELLED. IN ADDITION, THE COMPANY WILL NOT RETURN YOUR CANCELLED OPTIONS AND YOU WILL REALIZE NO VALUE FROM THE OPTIONS YOU EXCHANGED. YOU WILL NOT RECEIVE ANY
OTHER FORM OF CONSIDERATION IF YOUR RIGHT TO YOUR REPLACEMENT OPTIONS TERMINATES BECAUSE YOUR SERVICE TO THE COMPANY, FOR WHATEVER REASON, CEASES PRIOR TO THE GRANT DATE OF THOSE REPLACEMENT OPTIONS. </FONT></P>

<P><FONT SIZE=2><B>Q7. IF I AM A U.K. OR GERMAN EMPLOYEE WHO HOLDS OPTIONS UNDER THE PLAN, AM I SUBJECT TO THE SAME TERMS AS DESCRIBED IN THIS OFFER?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a U.K. or German employee who holds options under the Plan you are also subject to the terms of this Offer as described herein. U.K. employees should
refer to </FONT><FONT SIZE=2><B>Appendix&nbsp;A</B></FONT><FONT SIZE=2> of this document entitled "U.K. Tax Consequences" for a discussion of the tax consequences of accepting or rejecting the
Replacement Options under U.K. law. </FONT></P>

<P><FONT SIZE=2><B>Q8. WHAT IMPACT WILL THE OFFER HAVE ON MY EVERGREEN OPTIONS?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evergreen Options are options to purchase share of Common Stock granted under the Plan to employees that vest at the rate of 1/12th of the entire grant per month
over twelve months, beginning at the end of the vesting period of a previously-granted option. The Company is not offering to exchange Evergreen Options and therefore they are not considered Eligible
Options. However, if you elect to exchange any Eligible Options and you have received an Evergreen Option since July&nbsp;24, 2001, </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=7,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=467249,FOLIO='2',FILE='DISK040:[02PAL1.02PAL1091]NC1091A.;13',USER='DNICHOL',CD='25-JAN-2002;14:13' -->
<A NAME="page_nc1091_1_3"> </A>
<BR>

<P><FONT SIZE=2>
this Evergreen Option will be considered a Mandatory Exchange Option and will be required to be exchanged. As described in Question 5 above, Mandatory Exchange Options will be exchanged for
Replacement Options on a one-for-one (1:1) basis subject to the other conditions set forth in this Offer to Exchange. </FONT></P>


<P><FONT SIZE=2><B>Q9. WHEN WILL I RECEIVE MY REPLACEMENT OPTIONS?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Replacement Options will be granted on August&nbsp;26, 2002 (or a later date if Inhale extends the Offer). We expect the stock option agreements to be
distributed promptly following the date of grant. Moreover, if you accept the Offer and exchange all or part of your Eligible Options, we cannot for accounting reasons grant you any additional stock
options until, at the earliest, August&nbsp;26, 2002. (See Section&nbsp;5 of the Offer to Exchange.) </FONT></P>

<P><FONT SIZE=2><B>Q10. WHY WON'T I RECEIVE MY REPLACEMENT OPTIONS IMMEDIATELY AFTER THE EXPIRATION DATE OF THE OFFER?  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we were to grant Replacement Options on any date that is earlier than six months and one day after the date we cancel any of the Eligible Options or Mandatory
Exchange Options that are exchanged pursuant to the terms of this Offer, we would be required for financial accounting purposes to record a compensation expense against our earnings. By deferring the
grant of the Replacement Options for at least six months and one day, we believe we will not have to record such a compensation expense. </FONT></P>

<P><FONT SIZE=2><B>Q11. WHAT WILL BE THE TERMS AND CONDITIONS OF THE REPLACEMENT OPTIONS?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except for the number of shares subject to the Replacement Options issued in exchange for Eligible Options and the exercise price of the Replacement Options, the
terms and conditions of Replacement Options for all U.S. and non-U.S. employees of the Company or its subsidiaries will be substantially the same as the Eligible Options and Mandatory
Exchange Options that were cancelled. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
U.K. employees that were previously granted an "approved option" under the "approved section" of the Plan, please be aware that the Company is currently seeking approval from the
Inland Revenue for Replacement Options granted under the Plan. If you are an employee who works in the United Kingdom and were granted an "unapproved option" under the Plan, the Company intends that
your Replacement Option will also be an unapproved option. While the Company cannot be certain that it will receive the approval to grant Replacement Options under the "approved section" of the Plan
by August&nbsp;26, 2002, the Company expects to receive these approvals by such date and will use its best efforts to do so. You should consult with your own personal advisor with respect to all tax
matters. Please note that if you accept the terms of the this Offer and receive Replacement Options under the approved section of the Plan then, in order to receive the favorable tax treatment under
the laws of the United Kingdom, you must not exercise these Replacement Options for a three year period from the
date your Replacement Options are granted, nor within three years from a previous occasion on which you exercised, with the benefit of the favorable tax treatment, any other approved option (including
options from other schemes or other companies, except for savings related share options). In the event that the Replacement Options are not approved grants or you do not meet the requirements set
forth above, your Replacement Option will not receive favorable tax treatment under the laws of the United Kingdom. </FONT></P>

<P><FONT SIZE=2><B>Q12. WHAT WILL BE THE EXERCISE PRICE OF THE REPLACEMENT OPTIONS?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Replacement Options will have an exercise price equal to the closing price of the Company's Common Stock as reported on the Nasdaq National Market on the last
market trading day prior to the date of grant. We cannot guarantee that the Replacement Options will have a lower exercise price than </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=8,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=124785,FOLIO='3',FILE='DISK040:[02PAL1.02PAL1091]NC1091A.;13',USER='DNICHOL',CD='25-JAN-2002;14:13' -->
<A NAME="page_nc1091_1_4"> </A>
<BR>

<P><FONT SIZE=2>
those of the Eligible Options or Mandatory Exchange Options. (See Section&nbsp;7 of the Offer to Exchange.) </FONT></P>

<P><FONT SIZE=2><B>Q13. WHEN WILL THE REPLACEMENT OPTIONS VEST AND WHAT WILL BE THE VESTING SCHEDULE OF THE REPLACEMENT OPTIONS?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Replacement Option will have the same vesting schedule on a percentage basis as your applicable Eligible Option or Mandatory Exchange Option that is
exchanged. The vesting commencement date for each Replacement Option will be the original vesting commencement date of your applicable Eligible Option or Mandatory Exchange Option. The number of
shares of Common Stock issuable upon exercise of the Replacement Option that will be vested as of the date the Replacement Option is granted will be equal to the product of (A)&nbsp;the percentage
of shares issuable upon exercise of the exchanged Eligible Option or Mandatory Exchange Option that would have been vested as of such date and (B)&nbsp;the total number of shares issuable upon
exercise of the Replacement Option. Thereafter, the Replacement Option will continue to vest monthly in the same percentage amount as the applicable Eligible Option or Mandatory Exchange Option that
was exchanged. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
an example, assume that an Eligible Option to purchase 1,000 shares of Common Stock that would have been 50% vested as of August&nbsp;26, 2002 and thereafter would have vested 5%
per month until fully vested is exchanged as part of this Offer. The Replacement Option to purchase 500 shares of Common Stock granted in exchange for such exchanged Eligible Option would be vested as
to 250 shares (50%) as of the date of grant and would thereafter vest as to 25 shares (5%) per month until fully vested. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a further example, assume that a Mandatory Exchange Option to purchase 1,000 shares of Common Stock that would have been 50% vested as of August&nbsp;26, 2002 and thereafter would
have vested 5% per month until fully vested is exchanged as part of this Offer. The Replacement Option to purchase 1,000 shares of Common Stock granted in exchange for such Mandatory Exchange Option
would be vested as
to 500 shares (50%) as of the date of grant and would thereafter vest as to 50 shares (5%) per month until fully vested. </FONT></P>

<P><FONT SIZE=2><B>Q14. WHEN WILL THE REPLACEMENT OPTIONS EXPIRE?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Replacement Options will expire at 11:59&nbsp;p.m., Pacific Time, on the day prior to the ten-year anniversary of the grant date of the
Replacement Options (so long as you remain employed by or continue service with the Company). </FONT></P>

<P><FONT SIZE=2><B>Q15. HOW LONG WILL I HAVE TO WAIT TO PURCHASE COMMON STOCK UNDER MY REPLACEMENT OPTIONS?  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares subject to the Replacement Options will be vested on the date of grant to the same extent, on a percentage basis, as the shares subject to the Eligible
Options and Mandatory Exchange Options that you exchanged would have been vested on that date (See Question 13 above). To the extent vested, the shares subject to the Replacement Option may be
purchased immediately. You will not be able to exercise and sell any additional shares subject to the Replacement Options until they vest. </FONT></P>

<P><FONT SIZE=2><B>Q16. IF I ELECT TO EXCHANGE ELIGIBLE OPTIONS, WILL MY ELECTION AFFECT OTHER COMPONENTS OF MY COMPENSATION?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No. Whether or not you accept or reject the Offer will not affect your compensation in the future. Your acceptance or rejection of the Offer will not result in
your becoming more or less likely to receive stock option grants in the future, other than the Replacement Options. However, the Company cannot grant you any new options between February&nbsp;25,
2002 and August&nbsp;26, 2002 if you accept the Offer. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=9,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=1011925,FOLIO='4',FILE='DISK040:[02PAL1.02PAL1091]NC1091A.;13',USER='DNICHOL',CD='25-JAN-2002;14:13' -->
<A NAME="page_nc1091_1_5"> </A>
<BR>

<P><FONT SIZE=2><B>Q17. IF I ELECT TO EXCHANGE ELIGIBLE OPTIONS, DO I HAVE TO EXCHANGE ALL OF MY ELIGIBLE OPTIONS OR CAN I JUST EXCHANGE SOME OF THEM?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN ALL CASES, IF YOU ELECT TO EXCHANGE ANY OF YOUR ELIGIBLE OPTIONS, YOU MUST EXCHANGE ALL OF YOUR MANDATORY EXCHANGE OPTIONS. However, should you choose to
accept this Offer, you are not obligated to tender each Eligible Option and are free to elect to tender as many or as few of the Eligible Options as you wish. Please note that you must tender all
shares issuable under each particular Eligible Option you wish to tender. You may tender a partially exercised Eligible Option so long as you tender all unexercised shares subject to such Eligible
Options. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
an example, assume that Inhale grants an eligible employee four (4)&nbsp;separate option grants to purchase an aggregate total of 1,000 shares of Common Stock of the Company. The
first option grant is for the purchase of 250 shares of Common Stock at an exercise price of $16.00 per share and was granted on January&nbsp;5, 1999. The second option grant is for the purchase of
250 shares of Common Stock at an exercise price of $26.00 per share and was granted on January&nbsp;5, 2000. The third option grant is for the purchase of 250 shares of Common Stock at an exercise
price of $38.50 per share and was granted on January&nbsp;5, 2001. The fourth option grant is for the purchase of 250 shares of Common Stock at an exercise price of $18.00 per share and was granted
on January&nbsp;4, 2002. None of the option grants are Evergreen Options and none of the option grants have been exercised. Under the terms of this Offer, only the second and third option grants
with exercise prices greater than or equal to $25.00 per share and granted prior to July&nbsp;24, 2001 are Eligible Options as defined herein. Under the terms of this Offer, the fourth option grant
is a Mandatory Exchange Option. If the employee elects to participate in the exchange, the employee has the option to exchange either the second or third option grants, or both grants. Regardless of
whether the employee exchanged one or both grants, the employee would also be required to exchange the fourth option grant because that grant occurred after July&nbsp;24, 2001. If the employee does
not elect to exchange the second or third option, the fourth option would not be exchanged. For each of the grants exchanged, the employee would be required to exchange all 250 options to purchase
shares subject to that grant. If any of these option grants had been partially exercised, the employee would be required to tender all of the remaining unexercised shares subject to that option grant. </FONT></P>

<P><FONT SIZE=2><B>Q18. WILL I HAVE TO PAY TAXES IF I EXCHANGE MY OPTIONS IN THE OFFER?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you accept the Offer, you will not recognize income for U.S. Federal Income Tax purposes at the time of the exchange or at the time we grant Replacement
Options to you, nor will U.K. or German employees have to pay U.K. or German taxes at that time. (See Section&nbsp;12 of the Offer to Exchange.) We recommend that you consult with your tax advisor
to determine the tax consequences of accepting the Offer. If you are an employee based outside of the United States, we recommend that you consult with your tax advisor to determine the tax and social
contribution consequences of this transaction under the laws of the country in which you live and work. </FONT></P>

<P><FONT SIZE=2><B>Q19. IF MY CURRENT OPTIONS ARE NONQUALIFIED STOCK OPTIONS, WILL MY REPLACEMENT OPTIONS BE NONQUALIFIED STOCK OPTIONS?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Eligible Options granted to employees resident in the U.S. are nonqualified stock options, and all Replacement Options granted to employees resident in the
U.S. will be nonqualified stock options. If you are a U.K. employee please review Question 11 of this Summary of Terms for an explanation of the form of your Replacement Option. (See Section&nbsp;12
of the Offer to Exchange.) </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=10,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=539736,FOLIO='5',FILE='DISK040:[02PAL1.02PAL1091]NC1091A.;13',USER='DNICHOL',CD='25-JAN-2002;14:13' -->
<A NAME="page_nc1091_1_6"> </A>
<BR>

<P><FONT SIZE=2><B>Q20. WHEN DOES THE OFFER EXPIRE? CAN THE OFFER BE EXTENDED, AND IF SO, HOW WILL I KNOW IF IT IS EXTENDED?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Offer expires on February&nbsp;25, 2002, at midnight, Pacific Standard Time, unless we extend it. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we do not currently intend to do so, we may, in our discretion, extend the Offer at any time. If we extend the Offer, we will announce the extension no later than midnight,
Pacific Standard Time, on February&nbsp;25, 2002. (See Section&nbsp;14 of the Offer to Exchange.) </FONT></P>

<P><FONT SIZE=2><B>Q21. WHAT DO I NEED TO DO?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether or not you accept the Offer, you need to make your election, sign the Election Form and deliver the Election Form to Steve Hurst or Bob Harper at Inhale
before midnight, Pacific Standard Time, on February&nbsp;25, 2002 (or a later expiration date if Inhale extends the Offer). The Election Form may be sent via mail, courier, e-mail or
facsimile. Steve Hurst and Bob Harper are located at Inhale's corporate headquarters in San Carlos, California. Their direct facsimile number is (650)&nbsp;620-5360 and their
e-mail address is </FONT><FONT SIZE=2><I>exchange@inhale.com</I></FONT><FONT SIZE=2>. Election Forms must be received before midnight, Pacific Standard Time, on February&nbsp;25, 2002
(or a later expiration date if Inhale extends the Offer), not placed in the mail or other delivery system by the expiration time. If Election Forms are sent by e-mail or facsimile,
originals should be sent by mail, courier or hand delivery as soon as possible. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should direct questions about this Offer, requests for assistance in completing the related documentation and requests for additional copies of the Offer to Exchange or related
documents to Steve Hurst or Bob Harper via e-mail at </FONT><FONT SIZE=2><I>exchange@inhale.com</I></FONT><FONT SIZE=2>. Alternatively, you may reach Steve Hurst via telephone at
(650)&nbsp;631-3118 or Bob Harper at (650)&nbsp;631-3222. You should review the Offer to Exchange, the Election Form and all of their attachments before making your
election. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we extend the Offer beyond February&nbsp;25, 2002 then you must sign and deliver the Election Form before the extended expiration of the Offer. We may reject any Eligible Options to
the extent that we determine the Election Form is not properly completed or to the extent that we determine it would be unlawful to accept the options. Although we may later extend, terminate or amend
the Offer, we currently expect to accept all properly exchanged options promptly following the deadline of midnight, Pacific Standard Time, on February&nbsp;25, 2002 (or a later expiration date if
Inhale extends the Offer). IF YOU DO NOT SIGN AND DELIVER THE ELECTION FORM BEFORE THE OFFER EXPIRES,
IT WILL HAVE THE SAME EFFECT AS IF YOU REJECTED THE OFFER. (SEE SECTION&nbsp;3 OF THE OFFER TO EXCHANGE.) </FONT></P>

<P><FONT SIZE=2><B>Q22. DURING WHAT PERIOD OF TIME MAY I CHANGE MY PREVIOUS ELECTION?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may change your previous election at any time before midnight, Pacific Standard Time, on February&nbsp;25, 2002. If we extend the Offer beyond that time,
you may change your previous election at any time until the extended expiration of the Offer. To change your election, you must deliver a Notice of Change in Election Form to Steve Hurst or Bob Harper
before the Offer expires. If you change your election from reject to accept you will also be required to fill out and deliver a new Election Form. You may change your election more than once. (See
Section&nbsp;4 of the Offer to Exchange.) </FONT></P>

<P><FONT SIZE=2><B>Q23. WHAT HAPPENS TO MY OPTIONS IF I DO NOT ACCEPT THE OFFER?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing. If you do not accept the Offer, you will keep all of your current options and you will not receive Replacement Options. No changes will be made to your
current options. (See Section&nbsp;12 of the Offer to Exchange.) </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=11,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=791193,FOLIO='6',FILE='DISK040:[02PAL1.02PAL1091]NC1091A.;13',USER='DNICHOL',CD='25-JAN-2002;14:13' -->
<A NAME="page_nc1091_1_7"> </A>
<BR>

<P><FONT SIZE=2><B>Q24. UNDER WHAT CIRCUMSTANCES WOULD THE COMPANY NOT ACCEPT MY OPTIONS?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently expect that we will accept promptly after the expiration date all Eligible Options that are properly submitted to be exchanged and for which the
election has not been validly withdrawn. We may, however, reject any or all Election Forms, Notice of Change in Election Forms or exchanged options to the extent that we determine they were not
properly executed or delivered, to the extent that we determine it is unlawful to accept the exchanged options or to the extent certain conditions exist which in our reasonable judgment makes it
inadvisable to proceed with the Offer. (See Sections 3, 5 and 6 of the Offer to Exchange.) </FONT></P>

<P><FONT SIZE=2><B>Q25. WHAT HAPPENS TO OUR REPLACEMENT OPTIONS IF INHALE MERGES WITH OR IS ACQUIRED BY ANOTHER COMPANY PRIOR TO THE DATE THE REPLACEMENT OPTIONS ARE GRANTED?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If Inhale merges with or is acquired by another entity between February&nbsp;25, 2002 (or a later expiration date if Inhale extends the Offer) and the date the
Replacement Options are granted, then the resulting
entity will be bound to grant the Replacement Options under the same terms as provided herein; however, the type of security and the number of shares covered by each Replacement Option would be
determined by the acquisition agreement between Inhale and the acquiror based on the same principles applied to the handling of the options to acquire Inhale Common Stock that are outstanding at the
time of the acquisition. As a result of the ratio in which our Common Stock may convert into an acquiror's common stock in an acquisition transaction, you may receive options for more or fewer shares
of the acquiror's stock than the number of shares subject to the Replacement Options that you would have received if no acquisition had occurred. In the event that Inhale acquires another entity, no
change will occur with respect to your election to participate in the Offer. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your employment or service is terminated by any successor entity prior to the grant date of the Replacement Options, then you will not receive any Replacement Options in exchange for
your Eligible Options or Mandatory Exchange Options that were cancelled. In addition, your cancelled options will not be returned to you nor will you realize any value from the options that are
exchanged. For U.K. participants, a merger or acquisition may (depending on the circumstances) affect Inhale's ability to ensure that the new options are approved options. </FONT></P>

<P><FONT SIZE=2><B>Q26. AFTER I AM GRANTED A REPLACEMENT OPTION, WHAT HAPPENS IF THAT REPLACEMENT OPTION ENDS UP UNDERWATER?  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are conducting this Offer only at this time. Therefore, this Offer is considered a one-time offer and is not expected to be repeated in the future.
As stock options granted under the Plan generally are valid for up to ten years from the date of initial grant, subject to continued service with the Company, the price of our Common Stock may
appreciate over this period even if your option is underwater for some period of time after the grant date of the Replacement Options. HOWEVER, WE CAN PROVIDE NO ASSURANCE AS TO THE PRICE OF OUR
COMMON STOCK AT ANY TIME IN THE FUTURE, AND NOTHING CONTAINED IN THIS DOCUMENT OR THE OTHER DOCUMENTS YOU RECEIVE RELATING TO THIS OFFER SHOULD BE INTERPRETED IN ANY WAY AS A CLAIM RELATING TO THE
FUTURE PROSPECTS OF THE PRICE OF OUR COMMON STOCK, NOR SHOULD ANY INFERENCE ABOUT SUCH FUTURE PROSPECTS BE DRAWN FROM ANYTHING CONTAINED HEREIN OR THEREIN. </FONT></P>

<P><FONT SIZE=2><B>Q27. WHOM CAN I TALK TO IF I HAVE QUESTIONS ABOUT THE OFFER?  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For additional information or assistance, you should contact Steve Hurst or Bob Harper via e-mail at </FONT> <FONT SIZE=2><I>exchange@inhale.com</I></FONT><FONT SIZE=2>. Alternatively,
you may reach Steve Hurst via telephone at (650)&nbsp;631-3118 or Bob Harper at
(650)&nbsp;631-3222. In addition, there will be a company-wide meeting to present and discuss information about the Offer. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=12,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=104672,FOLIO='7',FILE='DISK040:[02PAL1.02PAL1091]NC1091A.;13',USER='DNICHOL',CD='25-JAN-2002;14:13' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->

<P><FONT SIZE=2><A
NAME="page_ne1091_1_8"> </A> </FONT> <FONT SIZE=2><B>THE OFFER  </B></FONT></P>

<P><FONT SIZE=2><B>1.&nbsp;&nbsp;&nbsp;&nbsp;NUMBER OF OPTIONS; EXPIRATION DATE.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are offering to grant Replacement Options to purchase our Common Stock in exchange for all Eligible Options and Mandatory Exchange Options held by Eligible
Participants. The Company is conducting the exchange with respect to Eligible Options on a one-for-two (1:2) basis and will grant Eligible Participants a Replacement Option
covering fifty percent (50%) of the number of shares subject to any Eligible Options that were cancelled. The Company is conducting the exchange with respect to Mandatory Exchange Options on a
one-for-one (1:1) basis and will grant Eligible Participants a Replacement Option covering one hundred percent (100%) of the number of shares subject to any of such Eligible
Participant's Mandatory Exchange Options that were cancelled. As of January&nbsp;25, 2002, Eligible Options to purchase 3,463,270 shares of our Common Stock were outstanding and held by 401 Eligible
Participants. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may exchange one or more of your Eligible Options, but you may not exchange less than all option shares subject to a particular Eligible Option. You may tender a partially exercised
Eligible Option so long as you tender all unexercised shares subject to the Eligible Option. If you elect to exchange any Eligible Options, you must exchange all Mandatory Exchange Options held by
you. Mandatory Exchange Options are options to acquire Common Stock, including, without limitation, options with exercise prices of less than $25.00 per share, Evergreen Options, and options granted
to you under plans other than the 2000 Non-Officer Equity Incentive Plan, granted on or after July&nbsp;24, 2001. If you do not elect to exchange any Eligible Options, no Mandatory
Exchange Options will be exchanged. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Offer is subject to the terms and conditions described in this Offer to Exchange. We will only accept options that are properly submitted for exchange and not validly withdrawn in
accordance with Section&nbsp;5 of this Offer to Exchange before the Offer expires on the "expiration date" as defined below. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
Replacement Options will represent fifty percent (50%) of the total number of option shares of all your Eligible Options that were cancelled and one hundred percent (100%) of the
total number of option shares of all your Mandatory Exchange Options that were cancelled. In the event that this
would result in the issuance of any fractional shares of Common Stock, the number of shares subject to the Replacement Option will be rounded down to the nearest whole number of shares. Replacement
Options issued in exchange for options granted under the Plan will be re-issued under the Plan. The number of option shares to be represented by the Replacement Options will be adjusted
for any stock splits, stock dividends, recapitalizations or similar transactions that may occur between February&nbsp;25, 2002 (or a later expiration date if Inhale extends the offer) and the date
the Replacement Options are granted. IF, FOR ANY REASON, YOU ARE NOT EMPLOYED BY INHALE OR ONE OF ITS WHOLLY-OWNED SUBSIDIARIES FROM THE DATE YOUR ELIGIBLE OPTIONS ARE CANCELLED THROUGH THE GRANT DATE
FOR THE REPLACEMENT OPTIONS, YOU WILL NOT RECEIVE ANY REPLACEMENT OPTIONS FOR YOUR ELIGIBLE OPTIONS OR MANDATORY EXCHANGE OPTIONS THAT HAVE BEEN CANCELLED, NOR WILL THE COMPANY RETURN ANY ELIGIBLE
OPTIONS OR MANDATORY EXCHANGE OPTIONS THAT YOU EXCHANGED. PARTICIPATION IN THIS PROGRAM DOES NOT CONFER UPON YOU THE RIGHT TO REMAIN EMPLOYED BY US. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term "expiration date" of this Offer means midnight, Pacific Standard Time, on February&nbsp;25, 2002, unless and until we, in our discretion, extend the period of time during
which the Offer will remain open. If we extend the period of time during which the Offer will remain open, the term "expiration date" will refer to the latest time and date at which the Offer expires.
See Section&nbsp;14 of this Offer to Exchange for a description of our rights to extend, delay, terminate and/or amend the Offer. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=13,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=606593,FOLIO='8',FILE='DISK040:[02PAL1.02PAL1091]NE1091A.;5',USER='DNICHOL',CD='25-JAN-2002;14:18' -->
<A NAME="page_ne1091_1_9"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will publish a notice if we decide to take any of the following actions: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>increase
or decrease what we will give you in exchange for your Eligible Options or Mandatory Exchange Options;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>increase
or decrease the number of Eligible Options to be exchanged in the Offer; or
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>extend
or terminate the Offer. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Offer is scheduled to expire within ten (10)&nbsp;business days from the date we notify you of such an increase or decrease, we also intend to extend the Offer until ten
(10)&nbsp;business days after the date the notice is published. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
"business day" means any day other than a Saturday, Sunday or federal holiday and consists of the time period from 12:01&nbsp;a.m. through 12:00 midnight. </FONT></P>

<P><FONT SIZE=2><B>2.&nbsp;&nbsp;&nbsp;&nbsp;PURPOSE OF THE OFFER.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many of our outstanding options, whether or not they are currently exercisable, have exercise prices that are significantly higher than the current market price
of our Common Stock. By making this Offer, we intend to maximize stockholder value by creating better performance incentives for our employees. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors has approved this Offer. </FONT><FONT SIZE=2><B><I>We cannot guarantee that the Replacement Options will have a lower exercise price than those of the Eligible
Options or Mandatory Exchange Options.</I></B></FONT><FONT SIZE=2> The Board of Directors recognizes that the decision to accept or reject the Offer is an individual one that should be based on a variety
of factors, and you should consult with your personal advisors if you have questions about your financial or tax situation. </FONT></P>


<P><FONT SIZE=2><B>3.&nbsp;&nbsp;&nbsp;&nbsp;PROCEDURES.  </B></FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Making Your Election.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;To make your election to accept or reject this Offer, you must make your election, sign the Election
Form and deliver the Election Form and any other required documents to Steve Hurst or Bob Harper at Inhale before the expiration date. The Election Form may be sent via mail, courier,
e-mail or facsimile. Steve Hurst and Bob Harper are located at Inhale's corporate offices in San Carlos, California. Their direct facsimile number is (650)&nbsp;620-5360 and
their e-mail address is </FONT><FONT SIZE=2><I>exchange@inhale.com</I></FONT><FONT SIZE=2>. If you have any questions regarding the Offer, you may also reach Steve Hurst via telephone at
(650)&nbsp;631-3118 or Bob Harper at (650)&nbsp;631-3222. Election Forms must be received before midnight, Pacific Standard Time, on February&nbsp;25, 2002 (or a later
expiration date if Inhale extends the Offer), not placed in the mail or other delivery system by the expiration time. Election Forms received by e-mail or facsimile will be valid if
received by the expiration time even though the originals are not yet received, but we request originals be sent by mail, courier or hand delivery as soon as possible. You do not need to return your
stock option agreements for your Eligible Options to effectively elect to accept the Offer as they (as well as your stock option agreements for your Mandatory Exchange Options) will be automatically
cancelled if Inhale accepts your Eligible Options for exchange. However, you will be required to return your stock option agreements upon Inhale's request. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Determination of Validity; Rejection of Options; Waiver of Defects; No Obligation to Give Notice of Defects.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We will
determine, in our discretion, all questions as to the number of shares subject to Eligible Options and Mandatory Exchange Options and the validity, form, eligibility (including time of receipt) and
acceptance of Election Forms and Notice of Change in Election Forms. Our determinations regarding these matters will be final and binding on all parties. We may reject any or all Election Forms,
Notice of Change in Election Forms or exchanged options to the extent that we determine they were not properly executed or delivered or to the extent that we determine it is </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=14,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=660624,FOLIO='9',FILE='DISK040:[02PAL1.02PAL1091]NE1091A.;5',USER='DNICHOL',CD='25-JAN-2002;14:18' -->
<A NAME="page_ne1091_1_10"> </A>
<BR>

<P><FONT SIZE=2>
unlawful to accept the exchanged options. We may waive any or all of the conditions of the Offer for all Eligible Participants. We may waive any defect or irregularity in any Election Form or Notice
of Change in Election Form with respect to any particular option or any particular optionholder. No Eligible Options will be accepted for exchange until all defects or irregularities have been cured
by the optionholder exchanging the Eligible Options or waived by us. Neither we nor any other person is obligated to give notice of any defects or irregularities involved in the election to exchange
any options, and no one will be liable for failing to give notice of any such defects or irregularities. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Acceptance Constitutes an Agreement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you elect to exchange your options according to the procedures described above,
you will have accepted the Offer. Our acceptance of Eligible Options that are properly submitted for exchange will form&nbsp;a binding agreement between us and you on the terms and subject to the
conditions of this Offer. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to our rights to extend, terminate and/or amend the Offer, we currently expect that we will accept promptly after the expiration date of the Offer all properly and timely made
elections to exchange options that have not been validly withdrawn. </FONT></P>

<P><FONT SIZE=2><B>4.&nbsp;&nbsp;&nbsp;&nbsp;CHANGE IN ELECTION.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may only change your election by following the procedures described in this Section&nbsp;4. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may change your election at any time before midnight, Pacific Standard Time, on February&nbsp;25, 2002. If we extend the Offer beyond that time, you may change your election at any
time until the extended expiration of the Offer. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
note you have been supplied with two different Notice of Change in Election Forms, one of which is to be used if you wish to reject the Offer after having accepting it and the
other of which is to be used if you wish to accept the Offer after having rejected it. If you intend to change an election, it is important you follow the procedures outlined below. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
change your election, you </FONT><FONT SIZE=2><B><I>must deliver</I></B></FONT><FONT SIZE=2> a Notice of Change in Election Form to Steve Hurst or Bob Harper at Inhale before the Offer
expires. The Notice of Change in Election Form must be signed by you, have your name on it, and must clearly indicate whether you elect to accept or reject the Offer. Please note that if you
previously elected to reject the Offer and wish to change your election and accept the Offer, you must also fill out and deliver a new Election Form along with the Notice of Change in Election. The
Notice of Change in Election Form and new Election Form (if applicable) may be sent via mail, courier, e-mail or facsimile. Steve Hurst and Bob Harper are located at Inhale's
corporate offices in San Carlos, California. Their e-mail address is </FONT><FONT SIZE=2><I>exchange@inhale.com </I></FONT><FONT SIZE=2>and their fax number is
(650)&nbsp;620-5360. Notice of Change in Election Forms received by e-mail or facsimile will be valid if received by the expiration date even though the originals are not yet
received, but we request that the originals be sent by mail, courier or hand delivery as soon as possible. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
we nor any other person is obligated to give notice of any defects or irregularities in any Notice of Change in Election Form, and no one will be liable for failing to give
notice of any defects or irregularities. We will determine, in our discretion, all questions as to the form and validity, including time of receipt, of Notice of Change in Election Forms. Our
determinations regarding these matters will be final and binding. </FONT></P>

<P><FONT SIZE=2><B>5.&nbsp;&nbsp;&nbsp;&nbsp;ACCEPTANCE OF OPTIONS FOR EXCHANGE AND CANCELLATION AND ISSUANCE OF REPLACEMENT OPTIONS.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On the terms and subject to the conditions of this Offer and as promptly as practicable following the expiration date, we will timely accept the Eligible Options
for exchange and cancel all Eligible Options properly elected for exchange and not validly withdrawn before the expiration date as well as </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=15,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=125741,FOLIO='10',FILE='DISK040:[02PAL1.02PAL1091]NE1091A.;5',USER='DNICHOL',CD='25-JAN-2002;14:18' -->
<A NAME="page_ne1091_1_11"> </A>
<BR>

<P><FONT SIZE=2>
all Mandatory Exchange Options held by those that elect to exchange any Eligible Options. The Replacement Options will be granted on August&nbsp;26, 2002 (or a later date if Inhale extends the
Offer). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
Replacement Option with respect to any Eligible Option will represent fifty percent (50%) of the total number of option shares of all Eligible Options that you exchange. Your
Replacement Option with respect to any Mandatory Exchange Option will represent one hundred percent (100%) of the total number of option shares of all Mandatory Exchange Options that you exchange. The
number of option shares to be represented by the Replacement Options will be adjusted for any stock splits, stock dividends, recapitalizations or similar transactions that may occur between
February&nbsp;25, 2002 (or a later date if Inhale extends the Offer) and the date the Replacement Options are granted. If you are not continuously employed by or in continuous service with Inhale or
one of its wholly-owned subsidiaries through the date the Replacement Options are granted, you will not be eligible to receive a Replacement Option. In addition, no portion of a Replacement Option
will be exercisable until it vests. We will give you notice of our acceptance for exchange and cancellation of Eligible Options validly elected for exchange and not properly withdrawn as of the
expiration date. We will notify you on or prior to February&nbsp;25, 2002 (or a later expiration date if Inhale extends the Offer), or as soon as possible thereafter, if we reject your election. If
you are not notified of a rejection and you receive notice of our acceptance for exchange and cancellation of all Eligible Options validly elected for exchange and not properly withdrawn, you may
assume that your properly executed and delivered Election Form has been accepted. After we accept Eligible Options for exchange and cancellation, we will send each optionholder who accepted the Offer
a letter confirming the Replacement Options that we will grant to the optionholder. </FONT></P>


<P><FONT SIZE=2><B>6.&nbsp;&nbsp;&nbsp;&nbsp;CONDITIONS OF THE OFFER.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will not be required to accept any Eligible Options that you elect to exchange, and we may terminate or amend the Offer, or postpone our acceptance and
cancellation of any Eligible Options that you elect to exchange, in each case if at any time on or after January&nbsp;25, 2002 and on or before February&nbsp;25, 2002, or a later expiration date
if the Offer is extended, we determine that any event has occurred that, in our reasonable judgment, makes it inadvisable for us to proceed with the Offer or to accept and cancel Eligible Options that
you elect to exchange, including, but not limited to, the following: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>any
action or proceeding by any government agency, authority or tribunal or any other person, domestic or foreign, is threatened or pending before any court,
authority, agency or tribunal that directly or indirectly challenges the making of the Offer, the acquisition of some or all of the exchanged options, the issuance of Replacement Options, or otherwise
relates to the Offer or that, in our reasonable judgment, could materially and adversely affect our business, condition (financial or other), income, operations or prospects or materially impair the
benefits we believe we will receive from the Offer;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>any
action is threatened, pending or taken, or any approval is withheld, by any court or any authority, agency or tribunal, which action or withholding, in
our reasonable judgment, would or might directly or indirectly:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>make
it illegal for us to accept some or all of the Eligible Options or Mandatory Exchange Options or to issue some or all of the Replacement Options or otherwise restrict or prohibit
consummation of the Offer or otherwise relate to the Offer;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>delay
or restrict our ability, or render us unable, to accept the Eligible Options or Mandatory Exchange Options for exchange and cancellation or to issue Replacement Options for some
or all of the exchanged Eligible Options or Mandatory Exchange Options; </FONT></DD></DL>
</DD></DL>
</UL>
<HR NOSHADE>
<!-- ZEQ.=4,SEQ=16,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=10239,FOLIO='11',FILE='DISK040:[02PAL1.02PAL1091]NE1091A.;5',USER='DNICHOL',CD='25-JAN-2002;14:18' -->
<A NAME="page_ne1091_1_12"> </A>
<UL>
<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>materially
impair our ability to provide employees with compensation by decreasing the value of the Replacement Options or otherwise; or
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD><FONT SIZE=2>materially
and adversely affect our business, condition (financial or other), income, operations or prospects; </FONT></DD></DL>
</UL>
</UL>
<BR>
<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>there
is:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>any
general suspension of trading in, or limitation on prices for, securities on any national securities exchange or in the over-the-counter market; or
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>the
declaration of a banking moratorium or any suspension of payments in respect of banks in the United States, whether or not mandatory; </FONT></DD></DL>
</DD></DL>
</UL>
<BR>
<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>another
person publicly makes or proposes a tender or exchange offer for some or all of our Common Stock, or an offer to merge with or acquire us, or we
learn that:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>any
person, entity or "group," within the meaning of Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934 (the "Exchange Act"), has acquired or proposed to acquire
beneficial ownership of more than 5% of the outstanding shares of our Common Stock, or any new group shall have been formed that beneficially owns more than 5% of the outstanding shares of our Common
Stock, other than any such person, entity or group that has filed a Schedule&nbsp;13D or Schedule&nbsp;13G with the SEC before November&nbsp;28, 2001;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>any
such person, entity or group that has filed a Schedule&nbsp;13D or Schedule&nbsp;13G with the SEC before November&nbsp;28, 2001 has acquired or proposed to acquire
beneficial ownership of an additional 2% or more of the outstanding shares of our Common Stock; or
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>any
person, entity or group shall have filed a Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 disclosing or made a public
announcement that it intends to acquire us or any of our assets or securities; or </FONT></DD></DL>
</DD></DL>
</UL>
<BR>
<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>any
change or changes occur in our business, condition (financial or other), assets, income, operations, prospects or stock ownership that, in our reasonable
judgment, is or may be material to us. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
conditions to the Offer are for our benefit. We may assert the conditions to the Offer in our discretion before the expiration date and we may waive the conditions to the Offer in
accordance with applicable law, at any time and from time to time before the expiration date, whether or not we waive any other condition to the Offer. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
failure to exercise any of these rights is not a waiver of any of these rights. The waiver of any of these rights with respect to particular facts and circumstances is not a waiver
with respect to any other facts and circumstances. Any determination we make concerning the events described in this Section&nbsp;6 will be final and binding upon everyone. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
currently expect that we will accept promptly after the expiration date all Eligible Options that are properly submitted to be exchanged and have not been validly withdrawn. </FONT></P>

<P><FONT SIZE=2><B>7.&nbsp;&nbsp;&nbsp;&nbsp;PRICE RANGE OF COMMON STOCK.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is no established trading market for the Eligible Options or Mandatory Exchange Options. The securities underlying the Eligible Options and Mandatory
Exchange Options are shares of our Common Stock. Our Common Stock is quoted on the Nasdaq National Market under the symbol </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=17,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=337212,FOLIO='12',FILE='DISK040:[02PAL1.02PAL1091]NE1091A.;5',USER='DNICHOL',CD='25-JAN-2002;14:18' -->
<A NAME="page_ne1091_1_13"> </A>
<BR>

<P><FONT SIZE=2>
"INHL." The following table shows, for the periods indicated, the high and low closing sale prices per share of our Common Stock as reported on the Nasdaq National Market. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=1><B>Quarter ended or ending<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>High</B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>Low</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>Fiscal Year 2002</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="72%"><FONT SIZE=2>(through January 23, 2002)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>18.55</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>15.82</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2><BR>
Fiscal Year 2001</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="72%"><FONT SIZE=2>December 31, 2001</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>19.47</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>13.13</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="72%"><FONT SIZE=2>September 30, 2001</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>23.91</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>11.01</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="72%"><FONT SIZE=2>June 30, 2001</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>35.47</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>18.37</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="72%"><FONT SIZE=2>March 31, 2001</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>48.25</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>17.12</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2><BR>
Fiscal Year 2000</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="72%"><FONT SIZE=2>December 31, 2000</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>55.19</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>35.50</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="72%"><FONT SIZE=2>September 30, 2000</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>56.37</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>40.88</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="72%"><FONT SIZE=2>June 30, 2000</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>54.34</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>23.16</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="72%"><FONT SIZE=2>March 31, 2000</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>63.31</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>20.84</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2><BR>
Fiscal Year 1999</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="72%"><FONT SIZE=2>December 31, 1999</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>21.84</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>13.44</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="72%"><FONT SIZE=2>September 30, 1999</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>17.44</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>11.81</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="72%"><FONT SIZE=2>June 30, 1999</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>14.84</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>11.50</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="72%"><FONT SIZE=2>March 31, 1999</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>17.31</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>11.94</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of January&nbsp;23, 2002, the last reported sale price of our Common Stock, as reported on the Nasdaq National Market, was $15.85 per share. </FONT></P>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We cannot guarantee that the Replacement Options will have a lower exercise price than those of the Eligible Options or Mandatory Exchange
Options.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We recommend that you obtain current market quotations for our Common Stock before deciding whether to elect to exchange your options. </FONT></P>


<P><FONT SIZE=2><B>8.&nbsp;&nbsp;&nbsp;&nbsp;SOURCE AND AMOUNT OF CONSIDERATION; TERMS OF REPLACEMENT OPTIONS.  </B></FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consideration.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company is conducting the exchange with respect to Eligible Options on a
one-for-two (1:2) basis. Thus, for those employees who elect to participate in the Offer, on August&nbsp;26, 2002 (or a later date if Inhale extends the Offer), the Company
will grant Replacement Options covering fifty percent (50%) of the number of shares subject to any of such employee's Eligible Options that were cancelled (so long as such employee's employment or
service with the Company or its subsidiaries continues through that date). The Company is conducting the exchange with respect to Mandatory Exchange Options on a one-for-one
(1:1) basis. Thus, for those employees who elect to
exchange any Eligible Options pursuant to the terms described herein, on August&nbsp;26, 2002 (or a later date if Inhale extends the Offer), the Company will grant Replacement Options covering one
hundred percent (100%) of the number of shares subject to all of such employee's Mandatory Exchange Options that were cancelled (so long as such employee's employment or service with the Company or
its subsidiaries continues through that date). The number of option shares to be represented by the Replacement Options will be adjusted for any stock splits, stock dividends, recapitalizations or
similar transactions that may occur between February&nbsp;25, 2002 (or a later date if Inhale extends the Offer) and the date the Replacement Options are granted. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we receive and accept exchange of all Eligible Options outstanding as of February&nbsp;25, 2002, we will grant Replacement Options in exchange for such Eligible Options to purchase
an aggregate total of 1,731,635 shares of our Common Stock and additional Replacement Options in exchange for Mandatory Exchange Options to purchase an aggregate total of 190,410 shares of our Common
Stock. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=18,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=45242,FOLIO='13',FILE='DISK040:[02PAL1.02PAL1091]NE1091A.;5',USER='DNICHOL',CD='25-JAN-2002;14:18' -->
<A NAME="page_ne1091_1_14"> </A>
<BR>

<P><FONT SIZE=2>
The Common Stock issuable upon exercise of all such Replacement Options would equal approximately 3.5% of the total shares of our Common Stock outstanding as of January&nbsp;23, 2002. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Merger or Acquisition of Inhale.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If Inhale merges with or is acquired by another entity between February&nbsp;25, 2002 (or
a later expiration date if Inhale extends the Offer) and the date the Replacement Options are granted, then the resulting entity will be bound to grant the Replacement Options under the same terms as
provided herein; however, the type of security and the number of shares covered by each Replacement Option would be determined by the acquisition agreement between Inhale and the acquiror based on the
same principles applied to the handling of the options to acquire Inhale Common Stock that are outstanding at the time of the acquisition. As a result of the ratio in which our Common Stock may
convert into an acquiror's common stock in an acquisition transaction, you may receive options for more or fewer shares of the acquiror's stock than the number of shares subject to the Replacement
Options that you would have received if no acquisition had occurred. In the event that Inhale acquires another entity, no change will occur with respect to your election to participate in the Offer. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Terms of Replacement Options.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Replacement Options issued in exchange for options granted under the Plan will be
re-issued under the Plan. Replacement Option agreements will be executed between each optionholder who accepts the Offer and Inhale. The Replacement Option agreements will not permit the
optionholders to exercise the Replacement Options prior to the time such options vest. The issuance of Replacement Options under this Offer will not create any contractual or other right of the
recipients to receive any future grants of stock options or benefits in lieu of stock options. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following description of the Plan and the Replacement Option agreements is a summary, and is not complete. Replacement Options will be subject to the terms and conditions of the Plan
under which they will be granted and the applicable stock option agreement. Additional information about the Plan may be found in the Form&nbsp;S-8 Registration Statement and related
Prospectus prepared in connection with the Plan. Please contact Steve Hurst or Bob Harper at </FONT><FONT SIZE=2><I>exchange@inhale.com </I></FONT><FONT SIZE=2>to request copies of the Plan or
related Prospectus and current form of stock option agreement. Copies will be provided promptly and at our expense. The form of stock option agreement may be changed with the
approval of our Board of Directors or the Compensation Committee thereof prior to the date the Replacement Options are granted. </FONT></P>

<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Plan was adopted on June&nbsp;6, 2000 as an amendment and restatement of our 1998 Non-Officer
Equity Incentive Plan originally adopted on August&nbsp;18, 1998. The Plan has subsequently been amended on August&nbsp;22, 2000, January&nbsp;16, 2001, June&nbsp;28, 2001 and
September&nbsp;6, 2001. As of January&nbsp;23, 2002, there were 11,250,000 shares of our Common Stock reserved for issuance pursuant to the Plan and options to purchase 8,780,623 shares of our
Common Stock issued and outstanding under the Plan. The Plan permits us to grant options intended to qualify as nonqualified stock options under the Internal Revenue Code. Each Replacement Option will
be a nonqualified stock option. </FONT></P>

<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors administers the Plan and has delegated administration of the Plan to the Compensation
Committee of the Board of Directors. The Board of Directors has the authority to construe, interpret and amend the Plan. </FONT></P>


<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The term of each option granted under the Plan is fixed by the Plan administrator at the time of grant. Replacement
Options to be granted under the Plan will have a term that expires at 11:59&nbsp;p.m., Pacific Time, on the day prior to the ten-year anniversary of the initial grant date of the
Replacement Option. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=19,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=180494,FOLIO='14',FILE='DISK040:[02PAL1.02PAL1091]NE1091A.;5',USER='DNICHOL',CD='25-JAN-2002;14:18' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->

<P><FONT SIZE=2><A
NAME="page_ng1091_1_15"> </A> </FONT> <FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Time of Exercise.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Generally you may exercise the vested portion of a Replacement Option at any time
prior to termination of
the option. If your employment or service with us terminates for any reason other than your death or permanent disability, generally your post-termination exercise period will be three
(3)&nbsp;months following your termination date. If your employment or service with us terminates as a result of your permanent disability, generally your post-termination exercise
period will be twelve (12)&nbsp;months following your termination date. If your employment or service with us terminates as a result of your death, generally your estate or beneficiaries must
exercise the vested portion of your Replacement Option within eighteen (18)&nbsp;months following your termination date (twelve (12)&nbsp;months for U.K. employees holding approved options).
However, under no circumstances may you exercise the Replacement Option more than ten years minus one day from the date of grant of the Eligible Options. </FONT></P>

<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise Price.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Replacement Options will have an exercise price equal to the closing price of the Company's Common Stock
as reported on the Nasdaq National Market on the last market trading day prior to the date of grant. </FONT><FONT SIZE=2><B><I>We cannot guarantee that the Replacement Options will have a lower exercise
price than those of the Eligible Options or Mandatory Exchange Options</I></B></FONT><FONT SIZE=2>. We recommend that you obtain current market quotations for our Common Stock before deciding whether to
elect to exchange your options. If any change is made in the Common Stock subject to any Replacement Option without the receipt of consideration by the Company (through merger, consolidation,
reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in
corporate structure or other transaction not involving the receipt of consideration by the Company), the number of shares subject to and the exercise price of the Replacement Options will be
appropriately adjusted. </FONT></P>

<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vesting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each Replacement Option will have the same vesting schedule on a percentage basis as your applicable Eligible Option
or Mandatory Exchange Option that is exchanged. The vesting commencement date for each Replacement Option will be the original vesting commencement date of your applicable Eligible Option. The number
of shares of Common Stock issuable upon exercise of the Replacement Option that will be vested as of the date the Replacement Option is granted will be equal to the product of (i)&nbsp;the
percentage of shares issuable upon exercise of the exchanged Eligible Option or Mandatory Exchange Option that would have been vested as of such date and (ii)&nbsp;the total number of shares
issuable upon exercise of the Replacement Option. Thereafter, the Replacement Option will continue to vest monthly in the same percentage amount as the applicable Eligible Option or Mandatory Exchange
Option that was exchanged. The Board of Directors has the authority to determine the time or times at which options granted under the Plan will vest and become exercisable. The Board may accelerate
the vesting and exercisability of options (except for U.K. approved options). </FONT></P>


<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax Consequences.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;You should refer to Section&nbsp;12 of the Offer for a discussion of the U.S. Federal Income Tax
consequences of the Replacement Options, the Eligible Options and the Mandatory
Exchange Options, as well as the consequences of accepting or rejecting the Replacement Options under this Offer to Exchange. If you are a U.K. employee, please refer to </FONT> <FONT SIZE=2><B>Appendix&nbsp;A</B></FONT><FONT SIZE=2> of this document
entitled "U.K. Tax Consequences." For all employees, we recommend that you consult with your tax advisor with respect
to tax matters. </FONT></P>

<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registration of Option Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All shares of Common Stock issuable upon exercise of options under the Plan, including the
shares that will be issuable upon exercise of all Replacement Options, have been registered under the Securities Act of 1933, as amended (the "Securities Act"), on a Registration Statement on
Form&nbsp;S-8 filed with the SEC. Unless you are considered an "affiliate" of Inhale, you will be able to sell your Replacement Option shares free of any transfer restrictions under
applicable securities laws. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=20,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=962118,FOLIO='15',FILE='DISK040:[02PAL1.02PAL1091]NG1091A.;6',USER='DNICHOL',CD='25-JAN-2002;14:18' -->
<A NAME="page_ng1091_1_16"> </A>
<BR>

<P><FONT SIZE=2><B>9.&nbsp;&nbsp;&nbsp;&nbsp;INTERESTS OF DIRECTORS AND OFFICERS; TRANSACTIONS AND ARRANGEMENTS INVOLVING THE OPTIONS.  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A list of our directors and executive officers is contained in </FONT><FONT SIZE=2><B>Schedule&nbsp;A</B></FONT><FONT SIZE=2> attached to this Offer to
Exchange. No director or executive officer of the Company holds Eligible Options under the 2000 Non-Officer Equity Incentive Plan. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is no agreement, arrangement or understanding between the Company or, to the best of our knowledge, any of our directors or executive officers, and any other person for the
purchase or acquisition from the Company of any of its securities, except for the following: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>outstanding
options to purchase an aggregate of 4,672,556 shares of our Common Stock (as of 1/23/02) pursuant to our 2000 Equity Incentive Plan, as amended.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>outstanding
options to purchase an aggregate of 54,600 shares of our Common Stock (as of 1/23/02) pursuant to our 1994 Non-Employee Directors'
Stock Option Plan, as amended. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2><B>10.&nbsp;&nbsp;STATUS OF OPTIONS ACQUIRED IN THE OFFER; ACCOUNTING CONSEQUENCES OF THE OFFER.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eligible Options and Mandatory Exchange Options that have been granted under the Plan and that we acquire in connection with the Offer will be cancelled and the
shares of Common Stock that may be
purchased under those options will be returned to the pool of shares available for grants of new awards or options under the Plan without further stockholder action, except as required by applicable
law or the rules of the Nasdaq National Market or any other securities quotation system or any stock exchange on which our Common Stock is then quoted or listed. We believe that we will not recognize
any significant charges in our financial statements as a result of the Offer. </FONT></P>

<P><FONT SIZE=2><B>11.&nbsp;&nbsp;LEGAL MATTERS; REGULATORY APPROVALS.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are not aware of any license or regulatory permit that appears to be material to our business that might be adversely affected by the Offer, or of any approval
or other action by any government or regulatory authority or agency that is required for the acquisition or ownership of the options as described in the Offer (other than that certain approvals may be
needed from the U.K. revenue authorities in order to enhance the tax status of U.K. approved options). If any other approval or action should be required, we presently intend to seek the approval or
take the action. This could require us to delay the acceptance of any Eligible Options that you elect to exchange or Mandatory Exchange Options you are required to exchange. We cannot assure you that
we would be able to obtain any required approval or take any other required action. Our failure to obtain any required approval or take any required action might result in harm to our business. Our
obligation under the Offer to accept exchanged Eligible Options and Mandatory Exchange Options and to issue Replacement Options is subject to conditions, including the conditions described in
Section&nbsp;6 of the Offer to Exchange. </FONT></P>

<P><FONT SIZE=2><B>12.&nbsp;&nbsp;MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a general summary of the material U.S. Federal Income Tax consequences of the exchange of options under the Offer. If you are a
non-U.S. employee, we recommend that you consult with your tax advisor to determine the tax consequences of the Offer. This discussion is based on the Internal Revenue Code, its
legislative history, Treasury Regulations and administrative and judicial interpretations as of the date of the Offer, all of which may change, possibly on a retroactive basis. This summary does not
discuss all of the tax consequences that may be relevant to you in light of your particular circumstances, nor is it intended to apply in all respects to all categories of optionholders. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=21,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=201068,FOLIO='16',FILE='DISK040:[02PAL1.02PAL1091]NG1091A.;6',USER='DNICHOL',CD='25-JAN-2002;14:18' -->
<A NAME="page_ng1091_1_17"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you exchange outstanding nonqualified stock options for a Replacement Option, you will not be required to recognize income for federal income tax purposes at the time of the exchange.
We believe that the exchange will be treated as a non-taxable exchange. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the date of grant of the Replacement Option, you will not be required to recognize additional income for federal income tax purposes. The grant of options is not recognized as taxable
income. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Replacement Options issued to U.S. employees will be nonqualified stock options and will not be eligible for favorable tax treatment applicable to incentive stock options. </FONT></P>

<P><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal Income Tax Consequences of Nonqualified Stock Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under current law, you will not realize taxable income upon
the grant of a nonqualified stock option. However, when you exercise the option, the difference between the exercise price of the option and the fair market value of the shares subject to the option
on the date of exercise will be treated as taxable compensation income to you, and you will be subject to withholding of income and employment taxes at that time. The Company will be entitled to a
deduction equal to the amount of compensation income taxable to you if we comply with applicable withholding and reporting requirements. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you exchange shares in payment of part or all of the exercise price of a nonqualified stock option, no gain or loss will be recognized with respect to the shares exchanged, unless the
shares were acquired pursuant to the exercise of an incentive stock option and the applicable holding periods summarized above were not met, and you will be treated as receiving an equivalent number
of shares pursuant to the exercise of the option in a nontaxable exchange. The tax basis of the shares exchanged will be treated as the substituted tax basis for an equivalent number of shares
received, and the new shares will be treated as having been held for the same holding period as the holding period that expired with respect to the transferred shares. The difference between the
aggregate exercise price and the aggregate fair market value of the shares received pursuant to the exercise of the option will be taxed as ordinary income, just as if you had paid the exercise price
in cash. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
subsequent sale of the shares acquired pursuant to the exercise of a nonqualified stock option generally will give rise to capital gain or loss equal to the difference between the
sale price and the sum of the exercise price paid for the shares plus the ordinary income recognized with respect to the shares, and this capital gain or loss will be treated as long term capital gain
or loss if you held the shares for more than one year following exercise of the option. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
recommend that you consult your tax advisor with respect to the federal, state, local and foreign tax consequences of participating in the Offer. </FONT></P>

<P><FONT SIZE=2><B>13.&nbsp;&nbsp;TERMS OF THE OFFER SPECIFIC TO NON-U.S. EMPLOYEES.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a U.K. or German employee who holds options under the Plan you are also subject to the terms of this Offer as described herein. U.K. employees should
refer to </FONT><FONT SIZE=2><B>Appendix&nbsp;A</B></FONT><FONT SIZE=2> of this document entitled "U.K. Tax Consequences" for a discussion of the tax consequences of accepting or rejecting the
Replacement Options under U.K. law. </FONT></P>

<P><FONT SIZE=2><B>14.&nbsp;&nbsp;EXTENSION OF OFFER; TERMINATION; AMENDMENT.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may at any time, and from time to time, extend the period of time during which the Offer is open and delay accepting any options surrendered or exchanged by
announcing the extension and giving oral or written notice of the extension to the optionholders. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the expiration date, in order to terminate or amend the Offer, we may postpone accepting for cancellation any Eligible Options if any of the conditions specified in
Section&nbsp;6 of the Offer to Exchange occur. In order to postpone the accepting for cancellation of any Eligible Option or Mandatory Exchange Option, we must announce the postponement and give
oral or written notice of </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=22,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=933689,FOLIO='17',FILE='DISK040:[02PAL1.02PAL1091]NG1091A.;6',USER='DNICHOL',CD='25-JAN-2002;14:18' -->
<A NAME="page_ng1091_1_18"> </A>
<BR>

<P><FONT SIZE=2>
the postponement to the Eligible Participants. Our right to delay accepting and canceling Eligible Options may be limited by Rule&nbsp;13e-4(f)(5) under the Exchange Act, which requires
that we pay the consideration offered or return the surrendered options promptly after we terminate or withdraw the Offer. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
long as we comply with any applicable laws, we may amend the Offer in any way, including decreasing or increasing the consideration offered in the Offer to optionholders or by
decreasing or increasing the number of Eligible Options or Mandatory Exchange Options to be exchanged or surrendered in the Offer. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may amend the Offer at any time by announcing the amendment. If we extend the length of time during which the Offer is open, we will issue the amendment no later than
11:59&nbsp;p.m., Pacific Standard Time, on the announced expiration date. Any announcement relating to the Offer will be sent promptly to optionholders in a manner reasonably designed to inform
optionholders of the change. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we materially change the terms of the Offer or the information about the Offer, or if we waive a material condition of the Offer, we may extend the Offer to the extent required by
Rules&nbsp;13e-4(d)(2) and 13e-4(e)(3) under the Exchange Act. Under these rules, the minimum period an Offer must remain open following material changes in the terms of the
Offer or information about the Offer, other than a change in price or a change in percentage of securities sought, will depend on the facts and circumstances. We will publish a notice if we decide to
take any of the following actions: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>increase
or decrease what we will give you in exchange for your Eligible Options or Mandatory Exchange Options;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>increase
or decrease the number of Eligible Options to be exchanged in the Offer; or
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>extend
or terminate the Offer. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Offer is scheduled to expire within ten (10)&nbsp;business days from the date we notify you of such an increase or decrease, we intend to extend the Offer until ten
(10)&nbsp;business days after the date the notice is published. </FONT></P>


<P><FONT SIZE=2><B>15.&nbsp;&nbsp;FEES AND EXPENSES.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will not pay any fees or commissions to any broker, dealer or other person asking holders of Eligible Options to exchange such options pursuant to this Offer. </FONT></P>

<P><FONT SIZE=2><B>16.&nbsp;&nbsp;INFORMATION ABOUT INHALE.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our principal executive offices are located at 150 Industrial Road, San Carlos, California 94070, and our telephone number is (650)&nbsp;631-3100.
Information regarding our directors and executive officers is contained in </FONT><FONT SIZE=2><B>Schedule&nbsp;A</B></FONT><FONT SIZE=2> attached to this Offer to Exchange and incorporated herein
by reference. Our web site address is </FONT><FONT SIZE=2><I>www.inhale.com</I></FONT><FONT SIZE=2>. The information on our web site is not a part of this Offer. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inhale
is pioneering drug delivery systems to deliver easily a range of inhaleable drugs, including peptides, proteins and small molecules, to the deep lung for treatment of systemic and
respiratory diseases. Information concerning our business, including our background, strategy, products, collaborative efforts, manufacturing, research and product development, competition,
intellectual property and employees, as well as the financial information, included in our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2000 and our
Quarterly Reports on Form&nbsp;10-Q for the quarterly periods ended March&nbsp;31, 2001, June&nbsp;30, 2001 and September&nbsp;30, 2001 are incorporated by reference herein and may
be inspected at, and copies may be obtained from, the same places and in the same manner as set forth under Section&nbsp;18&#151;"Additional Information." </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=23,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=1022912,FOLIO='18',FILE='DISK040:[02PAL1.02PAL1091]NG1091A.;6',USER='DNICHOL',CD='25-JAN-2002;14:18' -->
<A NAME="page_ng1091_1_19"> </A>
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set
forth below is a selected summary of our financial information. The selected historical consolidated balance sheets and consolidated statements of operations data for the years ended
December&nbsp;31, 2000 and December&nbsp;31, 1999 and the nine months ended September&nbsp;30, 2001 and September&nbsp;30, 2000 have been derived from the consolidated financial statements
included in our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2000, filed with the SEC on March&nbsp;1, 2001, and our Quarterly Report on
Form&nbsp;10-Q for the quarterly period ended September&nbsp;30, 2001, filed with the SEC on
November&nbsp;13, 2001, and should be read together with the consolidated financial statements and related notes included in such reports. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=24,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=278015,FOLIO='19',FILE='DISK040:[02PAL1.02PAL1091]NG1091A.;6',USER='DNICHOL',CD='25-JAN-2002;14:18' -->
<A NAME="page_ng1091_1_20"> </A>
<BR>
<P ALIGN="CENTER"><FONT SIZE=2><B>INHALE THERAPEUTIC SYSTEMS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> Condensed Consolidated Balance Sheets<BR>
(In thousands)  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH COLSPAN=3 ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>September 30, 2001<BR>
(unaudited)</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>December 31, 2000<BR>
*</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2><B>ASSETS</B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>Current assets:</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD COLSPAN=2><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>30,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>136,012</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD COLSPAN=2><FONT SIZE=2>Short-term investments</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>323,382</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>348,829</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD COLSPAN=2><FONT SIZE=2>Accounts receivable</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>5,321</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>7,234</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD COLSPAN=2><FONT SIZE=2>Other current assets</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>10,749</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>968</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="50%"><FONT SIZE=2>Total current assets</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>369,452</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>493,043</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2><BR>
Property and equipment, net</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2><BR>
138,837</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2><BR>
110,457</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>Marketable equity securities</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>964</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>9,140</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>Goodwill and other intangibles</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>162,631</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>4,969</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>Deposits and other assets</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>13,799</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>11,931</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>685,683</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>629,540</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2><B>LIABILITIES AND STOCKHOLDERS' EQUITY</B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>Current liabilities:</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>Accounts payable and accrued liabilities</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>36,161</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>24,313</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>Capital lease obligation &#151; current</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>977</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>977</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>Deferred revenue</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>7,774</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>4,913</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD COLSPAN=2><FONT SIZE=2>Total current liabilities</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>44,912</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>30,203</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2><BR>
Capital lease obligation</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2><BR>
29,611</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2><BR>
15,269</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>Convertible subordinated notes and debentures</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>299,149</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>299,149</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>Accrued rent</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>2,131</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>2,010</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>Other long-term liabilities</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>7,297</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>5,026</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2><BR>
Stockholders' equity:</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="18%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD COLSPAN=2><FONT SIZE=2>Common stock</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>5</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>5</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD COLSPAN=2><FONT SIZE=2>Capital in excess of par value</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>710,941</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>465,593</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD COLSPAN=2><FONT SIZE=2>Deferred compensation</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>(1,109</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>(1,827</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD COLSPAN=2><FONT SIZE=2>Accumulated other comprehensive gain/(loss)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>(1,629</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>5,981</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD COLSPAN=2><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>(405,625</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>(191,869</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="2%">&nbsp;</TD>
<TD COLSPAN=2><FONT SIZE=2>Total stockholders' equity</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>302,583</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>277,883</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="18%" ALIGN="RIGHT"><FONT SIZE=2>685,683</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="17%" ALIGN="RIGHT"><FONT SIZE=2>629,540</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE ALIGN="LEFT" WIDTH="120">
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(*)</FONT></DT><DD><FONT SIZE=2>The
consolidated balance sheet at December 31, 2000 has been derived from the audited financial statements at that date which are included in the Company's Form 10-K, as amended, for
the year ended December 31, 2000 as filed with the Securities and Exchange Commission. This balance sheet does not include all of the information and footnotes required by accounting principles
generally accepted in the United States for complete financial statements. </FONT></DD></DL>
<HR NOSHADE>
<!-- ZEQ.=6,SEQ=25,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=627197,FOLIO='20',FILE='DISK040:[02PAL1.02PAL1091]NG1091A.;6',USER='DNICHOL',CD='25-JAN-2002;14:18' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_ni1091_1_21"> </A> </FONT> <FONT SIZE=2><B>Condensed Consolidated Statements of Operations<BR>
(In thousands, except per share data)  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER"><FONT SIZE=1><B>Three Months Ended September&nbsp;30,<BR>
(unaudited)</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER"><FONT SIZE=1><B>Nine Months Ended September&nbsp;30,<BR>
(unaudited)</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2001</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2000</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2001</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><B>2000</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=2>Contract research revenue</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>17,236</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>14,061</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>48,132</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>38,483</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=2>Product sales</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>5,169</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>5,169</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=2>Total revenue</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>22,405</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>14,061</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>53,301</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>38,483</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=2><BR>
Operating costs and expenses:</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="10%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="45%"><FONT SIZE=2>Cost of goods sold</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1,979</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>1,979</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="45%"><FONT SIZE=2>Research and development</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>34,212</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>26,739</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>98,542</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>74,232</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="45%"><FONT SIZE=2>General and administrative</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>5,762</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>3,066</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>14,200</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>9,696</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="45%"><FONT SIZE=2>Purchased in-process research and development</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>146,260</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>2,292</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="45%"><FONT SIZE=2>Amortization of goodwill and intangible assets</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>8,943</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>194</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>16,478</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>565</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=2>Total operating costs and expenses</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>50,896</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>29,999</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>277,459</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>86,785</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=2>Loss from operations</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>(28,491</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>(15,938</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>(224,158</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>(48,302</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=2><BR>
Other income/(expense), net</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2><BR>
(263</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2><BR>
752</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2><BR>
(603</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2><BR>
752</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=2>Debt conversion premium, net</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>(15,157</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=2>Interest income/(expense), net</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1,833</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>1,971</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>11,005</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>4,913</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=2>Net loss</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>(26,921</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>(13,215</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>(213,756</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>(57,794</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=2>Basic and diluted net loss per share</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>(0.49</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>(0.31</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>(4.07</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>(1.42</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=2>Shares used in computing basic and diluted net loss per share</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>54,845</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>42,266</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=2>52,513</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>40,742</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE SIZE=4></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
financial information included in our Annual Report on Form&nbsp;10-K, as amended, for the fiscal year ended December&nbsp;31, 2000 and Quarterly Reports on
Form&nbsp;10-Q for the quarterly periods ended
March&nbsp;31, 2001, June&nbsp;30, 2001 and September&nbsp;30, 2001 is incorporated by reference herein and may be inspected at, and copies may be obtained from, the same places and in the same
manner as set forth under Section&nbsp;18&#151;"Additional Information." </FONT></P>

<P><FONT SIZE=2><B>17.&nbsp;&nbsp;RISK FACTORS.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information concerning risk factors included in our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2000 and our
Quarterly Report on Form&nbsp;10-Q for the quarterly period ended September&nbsp;30, 2001 is incorporated by reference herein. Additional risks and uncertainties not presently known to
us or that we currently deem immaterial also may impair our business operations. If any of the risks actually occur, our business could be harmed. In that event, the trading price of our Common Stock
could decline. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Common Stock is listed for quotation on the Nasdaq National Market System. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=26,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=777507,FOLIO='21',FILE='DISK040:[02PAL1.02PAL1091]NI1091A.;5',USER='DNICHOL',CD='25-JAN-2002;14:19' -->
<A NAME="page_ni1091_1_22"> </A>

<P><FONT SIZE=2><B>18.&nbsp;&nbsp;ADDITIONAL INFORMATION.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We recommend that you review the following materials that we have filed with the SEC before making a decision on whether to exchange your options: </FONT></P>

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>Our
Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2000, filed on March&nbsp;1, 2001, including all material incorporated by reference
therein, as amended by our Amendment to Annual Report on Form&nbsp;10-K/A for the fiscal year ended December&nbsp;31, 2000, filed on May&nbsp;1, 2001, including all material
incorporated by reference therein, and further amended by our Amendment No.&nbsp;2 to Annual Report on Form&nbsp;10-K/A for the fiscal year ended December&nbsp;31, 2000, filed on
October&nbsp;4, 2001, including all material incorporated by reference therein;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>Our
Definitive Proxy on Schedule&nbsp;14A, filed on May&nbsp;1, 2001;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD><FONT SIZE=2>Our
Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2001, filed on May&nbsp;14, 2001, including all material incorporated by reference
therein;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD><FONT SIZE=2>Our
Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2001, filed on August&nbsp;14, 2001, including all material incorporated by reference
therein;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD><FONT SIZE=2>Our
Quarterly Report on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2001, filed on November&nbsp;13, 2001, including all material incorporated by
reference therein;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>6.</FONT></DT><DD><FONT SIZE=2>Our
Current Report on Form&nbsp;8-K, filed on January&nbsp;11, 2001, and as amended by our Current Report on Form&nbsp;8-K/A, filed on October&nbsp;4,
2001;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>7.</FONT></DT><DD><FONT SIZE=2>Our
Current Report on Form&nbsp;8-K, filed on May&nbsp;23, 2001;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>8.</FONT></DT><DD><FONT SIZE=2>Our
Current Report on Form&nbsp;8-K, filed on June&nbsp;4, 2001;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>9.</FONT></DT><DD><FONT SIZE=2>Our
Current Report on Form&nbsp;8-K, filed on June&nbsp;20, 2001, as amended by our Current Report on Form&nbsp;8-K/A, filed on June&nbsp;20, 2001;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>10.</FONT></DT><DD><FONT SIZE=2>Our
Current Report on Form&nbsp;8-K, filed on July&nbsp;10, 2001, as amended by our Current Report on Form&nbsp;8-K/A, filed on August&nbsp;10, 2001,
and further amended by our Current Report on Form&nbsp;8-K/A, filed on October&nbsp;4, 2001;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>11.</FONT></DT><DD><FONT SIZE=2>Our
Current Report on Form&nbsp;8-K, filed on October&nbsp;25, 2001;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>12.</FONT></DT><DD><FONT SIZE=2>Our
Current Report on Form&nbsp;8-K, filed on January&nbsp;8, 2002;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>13.</FONT></DT><DD><FONT SIZE=2>All
other reports filed by us pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act since December&nbsp;31, 2000, including all materials incorporated by reference therein;
and
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>14.</FONT></DT><DD><FONT SIZE=2>The
description of the Common Stock contained in our Registration Statement on Form&nbsp;8-A. </FONT></DD></DL>

<P><FONT SIZE=2>The
SEC file number for these filings is 000-24006. These filings and our other SEC filings may be examined, and copies may be obtained, at the following SEC public reference rooms: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE WIDTH="70%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="49%"><FONT SIZE=2>450 Fifth Street, N.W.<BR>
Room 1024<BR>
Washington, D.C. 20549</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%"><FONT SIZE=2>500 West Madison Street<BR>
Suite 1400<BR>
Chicago, Illinois 60661</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may obtain information on the operation of the public reference rooms by calling the SEC at 1-800-SEC-0330. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
SEC filings are also available to the public on the SEC's Internet site at http://www.sec.gov. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=27,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=553616,FOLIO='22',FILE='DISK040:[02PAL1.02PAL1091]NI1091A.;5',USER='DNICHOL',CD='25-JAN-2002;14:19' -->
<A NAME="page_ni1091_1_23"> </A>
<BR>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Common Stock is quoted on the Nasdaq National Market under the symbol "INHL," and our SEC filings can be read at the following Nasdaq address: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>Nasdaq
Operations<BR>
1735 K Street, N.W.<BR>
Washington, D.C. 20006 </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will also provide without charge to each person to whom we deliver a copy of this Offer to Exchange, upon his or her written or oral request, a copy of any or all of the documents to
which we have referred you, other than exhibits to these documents (unless the exhibits are specifically incorporated by reference into the documents). Requests should be directed to: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>Associate
General Counsel<BR>
Inhale Therapeutic Systems,&nbsp;Inc.<BR>
150 Industrial Road<BR>
San Carlos, CA 94070 </FONT></P>

<P><FONT SIZE=2>or
by telephoning us at (650)&nbsp;631-3100 between the hours of 9:00&nbsp;a.m. and 5:00&nbsp;p.m., Pacific Standard Time. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
you read the documents listed in this Section&nbsp;18, you may find some inconsistencies in information from one document to another. Should you find inconsistencies between the
documents, or between a document and this Offer to Exchange, you should rely on the statements made in the most recent document. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
information contained in this Offer to Exchange about Inhale should be read together with the information contained in the documents to which we have referred you. </FONT></P>

<P><FONT SIZE=2><B>19.&nbsp;&nbsp;FORWARD-LOOKING STATEMENTS; MISCELLANEOUS.  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Offer to Exchange and our SEC reports referred to above include forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act and
Section&nbsp;21E of the Exchange Act. However, the safe harbors of Section&nbsp;27A of the Securities Act and 21E of the Exchange Act do not apply to statements made in connection with this Offer.
These forward-looking statements involve risks and uncertainties that include, among others, those set forth in Section&nbsp;17 of this document. More information about factors that potentially
could affect our financial results is included in our filings with the SEC, including our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2000, as amended, and our
Quarterly Report on Form&nbsp;10-Q for the quarterly period ended September&nbsp;30, 2001. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
at any time we become aware of any jurisdiction where the making of this Offer violates the law, we will make a good faith effort to comply with the law. If we cannot comply with the
law, the Offer will not be made to, nor will exchanges be accepted from or on behalf of, the optionholders residing in that jurisdiction. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors recognizes that the decision to accept or reject this Offer is an individual one that should be based on a variety of factors and you should consult your personal
advisors if you have questions about your financial or tax situation. The information about this Offer from Inhale is limited to this document. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE WIDTH="70%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="49%"><FONT SIZE=2>Inhale Therapeutic Systems,&nbsp;Inc.</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="49%"><FONT SIZE=2>January&nbsp;25, 2002</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=28,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=645730,FOLIO='23',FILE='DISK040:[02PAL1.02PAL1091]NI1091A.;5',USER='DNICHOL',CD='25-JAN-2002;14:19' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="CENTER"><FONT SIZE=2><B>SCHEDULE A  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> INFORMATION ABOUT THE DIRECTORS AND<BR>
EXECUTIVE OFFICERS OF INHALE  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The directors and executive officers of Inhale and their positions and offices as of January&nbsp;25, 2002 are set forth in the following table: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="26%" ALIGN="LEFT"><FONT SIZE=1><B>NAME<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="5%" ALIGN="CENTER"><FONT SIZE=1><B>AGE</B></FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="64%" ALIGN="CENTER"><FONT SIZE=1><B>POSITION(S) HELD WITH THE COMPANY</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="26%"><FONT SIZE=2>Robert B. Chess</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>44</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%" VALIGN="BOTTOM"><FONT SIZE=2>Executive Chairman of the Board</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="26%"><FONT SIZE=2>Ajit S. Gill</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>52</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%" VALIGN="BOTTOM"><FONT SIZE=2>Chief Executive Officer, President and Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="26%"><FONT SIZE=2>John S. Patton</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>55</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%" VALIGN="BOTTOM"><FONT SIZE=2>Vice President, Research and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="26%"><FONT SIZE=2>Brigid A. Makes</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>46</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%" VALIGN="BOTTOM"><FONT SIZE=2>Vice President, Finance and Administration, Chief Financial Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="26%"><FONT SIZE=2>Douglas Altschuler</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>46</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%" VALIGN="BOTTOM"><FONT SIZE=2>Vice President, General Counsel and Secretary</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="26%"><FONT SIZE=2>Stephen L. Hurst</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>46</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%" VALIGN="BOTTOM"><FONT SIZE=2>Vice President, Human Resources</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="26%"><FONT SIZE=2>Irvin Lerner</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>71</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%" VALIGN="BOTTOM"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="26%"><FONT SIZE=2>James B. Glavin</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>66</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%" VALIGN="BOTTOM"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="26%"><FONT SIZE=2>Roy A. Whitfield</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>48</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%" VALIGN="BOTTOM"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="26%"><FONT SIZE=2>Melvin Perelman</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>71</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%" VALIGN="BOTTOM"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="26%"><FONT SIZE=2>Chris Kuebler</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>48</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%" VALIGN="BOTTOM"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
address of each director and executive officer is c/o Inhale Therapeutic Systems,&nbsp;Inc., 150 Industrial Road, San Carlos, CA 94070, and the telephone number is
(650)&nbsp;631-3100. </FONT></P>

<P><FONT SIZE=2><I>BIOGRAPHIES  </I></FONT></P>

<P><FONT SIZE=2>DOUGLAS H. ALTSCHULER, J.D. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Douglas
H. Altschuler has been Vice President, General Counsel and Secretary since November&nbsp;2001. Prior to joining Inhale, Mr Altschluler served as Vice President, General Counsel
and Assistant Secretary with Axys Pharmaceuticals,&nbsp;Inc., a pharmaceutical company, from December&nbsp;2000 until November&nbsp;2001. From 1996 to 2000, Mr.&nbsp;Altschuler was Vice
President/General Counsel and Compliance Officer of Mentor Corporation, a medical device company. Prior to joining Mentor, Mr.&nbsp;Altschuler was in the private practice of law.
Mr.&nbsp;Altschuler received his J.D. from the University of Arizona School of Law and a B.S. in Chemistry and Biology from the University of Arizona. </FONT></P>

<P><FONT SIZE=2>CHRIS A. KUEBLER </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chris
A. Kuebler has been a Director since December&nbsp;2001. Mr.&nbsp;Kuebler is Chairman of the Board of Directors of Covance&nbsp;Inc., a drug development services company, and
from November&nbsp;1994 to present, has served as President and Chief Executive Officer. From March&nbsp;1993 through November&nbsp;1994, he was the Corporate Vice President, European Operations
for Abbott Laboratories&nbsp;Inc. ("ALI"), a diversified health care company. From January&nbsp;1991 until March&nbsp;1993, Mr.&nbsp;Kuebler was the Vice President, Sales and Marketing for
ALI's Pharmaceutical Division. Mr.&nbsp;Kuebler holds a Bachelor of Science degree in Biological Science from Florida State University. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
biographies for our other executive officers and directors are included in our definitive Proxy Statement for our 2001 Annual Meeting of Stockholders, filed with the SEC on
May&nbsp;1, 2001, and incorporated by reference herein. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=29,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=831274,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]NK1091A.;4',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_nm1091_1_2"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="nm1091_appendix_a_u.k._tax_consequences"> </A>
<A NAME="toc_nm1091_1"> </A>
<BR></FONT><FONT SIZE=2><B>APPENDIX&nbsp;A    <BR>    <BR>    U.K. TAX CONSEQUENCES    <BR>  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are subject to U.K. taxation, the information in this Appendix&nbsp;A provides you with certain information about the U.K. tax consequences of your
option. You should understand, however, that this tax information is not complete. Furthermore, because tax laws and regulations may change, and interpretations of these laws and regulations can
change the way the laws and regulations apply, you should consult with a tax advisor if you have questions relating to the tax consequences of your option and the sale of shares received under your
option. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options
granted to U.K. residents are either "approved options" or "unapproved options". Approved options are those options approved by the Inland Revenue that are given a certain
advantageous tax status. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that you are agreeing to cancel Eligible Options or Mandatory Exchange Options that are unapproved, your Replacement Options will also be unapproved. To the extent that you
are agreeing to cancel Eligible Options or Mandatory Exchange Options that are approved, the Company must obtain certain approvals in order to secure that your Replacement Options are also approved.
The Company is in the process of obtaining the necessary approvals but cannot guarantee that these approvals will be received by the time the Replacement Options are granted. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
tax consequences of the Offer for you are as follows: </FONT></P>


<P><FONT SIZE=2><B><I>At the Time the Options are Exchanged  </I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There should not be tax consequences for you at the time your Eligible Options or Mandatory Exchange Options are exchanged, either in the case of approved or
unapproved options. However, we recommend that you consult with your tax advisor to determine the tax consequences of accepting the Offer. </FONT></P>

<P><FONT SIZE=2><B><I>Unapproved Options  </I></B></FONT></P>


<P><FONT SIZE=2><I>Exercise of options  </I></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should you exercise an unapproved option in due course, you would at the time have to pay income tax on the amount by which the then value of the shares exceeds
the price you are paying for them. You would also have to pay employees' national insurance contributions ("NICs") on the same value, except that this will not be applicable to you if your earnings
are above the upper earnings limit for NICs. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
income tax (and NICs if applicable) would be collected from you by deduction at source. If necessary you would be required to agree to a sale of sufficient of the shares to raise the
necessary sums. </FONT></P>

<P><FONT SIZE=2><I>Sale of shares  </I></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should you sell the shares in due course, then for tax purposes you would be treated as making a capital gain of the amount (if any) by which the sale proceeds
exceed the value of the shares at the time you exercised your option. As to how this gain would be taxed, see "Both Types of Option" below. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=30,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=608420,FOLIO='2',FILE='DISK040:[02PAL1.02PAL1091]NM1091A.;4',USER='DNICHOL',CD='25-JAN-2002;14:20' -->
<A NAME="page_nm1091_1_3"> </A>
<BR>

<P><FONT SIZE=2><B><I>Approved Options  </I></B></FONT></P>

<P><FONT SIZE=2><I>Exercise of options  </I></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Replacement Option is approved, then you should not have to pay any NICs when you exercise it. You also should not have to pay any income tax provided that
you are exercising it: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>at
least three years from the date it was granted, and
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>at
least three years from the last occasion on which you exercised, without having to pay income tax, any share option which is approved by the Inland Revenue. This includes options
granted under other plans or even by different companies, except that it does not include savings related share options. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
however, you exercise an approved option outside these periods, you would have to pay income tax (but not NICs) as described above for unapproved options, except that this will not
be paid by deduction at source; rather the Inland Revenue would assess this amount in due course. </FONT></P>


<P><FONT SIZE=2><I>Sale of shares  </I></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In due course, should you sell any shares that you have acquired by exercising an approved option, you would be treated as making a capital gain on the amount (if
any) by which the sale proceeds exceed: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>the
amount you paid for the shares, if you did not have to pay income tax when you exercised the option; or
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>if
you did, the value of the shares when you exercised the option. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
to how this gain would be taxed, see "Both Types of Option" below. </FONT></P>


<P><FONT SIZE=2><B><I>Both Types of Option  </I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you sell shares, then as explained above you may be treated as making a capital gain for tax purposes (the preceding paragraphs explain how the amount of the
gain is calculated). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
so, you would have to pay capital gains tax ("CGT") on this amount at whatever is your top rate of tax, except that: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>During
the course of the tax year you do not have to pay CGT on gains up to a certain amount. This amount varies from year to year but in the tax year 2001-02 is
&pound;7,500.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>There
are also provisions whereby the longer you hold the shares the less CGT you may have to pay. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
note that the rules outlining CGT are complex and there are provisions under which you may be treated as selling a different "parcel" of shares of Inhale's stock from those that
you thought you were selling. For example, if you were to exercise an option to purchase 1,000 shares of Inhale common stock and then sell 1,000 shares of Inhale stock on the market it is possible
that you would be treated for CGT purposes as having sold a different parcel of 1,000 shares from the 1,000 shares underlying the stock option you exercised if you had bought or sold Inhale's stock in
the past or buy or sell additional parcels of Inhale's stock in the future. We recommend that you consult with a tax advisor if you have questions relating to the tax consequences of your option and
the sale of shares received under your option. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=31,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=492462,FOLIO='3',FILE='DISK040:[02PAL1.02PAL1091]NM1091A.;4',USER='DNICHOL',CD='25-JAN-2002;14:20' -->
<BR>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<P><br><A NAME="02PAL1091_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_na1091_1">TABLE OF CONTENTS</A></FONT><BR>

<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_nm1091_1">APPENDIX A U.K. TAX CONSEQUENCES</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DNICHOL,SEQ=,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A)(1)(B)
<SEQUENCE>4
<FILENAME>a2068683zex-99_a1b.htm
<DESCRIPTION>EXHIBIT 99(A)(1)(B)
<TEXT>
<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P ALIGN="RIGHT"><FONT SIZE=2><B>Exhibit 99(a)(1)(B)  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B><I>Memorandum</I></B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="9%"><FONT SIZE=2><BR>
To:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><BR>
Employees</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="9%"><FONT SIZE=2><BR>
From:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><BR>
Ajit Gill</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="9%"><FONT SIZE=2><BR>
Date:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><BR>
January&nbsp;25, 2002</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="9%"><BR><FONT SIZE=2><B>Subject:</B></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><B><BR>
Stock Option Offer to Exchange</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>Inhale
is pleased to announce that its Board of Directors has approved management's proposal to allow eligible employees the opportunity to exchange outstanding stock options granted prior to
July&nbsp;24, 2001, other than Evergreen Options, with exercise prices per share greater than or equal to $25.00 granted under Inhale's 2000 Non-Officer Equity Incentive Plan for
replacement options to purchase shares of the company's Common Stock. This is a one-time opportunity designed to refocus everyone's efforts on driving shareholder value. The key features
of this offer are summarized below. </FONT></P>

<P><FONT SIZE=2>Inhale
is offering employees of Inhale and its subsidiaries the opportunity to exchange eligible options on a one-for-two (1:2) basis. Thus, for those employees who elect to
participate in the offer, on August&nbsp;26, 2002 (or a later date if the offer is extended), Inhale will grant you a replacement option covering fifty percent (50%) of the number of shares of
common stock subject to the options that you exchanged. If you wish to accept this offer with respect to your eligible options, you must also exchange all mandatory exchange options. Mandatory
exchange options are all options that were granted to you
on or after July&nbsp;24, 2001, including options with an exercise price of less than $25.00 per share, Evergreen Options, and options granted under plans other than the 2000 Non-Officer
Equity Incentive Plan. Mandatory exchange options will be exchanged on a one-for-one (1:1) basis. Thus, for those employees who elect to exchange eligible options, on
August&nbsp;26, 2002 (or a later date if the offer is extended), Inhale will grant you a replacement option covering one hundred percent (100%) of the number of shares of common stock subject to the
mandatory exchange options that were cancelled. </FONT></P>

<P><FONT SIZE=2>There
are certain other conditions to exchanging your options that are set forth in detail in the offer to exchange and accompanying documents. In particular, if you elect to exchange any eligible
option or are required to exchange any mandatory exchange option, the entire option must be exchanged. In addition, you must be continuously employed by Inhale or one of its subsidiaries through the
date of grant of the replacement options in order to receive any replacement grant. </FONT></P>

<P><FONT SIZE=2>Your
replacement options will be granted on August&nbsp;26, 2002 (or a later date if the offer is extended) with an exercise price equal to the closing price of Inhale's common stock on the day
prior to the date of grant. Please note that for accounting purposes we must wait six months and one day after you exchange your options to grant you the replacement options. This also means that if
you accept this offer the Company cannot grant you any new options between February&nbsp;25, 2002 and August&nbsp;26, 2002. Your replacement options will have an equivalent vesting schedule on a
percentage basis as the eligible options and mandatory exchange options that you exchange. The vesting commencement date for the replacement options will be the original vesting commencement date of
the eligible options or mandatory exchange options that were cancelled. The replacement options will expire approximately ten years from the grant date of the replacement options so long as you remain
continuously employed by Inhale or its subsidiaries. </FONT></P>

<P><FONT SIZE=2>Program
participation is entirely voluntary, and although our Board of Directors has approved this offer, Inhale makes no recommendation as to whether or not you should tender your options for
exchange. You must make your own decision whether to tender your options. Participation involves certain risks that are discussed in the documents provided. Inhale is making this offer upon the terms
and subject to the conditions described in the offer to exchange and accompanying documents. You should carefully read the enclosed materials and understand all aspects of the exchange offer before </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="3",CHK=969388,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]OA1091A.;16',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<BR>

<P><FONT SIZE=2>
deciding whether to participate. In addition, we recommend that you consult with your tax and financial advisors before you make your decision regarding participation. </FONT></P>

<P><FONT SIZE=2>If
you decide to participate in this offer, please follow the procedures outlined in the enclosed documents. The Offer to Exchange is a topic for discussion at today's scheduled meeting for San Carlos
employees and we will hold additional meetings for other employees in the coming days. Details about these meetings will be distributed prior to each meeting. If you have any questions about this
offer please email your questions to Steve Hurst or Bob Harper at </FONT><FONT SIZE=2><I>exchange@inhale.com</I></FONT><FONT SIZE=2>. Alternatively, you may reach Steve Hurst via telephone at
(650)&nbsp;631-3118 or Bob Harper at (650)&nbsp;631-3222. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="3",CHK=350491,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]OA1091A.;16',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<BR>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DNICHOL,SEQ=,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="3" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A)(1)(C)
<SEQUENCE>5
<FILENAME>a2068683zex-99_a1c.htm
<DESCRIPTION>EXHIBIT 99(A)(1)(C)
<TEXT>
<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_oc1091_1_1"> </A> </FONT> <FONT SIZE=2><B>Exhibit 99(a)(1)(C)  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>SUMMARY OF TERMS OF OPTION EXCHANGE  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> RESPONSE DUE BEFORE MIDNIGHT, PACIFIC STANDARD TIME,<BR>
ON MONDAY, FEBRUARY 25, 2002, UNLESS THE OFFER IS EXTENDED  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You must check your election, sign and date the Election Form and return the Election Form to Steve Hurst or Bob Harper at Inhale's corporate headquarters in San
Carlos, California </FONT><FONT SIZE=2><B><I>before</I></B></FONT><FONT SIZE=2> midnight, Pacific Standard Time, on February&nbsp;25, 2002 (or a later expiration date if the offer is extended). If you
have any questions regarding the process for returning the Election Form, please contact Steve Hurst or Bob Harper via e-mail at </FONT> <FONT SIZE=2><I>exchange@inhale.com</I></FONT><FONT SIZE=2>. Alternatively, you may reach Steve Hurst via
telephone at (650)&nbsp;631-3118 or Bob Harper at
(650)&nbsp;631-3222. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following summarizes the principal terms and conditions of the Offer to Exchange outstanding stock options (the "Offer to Exchange," which, as it may be amended from time to time,
constitutes the "Offer"). Please also read the enclosed Offer to Exchange in its entirety, because the information in this summary is not complete and does not contain all of the information relevant
to your decision to participate in the Offer. </FONT></P>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Which Options are Eligible Options and Which Options are Mandatory Exchange Options?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All outstanding
options to purchase shares of Common Stock (the "Common Stock") granted prior to July&nbsp;24, 2001, other than Evergreen Options (as defined below), with exercise prices per share greater than or
equal to $25.00 per share granted under the 2000 Non-Officer Equity Incentive Plan, as amended (the "Plan"), and held by employees of Inhale Therapeutic Systems,&nbsp;Inc. (the "Company"
or "Inhale") or its subsidiaries (each an "Eligible Participant") are "Eligible Options." "Evergreen Options" are options to purchase Common Stock of the Company granted under the Plan to employees
that vest at the rate of 1/12<SUP>th</SUP> per month over twelve months, beginning at the end of the vesting period of a previously-granted option. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you wish to accept this Offer with respect to any or all of your Eligible Options, you must exchange </FONT><FONT SIZE=2><B><I>all</I></B></FONT><FONT SIZE=2> options to acquire Common
Stock of the Company granted to you since July&nbsp;24, 2001, including, without limitation, options with an exercise price of $25.00 per share or less, Evergreen Options, and options granted
pursuant to plans other than the 2000 Non-Officer Equity Incentive Plan (the "Mandatory Exchange Options"). For example, if you were granted an option on May&nbsp;9, 2001 with an
exercise price of $31.00 per share and a second option on October&nbsp;2, 2001 with an exercise price of $14.00 per share, and you elect to accept this Offer with respect to the Eligible Option
granted on May&nbsp;9, 2001, you must exchange </FONT><FONT SIZE=2><B><I>all</I></B></FONT><FONT SIZE=2> of your shares subject to the Mandatory Exchange Option granted on October&nbsp;2, 2001 as well. </FONT></P>


<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Who Can Participate in the Exchange?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;You can elect to surrender for cancellation any Eligible Options
if you are an Eligible Participant on February&nbsp;25, 2002. Termination of your employment with the Company or its subsidiaries on or before February&nbsp;25, 2002 will automatically revoke any
election that you make to participate in the Offer. Executive officers of the Company are not eligible to participate in the exchange. </FONT></P>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;How Many Replacement Options Will I Receive?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company is conducting the exchange with respect to
Eligible Options on a one-for-two (1:2) basis. Thus, for those employees who elect to participate in the Offer, on August&nbsp;26, 2002 (or a later date if Inhale extends the
Offer), the Company will grant you a Replacement Option covering fifty percent (50%) of the number of shares subject to your Eligible Options that were cancelled (so long as your employment or service
with the Company or one of its subsidiaries continues through that date). THEREFORE, FOR EVERY TWO SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF ELIGIBLE OPTIONS THAT YOU </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="4",CHK=981647,FOLIO='1',FILE='DISK040:[02PAL1.02PAL1091]OC1091A.;6',USER='DNICHOL',CD='25-JAN-2002;14:23' -->
<A NAME="page_oc1091_1_2"> </A>
<BR>

<P><FONT SIZE=2>
EXCHANGE, THE COMPANY WILL GRANT YOU A REPLACEMENT OPTION TO ACQUIRE ONE SHARE OF COMMON STOCK. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is conducting the exchange with respect to Mandatory Exchange Options on a one-for-one (1:1) basis. Thus, for employees that elect to exchange any
Eligible Options pursuant to the Offer, on August&nbsp;26, 2002 (or a later date if Inhale extends the Offer), the Company will grant you a Replacement Option covering one hundred percent (100%) of
the number of shares subject to your Mandatory Exchange Options that were cancelled (so long as your employment or service with the Company or one of its subsidiaries continues through that date). If
you do not elect to exchange any Eligible Options, no Mandatory Exchange Options will be exchanged. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
for the number of shares subject to the Replacement Options issued in exchange for Eligible Options and the exercise price of the Replacement Options, the terms and conditions of
your Replacement Options will be substantially the same as your Eligible Options and Mandatory Exchange Options that were cancelled. The exercise price per share of the Replacement Options will be
equal to the closing price of the Company's Common Stock as reported on the Nasdaq National Market on the last market trading day prior to the date of grant. The number of option shares to be
represented by the Replacement Options will be adjusted for any stock splits, stock dividends, recapitalizations or similar transactions that may occur between February&nbsp;25, 2002 (or a later
expiration date if Inhale extends the Offer) and the date the Replacement Options are granted. </FONT></P>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When Will I Receive My Replacement Options?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Replacement Options will be granted on
August&nbsp;26, 2002 (or a later date if Inhale extends the Offer). We expect the stock option agreements to be distributed promptly following the date of grant. Please note that if you accept the
Offer and exchange all or part of your Eligible Options, we cannot for accounting reasons grant you any additional stock options until, at the earliest, August&nbsp;26, 2002. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>What Happens if I Accept the Offer and Tender One or More of My Eligible Options but I am no Longer Employed by the Company on the Grant Date of the Replacement
Options?</I></B></FONT><FONT SIZE=2> If you accept the Offer to exchange any of your Eligible Options and are subsequently, for any reason, no longer employed by Inhale or one of its subsidiaries on the
grant date for the Replacement Options, you will not receive any Replacement Options for your Eligible Options or Mandatory Exchange Options that have been cancelled, and your cancelled options will
not be reinstated. Participation in this Offer does not confer upon you the right to remain employed by us. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>If I am a U.K. or German Employee, am I Subject to the Same Terms as Described in the Offer to Exchange?</I></B></FONT><FONT SIZE=2> If you are a U.K. employee who
holds options under the Plan, you are also subject to the terms of this Offer as described in the Offer to Exchange. U.K. employees should refer to </FONT> <FONT SIZE=2><B>Appendix&nbsp;A</B></FONT><FONT SIZE=2> of the Offer to Exchange entitled
"U.K. Tax Consequences" for a discussion of the tax consequences of accepting or rejecting the
Replacement Options under U.K. law. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>What Will Be the Exercise Price of the Replacement Options?</I></B></FONT><FONT SIZE=2> The exercise price per share of the Replacement Options will be equal to the
closing price of the Company's Common Stock as reported on the Nasdaq National Market on the last market trading day prior to the date of grant. We cannot guarantee that the Replacement Options will
have a lower exercise price than the Eligible Options or Mandatory Exchange Options. </FONT></P>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What Will Be the Vesting Period of the Replacement Options?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each Replacement Option will have the
same vesting schedule, on a percentage basis, as your applicable Eligible Option or Mandatory Exchange Option that is exchanged. The vesting commencement date for each Replacement Option will be the
original vesting commencement date of your applicable Eligible Option or Mandatory Exchange Option. The number of shares of Common Stock issuable upon exercise of the Replacement Option that will be
vested as of the date the Replacement Option is granted will be equal to the product of (A)&nbsp;the percentage of shares issuable upon exercise of the exchanged Eligible Option or Mandatory </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="4",CHK=318165,FOLIO='2',FILE='DISK040:[02PAL1.02PAL1091]OC1091A.;6',USER='DNICHOL',CD='25-JAN-2002;14:23' -->
<A NAME="page_oc1091_1_3"> </A>
<BR>

<P><FONT SIZE=2>
Exchange Option that would have been vested as of such date and (B)&nbsp;the total number of shares issuable upon exercise of the Replacement Option. Thereafter, the Replacement Option will
continue to vest monthly in the same percentage amount as the applicable Eligible Option or Mandatory Exchange Option that was exchanged. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
an example, assume that an Eligible Option to purchase 1,000 shares of Common Stock that would have been 50% vested as of August&nbsp;26, 2002 and thereafter would have vested 5%
per month until fully vested is exchanged as part of this Offer. The Replacement Option to purchase 500 shares of Common Stock granted in exchange for such exchanged Eligible Option would be vested as
to 250 shares (50%) as of the date of grant and would thereafter vest as to 25 shares (5%) per month until fully vested. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a further example, assume that a Mandatory Exchange Option to purchase 1,000 shares of Common Stock that would have been 50% vested as of August&nbsp;26, 2002 and thereafter would
have vested 5% per month until fully vested is exchanged as part of this Offer. The Replacement Option to purchase 1,000 shares of Common Stock granted in exchange for such Mandatory Exchange Option
would be vested as to 500 shares (50%) as of the date of grant and would thereafter vest as to 50 shares (5%) per month until fully vested. </FONT></P>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What is the Expiration Date of the Replacement Options?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Replacement Options will expire at
11:59&nbsp;p.m., Pacific Time, on the day prior to the ten-year anniversary of the grant date of the Replacement Options (so long as you remain employed by or continue service with the
Company or one of its subsidiaries). </FONT></P>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Does the Company Have a Recommendation with Respect to the Offer?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;While the Company's Board of
Directors has approved the Offer, each individual holding Eligible Options will need to arrive at his or her own decision whether or not to participate in the Offer based on individual circumstances.
We cannot guarantee that the Replacement Options will have a lower exercise price than the Eligible Options or the Mandatory Exchange Options. The Board of Directors recognizes that the decision to
accept is an individual one that should be based on a variety of factors and you should consult with your personal advisors if you have questions about your financial or tax situation. </FONT></P>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What Happens to My Eligible Options if I Accept the Offer?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you accept the Offer, the Eligible
Options that you choose to exchange will be cancelled, and you will have no further right or interest in them, whether vested or unvested. In addition, if you accept the Offer, in order to avoid
adverse accounting consequences to the Company, you must exchange all Mandatory Exchange Options held by you. Mandatory Exchange Options are all options granted to you on or after July&nbsp;24,
2001, including, without limitation, options with an exercise price of less than $25.00 per share, Evergreen Options, and options granted pursuant to plans other than the 2000 Non-Officer
Equity Incentive Plan. If you accept the Offer, you </FONT><FONT SIZE=2><B><I>will not be</I></B></FONT><FONT SIZE=2> eligible to receive any new options before August&nbsp;26, 2002, at the earliest. If
you do not elect to exchange any Eligible Options, no Mandatory Exchange Options will be exchanged. </FONT></P>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What is the Tax Treatment of the Replacement Options?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each Replacement Option granted to U.S.
employees will be a nonqualified stock option and, under U.S. tax laws, </FONT><FONT SIZE=2><B><I>will not</I></B></FONT><FONT SIZE=2> be eligible for the special tax treatment that applies to incentive
stock options. You should consult with your tax advisor with respect to all tax matters. </FONT></P>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What are the Tax Consequences of the Offer on Non-U.S. Employees?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you are a
non-U.S. employee, we also recommend that you consult with your tax advisor to determine the tax consequences of the Offer. U.K. employees should refer to </FONT> <FONT SIZE=2><B>Appendix&nbsp;A</B></FONT><FONT SIZE=2> of the Offer to Exchange
entitled "U.K. Tax Consequences" for a discussion of the tax consequences of accepting or rejecting the
Replacement Options under U.K. law. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=3,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="4",CHK=107013,FOLIO='3',FILE='DISK040:[02PAL1.02PAL1091]OC1091A.;6',USER='DNICHOL',CD='25-JAN-2002;14:23' -->
<A NAME="page_oc1091_1_4"> </A>
<BR>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What Happens if I Do Not Accept the Offer?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Nothing. If you do not accept the Offer, or if we do not
accept the options you elect to exchange (see Question 23 in the Offer to Exchange), you will keep all of your Eligible Options and Mandatory Exchange Options, and you will not receive any Replacement
Options under this Offer. In that case, no changes will be made to your Eligible Options or your Mandatory Exchange Options. </FONT></P>


<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under What Circumstances Would the Company Not Accept My Eligible Options?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We currently expect that
we will accept promptly after the expiration date all Eligible Options that are properly submitted to be exchanged and for which the election has not been validly withdrawn. We may, however, reject
any or all Election Forms, Notice of Change in Election Forms or exchanged options to the extent that we determine they were not properly executed or delivered, to the extent that we determine it is
unlawful to accept the exchanged options or to the extent certain conditions exist which in our reasonable judgment makes it inadvisable to proceed with the Offer (see Sections 3, 5 and 6 in the Offer
to Exchange). </FONT></P>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Can I Change My Mind?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Yes. After you turn in the Election Form, you can change your election at any
time on or prior to the February&nbsp;25, 2002 deadline by delivering a signed Notice of Change in Election Form to Steve Hurst or Bob Harper </FONT><FONT SIZE=2><B><I>before</I></B></FONT><FONT SIZE=2>
midnight, Pacific Standard Time, on February&nbsp;25, 2002 (or a later expiration date if Inhale extends the offer). Please note that if you previously elected to reject the Offer and wish to change
your election and accept the Offer, you must also fill out and deliver a new Election Form along with the Notice of Change in Election. If you have any questions regarding the process for returning
the Election Form or need to be provided with a Notice of Change in Election Form, please contact Steve Hurst or Bob Harper via e-mail at </FONT> <FONT SIZE=2><I>exchange@inhale.com</I></FONT><FONT SIZE=2>. Alternatively, you may reach Steve Hurst
via telephone at (650)&nbsp;631-3118 or Bob Harper at
(650)&nbsp;631-3222. These forms have also been included in the information distributed to you. </FONT></P>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After I Am Granted Replacement Options, What Happens if Those Replacement Options End Up Underwater?</I></B></FONT><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;We are conducting this Offer only at this time. This, therefore, is considered a one-time offer and is not expected to be repeated again in the future. As your stock options
granted by Inhale generally are valid for up to ten years from the date of initial grant, subject to continued service with the Company, the price of our Common Stock may appreciate over the long term
even if your options are underwater for some period of time after the grant date of the Replacement Options. HOWEVER, WE CAN PROVIDE NO ASSURANCE AS TO THE PRICE OF OUR COMMON STOCK AT ANY TIME IN THE
FUTURE, AND NOTHING CONTAINED IN THIS DOCUMENT OR THE OTHER DOCUMENTS YOU RECEIVE RELATING TO THIS OFFER SHOULD BE INTERPRETED IN ANY WAY AS A CLAIM RELATING TO THE FUTURE PROSPECTS OF THE PRICE OF
OUR
COMMON STOCK, NOR SHOULD ANY INFERENCE ABOUT SUCH FUTURE PROSPECTS BE DRAWN FROM ANYTHING CONTAINED HEREIN OR THEREIN. </FONT></P>

<P><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What Do I Need To Do?</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Whether you accept the Offer or not, you need to make your election, sign the
Election Form and ensure delivery of the Election Form to Steve Hurst or Bob Harper at Inhale before midnight, Pacific Standard Time, on February&nbsp;25, 2002 (or a later expiration date if Inhale
extends the Offer). The Election Form may be sent via mail, courier, electronic mail or facsimile. Your Election Form must be received before midnight, Pacific Standard Time, on February&nbsp;25,
2002 (or a later expiration date if Inhale extends the Offer), not merely placed in the mail or other delivery system by the expiration time. If sent by email or facsimile, originals should be
promptly sent by mail, courier or hand-delivered as soon as possible thereafter. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=4,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="4",CHK=214587,FOLIO='4',FILE='DISK040:[02PAL1.02PAL1091]OC1091A.;6',USER='DNICHOL',CD='25-JAN-2002;14:23' -->
<BR>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DNICHOL,SEQ=,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="4" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A)(1)(D)
<SEQUENCE>6
<FILENAME>a2068683zex-99_a1d.htm
<DESCRIPTION>EXHIBIT 99(A)(1)(D)
<TEXT>
<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P ALIGN="RIGHT"><FONT SIZE=2><B>Exhibit 99(a)(1)(D)  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>ELECTION FORM  </B></FONT></P>

<P><FONT SIZE=2>Inhale
Therapeutic Systems,&nbsp;Inc.<BR>
150 Industrial Road<BR>
San Carlos, CA 94070<BR>
Attn: Steve Hurst or Bob Harper </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have received Inhale Therapeutic Systems,&nbsp;Inc.'s ("Inhale or the "Company") Offer to Exchange and Summary of Terms dated January&nbsp;25, 2002, sent to employees of Inhale or
its subsidiaries that hold options to purchase Common Stock of the Company granted prior to July&nbsp;24, 2001, other than Evergreen Options (as defined in the Offer to Exchange), with exercise
prices per share greater than or equal to $25.00 per share granted under Inhale's 2000 Non-Officer Equity Incentive Plan, as amended ("Eligible Options"). Defined terms not explicitly
defined herein but defined in the Offer to Exchange, shall have the same definitions as in the Offer to Exchange. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the terms of the Offer, I elect to have one or more Eligible Options held by me, as specified below, cancelled in exchange for a right to receive Replacement Options, as that
term is defined in the Offer. I hereby agree that, unless I revoke my election before midnight, Pacific Standard Time, on February&nbsp;25, 2002 (or a later expiration date if Inhale extends the
Offer), my election will be irrevocable, and if accepted by Inhale, such surrendered Eligible Options will be cancelled in their entirety. I understand that, subject to my continuous employment with
Inhale or its subsidiaries through the grant date of the Replacement Option, I will have the right to receive a Replacement Option, to be granted on August&nbsp;26, 2002 (or a later date if Inhale
extends the Offer), covering fifty percent (50%) of the number of shares of Common Stock subject to my Eligible Options that were cancelled. </FONT></P>

<P><FONT SIZE=2>[&nbsp;&nbsp;&nbsp;&nbsp;]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>I ACCEPT THE OFFER AND HEREBY ELECT TO CANCEL</B></FONT><FONT SIZE=2>, upon the terms and conditions stated in the Offer,
the following Eligible Option(s): </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="13%" ALIGN="LEFT"><FONT SIZE=1><B>Option Number<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="13%" ALIGN="CENTER"><FONT SIZE=1><B>Option Grant<BR>
Date</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="17%" ALIGN="CENTER"><FONT SIZE=1><B>Exercise Price of<BR>
Option</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="13%" ALIGN="CENTER"><FONT SIZE=1><B>Option Number</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="13%" ALIGN="CENTER"><FONT SIZE=1><B>Option Grant<BR>
Date</B></FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="17%" ALIGN="CENTER"><FONT SIZE=1><B>Exercise Price of<BR>
Option</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>I understand that by accepting this Offer any options granted to me on or after July&nbsp;24, 2001, including, without limitation, options with an exercise
price of $25.00 per share or less, Evergreen Options, and options granted pursuant to plans other than the 2000 Non-Officer Equity Incentive Plan (the "Mandatory Exchange Options") will
automatically be surrendered for cancellation under the Offer even if such options are not listed above.</B></FONT><FONT SIZE=2> With respect to Mandatory Exchange Options, I understand that, subject
to my continuous employment with Inhale or its subsidiaries through the grant date of the Replacement Option, I will have the right to receive a Replacement Option, to be granted on August&nbsp;26,
2002 (or a later date if Inhale extends the Offer), covering one hundred percent (100%) of the number of shares of Common Stock subject to my Mandatory Exchange Options that were cancelled. I agree to
deliver to Inhale the original stock option grant form(s) for my Eligible Options or Mandatory Exchange Options, upon request. I acknowledge that I will have no right to exercise all or any part of
any cancelled options after the date of this election (unless I revoke this election), and that such options will be cancelled. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
further acknowledge and agree that neither the ability to participate in the Offer nor actual participation in the Offer shall be construed as a right to continued employment with
Inhale (except on an at will basis). I agree that Inhale has made no representations or warranties to me regarding this Offer or the future pricing of Inhale's stock, and that my participation in this
Offer is at my own discretion. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="5",CHK=929936,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]OE1091A.;7',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>I AGREE THAT INHALE SHALL NOT BE LIABLE FOR ANY COSTS, TAXES, LOSS OR DAMAGE THAT I MAY INCUR THROUGH MY ELECTION TO PARTICIPATE IN THIS
OFFER.</B></FONT></P>

<P><FONT SIZE=2>[&nbsp;&nbsp;&nbsp;&nbsp;]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>I DO NOT ACCEPT THE OFFER</B></FONT><FONT SIZE=2> to exchange options. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2>Date:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>Optionee Signature</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Name:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> (Please print)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Inhale hereby agrees and accepts this Election Form, and such acceptance shall be binding on Inhale's successors, assigns and legal
representatives:</B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3><FONT SIZE=2><B>INHALE THERAPEUTIC SYSTEMS, INC.</B></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="6%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
Date:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="6%"><FONT SIZE=2><BR>
Title:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="5",CHK=262418,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]OE1091A.;7',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DNICHOL,SEQ=,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="5" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A)(1)(E)
<SEQUENCE>7
<FILENAME>a2068683zex-99_a1e.htm
<DESCRIPTION>EXHIBIT 99(A)(1)(E)
<TEXT>
<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P ALIGN="RIGHT"><FONT SIZE=2><B>Exhibit 99(a)(1)(E)  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>NOTICE OF CHANGE IN ELECTION FROM ACCEPT TO REJECT  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you previously elected to accept Inhale Therapeutic Systems,&nbsp;Inc.'s ("Inhale") Offer to Exchange, and you would like to change your election and reject
the Offer, you must sign this Notice and return it to Steve Hurst or Bob Harper at Inhale before midnight, Pacific Standard Time, on February&nbsp;25, 2002, unless the Offer is extended. This Notice
of Change in Election may be sent via mail or courier to the attention of Steve Hurst or Bob Harper at Inhale's corporate offices in San Carlos, California. Notices will also be accepted via facsimile
at (650)&nbsp;620-5360 or via email at </FONT><FONT SIZE=2><I>exchange@inhale.com</I></FONT><FONT SIZE=2>. If you do elect to return this Notice via email or facsimile, please provide
us with an original executed copy as soon as possible. If you have questions regarding the process for returning this Notice, please contact Steve Hurst or Bob Harper via email at </FONT> <FONT SIZE=2><I>exchange@inhale.com</I></FONT><FONT SIZE=2>.
Alternatively, you may reach Steve Hurst via telephone at (650)&nbsp;631-3118 or Bob Harper at
(650)&nbsp;631-3222. </FONT></P>

<P><FONT SIZE=2>To
Inhale: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
previously received a copy of the Offer to Exchange (dated January&nbsp;25, 2002), the cover letter, the Summary of Terms and an Election Form. I signed and returned the Election
Form, in which I elected to accept Inhale's Offer to Exchange. </FONT><FONT SIZE=2><B>I now wish to change that election, and reject Inhale's Offer to Exchange.</B></FONT><FONT SIZE=2> I understand
that by signing this Notice and delivering it pursuant to the instructions above, I will be able to withdraw my acceptance of the Offer, and reject the Offer to Exchange instead. I have read and
understand all of the terms and conditions of the Offer to Exchange. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
understand that in order to reject the Offer, I must sign and deliver this Notice to Steve Hurst or Bob Harper at Inhale's corporate offices in San Carlos, California before midnight,
Pacific Standard Time, on February&nbsp;25, 2002, or if Inhale extends the deadline to exchange options, before the extended expiration of the Offer. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
rejecting the Offer to Exchange, I understand that I will not receive any Replacement Options, and I will keep my Eligible Options and Mandatory Exchange Options. These options will
continue to be governed by the stock option plan under which these options were granted and the existing option agreements between Inhale and me. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have completed and signed the following exactly as my name appears on my original Election Form. By executing this form, I hereby bind my successors, assigns and legal representatives. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
</FONT><FONT SIZE=2><B><I>do not</I></B></FONT><FONT SIZE=2> accept the offer to exchange options. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2>Date:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>Optionee Signature</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Name:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> (Please print)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2><B>Inhale hereby agrees and accepts this Notice of Change in Election from Accept to Reject, and such acceptance shall be binding on Inhale's successors, assigns and legal
representatives:</B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3><FONT SIZE=2><B>INHALE THERAPEUTIC SYSTEMS, INC.</B></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="40%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="6%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
Date:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="6%"><FONT SIZE=2><BR>
Title:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="40%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="6",CHK=705364,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]OG1091A.;3',USER='ESHERMA',CD='25-JAN-2002;04:36' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DNICHOL,SEQ=,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="6" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A)(1)(F)
<SEQUENCE>8
<FILENAME>a2068683zex-99_a1f.htm
<DESCRIPTION>EXHIBIT 99(A)(1)(F)
<TEXT>
<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P ALIGN="RIGHT"><FONT SIZE=2><B>Exhibit 99(a)(1)(F)  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>NOTICE OF CHANGE IN ELECTION FROM REJECT TO ACCEPT  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you previously elected to reject Inhale Therapeutic Systems,&nbsp;Inc.'s ("Inhale") Offer to Exchange, and you would like to change your election and accept
the Offer, you must sign this Notice </FONT><FONT SIZE=2><B><I>and</I></B></FONT><FONT SIZE=2> a new Election Form and return both to Steve Hurst or Bob Harper at Inhale before midnight, Pacific Standard
Time, on February&nbsp;25, 2002, unless the Offer is extended. This Notice of Change in Election may be sent via mail or courier to the attention of Steve Hurst or Bob Harper at Inhale's corporate
offices in San Carlos, California. Notices will also be accepted via facsimile at (650)&nbsp;620-5360 or via email at </FONT><FONT SIZE=2><I>exchange@inhale.com</I></FONT><FONT SIZE=2>.
If you do elect to return this Notice and a new Election Form&nbsp;via email or facsimile, please provide us with original executed copies of both documents as soon as possible. If you have
questions regarding the process for returning this Notice, please contact Steve Hurst or Bob Harper via email at </FONT><FONT SIZE=2><I>exchange@inhale.com</I></FONT><FONT SIZE=2>. Alternatively, you
may reach Steve Hurst via telephone at (650)&nbsp;631-3118 or Bob Harper at (650)&nbsp;631-3222. </FONT></P>

<P><FONT SIZE=2>To
Inhale: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
previously received a copy of the Offer to Exchange (dated January&nbsp;25, 2002), the cover letter, the Summary of Terms and an Election Form. I signed and returned the Election
Form, in which I elected to reject Inhale's Offer to Exchange. </FONT><FONT SIZE=2><B>I now wish to change that election, and accept Inhale's Offer to Exchange</B></FONT><FONT SIZE=2>. I understand
that by signing this Notice and a new Election Form and delivering both forms pursuant to the instructions above, I will be able to withdraw my rejection of the Offer and accept the Offer to Exchange
instead. I have read and understand all of the terms and conditions of the Offer to Exchange. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
understand that in order to accept the Offer, I must sign and deliver this Notice and a new Election Form to Steve Hurst or Bob Harper at Inhale's corporate offices in San Carlos,
California before midnight, Pacific Standard Time, on February&nbsp;25, 2002, or if Inhale extends the deadline to exchange options, before the extended expiration of the Offer. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have completed and signed the following exactly as my name appears on my original Election Form. By executing this form, I hereby bind my successors, assigns and legal representatives. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
</FONT><FONT SIZE=2><B><I>accept</I></B></FONT><FONT SIZE=2> the offer to exchange options as indicated in the Election Form completed as of the date hereof. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Optionee Signature</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2>Date:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Name:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="39%" ALIGN="CENTER"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> (Please print)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=7 VALIGN="TOP"><BR><FONT SIZE=2><B>Inhale hereby agrees and accepts this Notice of Change in Election from Reject to Accept, and such acceptance shall be binding on Inhale's successors, assigns and legal representatives:</B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 VALIGN="TOP"><BR><FONT SIZE=2><B>INHALE THERAPEUTIC SYSTEMS, INC.</B></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%" VALIGN="TOP"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="39%" VALIGN="TOP"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
Date:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Title:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="39%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="7",CHK=164278,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]OI1091A.;3',USER='ESHERMA',CD='25-JAN-2002;04:36' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DNICHOL,SEQ=,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="7" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A)(1)(G)
<SEQUENCE>9
<FILENAME>a2068683zex-99_a1g.htm
<DESCRIPTION>EXHIBIT 99(A)(1)(G)
<TEXT>
<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P ALIGN="RIGHT"><FONT SIZE=2><B>Exhibit 99(a)(1)(G)  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="50%" ALIGN="CENTER"><BR><FONT SIZE=2><B>
<IMG SRC="g1008932.jpg" ALT="LOGO" WIDTH="363" HEIGHT="342">
 </B></FONT></TD>
<TD WIDTH="50%" ALIGN="RIGHT" VALIGN="CENTER"><BR><FONT SIZE=2><B>
<IMG SRC="g16941.jpg" ALT="LOGO" WIDTH="154" HEIGHT="66">
 </B></FONT><FONT SIZE=2><BR>
<BR>
<BR></FONT> <FONT SIZE=6><B>Employee Stock Option<BR>
Exchange Offer 2002<BR> </B></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=56492,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]KC1091A.;7',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_ke1091_1_1"> </A> </FONT> <FONT SIZE=6><B>This presentation outlines our proposed offer to address underwater stock options  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>Discuss
issues related to current stock option grants and their value </FONT><FONT SIZE=6>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>Outline
Inhale's initiative to preserve the value the stock option plan is intended to deliver </FONT> <FONT SIZE=6>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>Highlight
a choice you will be asked to make regarding your stock option grant(s),
granted under the 2000 Non-Officer Equity Incentive Plan </FONT></DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=2,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=604433,FOLIO='1',FILE='DISK040:[02PAL1.02PAL1091]KE1091A.;2',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<UL>
<UL>
</UL>
</UL>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_kg1091_1_2"> </A> </FONT> <FONT SIZE=6><B>Stock options are an important part of the total value of working at Inhale  </B></FONT></P>

<P><FONT SIZE=5><B><I>The Concept  </I></B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>
<IMG SRC="g564615.jpg" ALT="LOGO" WIDTH="684" HEIGHT="255">
  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=3,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=739720,FOLIO='2',FILE='DISK040:[02PAL1.02PAL1091]KG1091A.;2',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_ki1091_1_3"> </A> </FONT> <FONT SIZE=6><B>The goal is to provide all employees a real stake in the value we create as a business  </B></FONT></P>

<P><FONT SIZE=5><B><I>Stock options help us ...  </I></B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>Attract
and and retain the superior talent we need to succeed </FONT><FONT SIZE=6>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>Focus
each of us on the factors that will make our business successful </FONT></DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=4,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=631883,FOLIO='3',FILE='DISK040:[02PAL1.02PAL1091]KI1091A.;2',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<UL>
<UL>
</UL>
</UL>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_kk1091_1_4"> </A> </FONT> <FONT SIZE=6><B>Yet, recent market conditions have made achieving those goals more challenging  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=6>Many employees have options with a strike price (or exercise price) that is higher than the current share price </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=5,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=850222,FOLIO='4',FILE='DISK040:[02PAL1.02PAL1091]KK1091A.;2',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_km1091_1_5"> </A> </FONT> <FONT SIZE=6><B>At the same time, we believe our business fundamentals are&nbsp;sound  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>We're
growing revenue </FONT><FONT SIZE=6>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>We're
developing leading edge drug delivery systems </FONT><FONT SIZE=6>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>We
have valuable relationships with key strategic partners </FONT></DD></DL>
</UL>
<BR>
<P ALIGN="CENTER"><FONT SIZE=5><B><I>We're doing&#151;and must continue to do&#151;<BR>
the things that it takes to win  </I></B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=6,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=386090,FOLIO='5',FILE='DISK040:[02PAL1.02PAL1091]KM1091A.;4',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_ko1091_1_6"> </A> </FONT> <FONT SIZE=6><B>But, there are many factors that influence the value of our business  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>General
market conditions </FONT><FONT SIZE=6>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>Interest
rates </FONT><FONT SIZE=6>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>Drug
approval process </FONT><FONT SIZE=6>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>Consumer
and investor confidence in Inhale and our industry </FONT></DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=7,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=924371,FOLIO='6',FILE='DISK040:[02PAL1.02PAL1091]KO1091A.;3',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<UL>
<UL>
</UL>
</UL>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_kq1091_1_7"> </A> </FONT> <FONT SIZE=6><B>As a result, we're faced with a critical question  </B></FONT></P>


<P><FONT SIZE=5><B><I>How can we address the high exercise price of many employee stock options, yet retain our accountability for
business performance?  </I></B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="80%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=5><B><I>Alternatives<BR> </I></B></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=5>&nbsp;</FONT></TD>
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=5><B><I>Considerations</I></B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=4>&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>Provide supplemental grants</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=4>&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>Dilution of value of Inhale's</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=4>&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>Reprice options</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=4>&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>Cancel current options and</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=4>&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>Investor relations</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>grant new ones</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=4>&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>Impact on company earnings</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=4>&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>Competitive environment</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=4>&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>Opportunity to provide<BR>
employees with choice</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=4>&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=4>Fairness</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=8,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=709847,FOLIO='7',FILE='DISK040:[02PAL1.02PAL1091]KQ1091A.;15',USER='ESHERMA',CD='25-JAN-2002;04:34' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->

<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_ks1091_1_8"> </A> </FONT> <FONT SIZE=6><B>Our response is to provide<BR>
employees with a choice  </B></FONT></P>

<P><FONT SIZE=5><B><I>You can elect to...  </I></B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="79%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=5><B><I> Maintain<BR> </I></B></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=5>&nbsp;</FONT></TD>
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=5><B><I>Replace</I></B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="42%" ALIGN="CENTER"><FONT SIZE=4>Keep your current<BR>
option grants and<BR>
strike price</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="CENTER"><FONT SIZE=5><B>or</B></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=5>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=4>&#149;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="42%"><FONT SIZE=4>Exchange non-evergreen stock option grants with exercise prices greater than or equal to $25 per share granted under the 2000 Non-Officer Equity Incentive Plan</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="42%" ALIGN="CENTER"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="CENTER"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=4>&#149;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="42%"><FONT SIZE=4>Receive replacement option grants for options you <U>elect</U>&nbsp;to exchange on a 1:2 basis on 8/26/02 (or later if Inhale extends the offer)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="42%" ALIGN="CENTER"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="CENTER"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=4>&#149;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="42%"><FONT SIZE=4>Options required to be exchanged (see next slide) will be replaced on a 1:1 basis on 8/26/02 (or later if Inhale extends the offer)<BR></FONT>
</TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=9,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=777782,FOLIO='8',FILE='DISK040:[02PAL1.02PAL1091]KS1091A.;16',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_ku1091_1_9"> </A> </FONT> <FONT SIZE=6><B>General terms of the exchange offer  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>You
can elect to exchange eligible option grants issued under Inhale's 2000 Non-Officer Equity Incentive Plan </FONT> <FONT SIZE=5>
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#151;</FONT></DT><DD><FONT SIZE=5>Eligible
options are option grants with exercise prices greater than or equal to $25 per share (excludes Evergreen Options, except as required) </FONT> <FONT SIZE=5>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#151;</FONT></DT><DD><FONT SIZE=5>If
you received more than one eligible option grant under the Plan, you can choose to exchange as many or as few grants as you wish </FONT></DD></DL>
</DD></DL>
</UL>
<BR>
<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>Certain
conditions apply:</FONT><FONT SIZE=5>
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#151;</FONT></DT><DD><FONT SIZE=5>If
you exchange an option grant, you must exchange the </FONT> <FONT SIZE=5><B><I>entire</I></B></FONT><FONT SIZE=5> grant </FONT><FONT SIZE=5>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#151;</FONT></DT><DD><FONT SIZE=5>If
you participate, you must exchange </FONT><FONT SIZE=5><I>all</I></FONT><FONT SIZE=5> options
granted to you on or after July&nbsp;24, 2001 (including grants with exercise prices &lt;$25 per share, Evergreen Grants and grants under different plans). These options will be exchanged on
a 1:1 basis </FONT><FONT SIZE=5>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#151;</FONT></DT><DD><FONT SIZE=5>You
must be continuously employed by Inhale or one of its subsidiaries through the date of grant of the replacement options </FONT></DD></DL>
</DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=10,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=389283,FOLIO='9',FILE='DISK040:[02PAL1.02PAL1091]KU1091A.;8',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<UL>
<UL>
</UL>
</UL>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_kw1091_1_10"> </A> </FONT> <FONT SIZE=6><B>If you maintain your current option grant(s), there is no&nbsp;change  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>Same
number of options you have now </FONT><FONT SIZE=6>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>Same
vesting </FONT><FONT SIZE=6>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>Same
terms and conditions </FONT><FONT SIZE=6>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=6>&#149;</FONT></DT><DD><FONT SIZE=6>Same
strike (exercise) price </FONT></DD></DL>
</UL>
<BR>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD WIDTH="40%" ALIGN="RIGHT" VALIGN="TOP"><FONT SIZE=5><B><I>You go "in the money" if the market price per share of Inhale stock exceeds the strike price</I></B></FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=5>&nbsp;</FONT></TD>
<TD WIDTH="58%" VALIGN="TOP"><FONT SIZE=5><B>
<IMG SRC="g669158.jpg" ALT="LOGO" WIDTH="436" HEIGHT="288">
 </B></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=11,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=414049,FOLIO='10',FILE='DISK040:[02PAL1.02PAL1091]KW1091A.;7',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_ky1091_1_11"> </A> </FONT> <FONT SIZE=6><B>If you elect to replace your eligible options, these grants will be cancelled and replaced at a&nbsp;1:2&nbsp;ratio  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>
<IMG SRC="g486593.jpg" ALT="LOGO" WIDTH="685" HEIGHT="211">
  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=4>&#149;</FONT></DT><DD><FONT SIZE=4>Exchange
ratio of 1:2 for eligible options you elect to exchange&#151;you receive a replacement option covering 50% of the number of shares subject to
the options you exchanged </FONT><FONT SIZE=4>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=4>&#149;</FONT></DT><DD><FONT SIZE=4>If
you participate and are therefore required to exchange options granted on or after July&nbsp;24, 2001, these grants will be replaced on a 1:1 basis </FONT> <FONT SIZE=4>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=4>&#149;</FONT></DT><DD><FONT SIZE=4>Each
replacement option will have an equivalent vesting schedule on a percentage basis as your exchanged options </FONT> <FONT SIZE=4>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=4>&#149;</FONT></DT><DD><FONT SIZE=4>New
exercise price will be the fair market value of the underlying Inhale shares on the day prior to the date of the grant </FONT></DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=12,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=820958,FOLIO='11',FILE='DISK040:[02PAL1.02PAL1091]KY1091A.;4',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<UL>
<UL>
</UL>
</UL>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_kz1091_1_12"> </A> </FONT> <FONT SIZE=6><B>Vesting terms of replacement options  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>Replacement
options will have an equivalent vesting schedule, on a percentage basis, as exchanged options </FONT> <FONT SIZE=5>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>The
vesting commencement date of the replacement option will be the original vesting commencement date of the applicable exchanged option </FONT> <FONT SIZE=5>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>Vesting
credit, on a percentage basis, will be given through the date of grant of the replacement option </FONT></DD></DL>
</UL>
<BR>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH COLSPAN=5 ALIGN="CENTER"><FONT SIZE=4><B>EXAMPLE<BR> </B></FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="54%" ALIGN="LEFT"><FONT SIZE=4>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TH>
<TH WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4><B><I>Current<BR>
Grant<BR>
(Eligible Option)<BR> </I></B></FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TH>
<TH WIDTH="21%" ALIGN="CENTER"><FONT SIZE=4><B><I>Replacement<BR>
Grant<BR> </I></B></FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=5 ALIGN="CENTER"><HR NOSHADE><BR></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="54%"><FONT SIZE=4>Number of shares</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>100</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="21%" ALIGN="CENTER"><FONT SIZE=4>50</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="54%"><FONT SIZE=4>Vesting commencement date</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>8/26/99</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="21%" ALIGN="CENTER"><FONT SIZE=4>8/26/99</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="54%"><FONT SIZE=4>Percentage vested on 8/26/02</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>50%</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="21%" ALIGN="CENTER"><FONT SIZE=4>50%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="54%"><FONT SIZE=4>Shares vested on 8/26/02</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>50</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="21%" ALIGN="CENTER"><FONT SIZE=4>25</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=13,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=507851,FOLIO='12',FILE='DISK040:[02PAL1.02PAL1091]KZ1091A.;2',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_lb1091_1_13"> </A> </FONT> <FONT SIZE=6><B>An example in which participating in the exchange would result in an increase in value of an eligible&nbsp;option  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD WIDTH="25%" VALIGN="TOP"><FONT SIZE=5><B>EXAMPLE 1</B></FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=5>&nbsp;</FONT></TD>
<TD WIDTH="74%" VALIGN="TOP"><FONT SIZE=2><B>
<IMG SRC="g378016.jpg" ALT="LOGO" WIDTH="570" HEIGHT="325">
 </B></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=4><B>EXAMPLE  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="63%" ALIGN="LEFT"><FONT SIZE=4>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TH>
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4><B><I>Current<BR>
Grant<BR> </I></B></FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TH>
<TH WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4><B><I>Replacement<BR>
Grant<BR> </I></B></FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=5 ALIGN="CENTER"><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Number of stock options</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>100</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>50</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Strike price</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>$45.00</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>$20.00</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Hypothetical 4&nbsp;year price</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>$63.00</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>$63.00</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Hypothetical gain per share</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>$18.00</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>$43.00</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4><I>Hypothetical total gain</I></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4><I>$1,800</I></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4><I>$2,150</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=14,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=623618,FOLIO='13',FILE='DISK040:[02PAL1.02PAL1091]LB1091A.;3',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_ld1091_1_14"> </A> </FONT> <FONT SIZE=6><B>An example in which participating in the exchange would result in a decrease in value of an eligible&nbsp;option  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD WIDTH="25%" VALIGN="TOP"><FONT SIZE=5><B>EXAMPLE 2</B></FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=5>&nbsp;</FONT></TD>
<TD WIDTH="74%" VALIGN="TOP"><FONT SIZE=2><B>
<IMG SRC="g146435.jpg" ALT="LOGO" WIDTH="547" HEIGHT="301">
 </B></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=4><B>EXAMPLE  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="63%" ALIGN="LEFT"><FONT SIZE=4>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TH>
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4><B><I>Current<BR>
Grant<BR> </I></B></FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TH>
<TH WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4><B><I>Replacement<BR>
Grant<BR> </I></B></FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=5 ALIGN="CENTER"><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Number of stock options</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>100</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>50</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Strike price</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>$45.00</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>$30.00</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Hypothetical 4&nbsp;year price</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>$86.00</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>$86.00</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Hypothetical gain per share</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>$41.00</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>$56.00</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4><I>Hypothetical total gain</I></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4><I>$4,100</I></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4><I>$2,800</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=15,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=369902,FOLIO='14',FILE='DISK040:[02PAL1.02PAL1091]LD1091A.;9',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<A NAME="page_ld1091_1_15"> </A>
<P ALIGN="RIGHT"><FONT SIZE=6><B>Examples of resulting values of options<BR>
required to be exchanged  </B></FONT></P>

<P><FONT SIZE=4><B>EXAMPLE 1: Increase in Value of Options  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="63%" ALIGN="LEFT"><FONT SIZE=4>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TH>
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4><B><I>Current<BR>
Grant<BR> </I></B></FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TH>
<TH WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4><B><I>Replacement<BR>
Grant<BR> </I></B></FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=5 ALIGN="CENTER"><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Number of stock options</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>100</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>100</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Strike price</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>$20.00</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>$15.00</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Hypothetical 4&nbsp;year price</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>$63.00</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>$63.00</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Hypothetical gain per share</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>$43.00</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>$48.00</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4><I>Hypothetical total gain</I></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4><I>$4,300</I></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4><I>$4,800</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=4><B>EXAMPLE 2: Decrease in Value of Options  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="63%" ALIGN="LEFT"><FONT SIZE=4>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TH>
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4><B><I>Current<BR>
Grant<BR> </I></B></FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TH>
<TH WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4><B><I>Replacement<BR>
Grant<BR> </I></B></FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=5 ALIGN="CENTER"><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Number of stock options</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>100</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>100</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Strike price</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>$20.00</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>$30.00</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Hypothetical 4&nbsp;year price</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>$63.00</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>$63.00</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4>Hypothetical gain per share</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4>$43.00</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4>$33.00</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="63%"><FONT SIZE=4><I>Hypothetical total gain</I></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=4><I>$4,300</I></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD WIDTH="20%" ALIGN="CENTER"><FONT SIZE=4><I>$3,300</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=16,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=103714,FOLIO='15',FILE='DISK040:[02PAL1.02PAL1091]LD1091A.;9',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_lh1091_1_16"> </A> </FONT> <FONT SIZE=6><B>If you exchange your options, the terms will be somewhat different than they are now  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>Eligible
Options elected to be exchanged will be replaced at a 1:2 ratio </FONT><FONT SIZE=4>
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=4>&#151;</FONT></DT><DD><FONT SIZE=4>New
exercise price will be the FMV of the underlying Inhale shares on the day prior to the date of grant </FONT></DD></DL>
</DD></DL>
</UL>
<BR>
<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>Grants
made on or after July&nbsp;24, 2001 and required to be exchanged will be replaced at a 1:1 ratio </FONT> <FONT SIZE=4>
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=4>&#151;</FONT></DT><DD><FONT SIZE=4>New
exercise price will be the FMV of the underlying Inhale shares on the day prior to the date of grant </FONT></DD></DL>
</DD></DL>
</UL>
<BR>
<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>Equivalent
vesting schedule on a percentage basis with credit for vesting through the date of grant of the replacement option </FONT>
<BR>
</DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=17,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=59613,FOLIO='16',FILE='DISK040:[02PAL1.02PAL1091]LH1091A.;6',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<A NAME="page_lh1091_1_17"> </A>
<UL>
<UL>
<P ALIGN="CENTER"><FONT SIZE=5><B>
<IMG SRC="g37986.jpg" ALT="LOGO" WIDTH="558" HEIGHT="594">
  </B></FONT></P>

</UL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=18,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=989598,FOLIO='17',FILE='DISK040:[02PAL1.02PAL1091]LH1091A.;6',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<UL>
<UL>
</UL>
</UL>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_lj1091_1_18"> </A> </FONT> <FONT SIZE=6><B>Making Your Election  </B></FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>Participation
is voluntary and </FONT><FONT SIZE=5><I>solely</I></FONT><FONT SIZE=5> up to you </FONT> <FONT SIZE=4>
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=4>&#151;</FONT></DT><DD><FONT SIZE=4>Inhale cannot advise you on whether or not you should exchange your options </FONT></DD></DL>
</DD></DL>
</UL>
<BR>
<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>Review
your current eligible option grant(s) and grants that would be required to be exchanged and their respective strike price(s) </FONT> <FONT SIZE=5>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>Review
the Offer to Exchange (including the Q&amp;A), Summary of Terms and the Election Form carefully </FONT> <FONT SIZE=5>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>Consider
both the upside and downside opportunity </FONT><FONT SIZE=4>
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=4>&#151;</FONT></DT><DD><FONT SIZE=4>Check
with your financial and tax advisors </FONT></DD></DL>
</DD></DL>
</UL>
<BR>
<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>Ask
questions about anything that is not clear </FONT><FONT SIZE=4>
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=4>&#151;</FONT></DT><DD><FONT SIZE=4>Contact
Steve Hurst at (650)&nbsp;631-3118 or Bob Harper at (650)&nbsp;631-3222 or email to <U>exchange@inhale.com
</U> with any questions </FONT></DD></DL>
</DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=19,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=702653,FOLIO='18',FILE='DISK040:[02PAL1.02PAL1091]LJ1091A.;14',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<A NAME="page_lj1091_1_19"> </A>
<UL>
<UL>
<UL>
<P ALIGN="RIGHT"><FONT SIZE=6><B>Making Your Election (cont.)  </B></FONT></P>

</UL>
</UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>Complete
and return your Election Form before midnight, Pacific Standard Time, 2/25/02 </FONT> <FONT SIZE=4>
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=4>&#151;</FONT></DT><DD><FONT SIZE=4>Submit
your Election Form even if you're not exchanging any options </FONT><FONT SIZE=4>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=4>&#151;</FONT></DT><DD><FONT SIZE=4>You
may change your election as many times as you wish up to the deadline </FONT><FONT SIZE=4>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=4>&#151;</FONT></DT><DD><FONT SIZE=4>Failure
to make an election before the deadline results in no option exchange </FONT> <FONT SIZE=4>
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=4>&#151;</FONT></DT><DD><FONT SIZE=4>You
cannot change your election after the deadline </FONT></DD></DL>
</DD></DL>
</UL>
<BR>
<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=5>&#149;</FONT></DT><DD><FONT SIZE=5>Remember,
this is a one-time only opportunity&#151;there are no plans to repeat it </FONT>
<P ALIGN="CENTER"><FONT SIZE=4><B><I>This presentation contained numerous examples including hypothetical stock prices. There can be
no assurance as to the price of Inhale Common Stock at any time in the future.</I></B></FONT></P>

</DD></DL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=20,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8",CHK=262662,FOLIO='19',FILE='DISK040:[02PAL1.02PAL1091]LJ1091A.;14',USER='ESHERMA',CD='25-JAN-2002;04:35' -->
<UL>
<UL>
</UL>
</UL>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DNICHOL,SEQ=,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="8" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A)(1)(H)
<SEQUENCE>10
<FILENAME>a2068683zex-99_a1h.htm
<DESCRIPTION>EXHIBIT 99(A)(1)(H)
<TEXT>
<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P ALIGN="RIGHT"><FONT SIZE=2><B>Exhibit 99(a)(1)(H)  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2>To:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2>[Employee Name]</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
From:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Date:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2002</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2><BR>
Re:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=2><BR>
Confirmation of Participation in the Offer to Exchange</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thank
you for your participation in Inhale Therapeutic Systems,&nbsp;Inc.'s ("Inhale" or the "Company") Stock Option Exchange Program. Defined terms not explicitly defined herein but
defined in the Offer to Exchange, shall have the same definitions as used in the Offer to Exchange. The stock option(s) held by you that have been surrendered for cancellation are identified as
Eligible Options or Mandatory Exchange Options on the following page entitled "Stock Options and Awards Cancelled." </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is conducting the exchange with respect to Eligible Options on a one-for-two (1:2) basis. Thus, on August&nbsp;26, 2002 (or a later date if Inhale
extends the Offer), subject to your continued employment with Inhale or its subsidiaries, the Company will grant you a Replacement Option covering fifty percent (50%) of the number of shares of Common
Stock subject to your Eligible Options that were cancelled. THEREFORE, FOR EVERY TWO SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF ELIGIBLE OPTIONS THAT YOU EXCHANGED, THE COMPANY WILL GRANT YOU A
REPLACEMENT OPTION TO ACQUIRE ONE SHARE OF COMMON STOCK. The Company is conducting the exchange with respect to Mandatory Exchange Options on a one-for-one (1:1) basis. Thus,
for employees that elect to exchange any Eligible Options, on August&nbsp;26, 2002 (or a later date if Inhale extends the Offer), the Company will grant you a Replacement Option covering one hundred
percent (100%) of the number of shares subject to your Mandatory Exchange Options that were cancelled (so long as your employment or service with the Company or one of its subsidiaries continues
through that date). The exercise price per share of the Replacement Options will be equal to the closing price of the Company's Common Stock as reported on Nasdaq National Market on the last market
trading day prior to the date of grant. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you have any other questions regarding the above, please contact Steve Hurst or Bob Harper via email at </FONT><FONT SIZE=2><I>exchange@inhale.com</I></FONT><FONT SIZE=2>.
Alternatively, you may reach Steve Hurst via telephone at (650)&nbsp;631-3118 or Bob Harper at (650)&nbsp;631-3222. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="9",CHK=1042641,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]OK1091A.;4',USER='ESHERMA',CD='25-JAN-2002;04:36' -->

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="26%"><FONT SIZE=2><B>Inhale Therapeutic Systems,&nbsp;Inc.</B></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="47%"><FONT SIZE=2><B>STOCK OPTIONS AND AWARDS CANCELLED</B></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="21%" VALIGN="BOTTOM"><FONT SIZE=2><B>Page:1<BR>
File: Cancelled<BR>
Date:<BR>
Time:</B></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="27%" ALIGN="LEFT"><FONT SIZE=1><B>Name<BR> </B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="3%" ALIGN="CENTER"><FONT SIZE=1><B>ID</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="8%" ALIGN="CENTER"><FONT SIZE=1><B>Number</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="8%" ALIGN="CENTER"><FONT SIZE=1><B>Grant Date</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="5%" ALIGN="CENTER"><FONT SIZE=1><B>Plan</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1><B>Cancel Date</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1><B>Cancel Reason</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><B>Shares</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="5%" ALIGN="CENTER"><FONT SIZE=1><B>Price</B></FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="8%" ALIGN="CENTER"><FONT SIZE=1><B>Total Price</B></FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="27%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="27%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="27%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="27%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="27%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="27%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="27%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="RIGHT"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="10%"><FONT SIZE=2>TOTALS</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="9",CHK=590439,FOLIO='blank',FILE='DISK040:[02PAL1.02PAL1091]OK1091A.;4',USER='ESHERMA',CD='25-JAN-2002;04:36' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DNICHOL,SEQ=,EFW="2068683",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="9" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g1008932.jpg
<DESCRIPTION>G1008932.JPG
<TEXT>
begin 644 g1008932.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+__@`L1$E32S`T,#I;,#)004PQ+C`R
M4$%,,3`Y,2Y/5510551=05)4,4,N15!3_\``$0@".0)<`P$B``(1`0,1`?_$
M`!P``0`"`P$!`0`````````````%!@(#!`$'"/_$`%80``$$`0$$!@0&#P<"
M!0(&`P$``@,$!1$&$B$Q$T%187&!%"(RD15"4F*"H0<6(R0E,S1#4W*2HK'!
MTD1C=9.RL\(FT35%<X/A5/`71E5DH^*5P]/_Q``;`0`#`0$!`0$`````````
M`````@,!!`4&!__$`#T1``(!`@,#"P,$`@$#!`,````!`@,1$B$Q05%A!!,B
M,G&!D:&QP=$CX?`%%#-B0E+Q<J+2%20TDD.RPO_:``P#`0`"$0,1`#\`^_HB
M(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`UOL0QS1POE8V277HV%
MP!=H-3H.O0+8H#:VK*[%LR-1F]=QD@MP@<WAOML^DPN'N4Q3M0WJ<-JN[?AF
M8V1CNUI&H5'"T%-?GY\F)YV-Z(N._E:&+AZ6_<@K,ZC-(&Z^&O-(HN3LEF:W
M8[$5<^VMUW_P;#W\@.J8L$$)^G)IKY`IT&U=_P#&6\?BXSR$$9L2#Z3M&CW%
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M_@EVQ7JT+>&_S/1LN]VG2[09N3GK]\M9K^RT+6_8?#S_`)6;MOU=TBQ<D<".
M\:K8_-YLG2+9:URYR6X6C7R<4;D-II=0W`TX>'`RY#73R:PHQ<H6:DEV2BO1
MA:&[R9S_`/X<[)?_`*+!^V_^I!]CK9(?^20>;GG^:ZC/M66G=H8@'JUN2?\`
M_-<=O([4T8FR68,(P/D9$S2>8ZO>X-:/8X<3S3JKRN62JO\`^WW,M37^/D9?
M_ASLE_\`HL'[;_ZEZW['FRT;@^+%,B>.3XY9&N'@0Y;XYMK1KTE+#.[-VW*/
M^"]=<VHB!)Q&-FX<!'?<T_7&L=7E>G._]_W-PT_]?(P;L?4A:&ULCEZ[0-`(
M[S]!Y'5>_:W<CXP;39AAX:=(Z*0?6Q/AC:!A._LN]PX?BKT3M??HO7;26H#I
M9V;R[->N)D<P_<>2D_\`</5I]\7\AT/RYB,7M-#QBVAKS]UG'C^+'-_@G3;7
M5P2ZKA[@[(YI(3]8</K3[=<0SA9]-J'LL4I6:>>[HNRKM/@KKMVOEJ3W_(Z9
MH=[CQ1)5DKSIY?\`3;TL:L.Q^9QC:')UQ]_;,9%@^55?'./J<#]2R9MIA`YK
M+5F2C(3INW8'P?6X`?6IYKFO`+2"#R(XH]C)&ECVAS3P((U!4<=)ZPMV/YN;
M:6QFJM=JW8^DJV89V?*B>'#ZEO4'9V/P%J3I78R"*7])7UA?[V$%:/M<R-3C
MB]HKT0_17`++/#UM'#]I&"E+25NU?%_0V\EJBQHJYZ=M/1_*L35R#.N2C/T;
M]/U).'N<MD&V.(=*(+DDN-L'@(;\9A)\"?5/D2C]O4UCGV9_?Q,QK:3Z+%CV
MR-#F.#FD:@@Z@K)0'"+QQ#1J>04%LS;LY1ES*RRO-6U,13B/)L+/5#O%QU=X
M:)XP;BY;$8WG8GD1$AH1$0`1$0`1$0`1$0`1$0`1$0`1$0`1$0`1$0`1$0`1
M$0`1$0`1$0`1$0`1$0`1$0`1$0`1$0`1$0`1$0`1<62R^/Q%?ILA;BKL/+?=
MQ<>QHYD]P4,,GGLR/P50;CZIY6\BT[[AVMA'']HCP584926+1;WI]^X5R2R+
M#9G@K0/FL2QQ1-&KGR.#6@=Y*H>SVT7HCKF$PM*7*,AF=+3?&X1Q"!QUT+W=
M37%S>`/(*P0;(TWSMLY::;+6FG4/N'5C#\V,>HWW:]ZU;3,^#+&.S\3=&TG]
M%9#1SK/T#OV3NN\BNFCS2O2ZS?<KK3CGILU$EBZVA[\%[093CDLLVA"?[/C1
MH[3OE=Q]P"[:&RV&QTW3PTF/L]=B<F60_2=J5IM;7XJ&<UJKY<C;'YB@SIG#
MQ(]5OF0M._M5D_8BIX>$]<OWQ-IX#1@]Y6/GG&S>"/AY:OS#H]K+$YS6-+G$
M`#F3U*$L[88.O*8676VK`_,TVF=_N8#IYK2W8ZG8<),O:N9:3GI:E^YZ]T;=
M&_45.5:=:E"(JM>*",<F1,#0/(*-J,=6Y>2]_1#=)\"#^&L[=_\`#MGI(F'E
M+D9VPC]AN\[WZ)\';3W.-G-UJ;>ME&KJ?VY"?X*QHCGDNI%+NOZW##O971L=
M1F_+[F3OD\_2+C]W]EI:WZEV5-E\%1(=6Q%)CA\?H6EWO/%2R+)<HJM6<G8U
M0BMAX&AH`:``.0"]T"(HC!$1`!06U7Y!2_Q&I_O-4ZH+:K\@I?XC4_WFJW)_
MY8]HL^JR=1$41@FB(@`N.WBL??&ERC6L?^K$UW\0NQ%JDXNZ8-7*\=BL&UQ?
M6JR4W]3J<\D.GDT@?4O/@#+UOR#:6WN_(NQ,L#W^J[ZU8D5OW-7:[]N?K<7!
M$KGI6U=/\=CL?D&#KJSF%Y^B\$?O+T;98^`AN3K7L6[736Y7(9^VW5OUJQ+P
M@$:$#3L1SM.76AX9?*\C,+6C.>I?IY"+I:=J&Q'\J*0/'U+9/7AM0F*>*.6-
MW`L>T.!\BHBWLCA;4WI#:8K6>JQ4<8)!YLTU\]5S_!FT>-&M#,1WXQRAR4?K
M>4K-#[VE"A3><)6?'Y5_.P7:U1Z_8VC`YTF(L6L3*3KK3E(C)[XSJP^Y8^D;
M3XHZ6*E?,5Q^<JD0S:=[''==Y$>"]&U;J&C<]B[6.[9VCIH/VV\OI`*<J7:M
M^N)ZEB*Q"[D^)X<T^859RK15ZJQ+>\_^Y?)B47U<OS<5+,[3ULQ29A*,DU;(
MWY16=%8B=%)"PZE[M#\T$`@\R%<*U>*I6BKP,#(8F!C&#DUH&@"JM3'5-K,M
MDLAD*\=FA&32ILD&K2&G[I(.\OX`CJ:NKX!RN)];!Y5SH1RI9`F6/P:_VV_6
M.Y-5C2LJ<7A:S=]+OCPTS66>9D7*^)YEE15R+:N.K,VMGJK\3.XZ-DE<'5Y#
M\V4</)VA5A8]KVAS2'-(U!!U!"Y)TIPZR^/$HI)Z&2(B0T(B(`(B(`(B(`(B
M(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(L7O;&
MPO>X-:T:DDZ`!5J3:*WF)'5]FJ[)V`EK\C."*[#U[O7(?#AWJE.E*>FBV[$8
MY)$YD<I1Q-4V;]J*O"#IO2.TU/8!UGN"@_A#.YXZ8RN<70/]LN1ZS/':R+J\
M7^Y=6-V8JU+0OW99,CDO_JK/$L[F-Y,'A[U*W+M7'U7V;D\<$#!JZ21P:!YE
M43A!V@L3WO3N6WO\!<WKD1V-V9Q^.G]+<V2W?/M7+3NDE/@3P:.YH`4C=O5,
M=5?9N6(J\#/:DE<&@>94!\-9;.>K@J8KU3P^$+S"UI';'%P<[Q.@\5T4]E*D
M5EMW(S392\WBV>V0X,/S&>RSR&O>FG%WQ5Y9[M7\+U6XQ/9!&G[8K^5]7`8I
M\L9Y7;NL,/BT>V_R`'>L3LF_)M+MH<G/D-X?D\9,%=OT&G5WTB59T2_N''^)
M8>.WQ^+&X+];,K>QA;6Q<V(>QC+.,F-:3=:&[XYL?H/E-(.O;JK(JUD_P/M7
M1R@X5KX%&SV!_$Q./GO-^D%95G*.E+G/]L^_;Y^5@ADK;@B(H#A$7CG!H)<0
M`.LH`]10UO:S`TG]'-E:QD_1QOZ1_P"RW4KF^VMT_P"08+,6M>3C7$+3YR%O
M\%9<GJM7PY<<EXL7''>6)%71?VIL\(L)2J#J-JZ7'W,:?XH*FU<_XS*XRL.R
M"F]Y][G_`,EO,6ZTDN^_I<,6Y%B15X8',2:>D;4WCH>(@KPQC_24;LL[4&3:
M#.2$?_NPW7]EH1S=-:S7<G\(,3W%A4%M5^04O\1J?[S5B[9.F]I:^]EW`\]<
ME-Q_>4-M!LKCZE*LYDM]Y?>K,/27IG:`RM!TU=P/'GS'4J\GC2YV/2>N[[BS
M<L+R+PBKS-CL?&[>9:RK3VC)3?U+)VRL.A$>6S46OR<A(?\`5JI8*.R3\/N-
M>6XG]45>^UJVS7H=ILRSE[;XGCZV(<3M'%J8=I62=C;-!COK86HYJ#TFO/X#
M$]Q845=UVN@U]7#6P!R!E@)_U!>#/9JOQN;+VBWK=3L1S#W$M/U(_;R?5:?>
MO>S,QK:6-%71MKB(SNW3:QSNR[6?$/VB-WZU,5,E1OLWZ=RO8;VPR!_\$DZ-
M2"O*+2-4D]&=2(BF,$1$`"`>85+VLPU"G7;8QD#J>9MS-KUY*;S$7O<>)>&\
M'`#>)U'(*Z*LU/PUMC8N<ZF)::T/8Z=P!D=]$:-\W+IY+)PDYIY+-\=R[WY"
M32:L:*4.>V6I0TXZ<.6QL#0UAK:16&M[V$[KSX$$J8Q>T>-RTCH8)RRTSVZL
M[3',SQ8>/F."E5'93!8W,QM;>JLD<SV)1ZLD9[6O'%OD5CJPJ.]16;VKW6GA
M8,+CU3MFABL1.BFC9)&X:.8]H(([P57G;,3XQQEV<O&CQU-*4&2L[Z/-GBTC
MP7AK;18,:U)QFJ;?S%DAEEH^;)[+_I`'O4ABMHL?EGOAB>^&Y'^-J6&]'-'X
MM/5WC4=Z9*I33E3=X[=J[T_==C,NF[/)G%6VI;7G93SU8XNV\[K'/=O02GYD
MG+R=H58@0>2U6:L%RN^O9ACFAD&CXY&AS7#O!5=.#R6!/2;/3]+5'%V,M/)9
M_P"T\\6'N.K?!+:G4TZ+\O'9WW[4;THZYEH10^)VCIY25U4MDJ9",:RTK+=V
M5O>!R<.\:A3"C.$H/#)68R:>:"(B4T(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B
M(`(B(`(B(`(B(`(B(`(B(`(B$Z(`**R^T%/$='$_I)[DWXBI`W>EE\!U#O.@
M"CK.=MY>P^ALV&/W';D^1D&]#`>L-_2/[AP'6>I2.'P%3#B21F_/<FXSVYSO
M2RGO/4.P#@%T*E&GG5UW;>_=Z^HF)OJD8S!7L\]MC:1S17!WH\7"[6(=AE=^
M</=[/<596LC@B:QC6LC8-``-`T#^`4=F,]2PS&"<ODLR\(*L+=^68]C6_P`^
M0[5%,PV2VA/3;0NZ"F>+,7!)ZI']\\>V?FCU?%,U*I%2J/#'9]EM[?%F9)V6
M;-D^TLV1G=4V;K-NR-.[)<D)%:$_K#VSW-\R%MI[+0^E,O9BP_*WV\6/G`$<
M1_NX^3?'B>]3D$$5:%D,$3(HF#=:QC0`T=@`6Q(ZV%8:2LO-]_LO,W#?.01$
M4!PB+QS@QI<X@`<23U(`X,WC&9C#6J#W;IE9HQXYL>.+7#P(!\EIV<RC\MA(
M+$X#+3=8K+/D2L.Z\>\:^!"Y)]KJ<DSJV(AFR]IIT+:@!C8?G2'U6^\GN5=C
MIYMFTYKW+OP37S.]/T=!P>>E8T`MWW#U7%O'4#CNE=U.A*5-PJ=':KZ\<M=,
M[\"3FD[K,NV0RV/Q4727[L%9IY&60-U\`>?DHC[:I;VHPF&NWNR:5OH\/[3^
M)\@5V8_9?$8Z;TB.HV6T>)LV"992?UW:GW*84,5&.B<NW)>"S\QK2?`K?H6U
M-\??&4IXUGR*4'2OT[-^3A[FK)NQF+E._D7V\F_MNV'2-\F#1H]RL2(_<U%U
M>CV9>>OF&!;<SEIXZECV;E.I!79V0QA@^H+JT1%%MMW8]@B(L`(B(`*"VJ_(
M*7^(U/\`>:IU06U7Y!2_Q&I_O-5N3_RQ[19]5DZB(HC!$1`!$1`'A:'`@@$'
MJ*A[>R>!NR=)-BZPE_2QLZ-_[3="IE$\*DX.\78QI/4KGVMWZG_A>T-Z%HY1
M6M+,?AZWK?O+ST_:?'G6YBJV1B'.3'R[CP/_`$Y.?DY61%3GV^ND^[W5F+@W
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MLT=S,[U[&CV<E$SUXA_?,'5\]O#M`6ZEM'+6MQXW:"NVC<>=V*=IUKV3\QQY
M.^:[CV:JQ:`A:W.ET*BO'\S3_%O092S6IKKV8;<#)Z\K)89!O,>QP<UP[00M
MJK-G`6L38??V:,<9>=Z?'2'2"<]9;^C?WC@>L=:D</GZN8$D;`^"Y#PGJ3#=
MEB/>.L=A'`I)TNCC@[KS7;\Z>AJEG9DJB(HC!$1`!$1`!$1`!$1`!$1`!$1`
M!$1`!$1`!$1`!$1`!$1`!$7#E<M3PU%UN[)N,!#6M`U=(X\FM',N/4%L8N3P
MQ5V8W;-G1;MUZ%62U:F9#!$W>?(\Z!H[RJST=[;$@RB:C@#Q$?%D]T?.ZV1]
MW,]P6RGB+>=M1Y/:"/<C8X/J8PG5L/8^33@^3ZF]7'BK%9LP4JTEBS*R*&-I
M<^1[M&M':2NE-47:&<]^[LWOCX;Q>MKH*U:"E6CKUH610QMW61L;HUH[`%`6
M\_:R=F3';-MCFE8=V>](-8*YZP/EO^:.`ZRM&M[;$\#/0P!Z^+)[H_BR,_M.
M[@K+3IUZ%6.K4A9#!&-UD<;=`T>"QJ-)WGG+=L7;O?#QVH,Y::'!B-GZN*>^
MP7/LWYA]VN3G>DD[M?BM^:-`%+(BA.<IO%)W8R26@1$2FA8R2,B8Y\C@UC1J
MYSCH`.TE05_:=@MOQ^(KNR>1;P?'$[2.'_U).3?#B>Y:6;,SY-[9]I+8O$'5
MM*(%E6,_J\WGO=[E=4;+%4=EYON^;"8MD0_:B3(O,.SE)V1<#H;;W='68?U]
M-7^#0?%&[+RY)PEVCO.R!YBI'K'69]`'5_BXGP5C9&R-C6,:UK6C0-:-``LE
MO/X?XE;CM\=G=8,-^L:X*\-6%L,$3(HF#1K&-#6CP`41M30FNX9TE0??U-[;
M57OD9QT^D-6^:FT4H5'":FM1FKJQR8S(0Y7&5K]<_<K$;9&]HU'(]XY+K5:P
M7X)SN1P3N$+CZ=3']V\^NT?JOU\G!65-6@H3M'35=C,B[K,(B*0P1$0`1$0`
M1$0`4%M5^04O\1J?[S5.J"VJ_(*7^(U/]YJMR?\`ECVBSZK)U$11&"(B`"(B
M`"(B`"(B`"X<QDHL1B+60FXL@C+MT<W'J:.\G0>:[E6<I^&=J*.);QK4@+UO
M3D7:Z1,/F"[Z(5:,%*72T6;[/OIVBR=ED=NS.,EQN'8+6AO6'NLVG=LK^)]W
M!H[@L\GLWC,K*)YZ^Y:;[%J!QCF9X/;Q]_!2R+'6GC=1.S>X,*M8K'_4F#^3
MG*3?"*TT?Z)/W2I/%;08[,;[*LQ%B/\`&UI6EDL?ZS#Q'CR4HHO*[/X_,[C[
M,1;8C_%68G%DL1^:\<1X<E3G(3_D5GO7NM/"W>99K0E$57-G/;/?EC'YG'-_
M/PL`LQ#YS!P>.]NA[E.X[*4LM4;:H68YX3PWF'D>PCF#W'BDG2E%8EFMZ_,N
M\U23R.M$12&.>[1JY&K)5N01SP2#1\<C=057#'D]D_6@$^3PHYQ$[]BJ/FD\
M9&#L/K#JU5K15IU7%87FMWYH^(KC?/:<M#(5,I3CMTIV3P/&K7L.H_\`@]RX
MLSL_7RSH[#)'U,A`/O>Y#P?'W'Y3>UIX%<>0P%BK<DRNS[V5[KSO3UW\(+?Z
MP'LN['CCVZKNPV>KY=LD89)6NP$-L5)N$D1[^T'J<.!5,+A]6B\EXKMX<='Y
M&7OT9''C,]/%=9B,[$RMD3^)D9^)M@=<9/)W:P\1WA6%<64Q5/,47U+L(DB=
MQ["TCDYIY@CJ(4'6R=O9NU'C\Y.Z>E(X,JY-^@U)Y1S=CNQW)W<48(U<Z:M+
M=\?'AP+N.NA:41%S#A$1`!$1`!$1`!$1`!$1`!$1`!$1`!$1`!$1`!$4;FLS
M7PM,33!\DLCA'!!&-7S2'DUH[?X<TT8N3PQ69C:6;/,WFJV$I=/,'R2/=N0P
M1#629YY-:.L_PYK@Q&%M3VV9K/;K\CH>AKM.L5-I^*WM=VO\AP6>&PUCTLYC
M,%DF4D;NL8TZQU6'\VSO^4[F3W+NS.9JX.B;-DN))#(HF#5\KSR8T=9*Z%T?
MI4LY/5^RX;WM[!->E(V93*4\-0?<NRB.%N@Y:EQ/)K1S)/4`H.KBK>T-B/(Y
M^(Q5F.#ZN+<=6LTY/EZG/[N3?%<\+!7NTLWM7(([<TG15(.)@I$C@">6^>1>
M>O@%<42?,*T-7M]E[OPRU%TGF`-$1%RE`B*`R>T+Q==BL-`+V3'MC72*L.V5
MW5^J.)3TZ<JCM$QM+4D<IF*.&J^D7IQ&TG=8W35TCNIK6CBX]P4(*N8VF.]>
M=-B<6>56-VEB8?WCA[`^:WCVE=N*V<94L_".0G.0RKAH;,C=!&#\6-O)C?#B
M>LE3BKCA2_CS>_X7N\^P6SEJ<U#'U,9495I5XX(&>RR-N@\>\]ZZ410;;=V.
ME8(B+`"(B`*YM9&ZG%4ST+2Z7&2=)(!S=`[A*/(>M]%6&.1LL;9&.#F.`+7#
MD0>M>2QLFB='(T.8\%KFGD0>85?V2D?5@M8*9Q=+BY.B83S?`[C$[]GU?%I5
M^O2XQ]'\/U$TEVEC1$4!PB(@`B+%\C(VESW!K1UN.@0!DBB[&TF#J@]/EZ$>
MG4ZPS7W:KC=MML\';K<DR4\=.AC?)K^RTJJH59:1?@Q7.*VE@4%M5^04O\1J
M?[S5XW:_&R`&&')3`C76/'3'_BH;:/:6O8K5(VT,JT-O5GE[Z$C6\)6G3B.?
M#@.M7Y/R>JJL;Q>HLYQPO,NZ*"^VJI_]#E__`/&S?TK%VV6(CT$WIT))TTDH
M3-T/["C^VK;(OP&QQWD^B@8]M=G)!_XO6CXZ?=28_P#4`I"OFL7;T]&R5.;7
MET<[7?P*R5&K'K1:[@4HO1G<B\!U7JD,$1$`$1$`:+EN&A2GMV'AD,+'22./
M4T#4J'V3J3-QTF2N,W;N3D-J8'FP$>HSZ+=!XZK3M&?A;)X_9YO&.9WI5W0\
MH&$:-/ZS]!X`JRA7?0I);99]RT\7Z(3678$1%`<(B(`*"R.S,,]MV0QL[\;D
MSSL0#A+W2,Y/'CQ["IU$\*DH.\68TGJ5RGM'+4M1X_:&!M*V\[L5AIUKV#\U
MQ]EWS7<>S56-:+E*MD*LE6W!'/!(-'QR-U#AX*MF+)[*$OK"?)X4<X-=^Q5'
MS"?QC!\D^L.K55PPJ]7*6[8^S=V/QV"W<=="UHN7'Y&IE:;+=&=D\#^3V'ZC
MV'N/%=2@TT[/4?4*&S6`BR;X[<$KJ>3@!Z"Y&/6;\UP^,P];3]2F46PG*$L4
M=3&DU9D%A\[)/:=BLK$VKEHFZE@_%SM^7$3S;VCF.M2]JK!=JR5K,3)8)6EK
MXWC4.'85QYG"ULU5;'-O1S1.WX+$1TDA?U.:>H_4>M<.'S%F*[\"YDL;D6M+
MH9FC1EM@^,WL</C-ZN8X*SBIKG*>36J]UP]!;VRD<,=FSL=9CK79)+&`>=V&
MV\ESZA/)DAZV=CCRY%6UI#@"#J#UK&6*.>%\4K&OC>TM<UPU#@>8([%5622[
M&3M@G>Z39Z1P;#,XZFBXG@QQZXR>`=\7D>&BUVKZ=?U^_KVZG5["VHO`=1J%
MZN8<(B(`(B(`(B(`(B(`(B(`(B(`(B(`(BTVK4%*K+9LRMBAB:7O>\Z!H',E
M:DV[(#1ELK5PV/DN6W$,;P:UHU<]QY-:.MQ/`!16%Q5JS=.=S+0+SVZ5ZVNK
M:<9^*.UY^,[R'!:<16FS^29M!D(GQUX]?@VK(-"QI_/.'RW#D/B@]I4[DLE5
MQ&/ENW).C@B&I.FI/8`.LD\`%TM.G]*&<GD_A>_AIK/7I/0U9C+UL)CW6[.\
M[B&1Q1C5\KS[+&CK)4?A\/9FN#-9H-=D7-(A@!U938?BM[7'XSNOD."UXC&V
M\CD&Y[,Q&.P`6TZ9.HJQGK/;(1S/5R"LB635)8(:[7[+W>WLUU+%FS3:JP7:
MLE:S$R6"5I:^-XU#@>HJM06K&R4[*60D?-A7N#*UU[M75B>4<I^3U!_D>U6M
M:YX(K4$D$\;9(I&EKV/&H<#S!"2G4P]&2O%_EUQ-E&^:U-@.J\<YK&ESB`T#
M4DG@`JHV>;8R1D-N5\VS[CNQ6'G5U(]3'GKCZ@[F.1[5X(K.VC@^PV2ML\#J
MR$ZMDO=CG?)B[&\W=?!4_;_Y-]#?[6W\/;,S'LVF<F2N[42NJX65];%@[LV3
M:/6D[6P:^XOY#JU4]C,73Q%)M2C`V*)O'AQ+CUN<3Q)/63Q73%%'#&V.)C6,
M:`UK6C0`#J`[%FDJ5;K!%6C^:[_RQJCM>H1$41@B(@`B(@`B(@`JUG?P1G\=
MG!P@D(HW#\QY^YN/ZK^'@]6&:>*M"Z6>5D431JY[W!K0.\E53*YRMM'C[6+Q
M./L95D['1/GC^YP,UZ^E=P.G/U0>2Z>31DYWMT='V/CIV<1)M6XEO7'?RV/Q
M<72W[L%9G499`W7PUYJJ8.#.[0T"W)9M]3T61U:>O1CW)"]G`ETAU/'@[U0.
M!4_0V6PV.FZ>"C&ZR>=B8F60_3=J43HTZ4G&<KM;OE^R8*3DKI')]MK+6@Q.
M)R60UY2-AZ*+]N3='NU3>VMN\0S%XR,_*+[,@]VZW^*L>B)>=A'J07?G]O(,
M+>K*[]K=ZQQR&TF3E^97+:[?W!K]:R;L3@-X/GH^E/'QK<KYB?VR58$1^YJ[
M)6[,O2P8([CAKX7%U-/1L=4AT_1P-;_`+M``&@X!>HHRDY9MW&22T"@MJOR"
ME_B-3_>:IU06U7Y!2_Q&I_O-5>3_`,L>TR?59.HB*(QB^-DC=U[6N'8X:J-L
M;-X2V#T^(HR:];J[=??HI1$T9RCU78QI/4KIV*Q$?&GZ91=VU+DD8'EKI]2?
M`6;J_D.TL[FCE'>KLF'[0W7?6K$BK^YJOK._;GZW%P1V%<].VII?E.)IWV=;
MJ5CHW?L2</WEDW;/%QR"/(,M8N0G0"]`8VZ_K\6_6K"L7QLD86/:US'#0M<-
M0?)'.4Y=:'@[>MUY!A:T9C!8ALQ"6"5DL;N3XW!P/F%E)(V*-TCW!K&@ESCR
M`'6H&?8[$ND=-29+C;#OSM"4PG7O:/5/F"J_M$W:.*.+`"Y#E!D0X'U.AL"%
MNADU<#N<1ZNN@XN3TZ$*LDH3\<NWAEVHQS<5FB=V48ZZVYGYFD29)X="'#0L
MKMX1CS&KOI*QJOX_:C%.DCH3MDQ=H`-95N,Z(D#@`T^RX>!*L`.J3E"EC;DK
M;NS8;"UL@B(H#A$1`!$1`!$1`%<R&!L5;LF7P#V07G<9ZS^$-O\`6`]EW8\>
M>H7=AL]7S#9(PR2M=@.[8J3#22(]_:#U.'`J54-F\`S)/BN59C4RE?\`)[;!
MQ'S7#XS#UM/EH5T1J1J+#5[G\[UYKR$LUG$F44'AL\ZU8?C,G"*F6A;J^'7U
M96_I(C\9OUCD5IRF9LVKK\-@MQ]X#[XLNXQTVGK=VO[&>9X)>8GCPOQV6WWW
M&XU:YLS&<ECMMQ.(C99RTC=[=<?N==GZ20CD.P<W=7:M3-CZ;\7+!:GGGNS2
M">2^7:2B8#U7M/Q=.0`X`<./%26'PU;#5710%\DDCC)-/*=Z29YYN<>L_4.0
M4BF=;!T:67':_MP\3,-\Y%=PF6MP73A,XYGP@T%T%AHW67(Q\9HZG#XS?,<%
M/3P16H)()XVR12-+7L>-0X'F"%PYK#09JD(9'.BFC=TD%B/@^"0<G-/\NL<%
MQX+,6)IY<1E6MCRU9H+MT:,L,Y"5G<>L?%/!$TJBYR&36J]UP].P%ET6<5.>
M79.]%B[LCY,1._<HVGG7H#U0R$]7R7'P/4K6N>]1KY*C-3MQ-EKS-+'L=R(4
M#A;UG%9`;/965TC]TNH6WG\IC'Q7'](WK[1Q[5LOK1<UUEKQX_/CO!=%VV%F
M1$7,.$1$`$1$`$1$`$1$`$1$`$1$`"=%4RW[;\N6DZX&A+H1U7)VGZXV'R+O
M!;\_<L9&\S9W&RF.:9G27+##QK0<N'SW<AV<3U*>ITZ^/I0U*L38H(6!C&-Y
M-`73'Z,<?^3TX+?VO9X[A'TG;8;)98X(7RRO:R-C2YSG'0-`YDE5?'12;4Y&
M+-6F.;BZ[M['5WC3I'?IW#_2.H<>M+I.UF7?BX]3AJ3QZ<\<K$HXB$=K1P+O
M(=JM36AK0&@``:`!'\,?[/R7R_)=N1UGP/41%S#A:+ERO0J2VK4S(8(FESY'
MG0-'>LYYXJT$D\TC8XHVESWN.@:!Q))56JUY-K[D>1NQEN$A<'TJSQH;#ARF
MD'R?DM/B>I5I4U*\I917Y9<192MDM3*M4FVML,O9&%T6&C.]5I2#0V#U2RCL
M^2P^)[%CO3;%RD.Z2;9UYX.XN=0/8>LQ=_Q?!6U8O8U[2UP!:1H01P(5/W%^
MBUT=WYMX^V1F#;M$<C)8VOC<',<`6N:=01VA9*I.9/L6\R1-=-L\YVKX@"7T
M=>;F]L6O,<V]7!6J*6.>)DL3VOC>T.:]IU#@>1!4ZE/#THN\7H_S;^:&IWR>
MIFB(I#!$1`!$)T5<M;3/M67T=GZHR%EAW9)R[=K0'Y[^L_-;J?!/"G*;Z)CD
MEJ3MJW7I5WV+4T<,+!JZ21P:T>)*KWVP9+,^KL[0!KG_`,PO`LB/>QGM/\>`
M[UMJ[+,FL,NYVP<I<:=Y@D;I!"?F1\AXG4]ZL(`"K>E3TZ3\OE]]NP7I/@5Z
M#9*O/*VSF[,N7L@ZCTCA"P_,B'JCSU/>K"UC6-#6M`:!H`!H`O44YU9U.L_S
M@AE%+0K,GX&VU9+RJYE@C=V"Q&-6GZ3-1XM"LRB=I,9)E<)-#7=N6X])JS_D
MRL.\P^\:>!*WX7)QYC#U;\8W1,P%S.MCN3FGO!!'DGJ=.FI[5D_;RR[A5DVC
MO1$4!PB(@`B(@`H+:K\@I?XC4_WFJ=4%M5^04O\`$:G^\U6Y/_+'M%GU63J(
MBB,$1$`$1$`$1$`"=%6MG?PME<AM`_C%*?1:7_HL/%P_6?J?`!;]J[<S,;'C
MJ;RV]DI!5A<!J6`^V_Z+`X^.BEZ5.&A1@J5V;D,$;8V-[`!H%=="DWMEEW+7
MQ?HQ-9=AY<HU<A7=7N5HK$+N<<K`X'R*@3L[?Q/K[/9$Q1#CZ!<)E@/<T^TS
MR)'<K,B6%:<%9:;MG@:XIE=K[51P66T\Y5=BK3CHPRNWH)3\R4</(Z'N5A!!
MY+79JP7*[Z]F&.:&0:/CD:'-<.\%5QV"R."/2[.V!)6'M8RW(3'_`.V\ZF,]
MW%O@GM2J:=%^7CL[[]J,Z2XEH10^*VCJ9*9U.1DM/(QC62G9&[(.\=3F][=0
MIA1G"4'ADK#)IYH(B)30B(@`B$Z#4JJV+UK:>S)0Q,SX,9&XLM9&,C60CG'"
M>WJ+^0ZN*I3IN;W):O<8W8Y\[_U3?9C<2`V6E*'2Y5O]D=\B,CVGGD1R`/'L
M71LI8AQ@^UVW794R40,G`DMMC7C,UQXN)^,#Q![E8:%"KC*452G`R&O$-&,:
M.`_[GO7+F\+!FJK&/<Z&Q"[I*UF/VX9!R<W^8Y$<%T<_"4>9>4/.^]_&S9GJ
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MI3:@-HL79>^',8H`96F#N-/`6(S[43NX\P>HZ*2Q.4K9G&PWJKB8Y1R<-'-(
MX%I'40=01W+*L5)<[#1ZK<_A[/#8;%VZ+.U$10&"(B`"(B`"(B`"(B`"C<[E
MV87&NLF-TTSG"*O`SVII7<&L'B?<-2I(G0*K8D?;'G9,X_UJ%0N@QP/)[N4D
MWGINCN![5:C!.\Y:+SW+O]+L63V+4D=GL0_%TGR6GB7(VW]-<F'QI#U#YK1P
M`[`N?:/(VM^#"XM^YDKH.DG/T>(>W*?#D.TD=BD\KDJ^'QD]ZTXB*%NI#1J7
M'D&@=9)T`\5';-XRQ"V?*Y)H^%+Y#Y1SZ%@]B(=S1S[2252,KMUZG=Q?POA;
M3&O\426+QE;$8Z&C49NPQ-T&IU)/62>LD\2>]=B(N:3<FV]6.E;((3H-2BJ^
M9L2Y[)NV=HROC@8`[)6(SH6,/*)I^4[K[&^*>G3QNVB6KW(R3L:N.V>0+?\`
M\O5)-#V7I6GEWQM/[1'8%;``T``:`+76K0TZT=>O&V*&)H8QC1H&@<@%M6U:
MF*RCE%:?F][?@R*MF]0B(I#'A:'`@@$'M55EKS;'S.LTHY)<$\ZSU6`N=4)Y
MR1CK9\IHY<QUA6M%2G4P9/-/5?FW<Q7&YJK68+E:.Q6E9+#(T.9(PZAP/6"M
MJJMFI9V6LRW\9"Z?%2N,ENC'[41ZY(A]99U\QQ5CIW*]^I%:J3,F@E:',D8=
M0X+:E/"L4<XO\L^(*5\GJ;UPY3+TL-4-F],(V:[K1IJY[CR:UHXN)[`N+,;0
M-I6&8^C`;N6E;K'68=`P?+D=\1O?S/5JL,5L\8;GPIE9Q>RI&@E(TC@!^+$W
MXH[^9ZRFC245CJ9+8MK^%Q\+F.5W:)R"CE-I_7R?2XW%.Y4&.TFF']Z\>R/F
M-\SU*Q5*=>C6CK58(X8(QHR.-H#6CN"WHEJ5936'1;EI^<6:HV"(BD,$1$`%
M6L6?@?:J_BCPKW@;]7L#M=)FCST=](JRJO[6UY6X^'+56%UK%R>E,:WF]@&D
MC/-A/F`KT'=NF])9=^SS\KB3W[BP(M5:Q%;K16('A\4K`]CAUM(U!6U0:MDQ
MPB(@`B(@`H+:K\@I?XC4_P!YJG-5![5'[PI?XC4_WFJW)_Y8]HL^JR=1>:KU
M1&"(B`"(B`"(H?:;)2XW#2.JC>NSN%>JWME?P;[N9[@4T(.<E%;3&[*YPXL?
M#6U-W+'1U:CK1J=A?KK,\>>C?HE69<.'QL6'Q%6A"2YL#`W>/-QYEQ[R=3YK
MN3UIJ4NCHLEV??7M,BK+,(B*0P1$0!'9;!T<U"QEN+5\9WHIF'=DB=VL<.(*
MAOA3)[,N$>;+KN,Y-R<;/6B_]9@ZOGCAV@*U+QS0YI#@""-""K0K66":O'T[
M'L]-Z%<=JU,89HYXF2PR-DC>-YKV'4.':".:S56FP]S9V5]S9Z/I*CCO3XHN
MT:>UT)/!COF^R>XJ:Q.8IYJGZ13D)`.Y)&\;KXW#FUS3Q:1V(G2LL<'>/IV_
MEF"EL>IWK%[VQL+WD-:!J23H`%C8L158))YY&QQ1M+GO>=`T#F255VQ6-LWB
M2PR2OL^"',@>W=?>Z]Y_6V/L;S=U\."RG3Q=*3M%;?C>_P`T!RMDM0^6QMD]
MT59\E?9\$MDG;ZK[O'BUAYB/M=S=R'#BK/6K0U*\=>O$R*&-H:QC&Z-:.P!9
ML8R-C6,:&L:``UHT``Z@LD5*F+HQ5HK9\[W^:!&-LWJ$1%(8A\]A?A2&.:M+
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M(B)#0B(@`B(@`B+58L15:TEB=XCAB:7O>[DUH&I*$KY("!VGLS6I*VS]*0QV
M<AKTTK><-<>V_N)]D=Y[E.U:L-*I%6KQB.&)@8QC>36@:`*"V6@EM^D[06XR
MVQD2#$QW.*N/Q;.XGBX][NY=.TV3FH8YL%+0Y*Z\5ZC3U/=\8]S1JX^"ZIQ;
MDJ$=FO;M[EIW7VDT\G-G`==I-J-.>+P\FI[)K6GUB,']H]RM*X</BX,-BX*-
M?4LB;H7'F]QXN<>\G4GQ7<I5IJ3M'19+Y[]1HJV;U"(M%RW!0IS6[,@C@A87
MR//(`#4J:3;LAB,VBR\U""&I0:V3*77]%5C/$`_&>[YK1Q/D.M=.$Q$.%QS:
MT;W2O<3)-,_VII#[3W=Y/_91NSE.Q;L3;0Y&,LM6VAM>%W.M7YM;^L?:=WZ#
MJ5C5ZK4%S4>_B_A?+W"1S>)A$1<XX1$0`1$0`7SW+SV\-F+D6R8?,7,,N0K,
MC$D=9Q_.-&H^Z'B>C'M<]!US^5RMJ_D78+"R;EEH!MW--6U&'EIVR'J'5S*E
M,1AZF$H-ITV$,!+G/<=7R./-SCUN/:NRE)<G6*:O?_'9;>_;QTUG)8\EXG%L
MO2QD&+;9QUCTOTK[I+<>[>DG=VN/=RW>KEHIQ5F_C;6$O29?"0F6.4[UW'LT
M'3?WD?4)!V<G>*FL9DZN7HQW*<HDA>.!TT((Y@CJ(/`@\E.M%R^JG=/Q7!^V
MQ^2V+MT3L1$7..$1$`$1$`%XYH<""`0>8/6O2=%`6MK*3;+Z>-BGREUIT=%3
M;O!A^>\^JWS.O<GA3G4=HHQM+4T[+$XZ>_L](=/09.DK:]=>0DL_9.\WR"G+
MN1I8Z$RW;4%:/Y4T@8/K5&SU?/-GK9Z]/%C(F.%:=M!V_*R"1PU+I'#0Z.W3
MP;PU)U5GI;)X:G,+'H@L6N9L6G&:0GMWG:Z>6BZZ\*>56<M=;9Y[<]..5]2<
M6^JD<_VXU;/#%4,CDSR#Z]<MC_;?NM]R>D[66_Q6/QN/;VV)W3O_`&6`#ZU8
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MS>C9PX.LO'K'Z+-!XO*XLUBOM7Q<^0P^3N4Q&!N4R[IX9'DZ-8&/XM))`]4A
M>8>UD=E,>VME\3++$7.EEOTB9PY[CO.<]F@<.)Y@$<%T4Z*4'.F[MY+8^/EE
MDWJ*Y9V9=$7)C\G1RM86*%J*Q$?C1N!T[CV'N*ZUPN+B[/4JG<(B+`"(B`"(
MB`"K&TF/9C^EVCI6HJ%V!FLSY>$5E@Y,D`Y]@(X@]O)3>4RE3#T7V[DFY$T@
M``:N>X\FM`XDGJ`4+1Q=O-W(LMG8NC;&=^GCCQ$'8^3J=)]3>KCQ7303A]1N
MT?7A\[O`2>?16I&XF9VVUU\F59Z/7I.:1B)`=XOT!$DVO,?)&FG6=3P%X`T"
MA<WA'W9(LACYFU<M7!$,Y&K7MZXY!\9A]XYA9X+-C*PR13PFKD:QW+55QU,;
MNHCM:>8=UIJSYR..GE%;-WRGO[GLOD>B[/4ET1%R%`B(@`B(@"J7@=E<R<I'
MPQ%Z0"\P#A!*>#9AV`\`[R/:K6#J-5JLUXK=:2O/&V2&5I8]CAP<TC0@JO[/
M6)L5=DV;O2.>Z!G249GGC-7UTT/SF<CVC0KH?U87_P`H^:W]WIV,3JNVQEE1
M$7..0.TV.L2PP93',WLGCW&6%OZ5OQXCW.'U@*3QF1KY;&U[U5V]#.P/;KS'
M:#W@\#X+K57J?]/;5243ZN/RQ=-7[([`XR,'9O#UAWARZ(_4IX-L<UV;5[^(
MCZ+OO-^T]*PQD&;Q[-Z_CM7[@YSPG\9'Y@:CO`4S2N09"E!<K/$D$S!)&X=8
M(U"Z.:J^'_`.T%C!.X4[.];Q_8WC]TB'@3O`=CNY"^I3P[8Z=FWPU\0>4K[R
MT(B+G'"(B`"(H&[D,[C[DK_@N._C]=6&I)NSL'>QW!WD1X)X0<W9>MC&[$\J
MSM(3ELC1V<9^+G^^;I'5`PCU?INT'@"NREM7A[I>P6Q!/&TNDKV6F*5@'$ZM
M=H?=JN;92%]J.UG[+"V?)O#XVN'&.!O")ON]8][E>G"5&]2:LUIVO3PU[A&U
M+)%B`#0```!U!5G#`YS:"UG7\:M;>IT`>1`.DLGFX;H[F]ZZ=J[T]?&,I4G[
MM_(2"K7(YM+O:?\`1;J?(*5QU&#&8^O1K-W8((Q&P=P"6/TZ3EMEDNS;XZ>)
MKSE;<=*(BYQPJMDC]L>T+,.WUL=0<V>^>J23G'%_R=Y#K4MG\L,-B);38^EG
M)$=>$<Y97'1C?,_5JO-G\2</B8X)7]+:>3-9EZY)7'5SO?P'<`NBE].#J[=%
M[ON]7P$EF\)*(B+G'"(B`"(B`"KV=RUI]IF#P[A\)SMWGRD:MJ1<C(X=9ZFM
MZSW!=6T&9=BJL<=:(6,C:=T52OK[;^T]C6CB3V+W`X5N'J/,DIL7K#NEMV7#
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MW\'TX9,ADS_9:^A+.][N3!WGR!7`)LMM2/O5TV*P[OSY;NV;`^8#^+:>T^L>
MH!3N,Q-'#U!6HUV0QZZG3B7GM<3Q<>\J^"%+^3-[OE^R\4)=RT(48#(YHB3:
M*YI">(QU)SF1?3?P=)]0[E8*E*M0K,K5((H(&#1L<;0UH\@MZ*<ZLIJSTW+3
M\\S5%(T7:D-^C/4L-#H9XW1O;VM(T*B-D[<TF+?0MN+KN-D-28GF[=]E_P!)
MI:?>IY5F]^!]KZE\>K5R;13L=@E;J8G'Q&\WW)Z73C*GWKM7RO.QDLFF69$1
M0'"(B`"@MJOR"E_B-3_>:IU06U7Y!2_Q&I_O-5N3_P`L>T6?59.HB*(P1$0`
M1%R9/(08K&6;]EVD,$9D=WZ=0[SR\UJ3D[+4&[$)<US.V%:D-34Q0%J?L=.X
M$1-\AO._95FT4)LM0FIXGI[C0+]UYM6NY[^.[]$:-\E-JM=K%@CI'+Y?CY"Q
M65WM(3(;+T;EDW:YDH9#_P"KJ.W'G]8<GCN<"N+X9RV`]7/5Q9ICA\)4V'U1
MVRQ<V^+=1X*T)HMC7=L-18EYKL?XN`..U9&FK;KWJS+%6:.:&0:LDC<'-<.X
MA;E6[6S4E*U)D-G9VT;3SO2UW`FO8/SFCV3\YO'MU73B-HHK]AU"Y"ZCE8QK
M)4E.I(^4QW)[>\>>B)4DUCINZ\UV_/H"EL9-HB*`P4=F,S5PU433[[WO=N0P
M1-WI)G]36CK/\.M:\UG(<1%&P1OL7IR6UJD7MRN_DT=;CP`7-A\',RV<OEY&
M6,K(TM!;KT==A^)&#R':[F?J5H4TECJ:;./VXBMYV1KQF&M6KS,SG0QUUOY-
M5:=8Z8/4/E//6[R'!6)$25*CF[O_`(-22"@L[A9;,T65QCVPY>JTB)[O8E9S
M,4G:T]O,'B%.HB$Y0EBB#2:LR-PF9AS5'IF,?#-&XQV*\GMPR#FUW_WQ&A4D
MJUG*%G'7?MAQ41DL,:&W*S/[5".SY[>;3U\E.T+U?)48;E25LM>9@>Q[>L%/
M5@K<Y#1^3W?&_P`3(MZ/4Z$1%$8(B(`*$VDQ<]ZG':HD-R=%_3U''D7`<6'Y
MKAJT^78IM$\)N$E)&-75CAP^5@S.+@O5P6MD;Q8[VF.'!S3W@@@^"[E5VD[/
M[7%O+'9EVH[([0'$?3:-?%O>K0FK0497CH\U\=VAD7=9A1>T&*.7Q$E>-_16
M6$2UI>N.5IU8[W\^XE2B)(2<)*4=4:U=69&8#*_#&(AM.CZ*?C'/$><<K3NO
M;Y$'RT7/M1CIKF+;8I`?"%&06JI[7MYM\'#5OFN-GX#VS+-=VEF07#L998./
M[;!KXM*LZM-\U452&CS7QZH5=)69R8O(0Y7%UK]<GHIXP]NO,:]1[QR\EUJL
M8?\``NTMW"GA5M`WJ0ZFZG25@\'$.^DI');28K%2"&S:!LN]FM$#)*[P8W4K
M)T7SF&FKIYKL^VWB"EE=DLB@*F2SF1MQ/CQ+:-#>U>^[)]V>WYL;==T_K'R4
M^IS@X.S];C)W"(B0TJFVM6OE68["N@BDL7K`:'N8"Z*)OK2.:>HZ#3Z2VC9_
M)XIH^`\N\0M]FG?!FB`[&N]MH\SX+W#CX4VIRN5=QBJD8^L>KU?6E(\7$#Z"
MD=H<F<1@[5QC=^9K=V%GRY''=8/-Q"[L=2."A'/@\U=]O<O$E9.\F5"IM`Y^
MT\V4SE*6"&BPTHIJ[73UXY-=97%P&HU]4:D<-"-5>J60IY&NV>E9AL0GD^)X
M</J7-@<6,/A*M$NWWQLUE?\`+D)U>[S<25RW-D\7:L&W#')1NG^TTGF%Y\=.
M#O,%+6G0J2LKI+)6S7AJKZZOL-BI11.(JUN[48GV75\W7'4[2O8`\?8=^ZN?
M(;=4JN-L:PV*V4:S2&G;B,;GO)T;H?9<-2-2">"FN2SF[4^EV?&J[T;C2UR-
MT8^'ML'S$;U'#:QL['VG#UC]!I`\7'L5G49L_BQA\+7IE_22M!=-)UR2..KW
M>9)4FEK34I6CHLE\]^IL5E=A$11&"(B`"Y[UVOCJ4URU((X(6%[WGJ`70JK9
M_P"IMI/0O:Q6+D#[/6V>QS:SO#/:/>0.I5I4U-WEHLW^<=$+)VT-^SU&>Y9D
MVAR<19<LMW:\+^=6#F&_K.]IWD.I6-$2U*CJ2Q/_`(1L59!$1(:$1$`%`9;#
MV8[WPSA2QF1#0V:%YTCML')K^QP^*[JY'@I]1>:S46(@C`C=8N3NW*U6/VYG
M]G<!S+CP`5:+FIVAFWLW]OYQ%E:V9P?;GC1BA:<V46NDZ#T`-UL=-^CW.WOY
M:<==%C3PEK*VH\GM$&.D8=ZOCVG>AK=A/RY/G'@.H=:CQLIDV3G:`7(G[1Z[
MQ&[I`6::=!ISW=.&_P`]>/+@K%A<W7S-=Y8UT%J%VY9JR<)(7]CAV=AY$<ET
MU%&G%RH=[W<%PX[=,MJ*[=IDFB(N$J$1$`%&Y[%C,86S2WMR1[=8I.MD@.K'
M>3@%)(FC)PDI1U1C5U9D7L]E#E\+7MR-W)R"R>/Y$K3NO;Y.!4HJS4_`VV=F
MGRJY9IM0]@G8`)!YMW7>15F5*\4I7CH\U^<-.XR+NLPB(HC!06U7Y!2_Q&I_
MO-4ZH+:HCT"EQ_\`,:G^\U6Y/_+'M%GU63J(BB,$1$`%6LV?AC:"A@V\8(M+
MUWCS:T_<V']9_'P8K#8GCJUY;$SPR*)A>]QY!H&I*@MDX)9:EC,VF%MK*2=.
M6N'%D6FD3/)NA\25>CT$ZN[)=K^%GVV$EF\)841%`<(B(`*.S&$IYJLV*TQP
M?&=^&>,[LD+OE,=S!_\`LJ11-&4H/%%V9C2>3*S2S-S$78L7M`YI,IW*F1:-
MUE@]37CXDG=R/5V+MS6=&/DBHTX?2\K8'W"J#IPZWO/Q6#K/D.*XMI;\=T/V
M>J5(;]ZS'Z\,OXN!A_.2D<AV`<2>7:HW#PNV*R/HN3<;,%]S&QY9^N]O@`-B
MEU)T'R3RZN:[HTH37.-=+_7?QX+AMV<)8FLMF\G\+@C0?)>NS>EY6P-)K!&@
M`Y[C!\5@[.OF>*F41<4YRG+%(JDDK((B)#0B(@`JH1]JF>#AHW"Y.70CXM6R
M[K[F/^IWBK6N:_1KY.A/2MQB2"9A8]IZP?YJM*HHNTNJ]?S>A9*^FITHJ[LS
M>L1FQ@\C(7W\?H!([G8A/L2>/4>\=ZL26I!TY87^<38NZN$1$AH1$0!&YW%,
MS.'GI%VX]P#HI!SCD!U8X>!`6&SN4=E\/%/,WH[;"8;4?R)6G1X]_$=Q"E56
M':X3;0.'"GF6[I[&V6-X'Z3!IXL713Z=-T]JS7OY9]PCR=RSHH6]M5BJ,_HH
MF=;N=56FPS2>8;R\]%R=+M1EN$45?"UC\>;2>P1^J/4;YDI50G:\LEQ_+ON1
MN-:(Z-KZ\5C9VPYUB*M-!I/7FD>&ADK#O-.I[QIX$K@I[92YFC!)A</:N2R,
M!>]_W&"-VG$%[N>AX>J"NZMLCC8YVVKW2Y.XWB)[S^D+3\UOLM\@N?"_@G:7
M)88C2"?[_J#J`<=)6CP?H=/GKHBZ7-N*Z3CGGDMSXO8]FT1XL5]+D-M-A\Y/
MCAF<C>:7T3TOHF/:8P(N4HZ3VR2S7EH.')6S#8K$X^JU^*JP113-#Q)&WC("
M-02X\3YE2+V-D86.:"UPT(/6%7MD7.JU[N#D)+L7.8H][F87>M$?V3I]%+*M
M.K0PZ8=BR5G\/U-45&7:6-$1<90*.SV2&'P=R_IJZ&,EC?E//!H\W$!2*K>T
M7W_FL)B!Q:^<W)Q_=Q#4:^+RSW*M"*E42EIJ^Q9L63LLB1V>QAQ&!ITGG>E8
MS65WRI'>L\^;B5&Y;\)[6XK%C0PU`<A8'>/5B'[1<?HJR<@JYLK]^SY7-.X^
MFVG1PG^YB]1NGB0X^:I"3;G6EK[O[7?<8UI%%D1$7,.%5<C!%M#M;#C9HF34
M,;%T]B-[=YKY9`6QM([F[SO,*S6)HZU>2>5P;'&TO>X]0`U)4%L=`\X=V3G;
MNV<G*ZY(#S`=[#?)@:%T47@C*IMT7:_M?OL)+-I&!V5EQ_K8#*6,>!_9I/N]
M<]VXXZM^B0O/AW+XOAFL.]\0YV\:3,SQ,9]=OEO*RHLY]R_D6+U\?FX8+:9'
M!C<UC<O$9,?<AL`>T&.]9OBWF/,+O43DMFL5E91/8JM;9;[-F%QCE;X/;H5P
M>@;28GC1R$65@'YB^-R73L$K1H?I-\T<W3GU)6X/YT\;!>2U1945=BVOIPRM
M@S%>QB)R=!Z6W[DX_-E&K#[PI^.5DL;9(WM>QPU#FG4'P*2=*=/K+\[1E)/0
MB=I,K+C<:&U`'Y"T\5ZD9ZY'<B>YHU<>X+IPF*BPN)@HQ.+]P:OD=[4CSQ<\
M]Y.I41C/PYM/:RY]:I0WJ=/L<_\`.R#ST8#W%6=4J_3BJ6W5]NQ=R\VQ8YO$
M$1%SCA$1`!$6JQ8BJ5Y+$\C8X8FE[WN.@:T<22A*^2`X\SEX,+CW69@][BX,
MBAC&KYI#[+&CK)7#@\-.RP_,9<LDR]AFZ0TZLKQ\Q$SN[3UE<V$K39S(C:._
M&YD8!;C:[QH8HSSD</EO^H:#M5H73-\TG3CKM?M\[WP6:+I9L*#S6%EL3QY/
M&2-KY:!NC'N'J3,ZXY!UM/;S!XA3B*,)RA+%$9I-69%87-QY5DL4D+ZMZN=R
MS4D.KHCU<?C-/4X<"I50N:P;KTD5^C/Z)E:X(AL;NH<WKC>/C,/9S',++"9L
M9,2UK,)JY*MHVS5<=2T]3FGXS#U._FJ3A&4><IZ;5N^W_#V7Q-IV9,(B*`P1
M%!;1[88796J9LI<9&[35L0.KW>7\SH$T(2F\,5=F-I:C:NE-8Q'I5-NMZA(+
M=?YSF<V_2;O-\UN=M-AXL37R5B_!!7GB$L9D>`2"->7,E?`MK/L_Y*[OU\#"
M*</$=*>+R/'J\M/%?)ILS=O66/MVIBT.U(8=-!KU!=35.--1J.[6[T;T[+7V
MB=)NZ1^MG?9,QEJ=U?#U;&0D;S<-(HQXN=_V4/B_LB9/:2>:*@<72;'(8RZ7
M?E=J.SV0OC.&DBVEQ+\=#AK?3/=H+<$_$$=<@ZES;,YR/9C-2ULDR8W!-NR:
MC4`]J3G:<>I!=^?V\A'C>K/T96AV@M0ZV]H982>&[6J1-T\SO+?)@;4[&"7:
M/*OW'!P!Z'34<0=.C[5`[*[3QY0R5Y&EDL9`!'LN!Y>:N37Z`(Y^>RW@O@YY
M3MJV0&2@R="C-:AVARKW0M+MPMA=O?N*EMV^VOJD.DEAF;S^Z5AIIXMT7U%S
M&2EP<`6$:$'K5$SF+^#+1#&D5)2=PZ\CU@KU/T^K1FW3JP3?8CDK5JD>E%Y"
MA]E:^YN]<PT;V`Z;\$I83X!P_FK72V_PUF**2SZ3CQ+[#KD)8QW@\:M^M?*9
MX7Q-Z,/$D1.@X<M5W7'NJX30.WNB;P:XDM&G<NZO^F\EG;!&U]S^;B0_4:JU
MS/I&T-B+-R8_!5)62Q7G=+9?&[>'HS""[B/E'1OF5:&M#6@```#0`=2_/^$M
M/KWNEHVI*,[VZB6#0!W7NN;R(5^QWV0+--S8LW7;-#R]+J-.H[WQ\_-NO@O/
MY7^EU8)0IYI>.>WT7=H=U'EM.;Z63/H:+FH9"IDZC+5*Q'/`_D^-VH_^#W+I
M7BM-.S._4(B+`"KN4S-FU=?AL%N/O`??%EW&.FT];NU_8SS/!87LK;S-V3$X
M*3<$;MVYD1H6P=K&=3I/J;U\>"F,7BJF'HLJ4X]V-NI))U<]QYN<>9<3S)70
MHJDL4U=[%[OV6W;EJEW+):&O#X:MAJKHH"^221QDFGE.]),\\W./6?J'(+JN
M4Z]^G+4M0LF@E:6OC>-0X+>BBYR<L3>8UE:Q5L5;L8#)1X')SOFKRZ_!UR0\
M7@?F7GY8'(_&'>%:5PY;%5LSCI:5IIW'\6N:='1N'%KFGJ(/$%1^SV3LO?-B
M,H1\*4P-]X&@L1GV96^/(CJ.JM.U6/.+5:_/SQ[<E71=B>1$7..$1$`$1$`5
MW:BI+`*^>HQEUS':N<QO.:`_C(_=ZP[VA3E2U#=J0VJ\@DAF8'L>.3@1J"MQ
MXJL8#\"YJ[L^[A`=;E#7ET3CZ[!^J\^YP70OJ4K;8^GV>?>Q.K+M+.B\)#1J
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M/"-SQ?K#YDA]<#P>#^TK*DY0K5&]CS[GF;#0*M;5CT!V-SK=?P?8`F(_02>H
M_P!VK7?15E7/?IQ9"A8ISMWHIXW1O'<1H4M&:A-2>FWLV^025U8WCB%6\@/@
MO;/'7P-(,C&:,QZND&KXC_K;YA=.R-N6ULY698.MJMO59]>>_&2P^_0'S3:Z
MG);V:M&N/OFN!9@TY])&0\:>.FGFJTX\W6=.6F:?I?W,;O&Z)Q%ST+D>0H5[
MD)UBGC;(PZ]3AJNA<[33LQPJYB1Z?M=F<@>+*P90A/9H-^3]YP'T5/SS,KP2
M32'=9&TO<>P`:E0>QD3QLS6LS#2:ZY]R37MD<7CZB!Y*U/HTIR[%XY^WF*\Y
M)'5M-D'XS9R]:BUZ81ED(',R.]5@_:(71A\>S$X>G09INUX6QZ]I`XGS.I45
MM'I<R^!QG4^V;4GZD+=[_46*QHET:48[[OV7N8LY-A$10'*YMBYUC'5L1&XA
M^4LLK.W>8C]J0_L-(\U86,:QC6,:&M:-`!U!5T?A';YQYQ8JIIX2S'^3&C]I
M617J]&$8=_C]K"1S;81$4!PB(@#"6*.:)T<L;7QN&CFN&H([PJ7M'A:^#I"?
M`S6<=>M3,@@AJR:122/.G&,ZM&@U.H`/!7=5H#X7VY<3QKX:$`=AL2CB?HLT
M_;75R6<H2<KY+-K8]R?:[(2:31S8YV:V6H049<2R_0@8&,GQYTET[71./$GF
M2UQ\%,XS:/%99YBJVV^D-]JO(#'*WQ8[0J54?D\'C<PQK<A3BGW?9<X:.;^J
MX<1Y%*ZM.H[U%9O:OA^S0*+6A((JT<)FL7QP^8=/$.57)@RM\&R#UQY[R]&U
M;J!W<]C+.-_OP.FKG_W&^S](!9S#E_&\7KX?%PQVUR+(BTU;=:[`V>K/%/$[
ME)$\.:?,+<HM-.S'"JN2_P"I<]\#-).,HELM\CE+)S9#X<G.\AUJ5VARKL1B
M7S0Q]+;D<(:L7Z29W!H\->)[@5E@<2W#8J.J9.EF),D\QYRRNXN<?$_5HKT_
MIQYW;HO=]VSCV"2Z3PDD!H-`O41<XX1$0`4/F\&W)=%:K2^BY.MQK6FC4M[6
MN'QF'K;_`#4PB:$Y0EBCJ8TFK,A<)G#?DDHWH/1,K7:#-7)U#ARWXS\9A[>K
MD5,/>V-CGO<&M:-22=``H;:3&U;-,79+0H6:0,L-X::P]NO:T\BT\_%?GW[(
MOV6<OFZ7P91`AK,]2S+!KNR/'CQTZ]T\NO4\NGF85%SJ>&.W[;[[-VW>)B:>
M'5ET^R']F^OBC+CMG2V>SIHZSS#?U?\`N?(=:_/&5S-_-6WVK]F2>5YWB7N)
MXKJJX&Q=KLLF9HZ0DZ./K$=O>M\F`$8W=]I=X\5SU>5)+!!6CZ]KV^FY'53Y
M'4DL5B`'$KH@DLT+`DBU;*.7J@_45VG`VG2;K`-">OJ\5<-G-A=HK08WT^"K
M7UWM=`]WEP_FH.K!9MF_M:S_`,2S?8P-_(BTZ>L^.1I`>_=#&R=@('8NK-?8
M\?ELC>MU*3'WI9F@SR2%C(>`U('QE]&V5V>AQ-"&%C]\M:`7=;NTGO7-@I]H
M'9'+#)T(65?2WBI+$?6<P'0%P\-.**4G.3>PC7CS<;;3#9+82#9J%OW]8M%Q
M#W"0\-_3B1W=RN.^5S0R$MT[%L.\5WJ.ESPZE1W-K9.8"YK]2'(57U[#=Z-W
MO'>%[H]IU_@LB\'DF4<,KQ(.5U9GRZ<=%9$0;HV-Q;H1WKR]8]41[NK=SUAV
MJUY;9A]JZZS5D8W?XO:_7WK74V-CXOM6G.)YM:."^ACRVAA4I/,Y%"29\WH%
M\<,>\`"UQW#V\58X6R3.`C8YSNK="O-79;$U)-]M?I'=0D.\!X!=LC8:L;WA
MC(V,&IW1HDK?JL)OH1*8&]2D5H<CA[K;5&5U*T\:N&FK)1V/9U^/-7[9[;"#
M*RBC=C%/)@:]$7:LE'RHW=8[N85&FO-LV7V'.UWCP&O(+3)%\(EE=K#O;X+"
MTZ.8X<G`]1':I\HY-'E$?J*SW[OE?B.CD_+)4G;5'V4D`:]2JUB]:VGLR4,3
M,^#&1N++61C(UD(YQPGMZB_D.KBJY!FK.2RD&RF8R\3(2"'V(?5DN<M(G'\V
M>>NGM=6FJ^D5JT-2O'!7B9%#&T-8QC=`T=@"\6I2?)6L6<GINMOX^VW/(]N$
MU55XZ&NA0JXRE%4IP,AKQ#1C&C@/^Y[UTHBXVVW=E@B(L`*!VDQEB9D.5QK1
M\*T"7P@_GF'VXCW.'+L.A4\B>G-PDI(QJZL<>*R5?+XRO?JDF*9F\->!!ZP>
MP@Z@^"[%5X?^GMK#7TW<=F'&2+LBM`:N;W!X&]X@]JM":M!1E>.CS7YPT,B[
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M6"*"%O*.)@:T>04%LF31%_`O.IQL^D.O,P/]:/W<6_15D2\HE/$X-Y;-BMLR
MTT-@E:X1$7..$1$`5O:0?!^4P^:'`0V/19^SHIM&\?!X859%'9['#+X&[0Y.
MGA<UA^2[FT^1`*QV>R)RV`HWG#1\L0,@['C@X>3@5>72HQENR\<U[B+*31)H
MB*`Y6\7^#ML<O0/".XQE^$=_L2?6&GS5C(!&AY*NY\>B9_`9+DT6'4Y#\V5O
M#]]K?>K&.2O7Z2C/>O3+V3[Q(Y717-C]:M*YB7'CC;<D#!U]&?7C_=<!Y*QJ
MN0GT';^Q%R9D:+91KUR1.W3^Z]ON5C1RC.>/_9)^.OG<V&EMQ`;:2O9LI=BC
M.DMH-JLTYZR.#/\`D5-P0LKP1PQC=CC:&-'8`-`H':,^DY?9Z@/SETV'?JQ,
M+O\`46JQ=2)Y4H+?=^WLS%UF5RL/3=O;\Q]FA3CKM_6D)>[ZFL5C5=V4^[G,
M9#GZ5D9=UW:V/2,?Z"K$CE&4\.Y)>6?G<(:7"%%%[1WCC=F\E<:='Q5GN9^M
MIH/K(4H1<Y**U8S=E<X-D!Z15R&4Y_"%Z65I_NVGHV?4S7S5C7!A:(QF$HT0
M-.@@9&?$`:_7JN]/7DI5&UIL[-GD9%62"(BD,$1$`:;5B.I4FLRG2*%CI'GL
M`&I_@H;8^M)'@([=@:6L@]UV;7J=(=0/)NZ/)8;9%T^)@Q;#H[)V8ZA(YAA.
M\\_L-<K"UH8P-:`&@:`#J"OU:/\`U/R7W?D)K+L/41%`<+P@$$$<UZB`(&UL
MCC9)W6:72XRV[B9Z+^B)/SFCU7>8*T=)M1B?QD5?-5Q\:+2O8`_5/J.\BU65
M1V>R8P^$MWRW?=#&2QGRWG@UOFX@+HA5J3:@^ELS^=?,1Q2S615J.?Q^T&VC
M'6)?1&XYA97JV](Y'V'<'G0\RUOJ\-?:*O04#B]FJD>S=?&Y*O#;<09+!E8'
M;\KCO/=Q^<2M/VLV\;ZV!R\]5@XBI:UL0>`!.\WR=Y*M9T:DK0=DLE?3QUSU
MT[Q8XDL\RR(JT-H<CC#IG</+'&.=NCK/%XEH&^WW'Q4SC\M0RT'34+D-F/K,
M3P=/$<QYKGG1G!8FLMZS7BAU)/([$1%(8+QS@UI)(`'$DKU4'[(&?(8_"5I"
MUIBZ6](UVA;%U1@]KOX>*I3AC=F[)9M[E^>89Z+4^9_9D^R!:R5;T'%3[F-Z
M3<+FG0S$?&_5UY>_LTHNR\3#B613#U7O<2"-?!0>U>0DM91T+MW=A.@W1IY:
M*1V<M]+`(RX`MX<U'E5:4XJRLEHOS:]OP>E^GTH*NXMYV)4X_P!(RE2L90V&
M-YW2WAH.Q=]S+U,=(8*K\>3)P>Y^A+5V8R)L3Y9#$R9[H]UC7=_6HJ_@JU:`
MN?CXCP)WNCY+A516M(]B?))YX+'9C<O5LY2.E\'TK&NC=8Y>?SO_`(7T>/(X
MO'XN2:N1+'3;I8?$TOW#V:#K7P*%CW3:,F,`!]4QMT\@5]4^Q16,TF2KOLO#
MG;ND1/`@<=[O*RI"+T.:G"HDW+1'T_`79K]$V]V2*'=#MV1FC@NN>X3?A@:P
M[G1NDD=U`=06YE=U3&&!FFKB-25@8FM]5OK./XR3MTY!>CR2E99GS/ZCRBTV
MD;(?58#UK;OZ'1:P=!IV+*(!S^_J7>TDKGA/I.YF'M/`\T="]XU8U=$==K?6
MDXGL[%N+P!H-`.P*,JMGT2JI?['$VI,>>@\2MK*;FCUGCBN+/9*;&XTSPLWG
M%X;J>3=>M4*YF;]F4OFMR.&OJL:=T#W+KY-R6MRA8DTD3G4IP=K79]'F;'7<
M.DGC:7<@3Q58VLOLCQQ@AD#GS.#3N\=!UJ!H7Y[%O5Y?(TC=+GG712T4I'M-
M:[3EO#F%UPY(Z$U*3O8C*I&6458A*F.M6-.BB+AU'3@K7B<2*(,DI#IW<^Y2
MM.N9:@?$`!KR`6,TC*T;GS.$;&\7%QTT25N63JMP1L:>%8F?-L_LYDY\Q*^M
M0DD8Z7I`]C@-1X]J^@[$[27K#&8?/1/AR;&%\3Y--;$8Z^'QAU]O/M5=O;5]
M-+T&-;ZO7.X<_!1ENPZ3<F-KHK<3Q)#.3H6/'(^'41U@KMJTZG*:*IUHI6T>
MU?;>/0Y5S$\LUM/M**%V7ST>T.&CM:-988>CL1-.NY(.?D>8[BII?,U*<J<G
M"2S1]%&2DKH(B)#0BU6+,%6%TUB:.&)O%SY'!K1XDJ`=M:RZXQX*A9RKAPZ:
M,='`#WR.X'Z(*I"E.><5EY>.ACDEJ2&T.*^&,--68_H[`TDKR_HY6G5CO>/=
MJHZIMIB_@>M9OV&06Y`6OJ-U?*)&DM<T,&KCHX'J3X'SN5XY;+>B0GG5QFK/
M)TI]8^0:N3#XRGLUMC8HP0,9!D*XG@>>+@]FC9&[QU)U!:[B>U=4(T^;<).[
M6:MYJ[\='H3;E>ZR.OX2VARO#&XQF/@/]IR7MGPB:=?VB/!9,V1KV7MES=RQ
MEY0=0VP[=A:>Z)NC??JK&BA^XDOXUA[-?'7V&P)ZYF$4,<$38XHVLC:-&M:`
M`/`!9HB@.$1$`5O*CX-VNQ62'"*X'8^?LU.KXC^T'#Z2LBA-K:<ES9JX(/RF
M!HL0'LDC.^WZQIYJ2Q]R/(XZM=B_%V(FRM\'#7^:O4Z5*,MV7NO6W<(LI-'2
MB(H#A$1`!5S9<>B7,WB^0K7G2QCJ$<H$@^LN'DK&JX_[SV_B<.#,ACW-/>^)
MX(_=D/N5Z.<90X7\,_2XDM4RQHB*`Y!;8UWV-E+YB_'0,%F(_.C(>/\`2I>I
M89;IPV8_8EC;(WP(U_FLYHFSPOB>-6/:6D=QX*#V*E>_9.C%(=9*S75G]QC<
M6?\`%7UH=C]5]A?\C7M*/1LE@,B.!BO"!Y^9*TL_U;JL8Y*!VSA?+LE??&/N
ME=@LL\8W!_\`Q4U!,RQ7CFC.K)&A[3W$:HGG1B]UU[^[!=9D#+]W^R#6:>+:
MN->_P,DC1_!A4Y:G%:I-.[V8V.>?(:J#Q6LVV6?F</Q4=:LT^#7//^L+?MA8
M-;9#+/'M&L]C?%PW1]93SABJ0I\(KQS]Q4[1;[3S8V`P;'XIKAHY]=LKOUG^
MN?K<IQ:*==M2E!7;[,4;6#P``_DMZC5GCJ2EO;'BK)(*N[8CI\=2Q_5>OP0N
M'S0[?=]3"K$J[F/NVUNSM?F&.L62/U8]T?7(GY-E43W7?@KF3TL6)$10&"(B
M`"(B`*Y9UN[>T8?S>/IOLN_7D.XW]T/]ZL:KN`^^=HMHKW-OI$=1GA&P$_O/
M<K$KU\G&.Y+SS?FQ(;6$1%`<(B(`*MYW3([187$::QM>Z_./FQ\&`^+W`_15
MD5<PGW[M3G<B>+8GQT(CV!C=Y_[S_J5Z'1Q3W+S>7O?N$GG9%C1$4!PH;(;+
MXK(S^DNKF"YU6JKS#*/I-TU\]5,HFA.4'>+L8TGJ5KT;:;$_DUJ#,5Q^:M:0
MS@=TC1NN\P/%;8-K\>)FU\G'/B;+CH([S=QKC\U_%CO(JP+5/7AM0NAGBCEB
M<-',>T.:?$%5YV$OY(]ZR^WEWBX6M&<>8RT.)PUC(O\`7;&S5C6_G''@UH\2
M0/-?$]L*UW#-;;O2.EER.KIY`1N-GT)W?#30#P"O\N"Q[-L:]+',DBITHQ<L
MUVRNZ'I2=(M&$Z`CUG<.P+S:S#0Y;$6:5F,/@F:1O::[AZG>(3UH1C2YN#ZV
M;V=B]^.0L:KC44FM#\H9LM?E)9&ZZ/T=Q[5GA)V0WF[Y`#CIJ3R6.;I6<=DI
M:-N/<F@=NGL=WCN*X(GB.0.(U'6%PN%X86=\:JARCG([S[)CJO3;CM=2X:@@
MKMOEM.FY\\@:S=T##QU5(V7VBE;#-$3J1P87'BT+;D\D^R?7;/8TUU,0U#5Y
M<J<E/"SZRERJ$J6,X*T<^1NR/@8R.!FIX#7WKZ3]C6L69ILK>!$;F.TZM5\Q
MP>#N6,BV7'V_NF^-V.1KF[Q[^Y?>=F<6_'WRRU'$VY'$UTCXCH'D]@[%UQI8
MIJ,6>?6Y6J/)Y2JQLW?:7"1P(8PG>W!Q.O,K%HU/!>-`'!91D-.I7MQCAC9'
MYY7J.K-R-XB&G%VJW1,;'KP7D+`27$<.I9.//CKJHRDV["15E<R+M=5CJ.?U
MK'71>ZZ]R7"-BN8SPQV8'13,#HWC1P/6HZ/9K#1LT%&,GGQ)4FT.=J0"?!>[
MKC\4^)3QJ3@K1DT9@OG:Y!7,%#$YTE2%H:=/4:.14?'1E#R!#(7'AH6E6T@@
M<01JFOK:@$+HARR:C9YDY44WN-="-U:FQCN!`XZ*N[>!LF*A8U^CI)1ZO:`K
M/J>/#@%3MI^EL92.(Q^I&S5A\>:WD*<N4J;V9C596IX2E/CLP!HB:&N</6?S
MT'8%S?!<4DH?.7R/[7.5G93/32;\9:S=]ZXO1"7.=H>?U+Z>'*%L./-&_9+*
M_:[M%$XDMHVRV"PT\F'7U'^1.G@5]H7R6KL[&^G+Z2-3.TM<#U`J>V;I7=I,
M9IE\S:<VK(ZM+4K'H`2SAJ]X]9VHT/,#BO#_`%*%*M+GD[6R?'=\9VV'L?I]
M:6'FWW%DR.T^*QLWHS['36SRJUFF64_1;J1YZ+B])VFRITK5(</7/YVWI-.1
MVB-IW6^9/@IC'8G'XF'H<?3AK1]8C8`3WD\R?%=J\GG*<.I&_%_&GC<]*S>K
M*_!LA0,S;&2?/E;33J)+K]]K3\UGL-\@I]K6M:&M``'``#DO44YU)SZSN,HI
M:!5S;%IKX^MF(P>DQ=AE@D<S'[,@\-QQ/DK&M%RM'=I3U91K'-&Z-P[01H?X
MK:4U":D]/;:$E=6-S7!S0YIU!&H(ZUZH+8ZS)9V6I-G.L]=IK2Z\]^-Q8=?V
M=?-3JRI!PFX/8[`G=7"(B0T(B(`\<`1H>76J[L9K!AYL:X^MCK<M4?JAV\S]
MUS58U7<9]Z;:9NL>`LQ07&#OT,;O]#5>GG3G'L?@[>[%>J98D1%`8(B(`*N[
M2CT?(X#(#G%?$+C\V5KF?QW58E7MMP1LI;F:-75G1V!W;DC7?P!5^3?RQ6_+
MQR]Q9]5EA1>`@@$'4'BO5`8*N[,_<;^T%/\`19%T@'=(QK_XDJQ*NT/O?;K+
MQ'E8J5YQX@O8?X!7I9PFN'NON++5$Y;@;:IS5W#5LL;F'7O&G\U$;'SNL;'X
ME[O:;6;&[Q;ZI_@IU5[8_P"YXV[3XZ5,C9B'ATA</J<$1SHR[5[_`&!]9#9K
M1^0VBG^7DW,YZ^S%&W^17NV?K[/]!QUGM5HN`UYS,6&QD@GQ=RT"?N^0LR<1
MH1]T(_DLMJV[XPL7#1^5@UU^;O._XJ^G*EP:\O\`@3_\9840<D7"5"KI^Z_9
M#:#H1!BR0.POE_\`Z*Q*O8_[KMQF7\=(JE6(<>'$R._F%>CDIO<O5I>XLMA8
M41%`8(B(`(47/>EZ"A8F_1Q.=[@2M2N[("&V+^ZX`VSSMVK%CR=*[3Z@%85"
M[(P]!LAAX]./H<1/#3B6@G^*FE7E#O6FUO8L.J@B(HC!$1`&,CVQL<]QT:T:
MD]P4!L4QQV7K6GC[I<=);>>TR/+A]1"Z]I[!J;+96<>TRI*6^.Z=/K75B:OH
M6(I5>70P,C]S0%=94'Q?HON)_D=B(B@.$1$`%X2`-3R7JA]J[CJ&RN3L1G20
M5W-C_6=ZK?K(30@YR45M,;LKD1LWK:J7,N\$OR=E\S-[JB'J1_NMU\U+::<#
MIQZDJ4VTL94H1Z#T>)D(T[`T!>D:#^*>M-3J.2TV=FSR(+(JNU_V-\!MA6)L
MP^C70W2.W"/6;XCD0O@.U/V(-I]FWOECJG(4AJ1/5&]H!\IO,+]5#4'AR6T:
M'N*B53/PHYLD+W,<',>#H0>!"LVR.7$%GT6P06..K">>]V+[YM[]B+';6V'W
MZKQ1R3P-Z5K=62:?*;V]_-?'IOL.;;8_+,CBQ3K<3'@B>"1NZ1KWG4>Y)5@I
MQ:9U<DY2Z-531]$V9BDFR0LVBR*M$PR;@;S([2OI&R^,?/AO2<FQK[5B1TN\
M!H6M)]4>04-@]A;;J\#<JYD4;0#)#&[4O(ZB>Q7X,;$UK&-`8T:`=@7/R2%2
M'2D=?ZIRF'*9)1S1$V:3X-7#5S.WL7*!O'@K%P<W0K@L4PPB2,>KKQ"]6%;9
M(^9Y1R7"L4#4T".,#77M6.OUH3J5CK_]ZH7$XFS(KSFL8I8IAJR5K@#IP.JV
M$[OL#CVE8\BL*,I9[#JK-]31PT'4MHC:[UB.(ZE7[N4?1GC;*R9Y=RZ-A<%V
MOS#HXFR/K6-TCF&:Z)949//>>C3G&,<.X[[1/1C@.'+0+DU6RKDH+P+-'`_.
M:0M,K#&\M)1%./19R\IC=XT\C(O!'!1N0I"S9$H]H-T"[6Z:?4O2T'CKQ"I"
M3A*Z.5K$K,CQC(Y6-Z?4GL".PT$0$D?K=SEWZZR@=H6V9S(J[B]P`[T<_4ND
MF%/!).ZT(?HP[U>I,"[X-VOGK<H<E6$S1U=+&=UWF6N;[EM@FA>_1KVN[@5R
MY=XJ9+#7FG3T>\QCC\R4&,_Q"Z8XI-TWM3^5YV*<GDE44D7I$ZD7F'MA$1`!
M$1`%=V>^]LYM%0ZFVVVF^$K`3^\URL2KK/N'V0IFC@+6,:X]YCD(_@\*Q*_*
M,Y*6]+TS\Q(:6"(B@.$1$`%7;GWOM[BY>'WS2G@/BUS'C_DK$J]M#]RS>S=C
MAPO/BUU^7"\?R"OR?K-<'Z,6>A840<D4!@B(@`HW:&`6MG,G`0")*DK>/>PJ
M26$S.DA?&>3FD>\)H2PR4MQC5U8XL%.;6S^-G)U,M6)Y/;JP*04#L7(9-C,3
MO:ZMK-8=3K[/J_R4\GKQPU91W-F1=XIA5V72+[(54\/NV,E;W^K*P_\`(JQ*
MNY0[FVFS[AKZ\=J,Z<O98[_BFY/G)K@_1L)Z%BZE3*61;C,OGH'.8W>R'2`%
M_P`J&(JYKXYMWD7X[:^XQCGCI6QR'33GN-;_`,5T_IU#GYRI;U[HG6E@2D7W
M8&5D^Q]2>,$-EDF>-1H>,KN:W;2LZ2]L\`=-,HUWNBD*Y?L;[OV@8K=^0_7Q
MWW:K/:WTOT_9XTFQF87SNB8D,UZ&3GIQ[5LU;EM1+?+W!?QKN+..2*`WMK/T
M6%_S9?Z4WMK/T6%_S9?Z5R<S_9>)3%P)]5[#LTVNVC?KS=6;IX1?_*RWMK/T
M6%_S9?Z5!XAVTGVQ;0=%'BS-T\/2[\DFZ#T3=-WAKIIV]:O2HO!/I+3?_9"2
MEFLORQ>T4!O;6?HL+_FR_P!*;VUGZ+"_YLO]*AS/]EXCXN!/HH#>VL_187_-
ME_I3>VL_187_`#9?Z4<S_9>(8N!/J*VF>8]E<N\<VTIB/V"N7>VL_187_-E_
MI49M&[:?[6<IT\6)Z'T27?Z.27>W=TZZ:C3715HT?J1Z2U6T64LGD67#L;'A
M:+&C1K:\8`[MT+M5;K.VJ]%AW(L-N[C=-99==-/U5MWMK/T6%_S9?Z4DZ-Y-
MXEXFJ66A/HH#>VL_187_`#9?Z4WMK/T6%_S9?Z4O,_V7B;BX$^B@-[:S]%A?
M\V7^E-[:S]%A?\V7^E',_P!EXABX&.W''9&['P^ZF.+B/E2-;_-6$<E1MJ_M
MB?@7MN,Q+8#8@U,<DNNO2LTYCEKIKW*:WMK/T6%_S9?Z5>5'Z,5B6KV\(BJ7
M2>7YF3Z*`WMK/T6%_P`V7^E-[:S]%A?\V7^E0YG^R\1L7`GT4!O;6?HL+_FR
M_P!*;VUGZ+"_YLO]*.9_LO$,7`GU7=L?NF-HU"1I:R-:(Z]8Z0./^E9[VUGZ
M+"_YLO\`2HG,/SGPC@&Y)F/;`[)Q_DSWN=O;CR/:`X*W)Z3512NLL]=V8LY7
MC8LS]WI0[CO<RL=T.'>MA:/5!Y]_-8\G<N!7&+;,P#2"LM.'!;-W>7FA"P>Q
MXW4`$A;&Z=G%`.M9#F@U(R'@O'<0LM%B1Q6FG@YKTCCW%8GFLP>I`$39C,<Q
M`]D\0J?MIGW8ZEZ%5>&69QQ?^C9UE6_:')U<5BGVK+]W=.C&CFX]@7Y_VLVE
MDL6I;3R#(\:`:\`!R&B]+D=/'TY:(\FK2P5<CZAL%D*$E'T%LQ-B(ZN;KU'K
M5V+&$<%^:/L89:,;9"2S;,<DH+='.T![M%^E8@!&/6UX*7*ETL:VG9&3T:-%
MJPVC%TLI(8#IKIJL*V9A>PN;TA'ZA6ZS897CWY2`P]HX+&OEJSAZKVD=P4E&
M\;VN9=IZV,XLI7D.@!U[V$+/(/C96Z?F&CJ6'PM6$C8R1OO]EN[S7/E)XO1-
M&<`X:K(QO-65B7**B5&3;N04]V><D[SFMUX`<%(XJPZ1IC>XNT&H)43KQTTU
MU77CW".VT<>Q>C4IK!9(^>IU7C5V2S7%MQO9HHK.3N?:,6\0P`:J4.@N@Z<-
M%`Y1X?;<[7B.04>2Q3J7X%,;49+B<P^YZ/;J".1"UYJZZ39Z]TA]=C!,QW86
M.#A_!;6DR,X\-.I<.7&Y@KP((U@?W_%*].$4YQOK="4ZKC.Q]88\21M>WDX`
MA9*L4)-JGX^LYL>'+3$P@NDEU/JCGHU=&]M9^BPO^;+_`$KP70L[8EXGUV/@
M3Z*`WMK/T6%_S9?Z4WMK/T6%_P`V7^E9S/\`9>)N+@3Z*`WMK/T6%_S9?Z4W
MMK/T6%_S9?Z4<S_9>(8N!C?!CVXPT@UTDJ6HSQX<#&[^2L*HN2DVD&U&#$D>
M*Z8BP(]U\A;IN`NWN&HY#313>]M9^BPO^;+_`$JU6CT8=):;^+%C+-Y$^B@-
M[:S]%A?\V7^E-[:S]%A?\V7^E1YG^R\1L7`GT4!O;6?HL+_FR_TIO;6?HL+_
M`)LO]*.9_LO$,7`GU7]JAZN'>"0696N1YDC^!7N]M9^BPO\`FR_TJ#VG.T1J
MX_TIF*`^$:VYT;Y3J_?&[KJ.6O-7Y/1^JNDO$6<NCH7L<D4!O;6?HL+_`)LO
M]*;VUGZ+"_YLO]*AS/\`9>(V+@3Z*`WMK/T6%_S9?Z4WMK/T6%_S9?Z4<S_9
M>(8N!/KPJ!WMK/T6%_S9?Z4WMK/T6%_S9?Z4<S_9>(8N!CL0SH]DJ;-==UTK
M=>W25ZL*HFR+MI/M=B]$CQ1AZ:?0RR2!VO2OUY#EKKIW*<WMK/T6%_S9?Z5?
ME-%\_/I+5[>(D)=%9$^J]FG[NU.S8TUWIIV__P`+O^RRWMK/T6%_S9?Z5%WG
M9S[9=G1?9C!]]2;O0/D)TZ%^]S'9]>BRA2M)NZTEMX,V4LO#U+FOB7V596Q;
M8`%IU-5AX#O<OMHY+XK]E@5_MMAWMW>]#9K^T]=?Z)_\KN9/E/\`&?1-@(6U
M]C:<#7$MC?,P$\^$KENVF>YEW9XMZ\HT>^*0+#8N,5\3:J\=8+]F,D\S]T)_
MFL]JR6,P\H.@CRM?7AKP)+?^2YY/%RN3WM^=QUE318!R1$7`5"KV'?KM;M&S
M3DZL[7QB_P#A6%5['#HMN,VSC]UJU91P[.D;S\@KTNI/L_\`Z0LM5^;"PHB*
M`P1$0`43M2"[9/,!HU)I3:`?J%2RY,I"+&)N0G322![./>TA4I2PSB^*,EFF
M,8\R8JF\G4N@82?HA=:B-EINGV3Q$O/>IQ<OU`I=956&<EQ81S2"(B0T(B(`
MKVW`'VIVG'71DD+SH->#96%6%0NU\!L;'Y>-OM>B2.'B!J/X*3I6&VJ4%AIU
M;+&UX\"`5>7\$>U^B%769O1$4!@B(@`J]M7HUV#E('W/*P<2=--X.;_R5A5>
MVV!;LO8LM!+JDD5H:=71R-<?J!5^3?S16]V\<A9]5DH6G5HT/`D<EX_@`1U%
M;007$@ZAPU!'8M<@!B<!S[U`5H]8=%FX:\0M49]4%;0=$#)G@0'BL7'CJHJ[
M?L?#57'5WLC;)#)/+(1JX-!#0&]^I"U1N+*2B3@/!:WNT'>JS#D[N.R@H.L>
MF13-=(R:;0.C(TU;PYJ1BL3.E:7R;[7.TY::*$ZT8O+-;]A!<JB]$2H<'#CS
M6NS:BIPNEE/`#EUE:R_=[UR9.OZ52<6#[LUI+-5T02<DGH7E*R;1\IVXR\V1
ML%\[]&1ZEC`>#?\`Y[U\:S5EN_H"YR^B[5[SY'.<7'>WAN]_9XKYCD2X.(UT
M/>OHJR5*FHQT/,I2QU+LAXII(+;)HW:21O#FGL(/!?K'87:/[8<#!9Z1KI&L
M`>!U%?DP,=)(&,:7.)X`#75?9_L.8_.5'V-VO-T$VGM#0,[UY$(IJ5]-YW5F
MDDS[F^=I;NG=<.P\EMKS-:\-#6<>H!52#)R#;@8":`F!E%UM]K4[NN\`&A36
M-%9]CIX[#'.$C@`U^H\%R3JP62.9U[27$FQ(Q\C6N`!X[O!06:J%G1R`N+0-
MPJ1E<]L\3VM)W9-#X%>Y.$S02L^(YFNO80BA5PU$Q.5?6HRCM168V[O/J6=0
M[MIAUX[PT2(M8-'.U/>M\<#`X2!W$\EZ\I6O<^5IU'&5V=[W@60[74#@H"UQ
MM2$GBK"*[1$2X\=.:B)H6VFET9&\.I1Y-)1D[Z'1.4X.\]'F1[`>#AV\EHVA
M;I@;DFO.!PT/#F-/YJ2@JO:_UF\.M<><A%B"&HT@FS9A@#?UI!K]0*[H37.Q
M)PECKQ4=Y])IQ=#2@BTTW(VMTU[``MR!%\^W=W/NPB(L`(B(`KV2=O;:X.,:
M>K7M//'B!I&/YJPJNNUF^R$P?%KXMQ/#D9)1I]495B5ZV48+A[M^XL=H1$4!
M@B(@`J]M8&F+$L=\;*UM!VD.U_DK"J_M)]TR6SL`U];)!YT[&12._P"ROR;^
M1/=?R0L^J6!$')%`8(B(`(46$KQ'$]YY-:3[D`06Q+Q)LE3>!H'.E=IXRO5@
M4!L4PLV,Q.O-]=LAX:>UZW\U/J_*?YYVWOU%AU4%7\RT.VIV;U/LS3N__A/_
M`'5@5=R@Z3;;`,'..&U*>/+@QO\`R1R?KOLE_P#JPGIX>I8E\1^RK$)-L&DN
MTTJL'UN7VY?&]O<<_([86WQM?I$V.,Z`<]P'_DO0_19*/*;MVR?L1Y2KPL?0
M]F=&7MH8.&K,FYV@^='&[^:;:Z,V;?-^@LUY>>FF[,Q>8DF+;'/P$_C6UK+1
MXL+#_H"Z=K:YM;(Y:)OM>BR.;X@:CZPN6Z7*8-_U]$/_`(-=I,HN>A9%S'UK
M(Y31,D'F`?YKH7&U9V94*N_B_LA\1H)\5P/:62__`-U8E7<N.AVOV>L<A)Z1
M6)[=Y@>![V*U#-M;T_)7]A9["Q(B*`P1$0`7A&HTZBO40!7MB?5V6K5R=75G
MRUSW;DCFCZ@%857=FOO?);04#SBOF9OZLK&O_CO*Q*_*?Y9/?GXY^XL.J@B(
MH#!$1`&JS"VS6E@?[,C"P^!&BAMC)GS;(XX2?C(8O1W_`*T9+#_I4\J[LW]Z
M93.XP\HK?I,8^9,-[_5OJ\,Z4ENL_;W0KZR98D1%`8(B(`+FR%1E_'6:<GL3
MQ.B=X.!'\UTHM3:=T!`;+6Y+FS6/DEU$[(^@G!YB1AW'?6U2CO6WAQ!'/50>
M,/P9M3EL6XZ16],A6UY>MZLH\G`'Z2FB\D'=83U<%6O%*HVM'FN_XT))]$UL
MU;P[%FZ1K&:N(`',DK@R>0CQN.EN2MU$;>#&G0N).@'UJ+92%[2?+V^E>3J*
MT;RV*/N('M^)X=REBIK.<DCGG747A6IUS[1TVO=%6$MR4<"VNPN`/87<AYE1
M[?3;.2DO3P""3H>ABB#PXM83O'>(X:D@<E+:P5JP9"R-D;1H&,``]RQCB+6:
MGVG>L>Y+.<*CYJGMU=]GW.2M*4\KE'K7\F_-&]D*L44<$3H(*[)>`<3ZSG'K
M.@T&G:N]NUL-6S'Z5+6CB#@2UKR7#7AK[U+92O5KUK%YU,3RQL+]T#4N(7S+
M&5)<[GWY#+1/BC!:_<=$1O`<FCN"]-TJ$J+O');%['C59UZ,NE4R/L0FZ:8/
M!U:QO,=9*WB3U0=5`T\S7=(VON/CUX-<_@'%29D+>`7#2Y-*"O/5YGIT.61G
M&Z=RK;2;(LO.FFKZ!LC@]S-.3NT+Y7F_L99.S8?)6<'=1:."^\S6A#&7.'UK
MDA>TR;YC'K+TXUYN&"6:!R<98X,^:[&?8K9CY&VLB&ZCXI&I*^MU!#5@$4$8
MC8WJ`6(`<-1H4W="N>I+G%9Z"<Y*^)ZFI^/IR7#:=$1.1NES3S'>M-R6O5K%
MC*\S03IOP,'JGM762>M<.6?I78T.`U<#IVKG7)83=A*E1QBY(VPY?H*$?2N,
M[P="2-UWB4M95]F(Q0M+`>;CQU4/%H]PYG3J72U[8V\O`+J7)(4],V<-;E]6
MV!,\BJ\>D>5G')TMF-K/9#M"O)Y3T;6GAKV+FCE,=F-HTU+N870DYJ[.:C''
M+%(L$[_5W&^:K;)O1;#@.1=Q4\>M5V?U;#^OCR*7DT5FCOY5%223)<S=)`7L
MYK@HL&1VPQ4`C&E827)?(;C/WG'W+RC/I)NGKX:*4V+9%/<R>5WFZV).AKCK
M,,9(WAW%Y=[@ME]*$WPR[\OE]PGZ70Q\J3?^.9<41%XY]>$1$`$18R/;'&Y[
MR`UHU)/4$`5_"_?.U>T-OFV-T%-I_49O.^N16)5[8QCG;/MO2`B3(327'?\`
MN.);^[NJPJ_*?Y''=EX*WL+#JA$10&"(B`"KN2^[[;X.$<>@@LV7=W!K!_J*
ML2KM/[[V\R4OQ:=*&O\`2>YSS]0:KT,G*6Y/SR]Q9;$6)$10&"(B`"CL_/Z+
ML]DI_P!'5E?[F%2*KVV[C]J5V%I]:QN5P.WI'M;_`#5:$<56,=[7J+-VBV2&
M`@-79[&P$:&.K$PCO#`I%>-:&M#6C0`:`+U)*6*3EO-2LK!5V3[I]D*`$<(<
M7([ER+Y6CG]%6)5W'??&W&;F/'T>O6KCNUWWG_4%6CDIRW+ULO<R6Q%BZE2J
MN.9E,SGIW-8=V_T8YCV88@KJJ]L?]UQ]ZWU6LC9E;X!Y8/J:FHR=.$YK@O._
ML9)7:3/)/N'V0823H+6,>T=YCD!_@\J>L1-GKR0N&K9&EI\"-%`[0CT;-;/7
M_DW'5G?JRL(_U!JL74EJ]6$N'HW[6".K1`[%RF78_&!WMQ0]`[N<PEA_TJ>5
M=V6^X6,YCSP]'R,CVCL;(!(/K<58D<I7U9-;<_',V'505=VO)@I8_(`Z"ED(
M)7'YKG=&[ZGE6)1.TU(Y#9C)U6C5\E9^Y^L!JWZP%G)Y*-6+>E_+:$U>+)8(
MN+#WFY/#4KS3J+$#)/>`2NU2E%Q;B]@R=PB(L`(B(`K@/H/V0"#P9D:`T[WP
MN/\`QD^I6-5O:S[S=B<P.`HW6=*X=44GW-W^II\E9!R5ZO2C"?"W>OM82.3:
M"(B@.$1$`%6\@?@[;;&7/9BR$+Z4AY#?;]TC\_;'FK(H;:G'S9#`3MJ_ED!;
M9K'^]C.\WWZ:>:M0:4[2T>7C\:BS61,HN/%Y"'*XNK?@/W*Q&V0#LU'(]X/#
MR6^Q9@JPNFL31PQ-&KGR.#6CQ)4G%J6%K,V^5S:BK;MK8[I,>"H6<J_ETL8Z
M.`>,KM`?HZKP8K/Y7CE,L*4)YUL8-T^<KO6]P"M^W<?Y'A[=?#7QL+COIF2>
M3S^+PX`O78HGN]F+7>D?X,&KCY!1GPOG<IPQ6(]$A/*UDSN<.T1-]8^9:I+&
M;/XK#DNI4XXY7>U,?6D=XO.KC[U)HQTH=57>]_"]VPM)ZLI.6PN1QL<6T4N3
MLY&_CW=(Z,,:R,PGA*UC!U[O'B2=6A6=LT5FHRS!()(I6"2-[?C`C4$>*[B`
MX:$:A53#ZX'+2[.2G2M+O3XQ[OD:ZOBU[6'B/FGN32DZ]-WZT?3[:][W"N-L
MMYNM48<KCIX99`Z21O-WQ'=1T[CHN5N3]"8(<G2E$C&^M/'&'1R'K((XCMT*
MG9:D+W%Q;SX=ZJ&0SC9\M-BL#2-ZS!PF<Z3=BB/8YW=V#BO.C&I&&!04N/N>
M;6A*GFK7]24BL4<ANSP3-,!'!S=1J5C<R%*@T%]PM+O99H7%W@`C(CL[L]))
M)NV+(WI7::-$LKSR'8"X@!9XO%.J,])N%LN1F`=-+U`_);V-')93Y#AO.36;
MV7^2+HS:V7(QVTE9S`'%T6^=&NFB<P'WKDOUJ>-H2WYK,PKQMW^C9IZVO(`]
M>I4WD<ACZY'PC8AC@=JQHF(W7GK'%1./JP7J5ZFUAEQSI-(.D'`#KTUZM>2O
MR?'3O74VUHD\[]AYU:DI/I6EN*-B8;.T6:](DL.KT8I&R2`S:`:<0P#K\5]0
MBN5[+BR&=LCF\2`5`2X1F.KR3/DJPUHQJ7"/4^[M4!LQE;N0VCFF9IZ%"QVI
MW=#Q]D'O[E[U>4:D'46B6A"C.K"6#!9>9;[TW23[C6DAJVP'4#AH.]:0T\7$
M'GQ*VM.G!W'^2\"7ZI*$^;<4GQ?J>A*M)=%H[F/+="/XK>V5KN!]4K@!W02W
M@0.2S#]X#3F1R752KN=3FYJSM?A8(RN[,[R!V\%#98ZV(VD<`-5N-@L<6[Q!
M41DK+C?&K_B#1=]"F\9.NFHF]HW&$@<?%;87;S"YXT`7!&_4C4DO/(!=TCPR
ML^+75P'%7FMAX\VM!8F$D8<W@`N6'C8C/SAQ7L9#J[F\01R6-8_?#!U[Z>,<
M*:1T4$TW$L(XJN6F@6I-=>)5C"KUPAMJ4GJ.NIY`*')GTF=_*-$<5B2=S8Z=
M,DW+3Q!`>>A/-W@T:GR5[?LAAI,?3JNJZ&G$(H)XW%DK`.Q[="./'S4'L1C#
M=LR;0SMTC+3#1:1\37UI/I$:#N'>KTH\MY0XS4*;M;7M^VGB>Q^G<EYJGBDL
MY%:]`VCQ/&CD(\K`/[/?]24#NE:./TF^:SBVOIPRM@S%>QB)R=!Z6T"-Q^;*
M-6'WA6)82PQSQ.BEC:^-PT<US00?$+CYZ,OY(]ZR?QY7XG?A:T9['(R5@?&Y
MKF.&H<TZ@^:R5<?LC7K/,N$N6,1*3J65SO0N/?$[5ONT6/PGM#BN&2Q;<A`/
M[3C3Z^G:8G'7]DE',QE_'*_!Y/X\^X,36J+*H#;&>2/9Z6K`[2S?>VE%XR'=
M)\F[Q\EV8S:'%9<EM*Y&^5OMPNU9(SQ8='#W*-D/PMMQ%$.-?#PF5_9T\@T:
M/$,WC]()J,'"I>:MASSX:>+L@DTUEM+!6KQU:L5>%N[%$P,8.P`:#^"VHBYF
M[YL<(B(`(B(`%5W9/[Y9E,GS%V_*Z,]L;-(V_P"@GS7?M%D/@K9Z]=!._%"[
MH].9>>#1YN(66"Q_P5@:-'XT$#&./:[3B??JKQZ-%O>[>&;]A'G(D41%`<(B
M(`*N[3'TB[@<>#QGR#97#YL372'ZPU6)5R7[\^R!79S;0Q[Y#W/E>&C]UCE?
MD^4W+<F_++SL)/2Q8^I$10'"KNRYZ>SG;G/ILE(QI[6QM;'_`!:5.V9FUJTL
M[SHR)A>[P`U4-L9`^'9''&0?=)H_2'_K2$O/^I7AE1D]]EZOV0KZR)FU,VM5
MEG=[,;'//@!JH;8Z%T.QV)#O:?7;*[7M?ZQ_BFV<[X-DLB(SI)-'Z.S]:0A@
M_P!2F:T#*M:*",:,B8&-'<!H$:4.U^B^YG^1";:1O=LM;GC;K)4++;=.V-X?
M_`%3L4C9HF2L.K'M#FGM!XK&Q`RS6E@D&L<C"QP[01H5"[&SOEV8JPRG6:IO
M5)->>]$XL_@`?-'6H=C]5]@TD:X3Z%M_8CY,R-%DH/:^)Q:?W7M]RL:KFTWW
MI>P>4ZJ]T0R'J$<P+#K]+<5C16Z483WJWAEZ6-CDV@O#Q"]10&*YL=][8^YB
MS_Y==E@:#\@G?9^Z\>Y6-5N,_!VWLK.465J"0?\`JQ'0^]CF_LJR*_*,YX_]
ML_GSN)#2VX(B*`X1$0!Q9>@S*XBY0D]FQ"Z/7LU&@/D>*Y-E\@_)[.TYYN%@
M,Z*=IYB1AW7CW@J85:QA^"]K\GCCPAOM%^N.K?X-E'OW7?2*O#I4I0W9KT?S
MW"/*29941%`<(N/(9:AB8.FOW(:T?497@:^`YGR4-]L61R7JX/#321GE;O:U
MXO$`C?=[AXJL*,YK$EEO>2\6*Y)9%E4+?VJQ-&?T43NM7.JK489I?,-Y>>BY
M?M;NY+UL[F)[##SJU-:\/@=#O.\W>2F:&,HXN`04:D-:+Y,3`T'QTYIL-&&K
MQ/ADO%Y^7>9>3TR*/B),^S*6<)6;%AX)R^]6])8)96QN=ZS6@'=!#B3H2=-X
M<%8Z^R&/Z9MG)/FRMIO$2WG[X:?FL]AOD%EM11GDJ0Y.@S>R&-?T\+1^<;IH
M^/Z3=?,!2F.OU\ICJ]ZJ_?@G8'L/<?YJ]:O.454AE?)VW]NN:XZW%C!)V9TM
M:UK0UH``X``<EZB+A*A$1`!1>>P[<SC^B;(8+43Q+6L-YPRCD[PZB.L$J41-
M";A)2CJC&DU9E<Q>9=?ISQVHQ7R=0B.Y7[']3F]K'<P?^RKGH5_"VK<M/6,6
M)72R&/1P<3UD'K5FVAP,MU\>2QKVPY2N-&EW!L[.9B?W'J/4>*H^TTT^TM&!
MF+L2570.<RY3W]'QR`Z%KR.8YZ=15X4YRJ8Z5E%Y.^S[;O`\;]4IO!C<FK:-
M$A\/#-U[%`RLDL1@31]%[1<PAVA;XA3WPS6L4XGPR#>F;JP.X$`]RKVR>/P6
MSTPEZ2=]UT>X99F:`#L&G`+0W$,=D<G(V&NZ6S9WY(+#-X%I`W7-=S;P'O7-
M^HRC%.$98>[N."G6FJ2>/$V2>:H#*10-;#'(R+75L@YZ]8/4HB3:+X)L,J2V
MXV:#412:$:`]O45(7J5N+9:Q0;/+&9)-=]CB[HF$^R">.@58PFSN-K3=+E)9
MK#@_>TC_`!9[W#F5;]/Q.D^DI*.6AQ<HPQK*2DXM]Q;<[1BSN'DK.E+`=U[0
MTZ$D<>*K,6/;A,4]H;9CJQ[TKWOF#03W]J^@0MKOB9)`&ECAJTCL57VVH6<G
MCXJU:5L;!)O3>J22-.'+O2\GK<HHVC5FDF]M_DMRF@\.-RRX$'LYM(,CE6TJ
M]:41%A<][GZ[FG(^?)6&UF*=:PZMO/DF9H7LA87EO9KIR4'A:LF&I"&)T;GN
M.KWLC+GO[-->`4SCZKJT,SW:M=-(9';QX\NLI.6\DINM.<7%)\<R7)YQG].G
MIO.BGDJU_?%:4/>.#F$:.9X@\0I6.,M`+N>G`=BKF.B;=VH;D*^A96A?#+,T
M<)"XC1H/7IIKKWJT:$KLCR?FYXV[MKPX'HI6;;=V1V0!86/`X'@56LC,!D1J
M?S;5;[D7357MTU.FH5`RTFY?T//HQK]:[^29R&J1Q4B=KRQMC!;ZSSR71$\.
M$SS[1&BK]*T[HR6\#IP[E)QEP:QA]HC5=$Z=CPYT\,G=G4TG<!U&I*SK-)N,
MUT]I:&D#NW>:Z:(+[D>GBEEDF=%*+Q*Q/*`.,?M)M!-C8B6T87`WY6_5$#VG
MK[!XK;D\P'7HL33M1P6)GB*6V_V*N\#H">72'0[K3U\U=\3BJN&QT=*HPB-G
M$N<=7/<>;G'K<3Q)7%*I+DT<7^3T^?CQ[??Y-R55'BEHCKBB9#$R*-C6,8T-
M:UHT``Y`+-$7E'KA$1`!$1`$'M-1PC\9/?R]6-[*T9DZ4>K(W3Y+AHX'P*@L
M!@]I,1C&6ZUR&:Q;^[VJ=YI)WR.0E'K:@`#B#R4EE/P]M)!AV\:5`LMWCU.?
MSBC]XWSW`=JLZ[>>G2I*GK?.SSRV=E]<N!+"I2N5MNUL5-PCSM&QB9"=.DE&
M_`X]TK>`^EHK!#/#9B;+!*R6)PU:]C@YI\"%FYC7M+7-!:1H01J"J_-LA19*
MZQBI9\39<=2^D[=8X_.C.K#[E'Z,_P"K\5\KS&Z2XEA15KTS:7$\+E*'+5QS
MFI?<Y@.TQ..A^B[R7=C=I<5E)C7AL[EH>U6G:8I6_0=H?<LE0FEB6:WK/_CO
ML:IK0ET1%$8K>T9%_+X7##BV2?TN<?W47$:^+RSW*R*M;/Z9/.Y?-D[T6^*-
M4_W<9]8CQ>7?LA657K]'#3W+S>;^.X2.=V$1%`<(B(`*N;,CTK(YW*'B)[I@
MC/S(1N#][?4GG,BW$X2[D'?V>%SP.UP'`>9T"U[-XYV*V=HTY.,L<0,I[7GU
MG']HE7CT:,GOR]W["/.2)1$10'(#;.9\>RUN&$_=K>[4C_6E<&?P)/DINO"R
MO7C@C&C(VAC1W`:!0&;/IFT^!QW-K))+T@[HV[K?WGCW*QJ\^C2A'?=^WMYB
M+.397=IOOF]@<>.)FOMF</F1-+S]8;[U8AR5<C^_MOY7<X\;1:SPDE=J?W6#
MWJQHK91A#A?QS]+&QS;85;PWWAM5F\<>#)RS(0CN>-Q_[S-?I*R*MY_[PS^#
MRW)G3.HS'YDH]7W/:WWHH9XH;UYK->EN\R>5F2.T...6V?O46\))82(SV/'%
MI_:`66!R(R^"I7^1GA:YP[':>L/(ZJ1ZE6]FCZ#DLQA7<!!8-F`?W4VKN'@_
M?"(]*C);L_')^P/*299$1%`<KFV`-6G3S+!J[&6FSOTY]$?4D_=<3Y*Q-<'-
M#FD$$:@CK6NU7CMU9:TS=Z*5A8]O:TC0J%V/L2NPGH-AQ=:QTKJ<I/,[GLN\
MV;I\U=].CQB_)_#]1-)=I/HB*`X1%%9/:/%8AXCMW&"=WLP1ZOE=X,;J3[DT
M(2F[15V8VEJ2JKNUT3X*5?-5VEUC%2^D:#F^+325OFTD^("P.2VARO#'8MF.
M@/\`:,D=7Z=T33K^T1X+)FR,%IXES=VSEI`=0R=V["T]T3=&^_5=-.*HS4JD
MNY9OLW>=Q)/$K)'K]L:$SNAQ,5C+3\/5ILWF-U^5(=&M]^O<L!5VFRWY5<@P
M]<_FJ8Z68CL,CANM/@T^*\V8/P5:N[-R<!3/35"?CUWDD>):[5I\`K,BK*-&
M6&G'O>>7IY76\(IR6;(;'[+XK'3^DLK]-</.U9<992?UG:Z>6BF41<TYRF[R
M=QTDM`B(E-"JU0_:SM&Z@[U<7E)#)5/Q8;!XOC[@[VAWZA6E<.7Q5?,XR:C8
MU#9!ZKV\'1N'%KFGJ(.A"M1FHMQEU7K\]WVVBR5\UJ=R*!V>RUB<S8O*;K<M
M2T$NG`3,/LRM[G=?8=0IY)4@X2PLU.ZN$1$AH0G1>$AH))T`YE52:U8VNFDJ
M8Z5T.$8[<L76'1UDCG'$>IO47^(':J4Z;GGHEJ_ST%<K&RW?M[1VY,;AY7P4
M8G[ES(L/'4<XXCUNZB[DWQ3(;%TC5A.(#*%NLS<B>&[S9&\RR4?':3QU/$'B
M"K#4J5Z%6*K5A9#!$W=9&P:!H[EO5'RAQRIY+U[=_9H*Z:DK3SN?'WTLQD-H
MVXZ0LQ5H#C"7:L>T?&CU]ORY=85OS,?06:]V`^K&.BM.#?B'D1W@_5JK%EL-
M1S53T>]`)&@[S'`[KHW?*:X<6GO"KQAS&ST#Z\\+\UBB".DC`]*C:>8<WE(.
M\:'N*:LH\J48JRMLW]C]GW7/-_\`3H4L2AHSOZ.6C!(X;DP#"\C70D`:KY3/
MD\_M-D37I4H:.X0]V@$>Z.K>>?:\`OHV#SF-DPEC>M1S1T=02P$'<^*"T\==
M-&Z'K"I^4R..Q\,DEJ7HY7:N;1+0\Q#J:YW;_!')(0Y')TW>[R7YJ<'ZC'#"
M.%)K=<F\7=M4L;!CH(Y,G9C;]TFA&['J>/M'@MD%U\MMM:Q%)5E?J&F30M>>
ML!PX$]RT[(VI\A@'W#"^O6+MV%CC[7:1\W7DNW(#T^>KBJGK".5DUAX_-M:=
M[GVDZ#WKR.4T.=Y2Z52[MQ_.\C&,W&+=UP_/4Z36C8UQ8W@T:N<>`"@H8K&T
M4SBTB+##@'#4/M'KT[&=_6IC/1].:&-+BV&Y.62[IT)8UI<6^>FBE!$R)C6L
M:UC&C0`#0#N"Z*?Z?0I1QSU.A\G6CT."")M-K:\<360!OJM8-``M_9H=0>2V
M1LZ1YD+3IIH!W+R(`-<#R:XC1-R2<J<L-[QE>U]1:<6G;8S!4#:VHZ#*"73U
M'M&FB^AENZ>0YJ!V@J,GC9T@U:=6KV:-3#.Y>,')X2AUY2P\2>)4JR^YSV/'
M$C@!V+&;!$<89>_1RYVT9/2A4K.?:MO/"O7&\\>/4T=Y(7IQJ0F<M3DCE*]B
M6AL;S7.?PX<]5WX2OD<](YN,<:],>K)D"WWB(?&=\[D.\KOP?V/9)6MFV@E#
MV#B*,3O4_P#<=\?P&@\5?XHHX8VQQ,:QC1NM:T:`#L`7#RKEU.%XTLWOV+Y]
M.T]#DOZ=9XZG@1U;9W%U<*[$MJ,?3D:1*R3UC*3S<X\RX]O-1-:Y9V6LQ8_*
M2NGQ4CA'4OO.KHB?9CF/U!_7R/%6I:K-:"Y6DK68F2PR-+7QO&H<#U$+RXUG
M=JIFGK\KB>LX[C;S152*>?8^45[CY)L"YP;!:<=YU,D\&2'F6=C^KD>U6IK@
MX`@Z@I*E/!FG=/1_FW>@C*YZB(IC!1>?RXPV,,S8S-9D<(JT`YRRN]EO\SV`
M%2$\\5:"2>9[8XHVESWN.@:!Q))5;PL,N>R8VCN1N97:TLQD#^!;&><I'4Y_
M5V-\5:E!9SGU5YO=^;!9/8M22V>Q!P^,$<TG37)G&:U-^DE=[1\.H=P"ED13
MG-SDY2U9J5E9!$1*:%PY+#X[+Q"/(4X;#1[)>WBWO!Y@^"[D6QDXN\79F-)Z
ME:^`LOB_6PN8<^(<JF1!F9X"3VV^>\HW.[7W\7AIXKV+FH7Y6]%7G#A)7+W<
M-[?'$:#5VA`/!7=5B`?#NV$MD^M2P^L,78^RX>N[Z+2&^+BNRC44Y8JL4TL]
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M>9D>2]WUG3R7FUEV2CLU<=!^42M%>`?WDA#&_6[7R7147.5L$>"7=E]Q%E&[
M.;9#[ZK7\P?_`#&Y)*P_W3?N;/J;KYJQKEQU*/&XVK2B_%UXFQ-\&C1=2G6F
MIU'):;.S9Y&Q5E8*,V@QOPO@;E)IW9)(R8G?)D'%A\G`*31)"3A)26J-:NK$
M;@,G\,8*G>+=U\L8,C?DO'!P\G`A1N<'P;M'B,P.$4CCC[)^;)QC)\'@#Z2\
MPA&+VER^'=PCF<,A5'S7G20#P>-?I*5SF,;F,+:H.<6&9A#'CFQXXM=Y$`^2
MZ>C3K_U?H_B_BA,W'B2"*)V<R;\M@Z]F8;MD`Q6&?(E8=UX]X/O4J3HN:<'"
M3C+5#IW5SU5F?\#;;0V/9JYB/H).P6(P2P_29O#Z(73<VMQ=:P:L#Y+]P?V:
MBSIGCQTX-\R%$Y>EM-M)0<P5ZF*9&X30"1_33](TZLXC1K..GREU4*4HOZG1
MBU;/UMJ[.SR$E)/3-ELM7:U&NZ>W8B@A;S?*\-:/,J".U3KYW,#C+.1__<.'
M0UQ]-W$_1!7+LUAL1E,?5S%B.:]=>WUWWW]*Z*0'1S0T^JW1P(X`*V@`#DDD
MJ5*3BUB:WY+RS\T:L4E?0K?P+FLIH[+YET$1YU<8#$WP,A]<^6ZI7&8/&8=A
M;0I10EWM/`U>[]9QXGS*D$4Y5YR6&]EN62-44LPB(I#%=VHJS0LKYVE&7W,:
M2\L;SF@/XR/W<1WM"FZ=N&]3AM5I!)!,P/C>.1:1J"M_-5;&'[6\^_"OX8^Z
M738\GE&_G)#_`,F]Q(ZET1^I3P[8Z=FWPU\1'T7?>6E$1<XX1$0`1$0!"9_#
M2W>AOX][8<M4U->0^R\'VHW]K7?4=#U+?@\U#FJ;I&L=#9A=T5FL_P!N"0<V
MG^1ZQQ4HJ_F\/:%MN9PI9'E(P&R1O.C+<8^(_L/R7=7@NB$HU(\W-VW/=P?#
MT?>(U9W18%C)(R*-TDC@UC02YSCH`!UE1F.V@I7\;+<<_P!&]'U;:CG]5U=P
MYA_9IV\B.(40R*?;*02V&2P;/C0QP.&Z^[U[SQS$?8WF[F>'!9&@[O'DEK]M
M[_-#7);`73[9R%D;GP;.@Z.>`6OO]H:>;8N_F[JX*TPPQP0LBBC;'&QH:UC1
MH&@<@!V+)K6L:&M`#0-``--`O4M2IBZ*5HK1?FW\T",;9O4(B*0P1$0!6]J<
M-A)*%C*Y"$Q2UXS)Z37=T<HTX@;PY\=.!U5.AV'SC17R[XZ-^W*P2S5[+>C=
MO$<B="UQ':0.*N&>_"V<QN!'&$$7KG9T;#ZC3^L_3R:595W1KSHTXK5O?G9;
MMZOGIP.6KR:G6?36A\]DSL["ROF:%C$L8P@2&$F+4#@-YNHT7'7VFKXG9FM)
M3?5OV"`961/!>2/:+N//7M[5].T49<V>PV0)=;Q=.9Q^,^%I/OTU7+&')74=
M1Q:;UL_9_)"?():PGGO9479FMM!08&,MP2@[T9;5D#XW^8T_DIC&BQ+298R3
M"R;4C1W`$`Z`Z=7@NC[2<(P'T>*U6U_^GN2QCW!VBBL]LY%1JUY(,EE09+D$
M)#KKW`-?(&NY]Q*=T*-1*$)-N^6+[,3]G-/')W9*N>9'EL#"[A[6G`+(Q"!G
MK:@#FX\./:L/M.I.:6RW\M(WL=?D'\"%DW8G9X.WI,<V=W;8D?+_`*B4E.G2
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MAP/,$*JATVQ<@:]TL^SKN#7G5[Z![#UF+OYM\%;5B]C7M+7`%I&A!'`A5IU,
M.35XO5?FC_-!6KZ:B.1DL;7QN#F.`+7-.H([0LB=!J54W1S[&2=)"U\VSSG:
MOB:"Y]'7XS>V+7F.;>8X+RQ:DVQE?0QTKF81IW;=UA(-CMBB/9\I_D%3]O?I
M)]#?^;>'MF9CV;1(X[99`P,<?M?JOTE<.5Z0?%!ZXVGF?C$:<@K8`&@`#0!:
MZU:&I7CKUXVQPQM#&,:-`T#D`MJG4J8K1CE%:?/:_P`R-BK9O4(B*0P1$0`1
M%XYP8TN<0`!J23H`@"'VERDN-QHCI@.R-MXKU&'KD=UGN:-7'N"ZL+BHL+B:
M]"$EPC;ZTAYR./%SCWDDE0V":<]EI-HY@?1FAT&,8?T>OK2Z=KR.'S0.U6A=
M%7Z<>:VZOMW=WK<2.;Q!$1<XYR7\91RE<P7JD-F+Y,K`X#PUY*%^UR]C/6P6
M7F@C'*I<UL0^`).^WR/DK*BK"M."LGENU7@Q7%/,K0VDNXWAGL1-78.=NIK8
M@\3H-]OF/-;LKM)5;LW/?Q=F&W(_2*OT3PX.E>=U@X=Y^HJ?5%NX"AM!MH\5
MXO1!CHPZ>U5TCD=8?Q8-1S+6^MQU]H+HH\S4E>:LEF[:>#SSTU[A)8DK)EJP
MF,9AL-5H,=O=#&`Y_P`MW-SO,DGS4@JUT>U&)]B2OFZXZI-(+`\QZCO,-714
MVMQDUAM6V9<=</*O>9T3C^J3ZKO(E2G1J3;FGBVY?&J\!E)+)Y$ZJUM/^$+V
M)P0U+;4_3V!K^9BT<0?%VX%9-00JUL_^%<WD\\>,1=Z%3/\`=1GUG#]9^ODT
M+*'1O4_U]7I\]P3SRWEF5:R>N3VOQ>.'&&BTWYQU;W%D0]^\[Z*LCG!K220`
M.))ZE7-DAZ:R_G7#CDIRZ+7J@9ZD?O`+OI(H]&,JF[+O?VNPEFTBR(B*`X1>
M.<UC2YQ#6@:DDZ`!5V3:^K8>Z'"U;.7F!TUJMTB![Y7:-]Q*I"E.?57YVF.2
M6IYM8TT6TMH(P=[&R[TVG-U=_JR#RX.^BI3(9S%XJ!LUZ]!"QPU9O.XO_5`X
MGR41)C-H,W$^/)WH<=4D!:^K1;OO<T\PZ5X[/DM\UR;%XJACIKU&2K$<I0FZ
M-]EXWI)8G#6-V\>(&[PT'#5I75@INETW=QV+<^.F3W7U)W>++:1U;,9&+:6S
M%A\>8J^7/3029)KH6=*UNDA:T#>.K0TZ'370E3WVK39#UL]E;%YIYUHON$'A
MNM.KOI$KKVGQLV0Q!=3T%^H]MFJ?[QG$#P<-6GQ7;B<E#E\56OU]1'.P.`/-
MIZVGO!U!\%M2NW!5*:ML>_+3/BMUM&"CG:1MIT*F.KBO3K15X1R9$P-'N"Z$
M1<+;;NRI6*I^`MKYZCO5IY?6Q`>IMAH^Z-^DT!P[PY6=16T6).8Q+X(G]%;C
M<)JLOZ.5O%I]_`]Q*RP.6&9Q,5HLZ*;C'/"><4K3H]I\#]6BO4^I!5-JR?L^
M]>G$2.3L2:(BYQPB(@`HW.8B/-8Q]5SW12@B2"9GM0R-XM>/`_5J%)(FC)PD
MI1U1C5U9D-L[EY,E6E@NL;%DZ;NBMQ#D'=3A\UPX@_\`93*KN?QMF&U%GL3&
M79"LW=E@'#TN'F8S\X<VGMX=:E\9DJN6Q\-VG)OPRMU:>1':".H@\"%6K%-<
MY#1^3W?'V9D7L9UHB*`P1$0`6BY<KX^I+;MS,A@B:7/D>=`T+7D<E4Q-&2Y=
MF;#`SFYW6>H`=9/4!S4%3QMO:"W%E,W#T5:,[]/'/&NX>J27J+^P<F^*M3II
MK'/*/KP7YD*Y;%J0UO9^[M9:=G6P140UK/1JUAA/I;6NW@;`'4>IO,<SV*T8
M7/Q9-\E2>%U/)P#[O3E/K-^<T_&8>IP^I3*BLS@:N99&]YD@MPG>KVX#NRPG
MN/9V@\"JRY0JJ4*F26G#Y7GNW"J#CFB515B#/6\+,VIM*UC&$[L63B;I!)V!
MX_-N\?5/459FN#@"T@@\01UJ%2E*&NCT>QCJ29ZB(IFA8R2-BC=(]P:QH)<X
M\@!UK)5S:V1]N"K@87$2Y23HI"WFR`<97?L^KXN5*4,<U'\MM,D[*XV3C=;B
MMYZ9I$N3DZ2,.'%L#>$0]WK?25C6$4;(HF1QM#6,:&M:!P`'(+-%6>.;E^6V
M>015E8(B*9H4%M5^04O\1J?[S5.J"VJ_(*7^(U/]YJMR?^6/:+/JLG41%$8(
MB(`*M;0_@G+X[:!O")CO0[I'Z%Y]5Q_5?IY.*LJYK]*'(T+%*PW>AGC=&\=Q
M&BK1FH33>FWL>HLE='2B@ME+LT^*=3N.WKV/D-2P3S<6^R_Z3=T^:G4M2#A)
MQ>PU.ZN$1$AH6JQ8AJ0/GL2LBBC:7/>\Z!H[25'Y?/T\.(XY=^:W-P@J0-WI
M93W-[.\Z`=JC8,)=SD[+FT>X(6.#X<7&[>BC/49#^<=^Z._FK0I98YNT?-]G
MSH*Y;%J:2^YMD[=CZ:GL_P!<G%DMT=C>MD9[>;NX+V6K8V/D?:Q\+IL&X[UB
MFP$NJ]LD0ZV]99YCL5L`T&@1/^YMT4NAN_-O'VR,P;=IIJVH+M:.S6E9+!*T
M.9(PZAP/6"MRJUFC9V8MR9#$P/GQLKBZWCX^;#URPCM[6=?,<>=AHWJV2I17
M*<S9H)6[S'M/`C_[ZE.I3LL4<XO\L^/J:I;'J="(BD,$1$`%5\Y+)GLF-FZK
MW-KAHDR<K?BQGE$#\I_7V-U[5W;0YB3'Q0TZ+!-E;A,=6(\@>M[NQC1Q/D.M
M;\'AXL+CQ`U[IIY'&6Q8?[4TA]IQ_P"W4-`NBG]*/.O79\]VSCV,1])X20BB
M9#$R*-C61L:&M:T:``<``LT1<XX1$0`1$0!'YO*18;$6+TH+NC;ZD8YR//!K
M1WDD#S7/LUC)<7AV,LD.NSN=8M/'QI7G5WD.0[@%'O\`^H-K1$../PS@]_9)
M:(X#Z#3KXN'8K0NB?TZ:AM>;]E[]ZW"+-W"T6Z56_7=!;KQ3PNYQRL#FGR*W
MHH)M.Z'*-M!B'[/4&_`&1MU)K4K:T%+?Z6)SG\.#7:EF@U=JTC31=>.OWME\
M=7H9'"R>AUHQ&VWCR9V:#K<SVV]IX%=%37-[83W3QIXD.K0=CIW:=([Z(T;X
MERLR[JM>T53J+$]7OX9\%OOJR48YW614<YGJF:PT>/PUZ*:?)RBH'1.U=$T\
M9'$<QHP.Y]9"M-:O%5K15X6AD43`QC1U-`T`5-APM+:G:7(Y1['10U#Z'6FK
M/,4CI&G623>;Q.A]4=7`J2]$VFQ/Y)<AS%<?FKGW*8#L$C1NN\VCQ65:=/"J
M<'9ZM/>^.F2WVSN$6[W:+*BK]?:ZCT[*N3BGQ5IQW1'=9NM<?FR#5CO(JP+D
MG3G3ZRL44D]#%[&R,<Q[0YC@0YI&H([$CC9%&V.-C6,:-&M:-`!W!9(D-"K&
MT(^!\Q0VA9ZL((J7NSH7GU7G]5^GDXJSK3;JPWJDU6PP/AF88WM/6TC0A4I3
M4)7>FWL%DKHW<PJQCS\`[4SXMW"CDBZU3X\&2\Y8_/VQXN6W9:U-%'8P=UY?
M<QKA&'NYRPG\6_W#0][2NS:/%/RN*+*[Q'=@>)ZDI^)*WBWR/(]Q*M%*G-TI
MO)[?1^_9<5YK$B611V#RT>:Q45MK#'(=631.]J*1O!S#W@J17/*+A)QEJAT[
MJZ"JUW_IO:1N2;ZN,R;VQ6QU13\F2=P=[)[]TJTKFOT:^3H3TK48?!.PL>T]
M8/\`-/2FH2Z6CR?9]M49)761THJ]LY>LQ2S8+)O+[])H+)7?VF`\&2>/4[O'
M>K"EJ4W3EA9J=U<(B)#0B(@`JKD()ME\E+F:;'R8RP[>R-9@U,;OT[!_J'6.
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M6D]CZT,36,>T@AP`YZCGKS\T[ISHTG*2ZV2[-7GX>9F)2E9;#O1$7(4"(B`"
M@MJOR"E_B-3_`'FJ=4%M5^04O\1J?[S5;D_\L>T6?59.HB*(P1$0`1$0!6;W
MX&VOJ7QZM7)M%.QV"5NIB<?$;S?<K,JSM=D,/)B;&,MWV1VIF_<8XM7S-D'%
MC@QNKM0X`KBQ.:VCVCQ\9IU*^.W1T5BS:.^X2MX/#8AIIH=?:(\%VNC.I2C4
M>5LFWEV/CNRW(EB2DT6J]D*>,JNLW;,5>%O-\C@T*`^%,SGQNX:N['TG<\A<
MC]=P[8HCQ\W:#N*ZZ.RM.O:;=NRS9*^WE8N.WBS]1OLL\@IU2Q4Z?5Z3WO3P
MV]_@-:4M<B+Q.`I8@OEC#YK<H^[6YW;\LOBX]7<-`.Q2B(HRG*;Q2=V,DED@
MB(E-"K%[&V\%<ERV%C?+#([?NXYO*7MDC'5)VCD[Q5G14IU'![T]5O,<;G)C
M<E4RU*.W2F$L+^1'`@CF"#Q!'6#R76JWDL5<QEZ7,X-@=+)ZURCKHVUI\9OR
M9-.OD>1[5+XK*U,S1;;IR;[#P<TC1S'#FUPYAPZP4U2FK8X9Q].#]GM\4L3V
M/4[5&YO,U\)1](F:Z21[A'!!&-7S2'DQH[3]7-9Y?,5,+3-FV\C4[D<;!J^5
MYY,8WK<>Q1F&Q-J>\[.9IK?3W@BO7UU;3C/Q0>MY^,[R'!;3IJW.5.KZ\%[O
M9VV!O8M3;@<//7EFRN4<R3+6P.D+>+8&=43/FCK/6>*G413J3<Y8F:E96"(B
M0T(B(`*&VCRTN-H,CIM$F2MO$%2,]<A^,?FM&KCW!2TTT=>%\TKPR.-I<]SC
MH&@<22JW@(I,UD7[2VXW,C<PQ8Z%XT,<)/&0CY3]`>X`!7HQ6=26B\WL7SP%
MD]B)?"8J+"XJ&E&XR%H+I)7>U*\G5SSWDDE2"(I2DY2<I:LU*RL@H?:7*R8S
M%Z50'W[+Q7J1GXTKN`/@.+CW!3"J^*/VP;1S9HC6C2WJM#L>[7264>8W0>P'
MM5*,5=SEHO/<N_TN9)[%M)G"XN/#8FO1C<7]&W5\CN<CR=7./>225R;49*;'
M8@MIZ'(6GBM4;_>/X`^#1JX^"FN2K&+_``]M+/F'>M2H%U2CV.?RED'F-P=P
M/:FI=*;JU,TLWQ>Q=[\KF2R6%$UB<;#B,56H0:F.!@:">;CUN/>3J?-=J(H2
MDY-R>K'2MD:Y8(IXC%-&R2,\VO:"#Y%;$18`1$0`1$0!6]I89<?8K;1U(R^2
MDTLM1M'&6L>+AWEI&\/`]JL$$\5JO'/"]LD4C0]CV\G`C4$+,@.&A&H*K&%)
MV?S4FS\A(IS;T^-<>0;KJ^'Z).H^:>Y="^I3MMCYK[:]E]PG5?:>7/\`IO:5
MN0;HW&91[8K?9%/R9)W!WLGOW2K2N:_1KY*A/2M1B2"9A8]IZP5#;.7K$$TV
M`R4A?>I-!CE=_:8#P;)X]3N\=Z)?5IXML=>S8^[3PX@NB[;&6)$1<XY!;1XF
M>U'!D<;NMRM$E]<N.@D!]J)WS7#AW'0KNPV6KYK&QW*^\T.U:^-_!T3QP<QP
MZB#P7>JMEHI-F\H_/U6%U";09.!@U(`X"=H[1R=VCCU+HI_5CS3U6GQW[./:
M(^B\1:46$,T=B%DT+VOC>T.:]IU#@>1"S7..$1$`$1$`>%H<""`0>U4?)6I-
M@[#32`M8VT7%F,:?NL+]"XNBY_<^'K#XNNH[%8<WG&XWHJM:+TK*6-16JM.A
M=\YQ^*P=;OYK'#8,TII,A?F;;RTXTEL;N@8WJCC'Q6#WGF5UT6J<<53.+V;_
M`(MO[EM)RZ3LM3EV<Q[;99M!<M0WKUEFL<L+MZ*",_$B[NUW,GGV*R*KV\/=
MP=J7);/-#XY';]K&.=NLE/6^,_$?W<CUZ<U,8C-4\U5,U1[M6.W)8I!NR1/Z
MVO;S!2UTY_4B[Q].%MG#8_$V#MT7J2"(BYAPB(@`B(@`B*/S>39A\-:OO:7=
M"S5K!S>X\&M'B2!YIHQ<I**U9C=E=D0UC<[ME,][0^EB(S"&N&K76)!JX]^Z
MS0?2*W2['8P2NFQYL8N=QU+Z$IB!\6>P?,+KV<QC\5A(()W!]M^LUE_RY7G>
M>?>=/`!2RO4KRC+#3EDLNW_EY]XJBFKM%<]%VJH#[AD*.38/BVXC#)I^NS4?
MNKT;19&M_P"([-WXQ^DJ.99;^Z0[]U6)$O/)]>*?EZ9>08;:,K[-M<"7B.:Z
M:CSPW;<3X/\`6`%(U\YB;?Y-DZ<W_ISM=_`KM<QKVEKFAP/,$:J/L;/8:T=9
M\31E/:^NPG^"+T'L:[T_9!TB0;(QX!:X.!ZP=5";5?D%+_$:G^\U8G8K9O>U
M;AZK#IIZC2W^!4)M%L=@:E*J^"CN.?>K1N/32'5KI6@CB[L*KR>-'G8])Z[E
M_P"1DW+"\OSP+SKHM$MZK7!,UF&,#F7R`:>]0S=A]FPTM^"XW`\P][W?Q*WQ
M;([.PNWF83'[W#B:[2?K"EAH?[/P7R-TMPL;7[/5A]TS-(G73=CF#W>YNI7/
M]M]:<?@_&Y6\3R,51S&_M2;H4W7I5:HTKUH81V1QAO\`!;]$8J*TBWVOX7N%
MI;RM^F;57>$&*I8YI^/<L=*X?0CX?O+W[6;E[0YC/7;+>N&K][1'N.[ZQ\W*
MQHC]PUU$EV+W=WYF8-YP8W"XW$1EF/I05P?:+&>L[Q=S/F5$0_@7;26'E4S+
M3*SL;88-'#Z3-#XM*LRA=J,=-D,,XU.%ZJ]MFJ?[UG$#SXM\UM*HY3:F^MD[
M^3[F$E99;":1<>*R,.6Q5:_!^*GC#P.L=H/>#J/)=BA*+BVGJAT[YA$18`1$
M0`1$0`5/VE#,!D(LQC7@9&P]L3Z+03Z>.S0<G@<G]0Y\%*9C:`U++<;C8/3<
MM(W>;7:=&QM^7([XK?K/4F(P!J679+(V/3<M*W=?8+=&QM^1&WXK?K/,KJHK
MFOJ3T>S?]N/AO4Y=+)$;LQ#'G+#MH,A()<A&]\+*W$"AU%FZ?C]KCSZN"MR@
M,QA9VV_AG"EL64:`)&..D=M@^(_O['<QX+MPV:KYFN]T;'PV(7='8K2C22%_
M8X?P/(CB%E?ZGU(Z;O\`7AV;GMVYA'+HO_DDD1%S%`B(@`B*`V@RUB.2+$8H
MM.6M@[A(U%>/DZ5W<.H=9T3TX.<L*,;LKG'DW':C,.PD))QE1S79*0'A([FV
M`?47=V@ZU:FM#6@```#0`+BQ&+KX;&Q4JP.XP:N>XZND<>+G./62>)7<GJS3
MM&'57Y?O^$9%6S>H1%QY3)5\1C9[UIQ;#"W>.@U)[`!UDG0`=I4HQ<FDM6,W
M8B=IKD\YKX&A(67<AJ'R-YP0#\9)W'XH[SW*;I4X,?2AJ5HQ'!"P,C8.H`:!
M0^S>-LLZ?+Y1H&3OZ.>SGT$8]B(>`/'M)*FK-F&G5ELV)&QPQ-+WO<>#6CB2
MKU6E:E#.WF_S)>.T2/\`LR%VGOSLAAQ./=IDLB3%$[]"S3UY3W-'+O(4MCJ$
M&,Q]>C59N001AC!W#M[U";,UIKLUC:*ZQS)[P#:\3AQ@K`ZL;XN]H^([%9$5
MK02I+9KV_;3Q>T(Y]((B+G'"(B`"(B`"(B`"BL_B!F,=T4<G06XGB:K8`XQ2
MM]EWAU$=8)4JB:$W"2E'5&-)JS(G9_+G+8\F>,0WJ[S#;@U_%R#GY'F#U@A:
M=HL58MQP7\<6MRM%QDKEQT$@/M1N^:X<.XZ'J7+G:TV'R`VDHQND#6"/(0,&
MIFA')X'6]G$]XU'8K!5LP7:L5FO(V6&5@>Q[3J'`\B%>70DJU/1^6]/AZKO%
M6?19RX;+P9K&QW(`YFNK9(G^U$\<',<.H@J056RT3]F\H_:"JQSJ,V@R<+!K
MH!P$X':WD[M;X*S0RQSPLEB>U\;VAS7-.H<#R(*2K!*TX=5^7#N],S8O8]3-
M>.:'`@C4%>HHC%2B<=C,@VN\Z;/VI-(7GE2E<?8/9&X\CU'AR(5M6FU5@NUI
M*UF)DL,K2U['C4.!ZBJW0M3[,7X</D97S8Z=V[0N2'4L/5#(>WY)ZQPYKI?U
MU===:\>/;OWZZW$ZN6PM2(BYAPH3-9Q]29F-QT(M9:9NL</Q8V\NDD/Q6#WG
MD%KS&:G;;&(P\;9\H]N\XN_%U6'X\G\F\SX<5UX7"08>&321]BU.0^S:E.LD
MSNT]@'4!P`71&$8)3J=RW\7P]?,1MO)&.%P;<7TMB>9UO(V=#8M/&A?IR:!\
M5@ZFC^*ED11G.4WBD,DDK(*#RVSK+ED9&A.ZAE6-T;9C&H>/DR-Y/;X\1U$*
M<1;"<H.\6#2>I7J&TCH[;,9G8&T,BXZ1G76"SWQO/7\T\1WJPKFOX^IDZCZE
MVO'/`_VF2-U!_P#GO5?%;-[-_D9DS&,;_9Y'_?,(^8\\)!W.X]Y5<-.KU>B]
MVSN>SL?CL%NXZYEI11V*SF/S,3GTY]Y[#I+"\%LD1[',/%I4BHRC*+PR5F,F
MGF@B(E-"K.3_``QM71Q8]:M0`O6NPOXB%I\]YWT0K!:LQ4ZLUF=X9#"PR/<>
MIH&I*A=DJ\IQTN5M,W;>4D-J1IYL:1I&SR8&^>JO2Z$95.Y=K^%?OL)+-I%@
M1$4!PB(@`B(@`H+:K\@I?XC4_P!YJG5!;5?D%+_$:G^\U6Y/_+'M%GU63J(B
MB,$1$`$1$`$1$`5K#?@?:/(85W""QK?ICJ`<=)6#P=ZVG8]655[:V"2*E!F:
MS"ZUBY/2`&\WQ::2L\VZGQ`4[7GCM5HIX7A\4C`]CAR((U!5ZW32J;\GVKY5
MGVW$CDW$V(B*`X1%!Y/::M3M>@4XI,ADR-14KZ$M[WNY,'>?<4\*<INT5<QM
M+4F9IHZ\3I9I&QQL&\Y[SH&CM)ZE6'9;(;2N,.`)K8_E)E9&>UVB%I]H_//`
M=6JV1;/6\O*RSM+-',UI#H\=#KZ/&>HNUXR.\>'8%96M#&AK0``-``.2K>G2
MTZ4O)?/IVBYRX(X,3A:6%K.AJ1G5YWI97NWI)7?*>X\25((BC*3D\4G=C))9
M(*#S.$EFLMRN*E;6RT3=T./L3LY]'(.MO8>;>84XBV$Y0=X@TGJ16%SD.7CD
M88W5KU<AMFI)[<+OYM/4X<"%*J%S6#=>EBOT)Q4RM<$0S[NK7-ZXY!\9A]XY
MA983.#)=+5LQ>BY.MH+-5QU+3U.:?C,/4[^:I.$9+G*>FU;OMQ[GLOB;3LR8
M1%'9K,5\+0-B8/D>YP9#!&-7S//)C1UD_P#RI1BY-1BLV:VDKLU9W-,P]5FY
M&;%VP[HJM5I]::3L[@.9/4%A@,*[&Q36;DHL92V0^U.!P)ZFM[&-Y`>?6M.$
MPUAMJ3,9<MDRD[=`UIU95C_1,_F>L]RGU:<E"/-P[WOX=B\WGN%2;=V$1%SC
M@\%5*_\`U9G&V^>%QTIZ#LM6!P+^]C.0[3J>I;<Y:FS%\[.8^1[-6AV0LL/X
MB(_$!ZGOZNP:GL5@J58*-6*K6B;%!$T,8QHX-`Y!=*^C'%_D]."W]KV<,]J$
MZSML-RJN0UVGSIQ+#KBJ#VOOD<II>;8?`<'.\@NW:'+3UNAQN-W7Y:[JV`.X
MB)H]J5WS6_6=`N[#8F#"XR*E7U<&:E\CO:D>>+GN/62=2LA]*/./5Z?/QQSV
M`^D['>!H$1%SCA$1`!$1`!$1`!$1`!$1``C55.$_:AEQ6<=W!7I?N+C[-2=Q
M]@]C'GEV'AUJV+1=I5\A2FIVHFRP3-+'L=R(*K2J*-XRZKU^>U?862OFM3<Y
MH<T@C4'F"JG`3L=DF57D_`%N32N\GA3E)_%GLC<>1ZCPZPM^&NV,/D&[/925
MTA()Q]M_]HC'Q''](T<^T:'M4_;J5[]26K:A9-!*TM?&\:AP*I_#)QEG%^:V
M-<5\I[3.LKK4WHJMC;EC9[(183)S/EJRG3'W9#[7]S(?E@<C\8=ZM*E4IN#W
MIZ/>-%W"Y[U&MDJ4M.W"V:"5NZ]CN1'_`-]:Z$2)M.Z-*I4R-K9J_%BLQ,Z:
MA,X,HY%_/7JBE/RNQWQO%=.4S-JU=?AL%T;[P'WQ9=QCIM/6>UYZF^9X+GS5
MM^T4MC9_&-BDCT++]M[-^.`?(:.3I.[XO,]BYJ(=L([T2RWI,%+)O1W=WUZ[
MW'B)SU@GD_R/:O04(R2FU]3_`%W\;;_Z[==,G&[66S>6+#X:KA:AAKASGO=O
MS32'>DF>>;G'K/\`#J4BL6/:]H<T@M(U!!U!"R7!*3DW*3S*I)*R"(B4T(B(
M`(B(`B,KLY0RLS;+VR5[K!I';K/Z.5GTAS'<=0H\7=H,'ZM^L<O3'*U38&SM
M'SXN3O%I\E9T5HUFEADKKC[/5>@KCM1'XO-X[,PF2A:CFW>#V#@]A['-/%I\
M0I!1.3V;QF5E%B:`QVV^Q:KN,4S?IMX^1U"C^@VFP_XF>'-51\2P1#8`_7'J
MN\P/%;S=.?4E;@_G3QL9=K5'NT[CDK6/V>9KI<DZ6UIU5XR"X']9VZWS*L@`
M```T`[%0MG=IL;8S%W+9.5U&>[NQ5&VFEC.@;RW7^R27%Q.A[%?&/;(P/8X.
M:>((.H*?E-.=+#3DK6]7K\=QD&I7:,D1%RE`B(@`B(@`H+:K\@I?XC4_WFJ=
M4%M5^04O\1J?[S5;D_\`+'M%GU63J(BB,$1$`$1$`$1$`>.:'-+2`0>!!ZU6
M]EW''3WMGI#^0OWZNOQJ[R2S]D[S?(*=MWJE"$S7+,->(<WRO#1[RJ-G-I8O
MA"GGL-4M6F5`Z*S8,9B@?"_0:;[AQT?NNU`(`U77R:E.JG!+)[=EUIXZ=Y.<
ME%IGT%0N2VGQV.L>AM=);OGV:=1O22^8'!H[W$!<8PN8RPWLSEC#`>=/&DQM
M(['2GUW>6ZIK'8FAB:_04*D5>,\2&-T+CVD\R>\I,-*'6>)[EIX_"[S;R>F1
M"&CG\\3\(3G$43_9:D@=.\?/EY-\&^]36-Q-'$5O1Z%6."+74A@XN/:3S)[R
MNU$DZTI+#HMRT^_>:HI9A$12&"(B`"(B`"A\W@QDNBM5I?1<G6U-:TT:EO:U
MP^,P];?YJ843FL[#B6QQ,B?:OSG=K4XO;E/;W-'6X\`J4<>-<WK^>6^^0LK6
MS(O[<XJ52:+*UGP9>$M9Z%%ZYL.=[)A^4UW;U=:Z<-A[4ML9K.;CLDYI;%"P
MZQTV'FUO:X_&=U\AP7$-D)\@TY'*7GC.'1T%BN2&4].38VGFWY6OM<5)8;-R
MS678K*Q-K9:)F\6-_%SMY=)&>MO:.;>M==3`H/F-?\OM_7SWY:HKWZ7<3B(B
MX"H4'G\Q/5=#C<8ULN6MZB%CN+8FCVI7_-;]9T"W9W--Q,$4<,1L9"RXQU*K
M3QE?IU]C1S)Z@L,#A'8X37+LHLY6WHZU8TX<.3&#J8WD!YGBKTXJ"YR?<M_V
M7GIOLC=W9&_"X>#"T!7C<Z61SC)//)[<TA]I[N\_4."SS&6KX7'/N6-X@$-9
M&P:OE>>#6-'62>"Z;=N"C5EM696Q01-+WO<=`T#F57<15GSV19M#D8G1PL!^
M#:KQH8VG\ZX?+<.78.\E;%8VZM73U>Y?F2\`>71B=6SV*L0.GRN4W796[H90
M.(@8/9B;W-Z^TZE3R(I5)N<L3&2LK!$1(:$1$`$1$`$1$`$1$`$1$`$1$`1^
M8P];-4'5;&\W1P?'*PZ/B>/9>T]1!4?@\Q9%MV%S.XW*Q-+V2-&C+4>NG2-[
M_E-ZCW*P*+SF%BS-1K.D=7M0NZ2M:C]N%_4X=W41R(5Z<XM<W4T]'\;T*T]4
M=&3QE7+X^6E<B$D$HT<-=".L$'J(/$%0V-REG$7H\-G)=]SSNTK[N`LCY#^H
M2C][F.L+=@LY/-8?B<O&VOEX&ZEK?8L,_21GK':.8/-2>3Q=3,8^6E=A$D$@
MXCD0>H@]1',%,OIOFJO5_,U^9^#6:]*.IV:\%5[61M;17),;AIGP4XG%ES(L
M'(CG'$>M_:[DWQ4`Z_E#:CV=R=Z>#&"=U?X7<QT;[.@&D.\>#7'B"_XVG#BO
MH%.G7H5(JM2%D,$30UD;!H&A/.FN3VD\V]-W;V\-FW<8I8\C#'X^KBZ,5.G"
MV*"(:-:/K)/63S)ZUODB9-&Z.1C7L<"US7#4$'F"%FBY&VW=ZE+;"INIWMD7
M&7&QRW<)KK)1;ZTM8=9A^4WYG,=78K%C\C4RE..W2G9/!(-6O8=1X=Q[EU*N
MW]GIJ]R3*8"9E2Z\[TT#A]PM?KM')WSQQ[=5T8XUNOE+?O[?GQWB6<=-"Q(H
M7$;1P9&9U*Q$^EE(QK+3F/K`?*:>3V]X^I32C.$H/#)#)IYH(B)#0B(@`B(@
M`H#:RU,W&,QU1V[<R4@J1$<V!P]=_P!%@<?<I]5G'?AC:Z[D3QK8T&E6[#(=
M#*X?NM\BKT%:6-Z1S^//RN+/2V\FXL=4BQL6/$$;JL<;8VQ/:'-W0-`""HAV
MQN/A<9,5-:Q,A.OWE,6L)[XSJP^Y6)$D:U2%[/7\S!Q3V%<,6UE#\58QV4C'
M5,QU>0_2;JT^X)]M$]7AD\!E*I'-\48L1COUC)/U*QIHGYZ,NO!=V7IEY&86
MM&0M7:W`7';D>5JMD_1ROZ-_[+M"I=DC)6AT;VO:>1:=0M5JA4NLW+56&=O9
M+&'#ZU$/V+V?+^DBQ[:S^>]5D?"0?H$(^@]Z\'\!TB?15X[*ECM:^>S<'8/2
M^D'N>"O/@3/,&D6U5@CAITU.%_\``!'-4WI-=Z?LF;B>XL2@MJOR"E_B-3_>
M:M9Q^U+&D,SM!YUX=)CB.'E(HG:"OM)'0JBUD,;*#?K;NY4>TAW2MW?CGAKI
MK_)5H4H\[&TUKQ^!9R>%Y%W15Y]3:USM6Y7$L'8*+S__`+%Z[&;2R$Z[15HQ
MI^;QPX'Z3RI<S'_=>?P-B>XL"*O?`.7EU%C:F]NGJ@@AC^O=)0;(UWZ^E93,
M60>!$E][0?)F@1S=-:S\$_>P7EN)JQ<K5&;UFQ%"WMD>&CZU#R[:8%DABAN^
MF2C\W3C=.?W`5G!L=L]7?OMQ%5[_`)<S.D=[W:E3,4,<+`R*-K&#DUHT`]R/
MH+>_!?(=(KYSV8N<,;LY9#3^=ORMKM'?N^L[Z@O/@O:2_P#EV;BI1GG'CH/6
M_P`Q^I]P"LB(Y]+J12\_6_E8S#?5D'4V2P]6<67UC;M#^T7'F=^O<7:Z>6BE
MK56&Y3EJSL#X96&-[3UM(T(6Y%.56<G>3;8RBEH5_9.S*,?+BK;RZYC)/19'
M'F]H&L;_`#81YZJP*LY4?`^U-#+CU:UW2A;[`XDF)Y^EJWZ05F5*Z3:J+26?
M?M\_*PL-VX(B*`X1$0`1$0`1:[%B&K`^>Q*R*)@U>][@UK1VDE5@WLEM4XQX
MI\M#$:Z.R!;I+..R$'V1\\^0ZU6G2<\]$MOYZ"N5CKRN?E-PXG"1,MY/3[H7
M'[E5!^-*1U]C1Q*Z,-@(L6Z6U-,^YDIP.GN2CUG_`#0/BM'4T?6NO&8JEAZ;
M:M&!L40.ITXESNMSB>))[2NU-.JE'!3R6W>_MP]3%'.["C<SA:^9K,9(]\-B
M%W25[,1TDA?\II_B.1'-22*49.#Q1U&:3R97\1FIVW/@;-!D64:"8WM&D=M@
M^.SO[6\QX+LS6;BQ$$8$;K%R=VY6JQ^W,_L'8!S+CP`4=MA/0=3AHRP26LC,
M_>I05W[DW2#D]KOB`=;CPT[>2Z,)A):TS\GE)6V<M.T-?(/9B9U1QCJ:.L\W
M'B5TN-/"JLE:^S?V;EO\%P2[OA1Y@L+8KSRY7+2,L9:P-'N;[$#.J*/L:.L]
M9XE3DDC(8G22.:QC`7.<XZ``<R4>]D4;I)'!K&@ESG'0`#K)51!FVWL@Z.BV
M;B=KQ&CL@X'ZH@?VO!(E*M)SF[)>6Y+V7M=FY15D9UXW[9W([MAI&`@<'U87
M#0VW@\)'#Y`^*.OF>I6U>-:UC0UH`:!H`!H`O4E6IC=EDEHOS;O-C&P1$4A@
MB(@`B(@`B(@`B(@`B(@`B(@`B(@`B(@",S6%@S-9C'/?!9A=TE>S%P?"_P"4
M/YCD1P*X\/G)C<^!\RQM?*L:2TMX1VFCX\?\V\QX<5/J/R^&J9JH(++7`M=O
MQ31G=DB>.3F.ZB%:%2+C@J:>GYM0K3O='1=I5LC4DJVX635Y6[KXWC4."K<=
MNWL@X5\E)+:PFND-YWK/K=C9NUO8_JZ^U;\?FK6,N1XC:![1,\[M6\!NQVNX
M]39.UO(]2L;V-D86/:'-<-""-01V)\Z70FKQ?Y=/\W-;#.MFM1'(R6-KXW!S
M'`%KFG4$=H62JC\?>V4D,^(BDMX@DNEQS3J^#M=#KS':SW=BG\9E:68IMMT9
MVS0NX:C@6GK!',$=AXI*E+"L<7>._P!GN?XC5*^3U.Q$11&(W+X.CFX&LMQ'
M?C.]%-&[<DB=VL<.(*AVY/+;-'H\TU]_&CV<E!'Z\8_OF#_4WAV@*U)HK0K6
M6":O'=N['L]-Z%<<[K4T5+E>]699J3QSP/&K9(W!S2.XA;U7+6S!K6GW\!9^
M#;;SO21!N]7G/SX^H_.;H?%>0;4^B3,J;0U3C+#CNLF<[>K2GYLG4>YVA3.B
MI9TG?AM\-O=WV,Q6ZQ9$7@<'`$'4'D0O5SCA$1`$5M%DW8C"3V8F[]DZ1UX_
MERN.ZP>\A;,'BVX;#5J+7;[HF?='];WGBYQ\7$E14_X9VTAK#UJN(8+$G8;#
MP0P?1;O.^D%9E>IT*:AM>;]O+/O$6;N$1%`<(B(`(B(`(B(`*"VJ_(*7^(U/
M]YJG5!;5?D%+_$:G^\U6Y/\`RQ[19]5DZB(HC!$1`!$1`!$1`!$1`'#F<;%F
M,1:Q\I(;/&6APYM/4X=X.A\ER[,Y*7)X6-]D`78'.KVF_)E8='>_F.XA3"K+
MOP+MH'#A4S+-#V-LQCA^TSZV*]/IP=/:LU[^6?<(\G<LR(B@.$11V5SF/PL+
M9+UAL9?PCC'K22'L:T<7'P31C*3PQ5V8VEFR14)E=I:V/LBC6BDOY-PU;3K\
M7#O>>3&]Y^M<7X?VAX:28/''K.AMRCZQ%];O!3.+PU##5S!1KMB:X[SW:ESI
M'=KG'BX]Y5L%.G_)F]R]W[+Q0MW+0AZ^SMK*SLN[32QV'L.]%0BU]'A/42#^
M,=WGAV!68``:`:!>HIU*LJFNBV;$,HI!$7A(`U/)3-/5!9?/O@M#%XJ`7,L]
MNHBUT9`T_'E=\4=W,]2Y+&:N9V9]'9UP;$UQ98RCF[T<?:V(?'?W^R.O7DIC
M$8:GA:I@JL<2]V_++([>DE?UN>X\25TJ$:6=3-[OGXU[-J7<M#GPF";C#+;L
MS&WD[.GI%MXT+NQK1\5@ZFCZRI2>>*K`^>>1D<4;2Y[WG0-`YDGJ6G(9&IBJ
M4ER[.R"",:N>\_5WGN5>AHV]JK#+F6A?7Q+'!];'OX.F(Y/F'9UAGO[%BBZK
M=2H[+?[+\L@OARB8M;-MI*'R,DAV=8=6L<-UU\]1(YB+NYNZ^"MC6M8T-:`&
M@:``:`(`&@`#0#L7J2I4QV25DM%^;>/L;%6"(BD,$1$`$1$`$1$`$1$`$1$`
M$1$`$1$`$1$`$1$`$1$`<U_'U,G3DJ78&3UY!HYCQJ#_`-CWJN-MWMD'"+(/
MENX/E'=/K2U1U-EZW-^?S'7VJV+QS0YI:X`@C0@JM.KA6&2O'=\;G^.XKC?-
M:F$,T5B%DL,C9(W@.:]AU#AV@J#R>STGICLIA9VTLF?;U&L5D#XLK>O]8<0N
M>;"WMGY76]G&M?6<[>FQ3W;K'=IB/Q'=WLGN4MB,Y2S4+G5GN;+$=V:O*-V6
M%W8]O,'ZCU*EI4_J4G>/YDU^(RZEE(Y<7M''9M#'9&!V/RH&IKRG42#Y43N3
MV^'$=8"G%PY7$4<S4-:]`)&:[S3KHYCNIS7#BT]X4&VQF=F?4NB;+XH<K4;=
M;,(_O&C\8/G-X]H68(5<Z>3W?#]GGQ87<=2U(N6AD:>4J,M4;$=B!W)\;M1X
M=Q[EU*#33LQT[A:YZ\-J!\$\3)8GC1['M!:X=A!6Q%BRS`K)V<NX@[^SE_T>
M,?V"UK)7/ZOQH_(Z=RSBVKCJ2-KY^J_$SDZ"20[U>0_-E'`>#M"K&L)8HYXG
M1RL:^-PT<UPU!'>%T<\I_P`JOQT?CM[[B8;=4]CD9*QKXW-<QPU#FG4%<^2O
MPXO&V;U@Z0UXW2.[P!R_DH9^R4=1[IL%=GQ,A.ICB]>!Q[XG<!]'10&:R68E
MOT\+E:#;,,;VW+3\;O2&2%I]4&,\0"\`D`G@#HJ4N30J26&5UMV.WIV9F2FX
MK-%FV5H34\.)K@TO77NMV>Y[^.[]$:-\E.*,QFT.*RY+*5V*25OM0GU9&^+#
MHX>Y2:A6QNHW-68T;6R"(BD,$1$`$1$`$1$`%!;5?D%+_$:G^\U3J@MJOR"E
M_B-3_>:K<G_ECVBSZK)U$11&"(B`"(B`"(B`"(B`"B=I,9)E,+-%7(;;C(GJ
MO^3*P[S3[QIX$J3EFC@C=)+(V-C1J7/.@'F57Y-KZEA[H</6LY>8'36HS[DT
M]\KM&CR)5J,:F+'36GAW[!9-6LR4PN3CS&'JWXV[O3,U<P\V.'!S3W@@CR6&
M4S^,PX:+MMC)'^Q"-72/_58-2?<J=2I9H;0S8NW<.'K9#?O1PTG![B[4"1@D
M(]4\G'0=9T*N&+V?QF'+GU*K6S/]N=Y+Y7^+W:D^]6K4J-.5V[IYI+=VZ<,K
MBQE*2(STG:/-\*D`PM-WYZRT/LN':V/V6?2)/<N_%[.4,7,ZTULEB\\:/N67
M])*[Z1Y#N&@4NBC*LVL,59</=ZL916KS"(BB,$0G0:E5NUM,^W9?1V>K#(66
M'=DG+M*T!^<\>T?FMU/@J4Z<JCZ/V1CDEJ2V3R]'#U39O3MB9KNM'-SW=36M
M'%Q[@H+T+);5'>R;)<?A_BT0[2:P/[TCV6_,''M/4NW%[-,K6QDLE8=D<J1I
MZ1*-&Q`_%C9R8/K/65.\E3'"E_'F]_Q\O/<D+9RU-=>O#5@9!!$R**-NZQC&
MZ!H[`%'YG/5<-'&V0/FMS'=KU(1O2S.[`.SM)X!<%[:">[;DQFSL<=JVP[L]
MI_&"K^L1[3OF#ST7;A]GZ^+DDM22/MY&8:3W)^+W]PZFM[&C@A4U#I5O#:^W
M<O-^87;RB<>/P=J]<CRVT#F2VF'>KTV'6&IX?+?VO/EHK&B*52I*;N_LADD@
MB(D-"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"A\ML[7R
M<S+D4DE+)1C2*Y7X/`['=3V_-/#P4PB:$Y0>*+,:3R968-H;.)G93VECCKEQ
MW8LA%^3S'L.OXMW<>'8596N:X`@@@\00L)H(K$+X9HV21O&ZYCV@AP["#S5;
M=@LC@3TNSDP?6UU=B[+ST?\`[3^<9[N+?!6^G5TZ+\G\>G8+G'BCIO[,,=;?
MD<19=C,B[B^2)NL<W=)'R=X\#WK3'M--C9&U]I*GH+B0UMR,E]60_K<V'N=[
MRNS%[2TLC.:<@?3R+1Z]*R-V0=XZG#O;J%+21,FC='(QKV.&CFN&H(["$TIR
MCT*\;^O<]WBMP))YQ9ZQ[)&->QP<UPU#FG4$+)5I^S,^,>Z;9RZ:.IWC2E!D
MJN/<WFSQ:?)>Q[5&C(V#:&B_%O<=UM@NZ2L\]T@]GP<`EYC%G2>+AM\/BX8K
M=;(LB+&.1DK&OC<US'#4.:=01XK)<XYC(]L4;I'N#6-&KB3P`[57MDV.NQW,
M_,"'Y.3?B#AQ;7;PB'F-7?23:V5]FO5P4#RV?*2="XMYLA'&5W[/J^+@K!%&
MR&)D<;0UC&AK6CD`.05^I1XR]%\OT$UEV'#DL#B\P!Z?1AG</9D<W1[?!PXC
MR*C/M=R-#CA\]9B8.5>Z/28_`$Z/`^DK(B6->I%8;Y;GFO!FN*>97/A7:*C^
M78)EN,<Y<=.''_+?H?<2MD.V>$=((K-EU";ET=Z-T!][@`?(J?6N6&*>,QS1
MLD8>;7M!!\BFYRE+K0\';UO[&6DM&>068;,8D@ECE8>3HW!P/F%M4#/L9@)9
M#+'CV593^<J/=`[WL(6L[.9"#\AVFR40^38#+#?WAK]:,%)Z2MVKXOZ!>2V%
MB15T0[6UB`VWB;S!SZ2&2!Q\VEP^I/A3:6'\;L[!-IUUK[3KY/:W^*.8;ZLD
M^]+UL;CWHL2*O_;-9C:?2-F\RQPZF1QR?Z7E>?;?49KTV/S$/$#5^.ET^H%'
M[:KL5^S/T#'$L*@MJOR"E_B-3_>:M?V[8,/W#-::==#O49AI^XHG:3:O#6*-
M41VG^I>K2.WJ\C0&ME:2>+>P*M#DU958MP>NYBSG'"\R[HJ^[;7!-;KZ3.[]
M6I,?^"\&V>)>`86Y";4Z:1X^<_\`%2_:U_\`1^#&QQWEA15YNU;7D=%@\X\'
M7CZ$6_ZB$.=S$Q^]ME[NG;8L0Q#_`%$_4C]O4VY=K2]6&-%A15WTG:V=OJ8[
M%5">N6T^4CR:T:^]>?!.TEGC9VCC@!YMI4FMT^D\N_@CF4NM)+S]+ABW(L>J
MC;VT.'QG"YDZD+OD/E&\?+FH_P"TZG/_`.(WLGD/FV+;@P_19NM^I25#!8G&
M:>@XZK7(^-'$`??S1AHQU;?8K>?V"\F1GVUFWPQ&&R5[7E*8N@B_:DT^H%>=
M#M7D1]TLT<1&>.D#38E_:=HT>XJR(CGHQZD5WY_;R,PMZLKT6QN+=*)LB;&4
MG!UW[\ID`/<SV!Y!3\<;(HVQQL:QC1H&M&@'DLD23JSGUG<912T(#:RI,_&1
MY&FTNNXV06HFCF\`>NSZ3"X>Y3%.W#>I0VZ[M^&:-LC'=K2-0MQ&JK>S?X*R
M.0V>?P9`[TFGKUP2$G='ZKMX>&B==.DUMCZ/7P?JQ=)=I9410V3VGQN,G%4O
M?9O$>K3JMZ24_1'(=YT"E"$INT5<9M+4F5#93:6CC;#:;1+;R#AZE.JW?E/>
M1R:.]Q`7#Z+M%G!]]SC#4W?F*S@^PX=CI/99]$$]ZF,7AL?AJYAH5F1-<=7N
MYN>>USCQ<>\JV"G3Z[N]R]W\7[4+>3TR(;X(RVT!WL],*M(\L;4D/K#^]D'%
MWZK=!XJQ5:L%*NRO6ACAAC&C(XVAK6CN`6<LL<$3I97MCC:-7/<=`!VDJMR;
M0W,RXP;-0-ECUT?DIP179^H.<A\.'>M^I65EE%=R7YWMAE'M)G*9BCAJOI%Z
MPV)A.C1S<\_):T<7'N"A/1LOM/QN]-BL2>55CMVS./[QP_%M/R1Q[2%W8O9J
MM1L^GVI9+^3(T=;L:%P'8P<F#N'UJ;68X4OX\WO^%[O/@@LY:G/2HU<=4CJT
MX(X((QHV.-N@"Z$10;;=V.$1%@!$1`!$1`!$1`!$1`!$1`!$1`!$1`!$1`!$
M1`!$1`!$1`!$1`!$1`!$1`!$1`'!E,-0S-<0WJS)6M.K''@YA[6N'%I[PH<0
M;08#\G>[-T!^:F>&VHQW/]F3Z6A[RK.BK"M**PO-;G^9=PKBGF16+VBQV6>Z
M&"8QVF?C*L[3',SQ8>/F-0I*2*.:-T<C&O8X:.:X:@CO"X<K@L;F6-%ZJR1[
M/Q<HU;)&>UKQQ'D5%>B;1X4?>=EF9JCE#;=T=AH[!(.#OI`>*?!3GU'9[G\_
M-NTR[6IF_9*.I(Z;!79L3(3J8XO7@<>^(\!]'18#.9G%'=S6(=-$/[9C096^
M+HSZ[?+>733VLQT]EM.V)<==/`5[K>C<[]4^R[R)6>U&1FH85XJ?EUI[:U4?
MWC^`/D-7>2JN=E-4ZL;WWZ]M]WBA>BE>+(O9O(4]H=HLEF(;$<C(@*=1FOK-
MC'K/>6\QO.(YCDT*W*O#8S"''U:LE-I?6C#([+"8YAIU[[=':D\>?6L/@K:'
M&_\`AN:9<B'*#)Q[Q`[I6:.]X*RJJ565X2ML2>Y<5\(V.**S19$5;^V:W1X9
MG!W*S1SL5OOF'QU;ZP'BU26/S^)RO"CD:T[NMC)!O#Q;S'N4)4*D5B:RWK->
M*R&4T\B21$4A@B(@`B(@!H.Q$1`#106U7Y!2_P`1J?[S5.J"VJ_(*7^(U/\`
M>:K<G_ECVBSZK)W1$11&"(B`"(B`"(B`"(M-FY6IQ&6U/%!&.;Y7AH]Y0DV[
M(#<BKKML\=,\QXJ*UE9>6E*(N9YR'1@]ZQUVKR0TTI8:(]9^^9OY,'UJ_P"W
MFNOT>WXU\A,:V9E@FGAK1.EGE9%&T:N>]P:T>)*H6T.TU-UNIFL+'-?DQI?Z
M1+#&1`8'#1[3(1IS#7#37DK!#L?CW2MGR<D^6L-XA]Y^^UI^;'P8/<IR2M#)
M6=7=&TPN86%FG`M(T(T\%2G.C1E?.7DN/%^1C4I+<5UN)S6::'Y;+"M6<-?1
M,8XM!'SI3ZQ^CNJ9QF'Q^'@,./J10,)U=N#BX]KCS)[RH39[)PXC&V\9E+<<
M+L1)T/2SO#0Z$C6)VI^;P\6E;#M+;R?J[/XN6TP\/3+6L%<=XU&\_P`AYIJD
M*TFX+JKN7#RWYF1<5GM+&][8VESW!K0-22=`%79MJA<E=6V?J/RDS3NNF:[<
MK1GYTAX'P;J4;LL_(O$VT5YV1.NHJL;T=9A_4UU?XN)\%88H8X(FQ11LCC8-
M&L8``T=@`4OI4_[/P7R_(;I/@5V+9>3(R-L;26_A"0'>;4:-RM&>YGQSWNU\
M`K(UK6-#6M`:!H`!P`7J*=2K*IUG\>`RBEH$1%,T(B(`(B(`(B(`(B(`(B(`
M(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`(B(`Y[M"
MID:SJ]RM%8A=S9*P.'N*HL.S\T^U$XP5^2M6Q&@C98+K$0G<T[S6M)U:`P@<
M#P+N"N^4MNH8NU;9"^=\,3GMBC:2YY`X``=I7)LWC),5A(89SO6Y-9[+_E2O
M.\\^\Z>`"ZZ%:5*G*2>N26SB[=F7>3E%2:1PC.9C&G=S&%?)&.=K&DS,\3&=
M'CR!4CCMH<1ECNTK\$L@YQ;V[(/%AT</<I-1V2P.+RX^_P"A!.X<GN9Z[?!P
MXCR*GCI2ZT;=GP_E&VDM&2*C<CL_B<MQO8ZM.[Y;HQO#P<.(]ZCOM;OT?_",
M_;@;U0W!Z5&.X;WK#]I>>G[3T?RK$5L@P?G*$^X[]B3^3DT:;3O2FK]MGYY>
M#!O_`&1[]JTM34XG.9*D.J-\@L1CZ,FI]Q":;74SP=BLE&.T/K//^IO\%DW;
M3$QN#+_I.-D^3>KNB'[6F[]:F*F1I7V=)3MP6&?*AD#Q]2:<JT5>K&ZXKWU\
MS$HOJLAOMDO5F_?^S>3B/RJX98;^Z=?J7K-M]GRX,FO>B//Q;<3X3^^`%8>"
MQ>QDC2U[0YIYAPU"GCI/K0\'\W-M+8SFKY3'VPTUKU:8.&HZ.9KM?<5U:ZJ)
ML;+X&T29\-0>X\W&NT'W@+E&Q.$C.M:&Q5=VUK<L>GD':(M0>UKN7RC>D6%%
M7SLJ==8\]G(SIIPN;WU.!08#)Q$]#M1DN0T$L4+Q_H".;IO2?BG]PN]Q8%!;
M5?D%+_$:G^\U8G#Y[0Z;3R`]6M*+_LN2WLUG+T+8K&T^^UDK)6_>$8(<QP<T
M\#V@*E*%.$U)S67_`%?`LFVK6]"U(J\S#[0#7?VH>>S=H1#_`+K(X3,R`B3:
MBV!I^:JPM/\`I*GS4/\`=?\`=\#8GN]"?U15X[+S/UZ7:/-OUT]F=C/]+`O7
M;(4)C]]VLG:TY":_+I[@X!&"DM9^"^;!>6XFY;,%<:S31QCM>X-_BHJSM=L_
M4>62Y>H9!\2.3I'>YNI6$.QFSD+MYN&IO=\J6/I#[W:J6K4JM-N[6K0PM[(H
MPT?4CZ"WOP7R'2(3[;H9OR'$Y>YKR='3<QI^E)NA>>G;4V_R?$4J+?E7;)>[
M]F,:?O*Q\%X2`CG8+JP7?=_"\C,+VLKWP'F[?Y?M)*QAYQT(&PC]H[SOK6VM
ML?@Z\HF?2%JP./37'NG?KVZO)T\EON[3X3'.W;64J1R?H^E#G_LC4_4N([52
M6^&)PF2NZ\I'1^CQ?M2:'W`JJ?*9++)?_5>.2,Z"_+EA:QK&AK6@-'``#0!'
MR,B87O<UK`-2YQT`\U71%M9?_&6<=BXSQW86&S)^T[=:/<5DS8['S/$F4FM9
M64'7[]E+F`]T8T8/<I<U"/7GX9_"\S<3>B,Y]L<4)G04739.P.'14(S-IXN'
MJCS*T_\`5.5Y>C82N>W2Q8_H;^\K#!7AK0MA@B9%$W@&,:&@>06Q'.PCU(][
MS\M/)AA;U91,EL]3P6:Q>:LNER#72^C6YKKNE+-_A'(.&C=UW#@!P<KT%RY/
M'PY7&6:%@:Q6(S&[M&HYCO'/R6.)BN08JK%D)&26V1ALLD>NCR.&O'MYK:M5
MU81<GFLN[9[^01CA>1VHB+G'"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`
M"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`
M/"T.:6N`(/,%0UO9+`W7])+BJPEY])$WHW_M-T*FD3PJ3@[P;788TGJ5[[5I
M(/R'/9>MI[+38$S1Y2`_Q6/H.U=7\1F*%P?)M4RP_M,=_)6-%3]Q/;9]J7KJ
M+@6PKQO[4P?C,)0L#3G7OEI]SV#^*#:+(1'2ULQE&=\)BE'U/U^I6%8E'.P>
ML%Y_(87O(`[7U&:]-CLQ$!IQ=CI2/J!0[;X!ITDMRQ'7=^ZU96<?-JL`Y+U&
M.CMB_'[!:6\KSMN=FF'1V8KM/8=1_);/MSV;TU^&Z('?,%+R^WY+FL?BCXC^
M(6KF'_B_%?\`B'2W_GB1[]MMFH]-[-4^/9)K_!8G;C9O<WQE8G-[6M<[^`4N
M.971'[`6-T%_B_%?^(=+?^>)`?;GB''2'TZ<ZZ?<J$SO^*]^VH/;K#@\W*>H
M>A%FOF\@*P+%R,=%:1?>_A(+2WE?.;SLOY/LM.T=MFW%']0+BADVNL`;E;#U
M-3Q+Y9)R!X`-'UJPHCGHK2"\_=AA>UE>&%SUC\KVFD8T\VTJC(OK=O%/M,QL
MVGPA/?R.G5;MO<W]D$-^I6)$?N:BZKMV)+TL;@CM.*CB,;C6Z4:%:L/[J)K?
MX!=NB(HRDY.[=S4DM`B(L-"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(B`"(
-B`"(B`"(B`"(B`/_V3\_
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g16941.jpg
<DESCRIPTION>G16941.JPG
<TEXT>
begin 644 g16941.jpg
M_]C_X``02D9)1@`!`0$`2`!(``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
M_@!)35),3%]&3TY44SI;1D].5%-?3$]'3UU,,#`U.$U%4E))3$PN4%-4"D9O
M;G0@4VEZ93H@-C8@("`@(%-T<FEN9SH@*&QM;BG_P``+"`!!`)@!`1$`_\0`
M'````@,!`0$!````````````!@<`!0@$`@$#_\0`3!```0,#`@(%!P8)"`L`
M`````0(#!``%$082!R$3,4%180@4(C=QL;(R<G-T@;,5%B,V0I&AP<,7)#0U
M.$-UT3-%4E:"A9.BPM+P_]H`"`$!```_`'V\^U&96\^ZAII`*EK6H)2D=Y)Z
MA7Y0;A#N<9,F!+8E,*^2ZPX%I/VCE734J5*2/&.QWNPZ:<O4'5]\<;,@(>BO
M/@("5Y`V[0G`'(8.>5=WD[/.R-%W1YYQ;CBKFHJ6LY)/1-]9IP5*E2I53?K*
M[>XK;#5XN-L*5;BY`<2A2AC&"5)/+MY5E[B$U>[+Q#59)U_GW*,EUI;:I+I)
M*%%*@".K(/NS6MQ4J5*">*NF+GJW0TBV6AQ(E=*AT-J5M#P2>:,]0[#SY9`J
MAX):(ONC;3<S>TAA<QU"FXH<"]FT$%1P2,G(ZNZFI4J5*67'KU72OK+'Q54>
M3A^8MR_Q)7W3=.2I4J5*E98XT>N1/S(O[JU.*E2I05(XN:#C?+U'%5]&E:_A
M2:M-/ZVL&IK5+N=KF])#B**7G5MJ;",)W'Y0'+'.J>5QAT%$SOU"RLCL9:<<
MS^I-$4;4]GDZ<:OXG--6MQOI$R'ST:=N<<]V,=5#".-&@7)?FPOR0<XWJCNA
M&?G;<?;1S&DL3(S<F,\V\PXD*0XVH*2H=X(Y$4M^/7JNE?66/BJF\G5UMC0%
MU==6EMM%Q6I2U'`2`TWDD]E%,GC-H*-,\V7?D+4#@K:9<6@?\03@_91A:KO;
M[Y`1.MDQF7%7\EUE84,]W@?`\Z["0D$DX`ZR:"+GQ?T-:IBHK]]:<=2<*\W;
M6ZD'YR01^VB&PZHLFIXRI%FN4>8VGY0;5Z2.[<D\Q]HJWK+'&CUR)^9%_=6I
MQ7#=;S;;'#5+NDZ/#C@XZ1]P)!/<,]9\!0H>+VBDK3ONKK;:SA+SD-Y+:O8H
MHQ1?;[C"NL-N9;Y3,J,X,H=96%I/VBEQQXMT-SAG*E+C-%^.\R6G-@W(RL).
M#X@FJ?R;P#H^[`\P9_\`#35!Y2-NB1YE@F,QVVY#Z7T.K2D`K"=A3GOQN/ZZ
M(^&6BOQETC9;CJG9+@QF=MMMN?R*$Y.77$_I+)SU\@/V$^M.%VFK]IZ4W'M,
M.#.;:4J/(C,I:4E8&1G;C<.P@]]+7R=-3R1<Y^FGG5+BJ9,J.E1R&U`@*`[@
M0H'VCQH[X]>JZ5]98^*EYP6TI(U;IZ3&N4DITVQ.+CL-I129;^Q/)PCGL2`#
MCM)\*<EQX:Z/N5J5;UZ?@,ME.U+C#"6W$'O"@,Y_^-(KA!=9FE>+3VFC)4N'
M(?>AO)_14XWNVKQWY3CV*-.[6UNN>I9MNTTQYS&M,H+>N<MKT<M)P`R%=ZR>
M?@#UUUM<.-&M6WS!.F[:6",'<P%+/CO/I9\<YK.U]8<X0\8$+M3[@AH4V\E"
ME9*F%_*;5WCD1S[@>NM8)4%H"DG((R#WUEGC1ZY$_,B_NK3-WNL:R6:9=)BM
ML>*TIUPCKP!G`\3U4F^&"'N)FJ;GK'4:!(;A.!FWQ%^DU')](D)/+(&WGVDY
M[J=DJ)'FQ7(TIAM]AP;5M.I"DJ'<0>59R-Q=X0<9G;;!<6+!-<;6Y%424I;<
M[1XH.<'N&*9?'7U4W+Z5C[Q-#_DW?F?=OK_\--5/E+]6F?;)_ATS.%/JNT_]
M5'Q&BN9_0G_HU>XUESR??64?J#WO33=X]>JZ5]98^*JCR</S%N7^)*^Z;IR5
MD_2W]HO_`)U)^)RM-W_4=ITO:U7&\3&XL=/(%7,K5_LI`YJ/@*$+=KS46KV2
M_I+301`4HA%QN[W1-JP<92VC*E#KZC2'XSQKK%UWMO%P:G2U1&EE;+'0H0#N
MPA(R3@=Y.36MHG]#8^C3[A67N-'KD3\R+^ZF]QT?=9X5W!+60''F4+(./1W@
M^\"EYP)TIIS4]DNWX7MK,N1'DHVJ4I0*4*3U<B.64FFS_)1H?_=^/_U'/_:H
M.$^A@H*_%V*5#F"5+/\`Y55<=2/Y*;CS_O6/O$T.^3<I/XI7=.X;A/!(SSP6
MT_Y&JGREUI*M-("AN'G!(\/R=,WA0H*X7:?((/\`-<<OG*HLFD"#(R?[M7N-
M9;\GY24\2\$@%4%X#/:?1/[J;G'QQ".&#Z5*`*Y3*4^)R3[@:JO)P(_$:Y#/
M^LE?=MTY#63=,.('E$)65IVJO<@`YY'*E@>^KSRCGIAU9:6G-WF28.YGNWE9
MW_;@(_93YT;+@3-&V=^VE!AF&T&PCJ2`D`I\"""#XBLS<<KI"NO$A]<&0B0A
MB.VPM;9RD+3DD`]N,X]N:U'#NT$RHUJ$A)FJAIE!H9)Z+(3NSU8R<5F?C,\V
MKC*H!8_)IC)7X'`/N(K1NLM/(U7I"Y652TI5):(;6>I*P0I!]FX#[*S?PKU,
MOAOKZ5;;^A<2/(_FTL.#'0K!RA9\.9Y]RLUJMMQ#K:7&UI4A8"DJ2<@@]H/;
M55J34L'3-M\[F*4MQ:@W'CMC+DAP\DH0GM)/ZNLT+WOA1$U(PEB\:HU),82H
M*#3DEH(W#J.T-@9\:Y['P;M>FG7'++J+44%3F.DZ&2WA>.K(+9!QD]E>+UP5
ML^HY@EWF_:@FOI3M2MZ2V=J>O``;P![*M]+<.(VD%LIME_OIB-J*O,GGT*95
MGKRG9D<SGD1SJPU/I`:H!:>OMYA15-=$Y'@OH;0X.>=V4$G(..O&.R@Z#P#T
MW;)K4V!=[]&E-'+;S4E"5)/@=E6-\X0P-2);1>=2ZCFH:.4(=DM[4G&,@!L#
M..VII_A!;=+/J=LVH=01-Z@7$(DM[',=6Y);P>WQYT67^Q.WUEMI%ZNEL2G=
MN-O=0V7,XZRI)/+'+&.NE\WY/FE69")#5SOB'D+"TN)DH"DJ!R"#LSG/;1-=
MN&UKO^FQ9KU.N-R+;A<8F27$&0R2`,)4E(!'+J(.>WLP%VW@"(+BV%:PNGX,
M<5ER(PGHM_@H[B/^VKO6/!6PZE@6]B`O\$.0&NA:6RT%I4WG.%`D$G))SG/,
MYSFNRP<+TV"TN,QM1W07)[HTN7$%!<Z-`(2TD+"@E'/..OD.=4$WR?+'<9KT
MR;?[V_)>45N.N+;*E$]I.VCS3&EY&G!T:]176Y,):#;;4U2%!&,<P0D'.!CF
M:Y-8\-M.:V2%W**IN8E.U$R.=CH'<3C"AX$'PQ0O:N$M_P!/I\WLO$.Y1(6<
MB.J,EP)]F58'V"BNPZ#A6FXB[3ILR\W@)VIFSW-ZF@>L-IZD#V<_&J?C%K"Z
MZ-T>U+M"4IDR)*6.G4C<&04J5D`\L^C@9JHX(Z]ONLHET8O9$A<,ME$H-A&X
M+W>B<`#(VY'+MIM5G6[\:=60N)K]N:89$!B>8H@ED%;B0O;G=\K<>L8Y<QR-
M:*H$XLZSN&B-(HGVR.AR2](2P%N)*D-92H[B.T^C@>VN?A%KJY:YTY)D72,V
MB1%?Z$O-)*4.Y2#U=A';[13#I-.<8;PCB_\`BH+0R;?YZ(?4KISV=)G.,?I8
MQU=M.6A#B5JZ7HK1[MWA0DRGPZAH!>=B-V?25CGCECKZR*_3ASJN5K/1T:\3
M(8BOK6MM249V+VG&Y.>>#[P:*Z6T;B=+?XO.:+-E4F.DJ3YSN.\81NWD8QL/
M5]H/A3)H:UYJEW1VE)-Y9MZYRVE)3T844@;CC<H@'`'^5=VE[RYJ'3-ON[L-
M<-<MD.%A9R49\>61VCP(JWH0MFMG[AQ$N>EE624RU"9#@G+/HN?)[,<@<G!R
M<X-5O&SU5W;VM_&*H?)V_,29]>5\*:;](6\?VG(7M:^[I]#JH1XH>KB]?0CX
MA7'P@]6]N]KGQ&CJEPKUX#ZF/AIC]E5NH/S?N'T"_=7JQ_U%!^@3[JL*KT?U
8ZOZN/BJPKP[_`*)7L->D_)K[7SN]M?_9
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g564615.jpg
<DESCRIPTION>G564615.JPG
<TEXT>
begin 644 g564615.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+__@`L1$E32S`T,#I;,#)004PQ+C`R
M4$%,,3`Y,2Y/5510551=05)4,D,N15!3_\``$0@`_P*L`P$B``(1`0,1`?_$
M`!P``0`!!0$!```````````````&`@,$!0<(`?_$`%$0``$#`P$$!`H'!@0#
M!`L!``$``@,$!1$&!Q(A,1,505$4(C124V%QD:&Q,D1R<X*BP2,S.'6!PP@6
M0M$78K,D-^'Q)2<U-D-T=H.2D[+P_\0`&P$!``(#`0$```````````````(#
M!`4&`0?_Q``W$0$``0("!P8$!@("`P```````0(#!!$%%2$Q05%Q$A,R89&A
M(C.!T0844K'!\".BTN%B<O'_V@`,`P$``A$#$0`_`._HB("(B`B(@(B("(B`
MB(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`
MB(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B(+53.RFA=+(>`^/
MJ6D\-KZV0BG!:!V,[/:2KU]><PLSXO$_U6#3U<T<+J:%HS(>8^EE<MI/'U3B
MIL35--,?IWS.6;/L68[OMY9S/-D&LN%%(.GRX'L?@@_U"W5+4QU4(DCY<B#S
M!6IN!,5M@IYG[\^=X\<D#_\`W!+$\B69G86@_P!5/!XFYA\;&&FJ:J:HX[9B
M<L\GERB*[7>993'+BWB(BZ9@B(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(
M@(B^.>UOTG`>TH/J*CI8_/;[PG2Q^>WWA!6BHZ6/SV^\)TL?GM]X05HJ.EC\
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M%:*CI8_/;[PG2Q^>WWA!6BI:]KOHN!]A52`B(@(B("(B`B(@(B(-==J1U13A
M\8R^,YQWCM6':GTD#'22RL;*3@9YM"WJQ9K=33NWGQC>/,@XRM3B='U3B(Q5
MG+M<IW==G%D47H['=U;FFKF4I:Z9E69I21D%;"STCH(72R##I,8![`LB&VTL
M+MYD0WAR+CG"RU#!Z,FB_P#F+L1%7*,\NNWB]N7\Z.Q3N$1%N6,(B("(B`B(
M@(B("(B`B(@(B("(B`B(@(B("(B`HQJ[ZG^/]%)U&=7?4_Q_H@AKZ^-CW-,;
ML@X[%\ZQB]&[X+!G\HD^T5;6_HT?8FF)F/=QEW36+IKF(F-D\H;+K&+T;O@G
M6,7HW?!:U%+5UCE[J]>8SG'I#9=8Q>C=\$ZQB]&[X+6HFKK'+W->8SG'I#9=
M8Q>C=\$ZQB]&[X+6HFKK'+W->8SG'I#9=8Q>C=\$ZQB]&[X+6HFKK'+W->8S
MG'I#9=8Q>C=\$ZQB]&[X+6HFKK'+W->8SG'I#9=8Q>C=\$ZQB]&[X+6HFKK'
M+W->8SG'I#9=8Q>C=\$ZQB]&[X+6HFKK'+W->8SG'I#9=8Q>C=\$ZQB]&[X+
M6HFKK'+W->8SG'I#9=8Q>C=\$ZQB]&[X+6HFKK'+W->8SG'I#9=8Q>C=\$ZQ
MB]&[X+6HFKK'+W->8SG'I#9=8Q>C=\$ZQB]&[X+6HFKK'+W->8SG'I#9=8Q>
MC=\$ZQB]&[X+6HFKK'+W->8SG'I#9=8Q>C=\$ZQB]&[X+6HFKK'+W->8SG'I
M#9=8Q>C=\$ZQB]&[X+6HFKK'+W->8SG'I#9=8Q>C=\$ZQB]&[X+6HFKK'+W-
M>8SG'I#9=8Q>C=\$ZQB]&[X+6HFKK'+W->8SG'I#9=8Q>C=\$ZQB]&[X+6HF
MKK'+W->8SG'I#9=8Q>C=\$ZQB]&[X+6HFKK'+W->8SG'I#9=8Q>C=\$ZQB]&
M[X+6HFKK'+W->8SG'I#9=8Q>C=\$ZQB]&[X+6HFKK'+W->8SG'I#9=8Q>C=\
M$%PB)`Z-W$X[%K54S]XWVA>3H^Q$;O=*G3>,FJ(SCTA/=)>65/W8^:EBB>D_
M+*G[L?-2Q<^[41$0$1$!$3*`B=BXX-L5RMMRU;;+[044-99Z=\E+T>\UL[@X
M-:#DG@[?8>'9E!V-%PR3;5J-]LLE+362BDOUX)DAC\<1-B+RQA(SDDEKCS``
MPMC;-KUX:S4MKOEII::_V>DEJ6-C<3#(6`9:>)(Y@Y!XCN[0[$BXA5;:;U!L
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M;2%FO]PL=LI:JDCDB?6RU&<1C+FM``<.9=ZT'K9%QNHVT5LDVCGT-MIN@OF&
MSME+BZ)PEZ-P:00,<R,CN5^HVHZADUEJFP6ZW4$KK332ST^\'ETO1EN6G#N9
M!=RQQP@ZZBX;+MUKY=)6:JH+=127JNK9*62F<7EC=W&"!G/'?9S/>NW4YF=3
M1&H#1,6#?#.0=CCCU907$1$!$1`1$0$1$!$1`1$0$1$!$1`49U=]3_'^BDRC
M.KOJ?X_T0<^G\HD^T5;5R?RB3[15M=9;\$='S:]\VKK(B(IJQ$1`1$0$1$!$
M1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`53/WC?:%
M2JF?O&^T+RK=*5'BA/=)^65/W8^:EBB>D_+*G[L?-2Q<B^EB(B`B(@@-5H6[
M3;4XM5QWLMH&M#74'C\?V98>W'/CR4?H-DVH:32E[L\FJ3)/7RP20U'[3]ET
M;B2/I9X@]A772]H."X9[LKZ@TNDK/56#2UOM5;5^%U%-'N/GX^/Q)SQX]J\[
M[2?!=H&TRDI;#05T=8X^!UKI(L-RQY;O\"<@#M[@%ZA+FM^DX#VE?-QH=O;H
MSWX0<UU=LE9>39*RQW(VNYV>)D-/+N;S2UARW(["#GCQY\0L*P;&YH9;[7ZB
MO1K[I=Z:6G?-$S=#!(/&=CM/`=PP,+K*^%S0<$@'NR@X`?\`#]?I+0+;+JN(
MTT,YE@AZ%W1@N&'.(SP<<#O[5W2GH6LM$5!.&R-;`(9!V.&[NE9BMRU$,)`E
ME8S>Y;S@,^]!Q4;%M36@5]NTYK#P.S5LC7OB<QPD&.7C-[1P&01G'%9NI=C%
M?='6&IH]0=-5VR$1/=<XS.V4AY?O'.>UQ\4Y&,=R["B#C%NV*W.BN-\JYK[3
M3NNUOFI9'"F+-Q\F"7!H.,`CD,<%\J-B5?/LZI-,=<TS9J>X/K.GZ%Q:X.9N
M[N,Y!7:$085KHGT-DHZ%[PY\%.R$N'(EK0,_!</AV":BH[976^DU9#'35SV>
M$PB!P;(UIRW/'.0>SXKOJ(./7[8E)4V33M-9;P*2LLS7-$LK"0\E^^7C'$.#
MLG_R5-CT%5;-KY==;7B[NNT7@SS4-CA/3/<YS2YW$X/'/#N78U3O-)W<@GN0
M>9MF&F*?4&UJINM%15,5AH9Y*F`3Q[N"3XC>[(SGV`+TVOC6-;]%H'L"^H"(
MB`B(@(B("(B`B(@(B("(B`B(@*,ZN^I_C_1291G5WU/\?Z(.?3^42?:*MJY/
MY1)]HJVNLM^".CYM>^;5UD1$4U8B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@
M(B("(B`B(@(B("(B`B(@(B("(B`B(@*IG[QOM"I53/WC?:%Y5NE*CQ0GND_+
M*G[L?-2Q1/2?EE3]V/FI8N1?2Q$1`1$0>=M<N(_Q)V/!(_;47(^M;FZ;:M1Q
M7G45MM>FJ>J-HEEWYND<6LAC>6N>\</5R/>I!J/9A<+QM5MVKH:ZE934LE.]
MT#P[?/1G)QPQQ5FW;*[E17O6U:ZOI71Z@IZF*$`.S$9'$@N]F>Q!S7:AK)VM
M=":6O#J;P:;PJIBEC8[+=YH9Q:>>"".:G^D-K5YKM<0Z6OU@;0.FBS`&O)D;
M^SWV[V>!WFCU<2M55;#+Q4:*M=C%UH6ST59/4.D+7[KFR!@`'#.1N_%2.LV6
MW&KVGPZJ%Q@CIFT[871-WA*T]`8B6G&.9R$$:O6VS5%IJ*I\]CM%+%#,&"EJ
M*O>J7`GN:[WG&!ZUI=<WYNI-H6SN\T['PMK(::01EW%A-001GMP01E9\&P+4
M$5NKK9UM9_!YI!(V<TI=,[=Y-+B,L;VD`GBMV_8W=WU.D)^LJ(&Q1L9*,._:
M[LQDRWAW'''M06+WMQN+=0W2BL5OM;J2W;^]-7U71NGW#@]&,C)X'`XD_!:S
M4]3/MET_IBY6BVU3:Z"NDIJAC"'0TY.XXN>XX."`".'>.8&=G>]B5T;J6YW#
M3]9:#37`N<8KE2B0T[G.WCN9:X<#G!X<#CCS72-"Z4DTEIX4%1/3U%4]YDFE
M@IV0M<>7)H'(#F>*#EU?MSO++Y<**BMMJBBHINA$=PJ'1RRX<6DY)#1RS@\L
M]J[59J^2Z66CKI:<TTD\39'1=(V3<)'(.:2'#N(YA<=U+L@U7>[G7N?=[/6T
M]4YNY4UE*&U,+0>&',;SQP)SQQV+JFCM/?Y5TG;[)X0:@TL>Z92,;Q)).!V#
M)0<LU'MNNUOU9=;1;[=;(H[?(8\W"9S'SD.`.[R:.\9/+CZEJ=KVM=25>E;`
M^*GDMM%<(R^=U/5AXD>"1T>\PX<W&'>O/'DM_K'95JF_WRX5,=UM%;2532R+
MP^E`FIFDY`:YK<Y;R!SR55XV*UE5LWM6G*2[1&LH*E\_23-(C=OYWFC&2W',
M?^*#[=MK5]LEML5K.G&?YGN+?)))"6,;OEC#D<R[&>?!95BVQ3-J;Y;M5VCJ
MZYVFG?4/C@?OB0-QEHSR/$$<2"#ZE8O6RC45ZHK'=);_`$[-5VH;@JA'^RE:
MUY='R`P6YQG!SVJNP[':N6NO=TU==F5UQNL$D#WTS=T,#L9<,@<1@8&,`#"#
M`M>UK75TIH[S2Z';5622<Q#P9SGR\.?MQW[N,\%$-1ZMATSM_KM030SF..G:
MYM.1NN+G4S0UKAV<2,]W%2NAV4;0+=016*CUG#2V6*H,S74P?'-QY\AGM)QO
M8RMA<-BKKMM`?>;G6Q5MKD@;$^*4NZ=Q$(C#R[D79&]E!+-G.I[YJ^R=<7.W
MT='23<*80RN>Y^"02<\AD8[U-%S[9AHF^:$I:RVUMRIJVVR/Z6G$8<'QNY'@
M>&",''81ZUT%`1$0$1$!%CUE6RDAZ1_$\FM':5HS<:VIF#8WEI<<-:P+6XS2
MEG"U115G-4\(76K%5R,XW)(BCS;C64DY9.=_'TFNQGWK>P3,J(6R1G+7!3P>
MD;6*F::<XJC?$[WERS5;RF=RXB(L]4(B("(B`B(@*,ZN^I_C_1291G5WU/\`
M'^B#GT_E$GVBK:N3^42?:*MKK+?@CH^;7OFU=9$1%-6(B("(B`B(@(B("(B`
MB(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("J9^\;[0J54S]X
MWVA>5;I2H\4)[I/RRI^['S4L43TGY94_=CYJ6+D7TL1$0$1$#*+B=QN%(S_$
MG2TO@U4*K<;^V%7B/]P3^[W>[AS]:UX_Q`WBHM-374NDFNBI)6MJ)O"'.CC:
M[@W)#1@DY0=\1:C3%^BU-IFWWJ&)T+*N(2=&XY+#R(SVX(/%<*IM;ZMJ-NIC
MEH:R<03.@;:Q,0V&,@`OP!@^+X^<=J#T8B\LV'6EXTGK;65;;[9+=`R68R!T
MCMR"-LY)>['9V=G-=(K]N=+2Z%M5YBM9?<KC))"RD=+AC',(#G%V,XXMQP&<
M]F$'7D7*M'[79[OJ]NF;[;*:CK)F[U/-2539XWG=WMTD9`.,\CSX8"O;=KO<
M[9L_?'00R]%52MBJ*F-Y:869!XX[''Q?ZH.GHO-&D-=U.SO2ENJC89II+S,X
M&6IJW8D;'N@/8-TX!WR,?\JZ5<=J-=3[2*_2%)8VU4L%.^6%[9R'2O$'2AF[
MCAD^+S0=-1><=FFT/5`K-37&NI*FZ1-@?43SRS$-IC''(YD>,8`<1CAA2IVV
M^I&SEFJ>HXND-R\!\'\).,=&7[V]N^K&,(.R(N-WS;5<K=>+?;*'3;:RHKZ&
M"HB:V<[V_*S>#<;O$`E?;OMDNM!76ZQQV"F%^EA;)615-6(HJ=SAD,WG8X[N
M"<D8SCB@[&B@.S;:5'KIM=2U%$**YT)'2Q-DZ1CVY(WFN]HP1[.)RI\@(B("
M(B`B(@T-\<351M[`S/O/_@J+;4QPOCC;$#*]^"\]C5F7BD=*QL\8RY@PX#N6
MGI7MCJX7N.&M>"2N+QLW<-I+MSLSF-OEL_\`C9VHIKL9<E^Z?^TI?Z?(+/L3
MR8YF=@((_JM;7R-GKI'QG>:[&".W@MW:Z1U+3>.,/><D=W<%;HVBJYI2NY1X
M8FK;PVYY(WIB,/%,[]C.1$77M<(B("(B`B(@*,ZN^I_C_1291G5WU/\`'^B#
MGT_E$GVBK:N3^42?:*MKK+?@CH^;7OFU=9$1%-6(B<^2`B(@(B("(B`B8/<4
MSE`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!5,_>-]H1C'
M2/#6-+G'D`,E;J@T[43YDE!`:-[=;SX<>)Y!8.-TAA\)3_FJRF=T;YGI&]FX
M+`XC%5_XJ<XC?/"/JD>D_+*G[L?-2Q1/27&KJ?NQ\UKM5S;2V7QPTO369]MZ
M-NZZK/C[W^KM'!<\^@)ZBY=H;6.KZO:%<-+:J@MS)::B%3FD:>!)9CCDYX/7
M44!$1!S&MV<W6HVT0:S944O@#&M!B+G=)PB+.6,<^/-1^S[';Y;]GNIM/2UE
M`ZINDL$D,C7.W&ACPXAWBY[%VY$$>T-8JG36B[99JQ\;ZBDB+'NB)+2=XGAG
MVJ!7?9OJB#:T[6&GZ^@9%,YCI&5&=X#=:U[<;I!R!P.0>*Z\B#C=MV2WJCK-
M;2OJZ(LOM-/%38<[+"]Y<-[AW'LRM;/L+N=3H.AMKZ^C;=[?5331.\9T,C)-
MW+7<,@Y:.P]O>N[(@Y!HC9?>K7JN.\WF.P010\8J>W4@!#L8R'$`M[^9S[%,
M]H^EZO6&BZJS4,L,51*^-S73$AOBO#CR![E+$0<6U)L?O%WT!IBUTU;2,NEE
M:]KMYSA'('D$D.QD$8'9WJ_I;9AJJW;2Z;5M]N]'7R%CO"',R'EQC+``-T#`
MX=WL78D0<6TMLHU-I^[7RB?<J%^G[M%-#/N`],X.:X,=@C@07<0#@J.#89K9
MU@ELC[Y;1;XZKPF&#+MU[R-TO)W<CAV<1S7HQ$'(8=EEYBV@:;U`:JC--;:.
MF@FCWG;Y=''N$MX8QGB.*:_V2U][UDS4]D?;9II&M;4T=S871/+6[H/`'LQP
MX<1D%=>1!SO9CH&OTB*NJNS[:ZLJ`&AM#3MC#&YS@N`&]V<QPPK^NM-ZPO-Y
MME5IR_=7TL`Q40].]G2'>!Y`$'AD<5/40<U&D]=#5-_K/\R_^C:RGJ64,'A$
MG_9WO'[-V[C`W3W?T6QT38-766S34VH+SUC5NJ'/9-TSGX86M`;EPSS#C_53
ME$!%A7*[VVSP-FN=?2T43W;C7U$K8VEV,X!)Y\"KU)64M?21U='415%-*-Z.
M6)X<UP[P1P*"^BM15$$[I6Q31R.B=N2!K@2QV,X/<<$<%=0%B2VVDF=O.B`<
M>9:<966BKNV;=V,KE,3'FE35-.V)8T%!34[MZ.,!WG'B5DHB6[5%JGLT1$1Y
M/)JFJ<Y$6#;[U:[K)/';KC25;X#NS-@F:\QGB,.P>'(\^Y9RL>"(B`B(@(B(
M"C.KOJ?X_P!%)E&=7?4_Q_H@Y]/Y1)]HJVKD_E$GVBK:ZRWX(Z/FU[YM761$
M135BF4++G4VNVLTO7VZ#HF;U9#-"'RR.X>O@,YR?9@J&K:7&72-9!1RUTTEL
MJ8V;I,5(]V\>'$/8,@\.\<U@8^GM4QGS^GU;C0U?9N5999S'E$_3/9ZME31S
M7#:$^.Z6F.@IVQ`Q1N>)/"7@GQL-'`8X\<_16KIJ&FN-[O;&7,&BM\LDM562
M0F..'+WDQC/`[@;@GEP5V#55+<=>4-P@%4VT4%(ZF-341.:Z=[B/&#2-X@`<
MR.)<<+'HKEIZ:/4=F=55=1;+D))9:IM*]FXZ5\CBP`C+MT'F!W+!IKO4Y33G
MNV>O]EM[EK"U]JFYE/Q1G,;.''Z[)RV<54U#0S62.\VBY-KZ!\@CW^C<PAQ.
M!P/821[PLF6TVNDN$=JK;Y#3W5\!J.A,9W&,X\7/Y-Y'F1G!PM7=;];W61E@
ML$E17RU-5%-4U3Z9\44$<;VN_P!0&2=P``9YDK97:XZ/FO=1=[A4U?25-.QL
M]"VCDD,A8'``.:T@_2QC/9V<5;.)OY;Y[.<[<M_T8\8'"9S\,=N8CX>ULC;M
MV]%^FIZB\:$9!:)&SN?=HVNDA>"TL;(T/.1S;@%:&KFHH[U56VAJ)*SP3Q)Z
MEK`V)LG;&#D[SAV]@Y<UFT6K7VG1]/!1PBWW*IN#7148A,G1TYD;D..-T'<Y
M\>&3CDK5YK+5+?Y1;)#_`-H;X1+$(7-$4AQO<<;ISG/`\]Y2PU=R+\Y[(F>7
M'+V0QUJQ.$CLQ$U4Q''=&?EO2&U27:+1-8^QPQRW#PMC6"1@<`TE@<<$C.&E
MQY]BQ]32U=-I2V/O+:9EVFN$=.SHH@PR-<[!\7)Y-R[G_I6IKKU%1Z)FMD-9
M407&JK8NC%/TC7EG21[_`([1XOB[W:.U:J&W4S;DRNE,]15-.&SU-0^9S1GB
M`7DX_HO/R]RN_553LRGSS>SC;-K!VZ*]N=,[-F7UX[$ANU+;--W*FI9;PV6Y
MOEA,%''#E[@^0,#B,\`#D\^32OAM=77ZMOL5PNC'BCZ.2HJ##T4<3.B#@&MW
MCV<2<\\E8-3=J:Y[1[A<*>1SJ-@I(FRF-S`=PO+AQ`S@E9L%]M5;J/5QEDF-
MKN<<=.9V0O!&(0QQ`(R<9/$#L5?;Q&5-S?.4\-R_NL%G79RRIB:>._[<F)(V
MT5%);ZFTWF&K97S=!`R1IBD>[L(:[B1Z\=H6P-FH)*ZNM=+=VSW:BB$L],('
M!HR,[H?RS@CASXC("U'6MAH:JSQV6&6ZUT$[72UDM,^)D$+>8RX#QC@``=^2
MMQ>=74E/4UM5#JB\DN8#3VNDMS-X/P,`/=$002#S..//@O:\3B(B)IG..>6_
M^_1&U@,'555%RF(G*-G:SRCGP_EH8WMEC;(QP<QX#FD=H*J6+;8'4ULI87M<
MUS(FAS7.#B#V@D``^X+*6YIF9B)ER]<1%4Q&X1$7J(B(@(B("(B`B(@(B("(
MB`B(@(BJ8QTCPQC2YQ.`!S*\F8B,YW$1,SE"E;2CL=350.E.8^&6@MR3ZSW!
M;>QZ:=(\2S`%P[^+6?[E36GIXZ:/<C'M)YGVKE,;IRY>J[O`SE3&^N8SS\J8
MXQSGTYNLT?H"FFGO,9&V=U/WG^/7DY-/1STT@9+&03]$CB'>Q;&@T_4U;QT@
M<P'_`$@9<?\`9=`FM=--('[I:<Y(;P!65%#'`S=C8&CU+&N:7TC=H[OX:.=4
M;9GI$[(^N?DR[6@,';N375,U1PB=GK,;_9IK;IRGI&C>:!WAO,^TK;2L9'22
M-8T-:&.X`>I7E;J/)I?L.^2P;=FFFJ:M]4[YG;,_5N8RBF*:8RB.$;(1S2/E
M51]VWYJ6J):1\JJ/NV_-2U;1!RBS_P`2U_\`Y/'_`&5U=<HL_P#$M?\`^3Q_
MV5U=`1$0$1$!$1`1$0$5FIJHJ6/?E=CN`YE:IU^.]XL`QZW<5A8G2.&PU79N
MU93Z_LMHLUUQG3#=HL"CND54[<(+)#R![?85GJ^QB+=^CMVISA"JBJB<JH$1
M%<B(B("(B`B(@\Z;:KM3ZDVB6O2TE?%1T5$W-1/*\-8R1XWLD^IH:/Q%7=E6
MI+G4;+]2Z?ML\3;I;HW3TCI'>+T3OIX]A#L>MP4VHMBEH=J6NO5^K'WM]9O.
M?'41;@#R0=X;I]6,*]9]CMML&KJJ\VVOE@I*F.2&2WAGB=&]N"T.SG@>(]B"
M'?X=3?705[PZG=8W2OZ3>_?>$89@^S=^*G6U?5-YTQ9Z62SUUJHWS/<'RUS_
M`!\#'[MF#O'CQ.#CNXJWH'9:[05VJ*BFU#5U5%,TM\#?'NLSPPXX."X`8S@=
MJS-H>S6EU[X!,ZX34%70N=T4K&!X()!(+21VM&#E!!MG.U*^W;:"W3UTKJ>Y
M4E1$YT-3'2F`AP9O9`(!P<$<1W%3;:YJNYZ/T8RYVE\3*DU<<1,D8>-TAQ/#
M^@6!8]D8L^M:;5,NHJNNKV`],:B)O[4EI:>(/BC&,#LPJ-N]NKKIL]9!;Z.H
MJYA71.,<$1>[`:_C@<<<0@AU!M/UQ;-1Z9EU#X!):KZV-S(8(@"QCB&[V>8<
M"0<$D<?==M.N=HNJ==7.Q6BIM\<%#6/Z21\#<MA;*68X\SC^O#F%FZ+V,QS#
M3U^N]VKY?!H8I66ZH9CH7#QMS).0T.R<8"FNDMF]/I/55XOD-QEJ'7(O+HGQ
MAHCWI-_@0>/<@Y3I/7+].4>O;Q%:Z!M12RQQQ"&,L#WOE>T%_'B!S_\`-2/3
M=^VN5M-:;[T5LN5LKB7&D'1PO;'GGGA@D9QQ=ZPI#:]C=JHJ?45+5UTU737L
M@R-+`QT1#R]I:>/$$_!:>FV#,Z6B@N.J;A6VJB>7P43F;K6Y.2`=XXSVX`01
M_5FV*^?YUN5HMMRHK+14#GQ":II73.ED;PP<-=C+L@<,#M*Z!LDUY6:YT_4R
M7*"..OHY1'(Z)I:V0$9:[!Y'F"%B7_8]#<-2U-]LE^J[+55<994B)@>'Y&"1
MQ!&<9/KXC"E6C-),TA:#1"XU=PD>[>?/5/+G$]P'8/4@D:(B`B(@*,ZN^I_C
M_1291G5WU/\`'^B#GT_E$GVBK:N3^42?:*MKK+?@CH^;7OFU=9$1%-6("1R)
M"(@+Z23S)7Q$'TDGF24R1R)7Q$#)QC*9.,9X(B!D]Z(B!DGF4R3S*(@^DD\R
M2F3C&3A?$0$1$!$1`1$0$1$!$1`1$0$1$!$6QH+/4UKFG=+&'D2.)]@6-BL7
M8PEOO+]44Q_=W.>B_#X6]B:^[LTYS_?1KV,=(\,8TN<>0`R2KD]--3.#9HW,
M)Y9[5T"UZ;AI&@O;C/,9RX^T_H%FUUDIJJ(M:QK<_P"DC+3_`++G*OQ#?FYV
M[=G_`!^<Y53YQ&Z.D[9\G24?AJGNLJ[GQ^7ACRY_7]W,Z:EEJY1'$W)[3V`>
MM3:QZ<9"T2R`\>;CP+O9W!;"UV*&B8-YC>!R&#B/:3VK<K`QN.O:1G*N)IM?
MIXS_`.W_`!]6ST=HJU@8[<_%<Y\(Z?=2QC8V!C&AK1R`52(JHB(C*&R$1%Z"
MMU'DTOV'?)7%;J/)I?L.^20(YI'RJH^[;\U+5$M(^55'W;?FI:M@@Y19_P")
M:_\`\GC_`+*ZNN46?^):_P#\GC_LKJZ`B(@(B("(B`B(@B]QF=-729/!AW6C
MN`6PHZALCHH::E!B`_:N>!D>M:^XPNAKI01P<=X'U%9L%#4P2Q/I9M^)Y!>1
MP'N[5Q>%G$1C+DY3.WXLLL]_#/AS\FSN=CNJ=O#8U]8(XZV00'#`[Q<=GL4C
MHIC/212GFYO'VK173HS<']$!R`..];VAA,%'%&[Z0;Q]JSM#TU4XV]3'AV[M
MV>>S^56)F)M4S.]D(B+IF"(B("(B`B(@(H]KF^5VF]&7*[VVD%75TT8<R)P)
M'%P!<0.)`!)/L7)]";6=17O5%MHJRY66>&J(;+3NC?3RQN)QACB-USAP(&>/
M+F@[RJ9)&11NDD<&L:,N<XX`'>2O.MVVY:@J[K='6NIM-NHJ,GH(*N)SY*G#
ML8!'#>.,XX`9QDK7[2-<W?66S>R7%K(Z:ADJ'P5L<3R,U#02!SXL+3O8/(H/
M3;'MD8U['!S7#((.00J7S1,DCC?(UKY,AC2[!=@9.!V\%&MGK[R_1-N-\BIX
MZH1-#!`?%,6!N'F>.[C*X=55NKY/\0[VL\&ENL$KF00R/)B;`69&,G@3&<_:
M)0>F47"Z_:AK2^W^_1Z2I;>RW6-DDDIJ6[SY6L)!//MW20!CAVJS<]O%PDT'
M;:VWT-/'>:JIDII=X%T;-P-.\T?\V^W`)X<>:#MQNMN%Q%N-?2BN(R*;IF])
MRS]'.>7'DLQ>9K1-?Y/\1-L?J2&GCNH:.D%.?$</!SND<>&1C/K67>ML>L:"
MIK)>L=.L,,H:RAIP:DN;GC^T;D<.TEP]00>CD7%JO:S?:.OT=<IJ>DCL-\8S
MI\QG>A>';D@#M[D,APR.2WNSK75[UIJN_A[*46*AD='3N9&0]YWCNY=G!\49
M/#M"#IB)E?,H/J(B`HSJ[ZG^/]%)E&=7?4_Q_H@Y]/Y1)]HJVKD_E$GVBK:Z
MRWX(Z/FU[YM761$135B(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(LB&A
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MB("(B`B(@*W4>32_8=\E<5NH\FE^P[Y)`CFD?*JC[MOS4M42TCY54?=M^:EJ
MV"#E%G_B6O\`_)X_[*ZNN46?^):__P`GC_LKJZ`B(@(B("(B`B(@QZJCBJX]
MV0<1R<.86NZFJ&9;'5X9W<0MRBPL1H_#WZNW73MYQ,Q^RVB]71&43L:ZCM,5
M,\2/=TCQRR,`+8HBNL8:UAZ.Q:C*$*ZZJYSJD1$5Z(B(@(B("(B#4ZCLS[_9
M)[?%<JRW2OP655)(621N!R.1XCL([05S.V;$*AM[ME?>M2>'QVUS70L92-C>
M[==O#??G+N..>3V978D0<AK]B4T=XN-5I[4LEJI;B<S4_@PD+<NSAKL@@9)Q
MVCEE;6_;)(;UH.DTX;S4]/33^$-K9F!Y>[!!#AD<,'AQX8"Z2B#0Z.L5=IO3
MD%KK[J^YRPDAM0]I:=WL;@D\!R'J4/U+LGJ+MKYNK;3J&6UU9W.D#8=XDM`;
MP(<,`M&"%TY$');YL6?57RXW*PZDJ;.VZ-<VMIV1[S'AQR\##AP)R<'/,]G!
M7:_8;:*G0U+8*:MEAJJ:=U0VM,8<7/<`';S>'`@#D>&!_7JJ(.26;8K-0:JI
MK_<-3U-RJ6,<R?IHO&D!C,?!V\2,-/#GR6MAV`304%?:V:LF;;*EXD$(I&[Q
M<WZ.^[/$#N&!GBNVH@\];2Z$V+0MKT"VUU]RK*8,GI+C!3_L_I.WFD#)WL9&
M/6"NF;)=+2:4T'24]3$8ZVI)J*AI'$.=R!]@P%.400/76SF36-ZMEQCO,M":
M$8Z-L>\)/'#N>\,<L+!&RF4:IO\`>.OYMR[T]3#T'1']CTPQD'>X[OL"Z4B"
M*:`T=)HBPRVR2Y/N&_.Z82O:6D9`&,9/<I6B("C.KOJ?X_T4F49U=]3_`!_H
M@Y]/Y1)]HJVKD_E$GVBK:ZRWX(Z/FU[YM761$135B(B`B(@(B("(B`B(@(B(
M"(B`B(@(BOTU)-5R;D+<][CR'M*KNW;=FB;ER<HC?,IV[==VJ**(SF>$+"*7
M4VDMZA<Y["]Y'!V<'\(_W6I9IZH=5]$7#<S](#QCZL=ZTM'XCP%4U=J9IB-V
M<9=J/_'C/3?Y-O<_#^.HBG*G//E.[K]]WFU4<3YI`R-A<X\@%)+1I=\[A).`
M['9_I;[>]2&U:=AI(QOLQGFW.2?:?T6\:T-:&M``'(!:C&:5Q.-^&WG;M_[3
M_P`8Z;?.&]P&A+.&RKO?'7_K'W_;R8E/;*:"/<,8>>TN'R[D?:Z1_P#\,M^R
M2%F(M;^4L=GL]B,NC>=Y7OS:V.R4L4XD&3WC`X^TK9(BG;LV[6?8C+-&:IG>
M(B*UX(B("(B`B(@(B("(B`K=1Y-+]AWR5Q6ZCR:7[#ODD".:1\JJ/NV_-2U1
M+2/E51]VWYJ6K8(.46?^):__`,GC_LKJZY19_P"):_\`\GC_`+*ZN@(B("+!
MO5=-;+%7U]/3.J9J:GDEC@;G,CFM)#1@$\<87,/^+E__`,F"]C1L_A/AYI#2
M;TF0SH]X2?0SC/#ECUH.NK&KZ^DM=#-75U1'3TL+=Z261VZUH]94`&TB\?YN
MLEH.F9A2W&"GEDJLOQ"9&Y</HX\4\.)"VNU.2NBV?7!U!:H+G+XF]!-#TS0W
M>&7[G^HMY^KGV(*K=M4T5=KE';Z._0/J97AD;7,>P/<>0!<T!5U^T_1MLJJV
MEK+[!%443BR>(L?O-<#C`&[XQSW97F>HI;I6QV&ICI+I,RFD'3!MM$4-.=\.
MW&;@X\!DDX4Q9IA]RVJZX?7V>6>G-+72TKI('%KI.;"PXXGNP@[G_GO3'^6O
M\Q=<4_56]N=/Q^GYN[C>WO5C*Y]-M@DN&T^R6?3]315=DKNB;)(8G=('.+@X
M<2,$8'`A<ICTU?*C8X\LMU8327ITTL)B<'ACH6M#]W&2`1@GU^U;:RPBY;6=
M+W.UZ7J[3;@ZG8X&G(:YS00Y^0,<^&>W&3S0>E;O>*"P6N6Y72I;34<..DE<
M"0W)`'``GF0H[1;4M%7"YTUNI;_3R5-3@1-W7@.)Y#>(P#ZB<K7[:_\`NDO7
M_P!G_K,7G=E+-?K%IBT6?3=3%<XY)'2U[8CBH#GC==O`<0W!XGEA!Z9NFU#1
MMEKJFBK[W%#54KMR6+HI"YI[N#>//L5=VVEZ/L<\,%PO<$4LK&R-8&O>0UPR
MTN#0=W((/'"Y5:=+-NO^(.\B]6AU10$2O!G@)B>[=;@@D8/;A:>\6]^D=I.I
MJK4>F:F[45QBG\`D;#TC,O.6<3P&!XI[1C@$'3MHFU:CT[I"EN-@JZ.LJZ]P
M\$+LO86`^.[ACB.`P2#D^I1&@VIZNG;899:_3CF7*?=+&LD:[&^UI:,\G<2.
M[DH7)HN\4VQ5\]7:9G5<EU9)2LZ$NECB+"'G&,M#B&Y'J"V^K=/ST]1LZ-OM
M4L<;::&2HZ"G(#9"]A<78'`]IR@GO_&VW/VD"P?L(;1&YT4E<\N+I)<8`:`/
M%&]PXYSCL"ZRO-MWME+IK;[45-QTY)56BH>UT4<-*',)>UOC@8QP?DGMSE>D
MAR0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0%&=7?4_Q_HI,HSJ[ZG^/]$'/I_*
M)/M%6U<G\HD^T5;766_!'1\VO?-JZR(B*:L1$0$1$!$1`1$0$1$!$1`1%LK9
M:)J^1I(<V(GA@<7>S_=8V+Q=G"6INWJLH_?RCG*_#86[B;D6[49S_=[%HZ*:
MMEW(QP'TG'D%<KK;-0O\<;T?(/`^![BNC6RSPT,3<L;O#DT<F_[GUK(J[=#5
MG>=EK^UP[?:N5JTYCJKO?44QV/T3OF.<U<)\MSK*?P[AHL]BJJ>W^J-W3+C'
MNY[;+#/6R-,C7-:>(:/I'_8*=6ZS044;06-)')H'`?[GUK.@IXJ:/<C;@=I[
M3[5=6%?N7L97%S%3GENICPQ]Y\Y^F3:83!V,'1V;,;>,SOG[1Y0*D1L#R\,;
MOGF['$JI$F(G>R1$1>@B(@(B("(B`B(@(B("(B`B(@(B("MU'DTOV'?)7%;J
M/)I?L.^20(YI'RJH^[;\U+5$M(^55'W;?FI:M@@X5=*K4E)_B"O<FE[=25U:
M;;$'QU4FXT1[L>2#D<<X]ZGFFKIM%J;W%%J+3]KH[:6NWYJ>HWG@X\7`WCS/
MJ6AL_P#$M?\`^3Q_V5U=`1$0$6!>KM2V*S5=TK)&LIZ:,O<7''L']3@?U7(]
M";9;C?ZZJJK])9+=9Z9I,N"\3-)(##Q)R,G!..:#M:*-T&OM*7.6ICH[[12F
MF@\(F(?AK(^'C%QX=HSQX92SZ_TI?J_P&V7RDJ*HYW8@XASL<]W(&]_1!)$4
M6K-H^CZ"6KBJM04<<M(_HYHRXES79((P!DG(/+*I?M+T8R2D8[4=!FK:'1?M
M,@@G'$X\7\6$$K3"9X*)5>T[1=#7/HZC45$V=CBQS0XN#2.8)`('O0;;4^G:
M/5>GJJRU[I6TU3N[YB<`X;K@X8)![0%]TUI^ETMI^ELU$^5]-3!P8Z4@NP7%
MW$@#M*LU^L=.VN6CCKKS1P&L9TE.7R8;(SS@[ECUY6)2;1-(UU!5UU-?:22G
MH\>$/R1T8)W02",X)(&>2"3HH_/KC3--9::\37JD9;ZEY9#4%_BO<,Y`]?`K
M>PRQSPLFB<'1R-#FN'(@C(*"M$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$
M0%&=7?4_Q_HI,HSJ[ZG^/]$'/I_*)/M%6U<G\HD^T5;766_!'1\VO?-JZR(B
M*:L1$0$1$!$1`5<43YY6QQMWGN.`%\CC?+(V-C2YSC@`=JF^GK`V)G2R\<_2
M=YWJ'J6ITKI2G!4111&=RK='\SY1[[H;31>C*\;<SG91&^?XCSE:MNE(9:0.
ME:USO.=GQO9ZED.T;3GD&?\`Y."E(``P!@#N1<G'?S\5=ZOM3ORJF/:)RCH[
M6,+A8IBF+5.4>43[[T0=HN,\OA(?U"LNT7W;_P#^P']%-44XN8F-U^OUS_>)
M0G`X2=]FGT^R$PZ.<R=KGM>]N>3R,?UPI91T,5&S#0"_'%V/@.X+*10JIKN5
MQ<O5S7,;L^'3*(CZ[UUFS:L4S39IBF)WY<1$136"(B`B(@(B("(B`B(@(B("
M(B`B(@(B("(B`B(@*W4>32_8=\E<5NH\FE^P[Y)`CFD?*JC[MOS4M42TCY54
M?=M^:EJV"#E%G_B6O_\`)X_[*ZNN46?^):__`,GC_LKJZ`B(@U.IZ&"XZ7N=
M)4P-GBDII,QN;D.(:2.'M`*\S6:P9V'ZBJC;7]9>'PQM?T1Z0Q[T9QWXSDKU
M>OF`@\]3:$DE_P`/M/466UNZVJ`R:M#&GI9XVO<2W';@X./^51"&&&_U^C*#
M2UAJZ.[T(:*^IZ+=WI`YIWR1W8<<G!XX7K7"^!H!R`,]^$'EZ#34=TUUM'?<
M+;)*8J:OGI2^-PQ*'DM<WO/<M#4Z9:S9!07)EKEZT?=Y(I9!&[?Z+H^`([LA
M>O\``3`0:FTOF&D*%_1NFF\`C/1DX+W=&.']2O)U7)57&V7B`6WJZJZ5I-LH
MK40`&GBYTARY@;Q&.TKV0OFZW.<#/>@\KW*V27*CV9T\])-+`8NAJ&F-W`>$
M8+7=W#X+?Z,TO`=L>KK(ZADI[144U72M8&$,#"]N`W/=S'L7HG`[EK[[:([]
M9*NV2SST[*F,L,L#MU[/6T]_!!Y8T_9+K==96O9]7>-36NY3R2@<MWQ=\^P[
MG#[:];L:UC`UH`:!@`=@4'T3LOM&B;A4W&GJ:JMKJANZ^>J<"X`G)QCO*G*`
MB(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("C.KOJ?X_P!%)E&=7?4_Q_H@
MY]/Y1)]HJVKD_E$GVBK:ZRWX(Z/FU[YM761$135B(KU/32U4FY"S>/:>P>TJ
M%RY1:HFNY.41OF4K=NJY5%%$9S/!95VG@DJ9FQ1C+G?#UJ_5VRHI96,+=_?X
M-+1S/<I=IRQ-B9TDHSGZ1\X]P]06EQVF[-O#TUX68KJK\/+SF?*./GL;C`:&
MO7L1-N_$TTT^+[1YS_VC\^FZF-H<QX<",C?:6Y6ODMM9$X!U.\Y.`6C(^"ZW
M@8Q@8[EC24%+*<NA:#WMX?):>UI725J-M5-?6,I]8^S?WM`X&YMIB:>DY_O]
MT8T[I_='2S#C_J</_P"1^I4O:T,:&M```P`%\8QL;`Q@`:!@`*I8-,5U53=N
MSG75OG^(Y1'!M+=NW9MQ:M1E3']SGS$1%8F(B("(B`B(@(B("(B`B(@(B("(
MB`B(@(B("(B`B(@(B("(B`K=1Y-+]AWR5Q6ZCR:7[#ODD".:1\JJ/NV_-2U1
M+2/E51]VWYJ6K8(.46?^):__`,GC_LKJZY19_P"):_\`\GC_`+*ZN@(B(,.[
M54E#9JZKA$9E@IY)6"1VZTEK21D]@X<5"](;1HJ_2G7&J:JTVTNJW4['15+7
M1.PT.QG>/C<3PRI1JS_W.O?_`,A/_P!-R\JSC_U$T?\`]02?]`(/5-!JS3UT
MN3K=07J@J:QH),$4[7/X<^`/8K-?K?2]KK7T5=J"VT]3&</BDJ6AS3W$9X+@
M,=GI+!MBT7#:813">CI)78)(,CV.#G'/?VK261^GM.-U'0:\L-967ISP(6\6
MN+LG>(?_`*<G!WN.1WH/4-RU38;/X-UC>**E%2W>@,TS6B0<.+3VCB./K5@Z
MUTPVT&ZF_6_P`2&+I^G;NE^,[H[SCCA>>=?4M-66W9_2T]LJK92S],QE+52F
M1\;'2L_U'C@YR!V96TVS:49IRXZ=?;:$4^GH,AV(S+''*9,N+FYXY&.!/'=P
M@[W9]2V2_P`$DUINE)61Q?O##*';GVAS']5KF;1-'25C:1FI;6Z9QW0!4-P3
MG&,\LY]:X-I!@?J#4=[M+'7*%MOJ&STE-;74U-4M+`-T8=D9/'=QG@>2@MRJ
M8:[3+9864M.]M42^CI:!S1$",!SIG9)SR#<GM0>O[WJ_3VG)617B[TE'+(W>
M;'+)AQ'?CGCUJ_%J*S368WB.ZT;K:!DU0F;T8]KLX"\U:Q%";S9;A)<:J@K9
M[/3[\];0B>EF'0`9:1O$Y^B?$.'9Y+$F@OEWV,&2"SB"DI+F))G4L)C$[.C(
M$CFCGNG@7#O&>64'I>S:RTYJ"H=3VF]457.T$F**4%^!S.[S(]:^:QO-5I_2
M=PNE$RF?4T[`YC:J0,C)+@/&)(QS[UYRTG!3W?7VG)K37`55*(2?`;086``^
M,)#O<\9!=@YSVKN6V#_NHO\`]RS_`*C$%[3^O:&?3-IKM0U]LM];<`[<C;4M
MW'X>6^(<G/9V\UO+3JBQ7V>6"TW>BK98AO/93S->6C.,X'9E>6]0PMGT1LXA
MD!+'LJ6N'+@:@`J::0MM)8O\2M=;;;#X/11QR,9$TG`!B:[''U\4'H9$1`1$
M0$1$!$1`1$0$1$!$1`1$0$1$!$1`49U=]3_'^BDRC.KOJ?X_T0<^G\HD^T5;
M5R?RB3[16SLUFDN$C7O83&?HM'`O_P!@NAQ.-LX/#Q=O3LV=9GE$<9<!:PEW
M%XF;5J-N<](\Y\FH1;*X6F:FK>BBC<YKSXH[CV@K=673!>X2S`.([3]%O^Y6
M'>T]A*+%-VB>U-4;*8W_`%Y93OF=S)LZ$Q=R_5:F,HIG;,[O^_)I[;9)ZY[2
MYKFQGD`/&=[/]U.[98X**-N\QN1QW1R'M[RL^FI(J5F[&WB>;CS*OKFL1=OX
MVOMXJ=D;J8\,?>?.?I$.NP>!L8*G*S&WC5.^?M'EZL*JML55(V0G<<#XV!S"
MRV,;&P,8`&@8`"J1546+=%<UTQE,[V;-=4Q$3(B(K41$1`1$0$1$!$1`1$0$
M1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`5NH\FE^P[Y*XK=1Y-+]AWR2!
M'-(^55'W;?FI:HEI'RJH^[;\U+5L$'*+/_$M?_Y/'_975URBS_Q+7_\`D\?]
ME=70$1$`C(P>2M^#P[FYT4>[G.-T85;G!K2YQ``&23V+24NL],UMP%!2W^V3
M5;G;K88ZICG./<`#Q/J"#<F&(N:3&S+?HG='#V+X^GAE<'21,>X<BYH.%`+C
MM;LU%M!IM*MZ,@O+*JNDG:V*%VZ2&@]KL@-.<8/#BI?<=26.T3M@N5XH*.9S
M=X1U%2R-Q'?@GD@V+HHWXWXVNQRRT'"^O8U[2U[0YIY@C(*QY;E0P6_K"6LI
MV46Z'^$.E:(]T\CO9QA85-J>S7&*HZKNU!72PQF0LIZALA``[0#R0;2.&.(8
MCC8P=S6@*D4T`WL0QC>^EXHX^U<YV>;5HM56>XW&^"AM,-)-'$)'S[K'%P)Q
MEW;P70Z&OI+G2,JZ&JAJ:9^=R6%X>QV.'`C@4%QU/"]@8^&-S6\FEH("J;&Q
MC=UK0&]P&`M1-J[3=.^=DU_M<;J=_1S-?5L!C=Q&Z[)X'@>'J*O5&HK)2TE-
M5U%WH(J:J.*>9]0P,E/_`"DG#OZ(,^.GAB),<3&$\RUH&56YH<TM<`0>8*YQ
MK/:<;0^W_P"7#:+NR:5\=0>L(V]$1NX'TN).3[E-;AJ*S6AT;+I=:&ADD;O-
M94U#8R1Z@2@SS3PEH:8H]T<ANC@OO11])TG1MW_.P,^]8\=UM\MMZQCKJ9]#
MNE_A+96F/=',[V<86-;M2V*[U!I[;>;?63`;QCIZECW8[\`Y0;1$1`1$0$1$
M!$1`1$0$1$!$1`1$0$1$!$1`48U=]3_'^BDZC.K6EW@F!GZ?Z((K;++)<*US
MWL/1[YPWSN/R70:.BCHX@UH!=C!=CY>I0^GN%=2MW87[H^RTJ]UU=?3_`)6K
M$NV[V(N][?F)F-E,<*8\O.>,_3<JPV'M8:B:;4;]LSQF?M'"$IFM\$\XE>#G
MM`Y.]JR6M#6@-``'(!0WKJZ^G_*U.NKKZ?\`*U0HP=-%4U4Q$3.]D37,QE,I
MFBAG75U]/^5J==77T_Y6JSN*GF:9HH9UU=?3_E:G75U]/^5J=Q49IFBAG75U
M]/\`E:G75U]/^5J=Q49IFBAG75U]/^5J==77T_Y6IW%1FF:*&==77T_Y6IUU
M=?3_`)6IW%1FF:*&==77T_Y6IUU=?3_E:G<5&:9HH9UU=?3_`)6IUU=?3_E:
MG<5&:9HH9UU=?3_E:G75U]/^5J=Q49IFBAG75U]/^5J==77T_P"5J=Q49IFB
MAG75U]/^5J==77T_Y6IW%1FF:*&==77T_P"5J==77T_Y6IW%1FF:*&==77T_
MY6IUU=?3_E:G<5&:9HH9UU=?3_E:G75U]/\`E:G<5&:9HH9UU=?3_E:G75U]
M/^5J=Q49IFBAG75U]/\`E:G75U]/^5J=Q49IFBAG75U]/^5J==77T_Y6IW%1
MFF:*&==77T_Y6IUU=?3_`)6IW%1FF:*&==77T_Y6IUU=?3_E:G<5&:9HH9UU
M=?3_`)6IUU=?3_E:G<5&:9JW4>32_8=\E$.NKKZ?\K5\=>+HYI:9L@C!\5J=
MS49LW2/E51]VWYJ6J*:3:YM749&/V8^:U&KM6ZSL]^?2633%+<*(1L<)Y*ML
M9+CS&"X<EE(M59_XEK__`">/^RNKKC^@*+4]RVK735%]L\=N9/;A!NQU#)!O
M`L`QAQ/)I*[`@(B(--JV.&;2%XBJ!5&%]'*R3P1N]+NEI!W!VG'8O)5'/36R
M>W&W/M]\#:HB.DEHGQ5',<7%O8>&,/.#V!>SEC-MU"R;IFT=.V7.=\1-#L^W
M"#S/K"AL-IV[-EO=`^*SU(94SQ^,XO>^/)((.3^TYX[<K#NC;5:MH&L/\]TE
M3/+/%,;>[#CON)_9.:01PW<8/(8PO4T]%2U3FNJ*:&8M^B9(P['LRD]%2U0:
M*BFAE#?H])&'8]F4'DNJM^I/^"U!)/%4]4QW223<(.&L+&AKL=C=[?P>63ZU
M--.UVSZIUG0#2MFNOAC*,[U1`\LBC.X=XR-/$\.!/(]@*]"=$PQ]'N-W,8W<
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MNX[``1PY'FO2TU'35#6-FIXI`SZ(>P.Q[,KY/1TM4UK:BFAF:WZ(D8'`>S*#
MS'>8J>NV-5,FE+7>*2U1W)DM6RKEZ0/;NN&\W'^D.W<\,9QSPM?IB&EN&LM,
MOL]PHX:^G$)W:"@F9G!\82DDY=C(<[ECM*]7LABBB$4<;&1@8#6M`&/8K<%!
81TKR^GI((G'FZ.-K2?<$&0B(@(B(/__9
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g669158.jpg
<DESCRIPTION>G669158.JPG
<TEXT>
begin 644 g669158.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+__@`L1$E32S`T,#I;,#)004PQ+C`R
M4$%,,3`Y,2Y/5510551=05)4,T,N15!3_\``$0@!'P&T`P$B``(1`0,1`?_$
M`!P``0`"`P$!`0`````````````&!P($!0,!"/_$`%(0``$$`0(#`P<(!@<#
M"0D```$``@,$!081$B$Q!Q-!%!4B45)AD1<R,U9Q<H'2-764E;&S(T)B=J&R
MT18WP21$1E6"DI.BX0@8-$-48X.CPO_$`!H!`0`#`0$!```````````````!
M`@0#!0;_Q``Q$0$``0,#`@,%!P4``````````0(#$00A,1)!!5%A%'&1H=$3
M,D)2@;'!%2(C-*+_V@`,`P$``A$#$0`_`+_1$0$1<+56J:>D\3Y=;BGG<]Q9
M#!79Q/D<&EQ`]0#6DDGD`$'=10MO:5C'8V.ZW%9Q[3QB9D6.?(:[F?.;)P\F
MG8[]=MN:^,[4M//K0V6MR)@?"VQ+(*3RVM$]Q#'RD?,:[8D'U<^B":HN1G-1
MT,!7KR6>_FDLR=U7@JQ&669VV^S6CKL`23T`7(F[1\#'4JSQ"]9=/')*8*]1
M[Y861NX9'2,`W8&NW!W\>FZ"7(O"G;KWZ4%RK*V6O/&V6*1O1S7#<$?@5[H"
M(AZ%!"+/:3%%ELACZFF-19%U"<P32TJK)(^/8';?C'@1X+'Y1Y_J)K#]@9^=
M?=!_I[6WZ[=_*C7AJ/M9PVFL]9Q%K%Y:::OP\4E>!KF'=H=R)</6KT455SBF
M,F7M\H\_U$UA^P,_.GRCS_436'[`S\ZA^HNWNM%B7/P>)NLN\;=CD*P$7#X_
M-?OOZE'\+_[0.:DS%9F5QM-U$N/?"E`\S$;'YN[]M]]OPW6BG17JJ9JPKU0M
M#Y1Y_J)K#]@9^=/E'G^HFL/V!GYUQ/EWT\`3YESW(?\`TK/SJR1?K^:QD9#W
M5?N>_<9!MP,X>([_`&!<*[5='WHPF)RB/RCS_436'[`S\Z?*//\`436'[`S\
MZPT;KR;+5<G+J"&#'&O"S(P[;@&C(TN8]VY/,<)#MO<O',]JF/JX2:U0I7GV
MVF!\<%FE+'WD,D@8)1RYMY[#WEH\0N:6S\H\_P!1-8?L#/SI\H\_U$UA^P,_
M.NTW6.%-`7#/(V$Y#S:2^%P(GX^#A((W'I<M^BC6=[5,?7T_=M8J&P;(JOLT
M9+E.2."V&;<18X[<0`._ARYH-OY1Y_J)K#]@9^=/E'G^HFL/V!GYULZXU3:T
MY%BA`^E4CNV#%+D+S'.@K`-XAQ!I!W<>0W('K7&J=H>1J9;&4,O!0L5KDLY;
ME,:2^O+"R,.#P`7<)!.SN(\@-^AW0=#Y1Y_J)K#]@9^=/E'G^HFL/V!GYULP
M]I>FI())YIK56$0&S%):J21BS$"!Q1;CT^;F\ASYCDM.[VC5>^QK*L;ZKG9.
M*K?BR4#H)((GQ22!^SB-M^[Y'F-MT&?RCS_436'[`S\Z?*//]1-8?L#/SKVU
M#K0P]GTNI,&UC@Z2)D#[L+VL<U\K8^/AY'AV<2#RW'-<3Y1+^!U%4QNH+.(R
M<=V&1T1P44DDS'LVV:8^)Q/$"=B-NA]2#J_*//\`436'[`S\Z?*//]1-8?L#
M/SKY#VD8NNR=MJ66Y.V>P>ZH4)7.@@C?PETC3N1P]"[H3OL%O6.T33L$P`GL
M35VLCDFMPUGO@KMD`+.\>!LW<$'GT!Y[(-+Y1Y_J)K#]@9^=/E'G^HFL/V!G
MYU..17W8>I!!OE'G^HFL/V!GYT^4>?ZB:P_8&?G4YV'J38>I!$<'KZ#,Z@9A
M9<#F\9;?7?89YPKMC#F-(!VV<3U(4N4'O?[Z<1^I;/\`-8IP@(B("(B`B(@(
MB("(B`B(@(B("(B`B(@(B("(B`H#VMLK.TBYUO'VIX6=XX6JKW!]1_=/#7D-
M&Y:2>!WAL[FI\L)8HYHGQ2L:^-[2US7#<.!Z@CQ""HZTN=SNAJF$G=>LT\EE
MF4F7)*YBE?CPT/>YP`&P/"Y@<0-P0?%>^H(Y,/9USC1B[DCLY0BCQ@K57R,>
M>X[GN]VC9G"[GS(Y'=6NUK6-#6@``;`#P7U!6^2E-++:4R#Z]Q]7!RS4;SXZ
MLCBQ[Z[6AX:&[N9ORX@".:CNG'V--ZJS.I,CB\B*&;ALR4XV4Y'O:>_<YK'M
M:"6.>"'#<`<SNKJV39!$-,::G;V88O`9.6U6F%.-DQ@E,<D9Y.+0X=-NG+WK
MF=G-FVW%9BG+=LV&4<U;J0.L2&1XC8X<(+CS/4]582KGL]^AU-_>._\`YVH)
MKW\OME?#/+L?3*P0]"@C>@#OG=;;_P#7;OY3%.5!M`?IS6WZ[=_*8IC);CC>
M6$.W'J"Y7K]NS3U7*L0F(F>'#UQI)FM=./P\EQU1KI62=ZV/C/HG?;;<*%:5
M[#Z^E]3T<TS.RV'5'EPB=6#0[=I;UXN756;)>;P^@T\7]H<E@V^[B'$T</CM
MU6;^OZ>U_BBYM/EQOZI^RF=\-_91_6>'O:@TW-B*4L<(MO9%8D>X@B`N'><.
MP.[BT$`>_JNMY=%ZG_!<O6.=GTYH[)YFM%'+-5@,K&2[\).XZ[<_%=[.JLW\
MQ:JB<(F)CE%<UV60OL1'!3R58K%.?'7A8LRS$UWL]'@XR[FQX:0W<`C=99/3
M&M,[I^U1OV\/"YD-=M:&#C='++%*R0R/<6AS00SAX1OMOOS72S':'B:&2P->
MIE,99COWA6G,<XD=&',<6D!IY>F&C<\N:Z>0UO@<7;DJVK<@GCL,JN9'7DD)
ME>SC:P<+3NXMY[#W+NA#[&B-63!U..QB(J3\VW,F4/D=*QY>)',`+>$AKN(@
MD\P`-@N%D.R?4^0JQ][)C/+!5FKS69+UB9]ATC=N\/&TAG,#T&C;F>?0*Q9.
MT73$=>&87Y).];(X1Q599)6B,[/+XVM+F<)Y'B`4=R?:S7KW;;:<+9*5:U08
M;9CD<R2&?F]XV&VX&W".?%S(!02C4V-SUDT;&$M5..#C;/1N[^3VF.`'I%H)
M!:1N#MXG=0-W97F)[[\@XXBH;DDT=FA3XVP0PRP=R]T?H\Y-CQ'<`$[*;Q=H
M&GI:[9!9LB1U@U15-.;RCO0WB+>YX>/YNQWVVV7$R?:A3[V>/$NA=$VBRW'<
MLPS]UQ&;NRQW"S<;<Q][T3S!0<[*=GNI=1T\;!E;>+KNPL&U&2MQO[^8%G"^
M5I`X6[1C=HWYD\^2W<WHO4&LA5CU*_&>1,R$4SZ-9[RUL38Y&N(D+0YSW.>T
M[<@`WXR2/76G),@ZDW(;2-DEB[QT,C8G/C&[VME+>!Q`!W`/@5QLOVG8V/#R
M6,07R6O^3R0LMU986SPR31QF1A<&\8''U'N\$'RYI+.9+LY?IF_9J6;$=B%D
M5A[CM-7CF8X=X.'YY8T@CF"?'FMR?0M"MJ?3^2PN-QF/AHV)I+(@@;$Z0/A<
MQH'"WGL2.J:SU9;P&1Q./JOQM5U\RDW<I(YD$?!P^ARVW>[BY`D="N?4[1+-
M/+U<9J*C%4+H+$\MZN725GQQEO#(QP!V807;\1]'8`_."#2HZ(U/@,UD\OB)
ML5+8R$EIKX[3WAL;'S.EC>"&G=PXR"TC8\MBM/(]EN6LY"[(Z7&Y`Y$1.L6[
M<D\;HI`QK)"(8R&2!W#N`2-M]N8"F+.T33#JUB=V0DB$#(Y'1S598Y'-D.S"
MQCFASP3R'""M*UVBXYN8Q<4$\3:$K[;+\MF-\+ZSH8P_8M<`6]?$=-MD$SBC
M$43(V]&M#1^"S4,U5K&S0TWB,G@XX'NR=Z"K"Z_')&P-EW`>X<G`<@?L7-K=
MHL^'U+YBU8_&]_+7$]:7$"68.]+A+',V+@?'?IL"@L5%":/:3AH\<Q^5R$)L
M_P!+))Y%7GDCBB;,Z,.>>'=@]'8EVPW!VY<UUI=;:?AR9H.O$RME9`^1L,CH
M62/&[&.E#>`..XY$^(]:#A95Q;VRX@M.Q\RV?YC%+._E]LJ)9;_?)B/U+9_F
M,4I0>G?R^V4[^7VRO-$'IW\OME._E]LKS1!Z=_+[93OY?;*\T0>G?R^V4[^7
MVRO-/%!Z=_+[93OY?;*K:CK?-7-478FQXOS=2DE;:I\9;;@B8]S3*23L3LWB
MX0/FD;<UEB=>YK,-<^AC\/D9):QGBIT[X,]8GAX!/Q'F"'<RP>B00@L?OY?;
M*=_+[946TKJ*SFK65I6CCYI,>^-AM8V1SZ\I>TDM!=S#F[;$;GJ%)4'IW\OM
ME._E]LKS1!Z=_+[93OY?;*\T0;U5[GQDN))W7NM>G]$?O+80$1$!$1`1%IY3
M+4,)CY;^3MPU*L8W=+,[A`]WO/J`YE!N(N8-1X1V+AR?G>B*$QVCLNL,$;CZ
M@XG;?D>7N7M+F,9!+7BFR-2.2R`8&/G:#+OTX03Z7X(-U%X7+U3'UG6;MJ&M
M`T@.EFD#&C?IN3R6O/F\55K06+&3IPP6/H99)V-;)]TD['\$&^JY[/?H=3?W
MCO\`^=JL4$$;CHJZ[/?H=3?WCO\`^=J"8H>A1/!!&]`?IS6WZ[=_*8ISL/4J
MV.D]34LSEKN$U;%0@R5HVGP/QC9BUQ:&_.+O4%Z^9NT#Z_5OW)'^9!/YX>^C
MX`0.>^^R\(J1CE:\O!V/390?S-V@?7ZM^Y(_S)YF[0/K]6_<D?YECNZ#3W;L
M7JZ?[HQWGLM%4Q&%B;#U*/ZXPUK4.BLKB:1C%FU`8XS([A;ON.I_!1OS-V@?
M7ZM^Y(_S)YF[0/K]6_<D?YEL5:':9HO`C"4[8KX[$UJLSWV+$,(C?SB>V/AX
M&[N/>%A`]RU*V,SF.QFC+@K16,_=RDV1N1V'&-IDDKR$M)`/`0S9HY'8@+M>
M9M?G_I]6_<D?YD\S=H'U^K?N2/\`,@TL3H_56G]0W]3U(<7:R&7$GEE22P^.
M.N2_BC+'AA+P!\[<#<]%H8[LQSF'EKU8I:=BKY3C;4LYE+'-=7>3(T,X>8/$
M=N8Z`+N>9NT#Z_5OW)'^9/,W:!]?JW[DC_,@YV=[.\M<UO>U'`V&PQ]D%E7R
M^6JZ2(UV1N/>1C=C@YG3F".JT;79MJ%N/D@J0XT>6U3'88+4I[F3RH3@ASPY
MTFXY$DC<\UW_`#-V@?7ZM^Y(_P`R>9NT#Z_5OW)'^9!C2TUJ_'8H:?H2XJO2
MK/LOKY!^\LKP_C,8,9;LUP<_F[<\ATYJ-6>S35%Z:K-)%69)'79!-)/EIK3Y
M'-FAD+_3;LT$1N`:T#;^$G\S=H'U^K?N2/\`,GF;M`^OU;]R1_F0=O5.,SMJ
MW6FQT>.R%'NWQ6\5D?1CEW(+7AW"[9PYC8C8@J`/[*<[+'.&#&5(KS;4;J=>
M5_=46R&)S.[W;Z8XH=W#9H]([*2>9NT#Z_5OW)'^9/,W:!]?JW[DC_,@T<MH
M_5>HL]2U'<AQ52]B6P^25([#Y(YW-D#WE[^`%@.VS=@=O%99W069UI;H2Y\4
MJT#)K,G=5)2YU?BB:V)P?PCO'![>([@#H.:W/,W:!]?JW[DC_,GF;M`^OU;]
MR1_F0>^=TQF]4Z3P%',149+E;)5Y\@T/)BFBC)#R.75S3OP[>)"VHM"T<7K3
M"Y3"8VA1IUH;3+(@C$;GND#`SD!SVX7=>FZYWF;M`^OU;]R1_F3S-V@?7ZM^
MY(_S(.9@-%:LTM'D3CH\59ERK'1RFS,X"LX2REC@.`]XW@D&[>7,>]83]F>4
M.1NP&*K<JWK[;C[DV0L1A@):YX-9A#'.W:>$[^K?HNMYF[0/K]6_<D?YD\S=
MH'U^K?N2/\R#VRW^^3$?J6S_`#&*4J)8G2V<AU7%G<WJ2/*20U)*L<;*#8-@
M\@D[AQWZ>I2U`1$0$1$!$1`3Q]:(@J[,:)U#J'4@BR;:!K1NW;F(_0G[GO'G
MNPT-&S^%P8>>W"`>:]ZVC]50185E=V&H3X"K)#4LQ$R>6%P#=GM+1P-+02>;
MCQ'<*RD01;36#OU,]E,Q=IT,=Y9%%"VC1DXV;LW)D<[A:"X[[<AT',E2E%\)
M`'-5KKIHIFJJ<1`$[#=8A^Y`V38OY]`@9L=]UX-V]KK]ZFO31,6]O+??>=]W
M6(IB-^6:(B^@<F[3^B/WEL+7I_1'[RV$!$1`1$0%7O:Y7IV=.UVS9%E.W&^:
M6IWL)DCF>*\F\9Z`$M+N$D]0-MSR5A+0S.&H9_%3XW)5H[%69I:YCV@['P(W
MZ$=0?`H*,Q1FS>K:N.A@P>*=5K6Q)+-#Y35EL@Q&1\;7%HXBPL#M^@XECAYL
M7D=%:SMY*E3JS1XB$48B>(1QMC>&.A+SQ!IF!(V/4M]RNLZ3T\[%5\7)A<?+
M1K\XH)*S',8?$@$;;GQ/BO6QIO!W):TMG#T)I*K0VNZ2LQQB`Y@-W'H@>Y!#
M,R^*YG]!0Y1T4L`DF%EDY!:+0K`L#P>7'N7;`^*B.DHL1-K'/PY5E1^!BK7O
M-C9@WNFP^4O[TQ[\MAZQX>Y7)8P&'MUYZ]C%4IH;$O?S1R0-<V238#C<".;M
M@.9Y\EYV-,X&W4K5+.%Q\U:J-J\,E9CF1#^R"-A^"#@:.&:F[)L**LT,64=0
MB[J2TPO8!RV+@""?1V\5Q^S%MEN+S[;CXWVAG[HF=$TM8Y_$WB+0>8&_0*RP
MT-:&M``'(`>"KKL]^AU-_>.__G:@F*(B`B(@(B("(B`B(@(B("(B`B(@(B("
M(B`B(@(B("(B`B(@(B("(B`B(@(BQ<[;[5RO7J+-$UW)Q"8B9X?2X!?`.([N
M^"!OB>JR6&BS7JJHN:B,4]J?YJ]?3LMG&T"(B]-01$0;M/Z(_>6PM>G]$?O+
M80$1$!$1`1$)V&Y0$1$!$1`5<]GOT.IO[QW_`/.U6,JY[/?H=3?WCO\`^=J"
M8HB("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(2!U6
M)=N=FK+J-9:L;3.:NT1S,^Y,4S(7<]AU7UK=N9YE<O.:@Q.F*`N9>XRM$X\+
M=P7.>[KLUHYDKQGUCIJM4JVY\[0BKVV%]>1\P`D:#L2/L/(^HKC9TU==<7]3
M][M':GZSZ_!,SC:';1:0R^.<Z@T78"<@"ZH`[G.`WB);ZQMSW6ZO05$1$!$1
M!NT_HC]Y;"UZ?T1^\MA`1$0$1$!0+M:K9*SI!PH.<Z*,R26Z[+/</FB$3]]G
M<MPT\+BWQ#2%/5']7Z4K:MQ!J2S2UK,8>ZM9B=LZ)[F%A^UI#B"/$%!6=*/+
MY.CBJN`CU!<H4W61<JV,F:4T$I;'P0ND!XBT`ES>O)PY[=,:F6EU'@=49>AE
MLS29@*$?D$3[K^)DK(W22&;F>])>"P\6XV!V4WK=F.+J1025\CE:^28)!+D(
M+/#//Q@<0>2""/1;L-N6PV64W9?@'P-K5Y+].JZNRM8KUK)8RU&PD@2\B7=7
M;D$$@D%!KYV[:S&1T9C'6K%6ME.]L6O))G1/?W<`>&<;2"&ESN>Q\%%=//R.
MI=3Y;3%W.95E7!Q68X+$-M\<DKN^<UCY'-(+RQH`Y[@D;E6)D-&T\BUIDO9&
M.:*V;=6>*?A?5<6!A9'RV#"W<<)!',K0?V:X<5H(ZMK)TYHXY8I;5>T6S6&R
M.+GB5Q!XMW$G?D0>FR#UTUJ')7>S/&9LT9<AD)*<;W01.:QTS^0)!.P&_-RX
M'9C-+8QF?FFKNKRR9^Z]\+R"8W%S26DCD2.G)6)0HUL9CZ]&G$(JU>-L448Z
M-:T;`*`]GOT.IO[QW_\`,U!,41$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1
M`1$0$1$!$1`1$0$)`ZKX7;<O%?`TGF[X+#=U<S5-K3QU5=_*/?/\<K1'>6+B
M7>')&?.7HBQT^$3[3&IKN9JC$\+=>V,*Y[6?(6X^J^3(24<@V"R*DAC#HI06
MM[R)Q/0D;;;<^1V7`J9.M>M298ZEIZ=NUJ%F.,5JD8K6@+#RZ:-TF_$U[F@E
MK?2]_-6UD\92S&/EHY"M'8K2C9\;QN#_`*'WA9R4:<K(F24ZSV1?1M?"TAGW
M01R_!>TYJ\97;;U+V?ZCM5.YR^2#S:W+O1`J.(8UI/HC<[[>L\U9:Q='&]['
MO8QSV$ECG-!+2>1(/@LD!$1`1$0;M/Z(_>6PM>G]$?O+80$1$!<C46IL1I3&
M><<S<;6K<88TEI<7./0``$D\BNNJ_P"U.I6MT\,T9-U#*.O=U0<*_?A[Y&%C
MFN9[/"XDN\-D$HP&J,1J>&:3$VQ/W):)6EI:YG$T.;N"/$'^/J7859=DN+K8
MN?.U9,HZ[EZKX*-IAK&%L4<+"R+A!^<"-SQ>/^)LU`1$0$1$!5SV>_0ZF_O'
M?_SM5C*N>SWZ'4W]X[_^=J"8HB("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B
M`B(@(B("(OA<!U5+ERBW3-=<XB"(R^K$N+N3?BFQ=S/3U++HL&;VLXS1;_ZG
MZ1\U]J?>^!H"^HBW6K-%FB*+<8A69SR(B+H@1$0$1$!$1`1$0;M/Z(_>6PM>
MG]$?O+80$1$!5GVC9&G<<V$0:CJY'$W(WUKN.H=]L]\;B>$$[/;P[@^H[!68
MJK[4<WB7YC#8Z'5-/$9VA;;:C-B!\C1Q-+0';`M&^X/I>"#?[+(H7NS5^23.
M6,E:DB-JUEJ?DQD#6D,#&@D;`;_%;_:?J+)Z;TN+.->VN99#'+<=$917;W;W
M`\(\2YK6@GD"[FNQIFKJ6K'9&H\E2NO<6]R:L!B#1SWWWZ^"U==XC-Y?3\L6
M"N-BLADK7UY!Z%ECXW,+"?`^D"#T!`W01JWKS*87L\\MDGQ^7S$T<SJ4E([Q
MRQ1LXW3/`/H\`WX@#MOL`>:SNZRU'-#EKF,;097P5""U;CGB<YUI[XA,YC2'
M#NP&=#L>9]2TZ_9"R7`Y::U/W&>R,,K1Y%-)#6AXV@",M:?2;N`7;CTCOR6W
M+V>9JI3OX[$Y.J*67HPU,@ZYWDLL9:SNW/C._I;L.VSMMMAX#9!WL[J*\^;3
MV/PKH8+6:+GML6HC(V&)D?>./`'#B=S:`-]N94=Q^M-3Z@R5C!8[S96RV*BF
M-^26%\D4TC)"QC8P'`M:X#B)))&^VQ7:R&F<Y+/CKM*?',MX>R\8]DC9.!]5
MT0C+)2.8?RWXF\N0Y=5RJ>@M0X2Y+E\5DL:_,9&.9N2=8B>(N-\AD#XP#OZ.
M_"`>H\0@E&/UACY]#5-57I!3I2UF3REP+A%OL".0W.SCMT45[,K4-[&9^W6?
MQP3Y^[+&_8CB:YS2#L>?13C3V%AT]IS'X>%YDCIP,B#W#8O('-VWO.Y4-[/?
MH=3?WCO_`.9J"8JNNV;,9+":0J6<7>GISNO-8Z2!Y:2W@>=MQX<@K%4.[2-(
M6]:Z>KXZE9@@DCM-G+I^+8@-<-N0//TEVT\TQ=IFKA$\/SPSM`U>7M'^TF4Z
MC_G+E^E]99B[A-,/NT0P2][%&^>2,R-KQN<`^4M'-P:.>RIX=@&>!_3&,_\`
MV?E78O:MUAI2*+`ZEL^3RME8^GFFL,D,[6]8Y=AN6D<B1Z0Y;@]5NU<6[V/L
M,9CLK3F.4GP6L<E#H-F1NVJ69O6"R+'"H0'SR&,.+)6CDUS#Q%Q]D;G9?:&J
MM29ZG29C'8ZO:9A8\G;DL0.>V1[R[AB:T.'"#P$EW/;<+0TEV;5;&*BR^1L!
MMZQ5C;`<5:?%'$T1!G-S#Z;G;>D>AZ<UO8S0F;T]0JC#9&F;;\8W'W?+3+(S
M<$ELD1ZCAXG`,(`V]2\M=,\%E&YO3^.RK(S&VY69/P$[\/$-R/P.ZZ"T<-C(
ML+@Z&+A>Y\5.NR!KG=7!HVW/V]5O("(B`B(@(B("(B`B(@(B("(B`B(@(L2[
MP',IPD_.^"P5:[KJZ-/'7/G^&/?/\1E;I\V+G<^17UG,DE?2T%?0`.B\ZUX=
MJIUD7K\Q-.<XW\NT3Y2O-4=.(5AVD396KJ&A/-D,M0POH"*UC_2;#*&RE[I&
M-])QY,(',<(>O>WK*W<U'IV'%Y*"7$,OPU+MQCFM\LE=$YS@T>#&@`GPXG`?
MU5V=3Z(DSN7AR%/,6L>YY8RVV,-<'L:R1H<W<'A>!(X;]-B?$!>DG9MI9S<6
MV+$5(1CYF2@MKL+IPUI:&R.(W<#ON?60"OH')YXZ]G?E-MT,E:A-%V,-BM6@
M!X6`3\`<XGJ\CKX#?8*8+F^9H?\`:;S[WLGE'D7D7=\N'A[SCW]>^_)=)`1$
M0$1$!$1`1$0$1$&[3^B/WEL+7I_1'[RV$!$1`5+ZUT-J[)YS58Q>,Q<]+."L
M/*+$VTL8B8WYH\.8*NA0#7W:-6TD8W5+>.LV:LP\NQS[+63F)S>18#_6!+3M
MXA!VM'RZJ?5GCU/1Q]5T?`VOY'*7\0V.Y=N>O(*2J#]G&J[^L*EW)W+6,[MY
MC,%*E+WCZK2#RE=M\\^KPV\%.$!$1`1$0%7G9[PNQF:F#>$RYZ^]W/Q[S;^`
M5AE5WV=?H3*?KN]_-02]$1`6IDL91S%"6CD:L5FK*/3BD;N#[_<?>.86VBF)
MF)S`J.QI[4O9A8ER&EGRY73Q<7V,9*27Q#Q+=O\`,.?K!ZJ=Z3UIAM8T>_QL
M^T[!O-5DV$L7VCQ']H<OLZ*0J`:L[-8LC>\^Z;L^9\_&>-LL1X8YG?V@.A/K
M'7Q!6CKHN[7-I\_K]5<8X3]%6VF^TN:OD1I[6]88K+LV:VPX<,,_J._1N_K'
MHGW=%9/4;KE<MU6YQ4F)RQDDCAB=+*]D<;!Q.>]P:&CUDGH%K5LKCKF/%^M?
MJRTS_P`X9,TQ_B[?8+D:WIU\AIE].Q=KU!-8@;&^RPNB?)WC2V-X'5KB-C]J
MK[1M?"9"C'B;F*Q\&;:(;,$$T[GU;\AB?P.?&!\X-#B6[;]#S7-*WI+5>&-D
MDMB&.-Y`:]\C6AQ/0`D[%>JIC1=&CD\]:PN>JU9H<72N,;`[9U=DILN[UT0/
M1K6E@!ZM"L/L^FL6.SS3\MI[WS.I,W<_J0-P"?P`021$1`1$0$1$!$1`18E^
MQVV7SF[W!>=7XG9ZYM6LUU^4?6=ENB<9E]+@/>4V+NO(>I0J36]XZQDQ%#!.
MMTZ\SH+,S)QWP<TQ!SVQ[?,;WK>IW(W(VVY[`US+%>@CNZ?OUJML6#2DX@Z6
M<PM+B##MQ-X@T\/7?ETW3V6[?WU-6WY8X_6>9_8ZHCA+@`.B^J.X34]C)9>3
M%9##RXRZ*C;L<;YVR\43G<//A`X7`]6GXJ1+?11313TTQB%1$16!$1`1$0?'
M.:QI<YP:T=23L`N#D-7XNENV.1UJ4?U8>GXNZ?#=1C6GE<>9<R6>5]=[1)"P
MN]$#H1MTZA=O%:7PT-&*_8D\H8]@>'3$,8-QZO\`4H-O3FHI,W/99)7;$&`.
MCX-R-NA!/KZ*0+A1ZFPT5N"A5<'![PP&)FT;-^G/_1=U`1$0$1$!$1!NT_HC
M]Y;"UZ?T1^\MA`1$0%7/:6^CB)\+=FI8R&O:R+(\AD;-!DY9$&D\)W!VXMN'
M?P5C*`=JN7M8[%8NK'D&8NGD+HKV\B^`2B!G"7#T3RYD`;GH@\.S/*PY',ZJ
MBQWD,^(AM1FG;ITVP-<'-),1V`X^#D.(\SO[U*]4:HHZ3Q7EUUD\I<XLB@KL
MXY)7!I<0![FM))/(`**=EF7GMS9[%-RL69QV.GC;5R4<+8Q+QM+GL]'D2T@<
MQUW^Q>_:XVH=)\5VI<=&PRN9<J.<'5).Y>&N=P@G@<3P'PV=S0="#M)P$]*"
M9GESIY3(#393DDGB,>W'QL:"0!Q#GT.XVW7I<[1=.4_)W&U--#+!'9?/!7?)
M'!#)\Q\K@-F`^_FH/CM0RS::-3/V,S7ISF2*AJ"K3[N9\30PAA#6$MW/$`>$
M!P9Z^:XN%==PFC]0XO+XNU%D,UB((L=#'4>>]_H70M8=@0UP/"YP)&W&2@N?
M.:BH8"M!+:[Z1]B3NJ\%:)TLLS]B=FM;S/($[]%R)^T;3T-.K99);L"Q&^81
MUZDDDD<<;N&1TC0-V!KN1W\5P<I<CH932>2F%A]3!RS4<C)'7D=W,KJ[6AVP
M;NYN_+B`(Y_:HYIRW_LYJS,:DRM*ZS&9R*R^CM4D<3_3N<&%H:2TO!#@"!ON
M@NBK:@NTX;=:5LL$S&R1R-.X<TC<$>X@J`]G7Z$RGZ[O?S5T]+Z>N#LNQ6$N
MVKN/MBE&R26L\,FA/([`D'8CYOQ7'[,8?)M-7H#+)*8\Q=9WDKMWOVDVW<?$
MGQ031$1`1$0$1$''U'I?$ZJQII9:J)6#?NY&\I(CZVN\/X'Q"K5]S5G9$#'9
M8[/:7'HQ2[\,E?U-)Y\/JV.[3X;'DKB41[4&N?V:YQK&ESC"S8`;D_TC%HL7
M)S%NK>F91,=U?7NW7$9.G+2O:3?9K2CADBELM<UP]XX%/=+Z8TOD-"XYD>#@
M%*W'':,4WIOX]N3G/&Q+@.6XV7Y;\BM;_P#PTW_AG_17EIK"]I6.TOB[F#SM
M2W4EK,>S'W6;=T"/F@N'A]X+=J])9HICHF(GUE2FJ>ZR)]&Z:M4*M&;!T7U:
MF_<1=WL(]_G;;<^?COU\5VHXV11MCC8UC&`-:UHV#0.0`'@%61[1]58(`:HT
M1:9&.MF@XN9__0_\P78Q7:UHW*\+3E/(I3UCNQF/;_M<V_XK!5I[D1F(S'IO
M^R^83=%Y5K5>[")JD\5B(]'PO#V_$+U7!(B;'U%#RZJ)F(C,@BQ+_`#=?.$N
M^<5@JU\5STZ>F:Y]./CQ\,K=/F^EX'3FFSG=>07T`#HOJCV6]>_V*]ORT[1^
ML\S\C,1PP+#NLF@@+ZB:?PO3Z>[-VW$Q/R)KF8Q*I=3X7/7]>-=4P@K9`EYJ
M9>G*(VF(20D.F.^[BUO>-+2#Q<0V&PY=*UCM29'45'*P:=BQ^>IOE\HR+[&]
M6S$&.:R)H#BXAQ+-]P.'8\U9"+T54%TWB[SM9RYOS!-@XYZ19D&2SM?Y79+@
M0YH:YW)OI>D=M^+;93I%S\CF\?BN5JP&R;;B-HXG'\`@Z"QDDCAC,DKVL8.K
MG'8#\5S:>4\]8B>QCR8IAQL8)`"6N`Y;CISY*OZS;FHLM'5N7G"1^^QEW(!'
M@!TW03J35F$CE[LW.(^TQCG-^.R^YV::QIV:SC+1!#1('Q'YS1U`/V?P7#R6
MBZE3$3V(K4QGA89-W[<+@.HV\%CH.T][KE%^[H>$2`'H"3L?C_P0>^ALFZ:.
MS1FD<Y[3WS"X[D@\G?X['\5,%641=IK5O"2>[BEX3[XG?^A_P5F\O`[CUH(U
MK7'^58<6F#>2J[B/W#R/_`J)8;$VL^XUQ;:R&N!Z,CB>$$_U6_:K-G$,D9KS
MEO#,TLX2=BX$<]AX\E6%6W9TQFYPUK7OBXHG->2`X>!_@4$VQVD,91<U[V.M
M2CGQ2]`?<T<OXKLQ68)Y)&131R/CVXPUP);OZU`M]3:DZ=Y'6=_^*/\`U/\`
MBI%IW31PDCYGVS))(SA<QC=F==_M*"0(B("(B`B(@W:?T1^\MA:]/Z(_>6P@
M(B("J_M"MZ@?GHZF/S6GF8Z&+RJW4OC<LB#2"Z9N_I1\1;ML-^(CU*T%2^K=
M`:ES&M<M%7HUY,3FYZCK&1=*T2001`<<0;U.Y:#RY'8?@$G[+GVK%?)VWYS#
M7ZCY(V0UL/&8X:Q:#Q>B0""[<'\-U/I8HYHGQ2L:^-[2US7#<.!Z@CQ"@?9W
MI_)8[-:FR]W%0XB#)3Q-K4(GAP8R)I;Q^CR'%ONI^@^-:UK0UH``&P`Y;+[L
MB(&R;(B`57?9U^A,I^N[W\U6(57?9U^A,I^N[W\U!+T1$!$1`1$0$Z(B#[Q.
M]H_%?$1`!(Z$C[%Q\KI/3^<W.2PU*P\\N\=$&O\`^\-C_BNPBF*IIG,2*VM=
MC&&CG-G`Y3*86QX&"8O:#^.SO_,M.YB^U/3U*RZMGJ6:ILA>3Y2."5K>$[D$
M['<#G\XJU5X78#:H6:[7!IFA?&">@XFD;_XKO&IK_'O[T8?D3_;+4X_Z19;]
MLD_U7Z%[(;ES)Z"AM7[<]J<V9FF2>0O=L"-AN>:@/_N^Y/\`Z^H_^#(I_BJ4
M_9?V;RQRO@O2P3\0<'&*/^ED:T%SB-VM&^Y/J"T>)>RZFS%&(G?*M'5$IX`!
MT103"ZJU7?PM>5VGZMFS:F#*]F"P6U7,]+B>\[%S.'AVZ'B+AMXK7/:5,Z0T
M!2QM?*02SQVS<R(BJQB-P;NV7AW<7.<`!MN"';]%YU-,4QB(Q"ZPT6KC+4M[
M%U;4]5]26:,/?`]P<8R?#<<C]HZC9;2D$10G,ZRN5<E-5K00M;!(6N<_=Q?M
M_!!-EP<]J:/"RM@%6269S.-I)X6;?;U*W\1EJ^8I"Q!R(Y21D\V.]1_X%<?6
M^/\`*,4RXP>G6=Z7W#R/P.Q0>NF]2^>'2U[+8X[+27,#.0<WW;^(4?US#MG(
M'CEWL#1O[P2%Q*[)Z]>/)U'EKX)0UY']1W5I^P\Q^'O76U-D8LQ0QUZ/9LFS
MXI6#^H[D?AXA![Z*NNIYB;'RGA$P(`/A(W_TW6MJ2N_#ZF\I@'"'N%B,^&^_
M,?'?XK'.,?0RM/*0#86(X[+3_;`'$/C_`!4AU7!'EM.0Y*`;]T!*-O8=U'X<
MO@@XDEC46J=XV1N;5<>;6#@B_$GK_BI9I[`MPE9X<\26)=C(\#D`.@'N7.T/
MD._QTM%[O3KNW9O[#O\`0[_%2I!"M>8_E7R#&_\`V9/XM/\`$+G0:ESEJK!0
MH1DOC8&%\3.)[MO'<\@K`M5(+U9U>S&)(G;;M/CL=UE!7AJQ"*O$R*,?U6-V
M""&XO2N5=D(<A?M]U+&\/&[N\>=O`^`4K=C*+[SKKJL3K#@!WCF[GETZK;1`
M1$0$1$!$1`1$0;M/Z(_>6PM>G]$?O+80$1$!$1`6KD<E1Q%&2[D;<-6M&-WR
MS/#6C\2MI5[VNUJEK3E=LM^*M;C?++49/$9(YWM@DW8?`.X2XM._)P&VZ"8^
M?\/YNAR!RE(4IMNZL.L-$;]_4XG8KVGRF/K35X9[U:*6Q]`R25K72_=!/I?@
MJ>QE[3S*48=ING8U)%8L4H,?'+WM661S8W23>D.%C-BWB=L".8YK2KX"CBM-
MZXHYB6O;N8S#P,J3OV/=M[ESVF$GF!WQ(&WBUOB@O*W=JT*SK-RS#7@9\Z69
MX8UOVD\@O&?+XVK7AL6,A5AAG($4DDS6MD)Z<))V._N4%S)CR>>T%6R9CL5W
M/F\IBFV<TV16!8'@\N+<N(!\5$M)4\5=UEGZ&4AK2X.K6NMQD<P!CCA\I=WI
MCWY``C;<=`!X(+T5=]G7Z$RGZ[O?S5T-'R9R?LFPKZCZ_G9U"(Q/O!SHSTV+
M^$\1]'WKE]F(G&FKXLF-T_GB[WAC!#2[O.>P/,#=!,T1$!$1`1$0$1$!$1`1
M$0$1$!<W/1Y&7#3-Q4=66WNTB&T!W<S.(<<9W!`XF[C?;ENND>0W/1<7(:JQ
M6/+F&?OY1_4A]+XGH$%:X'3>LJ.#L'#8UF*9D',9-7%MK)6-:Y_'(WB'"Q[@
MYK`0.0;OXA=&73\N%LX_+.TMBVUZE.6AYLLY".3DYP>)@]S=G.)+@X'TMCN.
MNRZL^K,QE93!BZQBWZ=VWO'_`(GH%(<C@(L[1AEM1^37Q&-WCGPG;F#ZQN@Q
MT30=C-%XFBZS%9?#!PNDB<2S<DGA:3SV&_"-_4N#+D[N5U>RCY2\5&VN$1M.
MP+6G<[[=>GBM!DF7TAD-B-F.._"><4H]WO\`\0O?1C6SZD?-(X<8C>\`GF7$
M^'Q*"Q2=^:K>Q5AM:\FJS-+HI;+FN&^QYCK\>:LCP58Y:S-3UC:L0`&:.P2P
M%N_/;U>*#Z]E_2&:#FGB8?FGHV9GJ/O_`(%3ZI;J9[%.=&=X9F%DC#U82.8/
MO4,;A=0ZA>V6\]T<?5IG]$#[K!_Z+3KS9#2>;,;F%V_)T8^;,SP(_P"'J0>F
M##:&H)L5=:'0V.*K*T]"=_1/Q_BN?F,7-A\@^K(2YGSHW^VWP/V^!4JR^G;&
M:R-?(TB*[9HVND,P+7,<.GH]=]MO@I);QE3(,A%Z!D[HCN"00-]N?X>Y!&I,
M?)F]"T.X9QV8&C@`ZG8EI'P_@NO@,;:JX(T,B(W`\0#6NXMF.\#^)*[$<<<,
M;8XF-8QO(-:-@/P62#GXW"4,2#Y)`&O(X72./$XC[5T$1`1$0$1$!$1`1$0$
M1$!$1!NT_HC]Y;"UZ?T1^\MA`1$0$1$!<_-83':AQ<V.R=6.Q6E&Q:]H/"=N
M3AZG#?D?!=!$$;?H#24E:M7ET]C9(ZS.[B#Z[3PC?<^'B22?>5L'1FFG>1<6
M"QQ\B&U;>NT]T.+BV;RY<R3]J[B(.5:TUA+M6S6M8JI-!:F\HFCDB!$DNP'&
M?[6P`W]R\K6D=.W:-6E9PF/EJU.5>%]=I;$/$-&W+?\`Q7:1!BUC8XVL8T-8
MT`!H&P`]2KWLZ_0F4_7=[^:K$*KOLZ_0F4_7=[^:@EZ(B`B(@(B("(B`B(@(
MB("(B#3RU$9+%6:G0R,(:?4[J/\`%5SINO1GS+:^2CW86NX0YW"`\<]C\"K2
M59:NQ_D.=E>UNT5@=ZWU;_UA\?XH)59U/A,1%W%,-E(_^76:`W\7=/XK9T[G
MO/D-A[H1$^)X'"TDCA(Y<_7U7/PFE,2ZI!;>7W#*P/''R:-_[(_XKK6\QB<-
M%W<DT4?".4,0W=_W1T_%!IZSF;%IR1K@"Z21C&[CH=]]Q^`4'K8>_+C?.E5I
M<R.0C^C)XV[;>D/=S\%(];VO*H\;7K[R=Z#.`T;D@@`<OQ*D.G*;Z.`J0R,+
M)>$O>TC8@DD\T$=P>M.3:^5/N;9`_P`P_P"(6JRK/;UVZS6B?+`RV'F5@W8&
M\N>_12U^GL3+=-M]*-TKNH/S2?7P]-UTFM:QH:UH:T<@T#8#\$'U8F-A>UY8
MTO;R:XCF/L*R1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1!NT_HC]Y;"UZ?T1^\
MMA`1$0$1$!$4$[6(LO)HY[L8ZQW,;GONLJS"*1T(B?T)(Y!W"7`<R`0@G:*F
M;V6S$79'=MZ>U!9X*1D\I??C<+E;;@(@!//?TCZ;MSPD;>[J:BM9:[>UE=@S
M5ZC_`+.5(GTX8)`V-\G<]\YTC2/3!Y-Y^`*"TD4$S^1NY>]I'%17+&/AS`EG
MLR4Y."3ACA#PQKNK07.&Y'/8;>*B^"N9G4^I,II>QJ#)5X\%'.QEJO*&2V'B
M9S8WR.`]+A:`".A/,H+C*KOLZ_0F4_7=[^:NQIW4MV]V;8W/RT9[UV6I'))!
M6:WCE?N`2T$@>L[+A=F,SK&F;TSX7PNDS%UYBDVXF$R;\)V\1T031$1`1$0$
M1$!$1`1$0$1$!$1`4<UI0\KPOE#1_257<?\`V3R=_P`#^"D:^.:'-+7`%I&Q
M!&X*"L\<W4-^BRE1,XJ-WY@\#>9W.[O$>Y=O'Z$C:0_(62\]3'#R'XN/,J9`
M;``=!T"(/&M4@J11QP1-8V-G`WQ(;ZM^J]D1`1$0$1$!$1`1$0$1$!$1`1$0
M$1$!$1`1$0$1$&[3^B/WEL+7I_1'[RV$!$1`1$0%'=8Z4AU7B/)_*):MR(/=
M6L1GFQSF.801L=VEKB"/4?`J1(@B4&@:`T?D,!8MVYO.1+[MMSF][(\AH)'+
M8`!H`&VP`7W-Z#IYJ]:L#(7Z<=^%D&0@K/:&6XV;\(=NTEIV);NT@D'92Q$$
M:R&CH[O=R,RE^O:K6C9I6(RPNJ[L##&P%I!C('S7`]>JYOR:4H:\0H9;)TK?
M=2PV;D+V&6TV5Y>_O"YI'$7$D.`!;OR4W1!JX_'UL5C:V/IQB.M6B;%$S??A
M:T;!07LZ_0F4_7=[^:K$*KOLZ_0F4_7=[^:@EZ(B`B(@(B("(B`B(@(B("(B
M`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B(-VG]$?O+86O3^
MB/WEL("(B`B(@(B("*NNTG5V6P&1Q5"C<J8R&V077[4/>,+N]C;W?4!OHN<X
MD^#3ML>:\;.L]5"OE;%>OA]L#2AL9%F[Y!8>YG>O;"\$!H#-B"0[FX>'-!9:
M**9W4MT38"AA&UVV\T7/CFN,<YD43(^\<2UI!<=B`!N.94<Q^N-3YW(6,)C(
M,5#E\9'.<@^=DCXGO9(6,;&`X$!VW%N2=M]N:"SBJ[[.OT)E/UW>_FJ28S5N
M/MZ)IZGN2LITYJ[)Y72'E$3L""?<X[*-=F;O*--7+40<^"QEKLT,@:=GL=+R
M</6"@F"++@?[#O@G`_V'?!!BBRX'^P[X)P/]AWP08HLN!_L.^"<#_8=\$&*+
M+@?[#O@G`_V'?!!BBRX'^P[X)P/]AWP08HLN!_L.^"<#_8=\$&*++@?[#O@G
M`_V'?!!BBRX'^P[X)P/]AWP08HLN!_L.^"<#_8=\$&*++@?[#O@G`_V'?!!B
MBRX'^P[X)P/]AWP08HLN!_L.^"<#_8=\$&*++@?[#O@G`_V'?!!BBRX'^P[X
M)P/]AWP08HLN!_L.^"<#_8=\$&*++@?[#O@G`_V'?!!BBRX'^P[X)P/]AWP0
M8HLN!_L.^"<#_8=\$&*++@?[#O@G`_V'?!!BBRX'^P[X)P/]AWP08HLN!_L.
M^"<#_8=\$&W3^B/WEL+PJ`B([@CGXKW0$1$!$1`1$00?M`P>HLH*SL.ZI;J&
M2%MG&W&_T;N&9CQ)N`3RV(<#U;OMSZ\*EV:9W"X*]AL9DJ#JV6I,K7I)V/#H
MG`.:YT0'(C@=P@$C;A'/P5JH@A>0TUFI+6+O4I,>VSAK#VTHY3)P2U7Q",MD
M(&X?RWW`(Y#ES*Y%'0FH\)<GS.,O8R3,9**9N0[]LC8A(^0O:Z/8$[-WX=CU
M`ZA66B#DZ?P4&!TSC\(TB:*I`R$N>WYY`YDCWG<KJ,8R-@8QH:T=`T;`+)$!
M$1`1$0$1$!$1`1$0$1$!$1`1$0$1$'QS@UI<X@`#<D^"\!>J.(#;,))Z`2#_
M`%6=JM#=J35;#!)!,QT<C#_6:1L1\"J5T[HC3</:GK"NS$Q=SB8JLU)A>_:)
MYCXB1SY\^?/=!=K)&2L#XW-<T]"T[@K)4'I[5>I6X+&X[!38['P0Z;ERKFNJ
MEXXF3R-+6^ERWV'7?;F5U\7VC:GKVJ]C*.HVJ]S3TV8CKP0&,Q%@)#.+<EVX
M;S^WETYA<J*J>S_7&I<SGJ%;*L$U3(4#:#Q1-<0/Z@-)<>\81RXO7_C:R`B(
M@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(
M@(B("(B`B(@(B("(B`B(@+FPX#&5\I?R451K;F0:UEJ7B.\@:-F@C?8;#U+I
M(@C]31.G*#0VMC(XPVD['C9[S_R=SBXLYGH22=^O/JO6OI#`5;%.>+&QB2G4
M-*`ESG!D!ZLV)V(^W<KMH@CV#T-IG3=U]S$8BO5LO:6&1O$2&D[D#<GA'N&R
AD*(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B#__9
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g486593.jpg
<DESCRIPTION>G486593.JPG
<TEXT>
begin 644 g486593.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+__@`L1$E32S`T,#I;,#)004PQ+C`R
M4$%,,3`Y,2Y/5510551=05)4-$,N15!3_\``$0@`TP*M`P$B``(1`0,1`?_$
M`!P``0`"`@,!```````````````"!00&`0,'"/_$`%,0``$#`P$#!P@&!@<&
M`@L```$``@,$!1$A!A(Q$T%159.4T0<4%1<B5&%Q,E.!D=+B%B,UDJ&Q-$)2
M=*.DP3-RLL+P\6+A""0E-D1'97-UA(7_Q``:`0$!`0$!`0$`````````````
M`0(#!`4&_\0`-A$``@$"!`,&!00"`04```````$"`Q$$(3%1$A-!!15A@:'1
M%")2<?`RL<'A%I$&(T)#8O'_V@`,`P$``A$#$0`_`/:9+A/1UACJ0UT>,M<U
MN"5&DNDC@^6I+&0CV1AIR7=`7;>8'RP1F.-SW!W]49.,+'JJ"1UOI3'&<QL]
MN/GUXKX-3XRE5J.+<HQS6N=_WX=CUKERBKY-Z_GB6#;E2OB?(V3+6:N&-1]B
MX-SI0R-Y>0V3.Z<'F.%5,HJFHEGD$'(M+"`TC&>&`%T.IZMT4<9II,,)P=WI
M.5?CL;E_T]?_`%?U6\OESS'*I;^OA[FRR2,BC,CW!K1Q)6/#<J6HDY..3VCP
M!&,I<:=]31NCC^ED$#IQS*CAHJIT\+>2E:&N!)(P!KGBO5B<3B88B-.G&\7;
M.S?7/-:66YSA"#@VWF65%='/,YJ"QK(\$$#XD++@N--4OW(Y,NZ",*E905+V
M5(Y)[2""`1C>U/#[U&"AJI*B-ICE8T#Z3AC=7BH8K'1Y<'"^]T[O-]>EE;4Z
M3ITG=IER;K1B3<Y77.,X./O71/=A%6B(!O)-/MO/^BKVTU13M?":$2N+A[9;
MD8^"[:JDF94PR^:"1NZW>C8,C(&H5>+QLZ:E:SO&_P`KR75>/D.724K>#ZEO
M5U3::F,Q&]T#I*QJ2Z1R4[Y)W-8YIU`Z#P6160F>A?&UOM%N@/2J1E%42TCV
M"F<R1CM[)&"\'F^Q>C&5L52KWI*\>%Y6ZWW^WMJS%*-.4/FUN7=/7T]4XMB?
MEPUP1@KLJ*F*FCWY7;HX#XJFHZ:=]PBD\W,$<8&<C'`8_BLN\4DM1$QT0+BS
M.6CCJMQQ6)^%E4X+R3RR:NM[:^1'"',4;Y'>VYTKXW/:\D,U<,'('2N#=:0!
MAY3.]PP#_%4\$%7',Z;S>5VZT@!S>.1CASKFGI*FGEAG?3/<W>SNAN2/CC^2
M\RQN-O'Y,GJ^%Y*^O^NG370WRJ6>?JBX?=:2.0QNEU!P<`D+%FNCH;@&$M-/
M@$D#)P0L(4L],9F>9\MO8W7EN1A3;13&NAY2E#6%HR&C+1H=%B6)QU51LK/B
M7_:\M=7U6FA5"E&_7+<MO2-+R'+<I[&=WAKGHPN([E2RA^Y(?9:7$$8.`J-E
M)5^:2M$#\;P)!;J=#P7,%)4ME!,$N"QP!+?_``D*K'XWBBN7JE?Y7U\1R:5G
MGZER+M1DM'*_2Z0=/FI27*EBE,;Y/:''`RJ,T4_F.]YM)RG*'/LZXW1_#*C4
M#DJJ<-#7Y!!SQ;G&?M6)]I8RG"]2*6G1]8MVM??)[%5&G)V3_+E\;E2B!LQD
M]EQ(&ASI\%V4]9!5`F%^]CB.!6OMI)9Z&.6-I>&N<TM`UX\5F6FEJ&UCYI&2
M-;ND9<,9RO1A<;BJM6*E#Y6D]'U5[WTUZ&)TJ<8MIY_V6;JV%E2*=SB)'<`1
MH?M74+K28>>4^CQT.OR6'>@S,;VO`F8>&=<+#;;99+<V>-N\YSB2WG+>`_Z^
M*E;'8I59TZ<4^'/R=K==5G?>Q8TJ;BI2=KETRY4LD;WMDR&#+AC7'R7!NE*(
MV/+R&O)`.#S<55,HJFIGE>(#`TL(`(P#I@!=#Z>L=`V/S63#'$YW>)/_`&6'
MCL:O_'KI\K^JVG3+/,O*I;^OA[EVZZTC'N8YY!:<'V2LU4M)1N==I730'D_:
M+2YNF<C"NE]/!SKU(.596S=E:V2?\G"HHIVB$1%ZSF$1$`1$0!$1`$1$`1$0
M!$1`$1$`1$0!$1`$1$`1$0!$1`$1$`1$0!$1`%PX;P(SCXA<H@*":LJZ&2:&
M20O)'L//-\5V4]QDI8F^<F2627#FLT]EO-]I7?<Z&:KEC='NX:,'>..=<UU#
M,^J954Q;RC?ZKO@O@*ABZ4YN#;2:2Z_*\V\WFUHK]#U\5.25[>/W.3>(?-^5
M#'$AVZYG./\`K"F+I&:F&'DW_K0T@Z:9&5@LL\YIY2]S>6<00`=/M/VKFGMM
M8*J":7<PPC(#M0!H%NG5[1XX*<<GPWTTN[^=K$<:-G9[EE6UK:)C'.8YV\<:
M%8GIR'DRXQ29S@#34=*[;I1RU<,;8MW+23[1QS+JKK8^:"'D]W?C:&[I.A"[
M8F6.4ZCI:*UM,]_]&8*E9<7F=L=W@='(Y[7,<P9+3Q/R4(KU#)(UKXWL#C@.
M/#*Q8+/*X2&8,CR/9W23@^"G#1W)IBBWV1Q,/$$'3*YPJ=H<4.-9>"6_7-6R
MV_HK5&SL=S[W$V1S6Q2.:TZN&%TU%?(;A3F"1QB>`=SIXZ+IFL]0V5PB:Q["
M<@N=@A=[;5,RII7@Q[L>Z78)XYR<+E!]HS:YBM\RVWS\K;W-/DK].QW>FH?-
M^5Y-V0[=W<C/#.5$WR+.&P2'`R>&BZGV=[KAOC=Y`OWB,Z].%UU-HGY=[H6L
M>QQR-YV"U)3[44;VZVZ=%KYL)4+ES!.RIA;+&<M*KY+W&R9S!"\AIP3P_@LN
MAIG4M(V-V[O:D[N<9^U5+[15NE?]!PSD/<_4KU8R>-5*')7S6SM;6WCXG.FJ
M3D^+0O(9F3Q-D8<M<,A=BQJ"%]/1QQ/QO-!S@YYUDKZ5-MQ3EJ<7:^01$6R!
M$1`$1$`10ED;#$^1W!H)*IQ?'[V70`1YYG:KR8G'4,,TJKM<Z0I3GG%%VBUV
M29SJ^J+7NW#&\CVCT#"G3W)]+11-#3+(YSOI'XKRQ[5IW?&K)7\=)<.W4V\/
M+I^97+]%1RW*6H@J871\FYK,Z'4$$!8;YI61TCFR/+@W/TCK[14GVO25G%76
M6]_U<.EBK#R>OYE<VA%1SW%U11S1O88I6$9`/QPC;JZGIJ>-K.4>6`N+G+7>
MU"^>ED[_`';5K:]"?#SMXEXBPK?7BM:X%N[(WB,Y"Z:NYOBJO-X(>4>..OVK
MTO&T52C6O=2TR>?EJ8Y4N)QZHLT5.Z]?^K,D;&-[>W7M)X:<R-NTSP]A@W9"
MS>8,\=,_RU7'O3#-V3OY/JKKS>QKD3V+A%K3*J=]#4!Q>X$@\IDZ'(T63%<W
MPTM-#&QTLKFZ[Q^)P%BGVK2FDVFKI/K?-M6M;P++#R62+Q%4&\$TSGB("5C@
M'-)TP?\`LD%X=),&/@W6N&6X.IZ%T7:F&;24M;='U\O`G(G9NQ;HJ6*]R/E:
MTP`M)QAKM5:550VFIG3.!..`Z2NM''4*U.56#R6IF5*46HM9L[D5/#>'F2/E
MH-R.0X#P?CA0=>I0YX$#3NDY.3C&<+@^U<,E=M_Z>U]MLS7P\[V+M8TUOI:B
M3?DB!=T@D9^Y3@F%33,E8,;PSKS+7ZH2TTCN4JG/FR#[#CI\_C\%<=BHTJ<9
MN'%%_;RLGJWT%*FY2:O9FQQQQPQMCC:&L'`!35)(:FJJX(@\QS,@WG'A@GI_
M@L/>F@J&,AG=+-O8]DDM^7Q^*Q5[1=-I*%U>VJ^V2\,_]:EC1OU+Z>AIZEX?
M-$'.`QG)&BR``UH:```,`!:U5NF-;.3RS6AQX9T"[WRYAHHXIGOP72%QT.F3
M@_Q"YT^T8<<UP6?J\[7T\^I94799_EB_1:NU\_FYJ^7?O\KN@9^&5D5G*.W*
MF6IPR1@+(VDYX='1GG4CVMQ4W/@TL]5H]'_17A[.US8$5?9Y)I*/,I)&]AA/
M.%8+ZE&IS:<9VM=7L<)1X6T$1%U,A$1`$1$`1$0!$1`$1$`1$0!$1`$1$`1$
M0!$1`$1$`1$0!$1`$1$`11><,)''"H8+A7R!TN\UT<0WGY`&0O)B,9"A.,))
MN]]/#6YTA3<TVNAL"+7&7>K:[?<\.&=6;O-\UV27&L?/*V)[0QN7#(&C1JO(
MNV:#CQ*+_P!+:^_@=/AI7M=%XZ2-A`<]K2>`)QE36M5-4:P4KW@;X<6NQSZA
M=M3=*IE5(UDK-UKB!NC*SWQ37%)K+*UM<U?JT/AI9+\UL;`BHGW2JF$$<.ZQ
M\@U..)SC_1=C[A5P4T@E$;GAVZU[2#]X"[=Z4;.5GPKK;+2]MS/(EDNI<HJ"
MFNM3RS&RN$C7Z?1P6KK%TKC'RG*-W6D`^R-2?^RYOMF@H\3B^O1=+>/B:^&G
M>UT;&BH8;K4QS?K\.:YF\&@<-,A=3;O5AV^7M<,_0W=/O1]L4%JG?/*VEO/]
MKCX:9L:X<X-&7$`#G*H9+E5OJ)&0N`;C>&0,@`9735U4U51Q/D(W0XM('.1S
M_<LU>V*<8RX8MM7^SL[?N(X:3:N]3946-3&5E$UT^"\-R=WHYOX*G%SK7A\X
M<P1M<!N8Z>9>K$8^GATN-/-7^R6M\^AB%)SO8V%<$AHR2`.DJCDN55+4L;3N
M:T2-!`<!IIDZK'J*V:KHAOD8:_#L:;V1I_(KS5>V*4(RX8MM7^SM:_[WT-QP
MTFU=FQ&:-I`+V@NX9/%36LS<H&47*AAT&[_NY&,KO=<:R1\TD3FMBBX@CXX'
MS5[UA%M3B[[+71-W^P^';T?Y>Q?HJ%]TJI98FP$-,C0-TC^MDCBLRU5LM298
MYB"YF,.`X_\`6%VH]I4:U54HIYWSZ9*_[,S*C*,>)EDB(OH'$(B("$D;98W1
MNU:X8*IG6%Y?@3,W,\2S57B+SUL+2K24IK->+7[&XU)15D51M#_.97ME:&/8
M6@8U&1A8=7124M-"'`N+7$\HS/L_8KN2JABF9"]X#W_1'2NY>:IV?AZL91AD
M]];9\7[FXUIQ:;_.AK=#2RU3J@#>`<PC?>.)R#_HLMUGF+(`)F!T8.3@].=%
M<HI2[+P\(*$E?Q\[]/$2KS;NBG;9I.2FWYVNEDQ@XTXY.5S)9G/BAW9&B1C=
MUV6Y!5NNN:>.GCWY7;K<XRMRP&$C#YHV2\7T=];[O4BK5&\F8EMMWF(>7.:Y
M[N@8P%"KMCY:CSB"7DY",.R/L5A'(R6,/8X.:X9!'.DDC(F%[W!K1Q)*ZSPU
M"5)0DOE6:S>7C?7U(IR4KK4U^MM[J.B8`3(YS\N(;IPT"RZ2UR<LVHGFWO9T
M&-=1C^`5JQ[9&!["'-<,@CG4EPI]F8>-3F);67165O/S-.O-QL4S;/.R*6(5
M#>3=J!N\X.A4S9WB*$QS!L\8QO8T.I\5;+AS@QI<XX`&25ON["QC;AR7B\K.
M^M\K$YU1N]RG%E>*9[>6:97N!SC0`?\`==AM,GG$$G*@"-C6NP-=!C16$%1%
M4,+XGAS0<9"["0!DG`'.4A@<(XJ48JV5L]M/W#JU+V;*5UCF>_VJAA!.2[=]
MHJUJ*=E13F%V=TCCSA2BFCG:71O#F@XR%V+='"8>$&H+*6N=[_[)*I-M7Z%.
MRS2F2,2U`=%&=&ANN,YPN1:)-RI;RK/UI!;H=,'.JLIZF*F:'2O#03@$KJDN
M%+"\,DE`)&5P>%P--<,K*V[W5M^JT]#:J57FCFEIWT]$R$O&\T$;P"JQ9:D/
MWQ4,W\YWL'.5=2S,AC,DCMU@XE(IHYXQ)&X.:><+K5PN&JN-.:SBLE=W2\F8
MC4G&[74KH[94-94%]0'32,#0_!T'.L>.S543MZ.I8QW2`5<RRL@C,DCMUHXE
M(I63QB2-P<T\"%F6"PLII-?,O%WS?WW*JM1+P*V>USN?)R521')])KLE2I;2
M*></<\/8(RW&,:GB59KI?5P1SMA=(!([@T\ZU\)A:4N-JS\7Z*[\=!S)R5BK
M?9),F-E0!"79P1J/_-<U%FFEF+FS,W,!K0X'0`<%<HL]V87AX>'+75]-.O0O
M/J7O<Q:&GGIXG-FFY0DZ'70+*1%[80C"*C'1')MMW81$6B!$1`$1$`1$0!$1
M`$1$`1$0!$1`$1$`1$0!$1`$1$`1$0!$1`$1$!P0'`@\ZQ::WQ4K)&-+G-DX
MARRT6)4X2DI-9K^2J32LBL]"0[^>5E#,YW`=%BFV23W&;E&/9$22'@C[%>HO
M)/LW#3LN%))WMOTS.BK374K_`$1!R<30YXY,YSGB?C]RB^RP/F<_E)&M=J6@
MC"L=X9QD9Z%CR5T,=4RG))D>>8:#YK53#X16XXK-VT6NB(IU.C9T.M$#H&1[
M[P69W7C&=3E(;13112,.\\OT+G'4?)9LLK(8W2/.&M&25B.NL#:9L^Z\L+BW
MAKD+%2G@J3;FHIVV6FG^NA5*K+1LA#:(HI1(997[O`$Z#[EP+-`(71B23#G!
MV<CFS\/BL^.1LK&O:="`?O4MX9QD9Z%U6$PUK*"M]M]3/,G>]S";:H6SQR[S
MR6-#<'&#@8U72;)`7Z2RAF<[@.BM%P'`G`(RK+"8=_J@M].H52:T9A>BX?.'
MS;S\O:6D9TU&%$VF'S7D-]^`[>#M,@K/W@F\%7A:#O>"S\-W=^HYD]SJIJ<4
MU.V$.<\-YW<5A262G?)O!\C&DY+6G16.\,9R,?-"X#&HU5GAZ%1)3BFEIX$4
MY)W3*:>VNEN+6B-S:;=`WFD:8"S&VF!M*Z#+CO'>+^?/,L[(472L8QSRX!K1
MDGH7&."PT'.3BGQ7O?QU7V-NK-V5]#`%FAW(PZ64[AR#D=.5S/9H)I3('O9O
M')#<8*RJ6KCJV.?%G#3C487>K'"X6I!-03B\]/"W[$=2I%YO,P1:H&RPR-+F
M\EC`!T..E3I*".CDD>QSR7\0[F66B[1P]*,N*,5?WU,N<FK-A$1=C(1$0!$1
M`48)=?)GNU,37%H^0T_FL5M;5\F:CSHY#P`SITSPZ%;RT<C;G'51`$'20$XT
MZ5)]IHWR%[HM2<D!Q`/V+X,L!B9IJ,K9RZM:NZEEJUI9GK56"U5\E_\`"L=4
M5=77-CAF='RC0<9T;[.59ULCZ>W$\J1(`&[^,DE=HHH15"H#2)`,:'3AC@NV
M6)D\9CD:'-/$+W4\)4A3J+BO*3=G=Y;?;R.4JD6XY9(URFKZID\1=*]S7.`(
M=P()PK:\_P!`/^^U<MM%&T@AC@0<@[Y6544\=3$8Y02TZZ'"X4L!76%J49RN
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M4L<9"<`<=!SJ3*JIE9-`^5Y!87>UQTYE<^BJ3D>2Y,[N]O#VCD'YKF*V4L+P
M]C"#NENKB00>*\:[+Q'RQ<\DK:OZ;/+[_8Z.O#-VS_LI(9IZ>A>^*;`<_=W1
MQ;SY^W@NZ@KZGSR.-SY)&OP'!PX?$*UCME+$)`(R0\8<"XE(+92T\HD9&=X<
M"YQ.%NAV;B(2IMSRC;)-]->G7R)*M!IY:F+?M:2,<V__`*%5XIWR7..(R`N.
MZ=YPS_5SC'\%?U-)%5QADH)`.1@X4100-J6U`:>4:,`[QZ,</DN]?L^=7$<U
MO*\7;/HG?^#,*RC#A^YUW;]FR_9_,*F-1-!14W)2.9DOS@\=5L4T+*B)T<@R
MUW%8QM5*Z)D98[=826^T>=7%X"I6K.I"5KQ2ZWRE?]B4ZL8QLUU_@J'S5`95
MTTTID#1Q/2'#@H05%12^;O$IY-Y.&9TQO8*O'6VF?)*\L.]*,.]H_P#7,HFU
MTI9$TL=B/Z/M'IRO,NRJZFI\>FF;^J_GED=.?&UK?EBEFK:DU$A94R%@=H1H
M.*F9GS5U'*_5Y:TG'.02K=]II'R.>8SEVIPX@+EMLIF.B<&NS%]$[QZ<J1[,
MQ/%>4U:Z>K>COU\`Z\+9(HC<*LN,G+2#70`>R%L5)*Z>ECE>W=<YN2%TR6JD
MDD,CHSDZD!Q`*RV,;&P,8T-:T8`',O9V?@ZV'<G5GQ7\?7P]3G6J1G;A5B2(
MB^F<`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(`
MB(@"B\X8XZG`/!211Z`TXNRXN!(UTR[59$S6><PNE>X,D:U[W\^HU(6R>:T^
M\7<C'EW$[HU1U-`\-#H8R&_1!:-%\"'8CCK-/-/].65^E^MSUO%7Z>ICW.,2
M6Y_$[HWACX*@_5B@)#R9.4]IO,!@X6V8&,8T72*6G`($$0!U(W`O7C>S?B:C
MFG:ZMIZZG.E7X%:W6YKT`D@J]R%[MYT6=.<EF5C->6>V'[KP?I;VH6VB&(/#
MA&S>`P#NC(7'F\)?OF*/>SG.Z,KS3[%N\IV5V[6TNT\L\FMSHL5;H=%4Z8VQ
M[FYY7<!]G^.%0P.IXV1R&>9LV\2=P`X',MI74*:`2<H(8P_^T&C*]N*P+K58
MU.+16S5^M[K-69RIU>&+C8UQ\@BEK&O)!?EH'QWLKK.7QTK=XC>RW.>EV%M#
MJ>%[]]T3'.QC):"4\WAT_4Q^SP]D:+QKL9WM*=U]NG%Q;^1T^)V7Y:QK]52-
MBKX:5KW;I#6[Q.NI*ZJN(P51A<26,'L;[L9"V9T4;GA[F-+AP)&H1\4<F.4C
M8_'#>:"MU>QXS4N%I-ROITMIKH2.):M?;\9JLDLCJ6/>?D-<X-.>&@7>V(LJ
MJBE:]Q;N.SKQ(`(_BMB,$)8&&)A:.`+1@+D11B3E!&W?_M8U^]9CV,E/B<KZ
M=.G#PM:]2O$Y6M^7N4]B$>_([?/*X^CS;NFOWJ[76R"*-Q<R-C7'B6M`RNQ?
M3P>'^'H1I7O;R.%2?')R"(B])@(B(`B(@"(B`(B(`NN2>*(@22,83PWG878M
M<NL;V7!SY-&.U:2,CAP7BQV*GAZ:E"-[NWV\3K2@INS9?&I@;N[TK!O<,N&J
MC)64\0?O2LRT:M#AG[EK8<!0[CFN<7/RSV3ITXZ<Z+OI:=F:F&:)WG!8=P'I
MXZ?%?/7:=>4E!0M=7OGK:]OO_'B=>1!*]RYI*^.JB?)HS=.H<1H.E=S*B&3.
MY*QV!DX<#A:U$P24<K8VN,K2'/\`BW_R*4@<ZI8(B<@'.ZT\,:Y6:/:F(?+B
MX7NE=_?VZEE0AFTS9!5TYQB>/7A[0U7$]3%""'/:'AI(:78)6L-A!HGR[IW@
M]K1\L%=L["RH#IVN<'Q@L^)W1C[BIWKB."[A9NV_5/P\/4OP\+ZEY27&.>G,
MTF[$`[=]IWPRLJ.6.9N]&]KAT@Y6L;G_`+/!<UXQ*?:QH-!Q6=8R>7F`9EN-
M7C../!=<'VA6G4A2J1U2S\;7\C-2C%)R3,^KN,=+*R(C><XC.#]$?%=;;I'Y
MX^!X:UC<_K"[0K#O436U44I8=UP]LCGP?!8O(QRUDH:QPC$;GL&O,W1<:^-Q
M<:\H1ME+3PLWM^,L*5-Q3>W\FQF>(1B0R-##P=G1<QRQR@F-[7`?V3E:L62N
MH6NPXQLD(/PR!JLRSAQKW&,^P&G>PT@'H7HH=I5JM:--T[)I>JO_`$9E0C&+
M=R]DE9$,R/:T=+CA=-16Q14KIFN:\#0`.XGH5=>8G&>&5[7&`:.W>;77^"P&
ML,D=4^.-PA&K1T'.G\,K.*[1KPJ3I0AHG;6^2O?2UNGW$*,7%2;_`"Y8"^'D
MBXP#>S@#>T*S:>OCD@;),6PEV<-<X:CI5'-`UELAF:P\H]S@XZ_'"C4T_FTS
M<MW8W-!:2,CAXKRPQV,I7E/YLH^JO=Y+[;'1TJ4LEEJ;,ZHA:UKG2L`=P)=Q
M6*^XL9511Y:Z*302-=G!Z%0O$@H&'VBS?=NY;\%F7*GBI:2".(8<X[QZ2<`+
MT2Q^)E"4N'AX>'SO;+\\#"HP32O>]S8$7#<[HSQQJN5]T\H1$0!$1`$1$`1$
M0!$1`$1$`1$0!$1`$1$`1$0!$1`$1$`1$0!$1`$1$`1$0!$1`$1$`1$0!8E1
M<:>EDY.1QWL9PT9PLM4ETI)Y*L21P.<-W&]&=?M7BQU6M2I<5%7=]F_V.E*,
M92M([:VYN8R"2F>US'DYR.C"RXKG2RM>X28#!D[PQHJ9]%6.I(F.@<0''``&
M0-.*[7452VKJ>2APTM<&'`P1IH/L7S(XG&QJ.?"[.V5GE\M\L]^F_4[N%)QM
M?/\`LL8KK2RRB-KR"3@9;A#=J0/W2]V=[=^B=%2LH*IKFN\WEP'`G0=*S:*@
M>:NH,\)`(.XYPYR>(6Z&+Q]248N%KO7A>EK_`-"=.DDVGZF:;O1B7<Y0\<9Q
MHLQTC6QF0GV0,Y'0M:=;JN,NC$,CM>+<8*O!$Z&UF-V=YL1!R<\R]&"Q.*J1
MFZ\;66S7EGKY'.K"$6N%D!=Z-SFM$AUYRT@!<RW6EAD<Q[G;S3@X:J"*&:>`
MLB@+\OU>!J-.'R5A3T,@N@,T.]$!](C+2<`+R8?'8ZNHVCDVL^%VLTV^O3+/
M0Z3I4H-YZ>)W4=S+WSF>2/DF#((&#Q65!<Z:HDY-CR''@'#&54MMU2]U2.3<
MT\6YX.P>"G!!4/DAB\Q8QK!NE[VZCI.>E;P^)QBX(RB[?9N^;ZWRLK:DG"GF
MT_7P+$W>C$FYRAXXSC19H((!!R#SK676^KC+HQ#([4:MQ@A;!21.AI(HW<6M
M`.N5ZNS\1BJSESXV\FO+/7[HQ6A"-N!W.]$1?3.`1$0!$1`$1$`1$0!$1`$P
M"B(`B(@&!T)@="(@"8"(@"<$1`=9FCY3DR1O?%=BH;Y_1ZGY#^85\MRC9)F4
M[L)A$6#03"(@"8!1$`6++0QS54<[RXF/@W.BRD690C+]2N5-K0(B+1`B(@"(
MB`(B(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(
M`B(@"(B`(B(`B(@"P#7LY9D$K/\`:NY-N!SX)U^P%9Y5#-^TJ'^\?\CEN$5)
M.YF3:L7,%-%3M+8HPP$Y("[41<TDE9&@B(J`B(@"(B`(B(`B(@"(B`(B90!$
MRF4`1,IE`$3*90!$RF4`1,IE`$3*90%#?/Z/4_(?S"OE17QKO-JD[IQ@<WQ"
MO,KK/]*,1U9RB93*Y&PB93*`(F4R@")E,H`B93*`(F4R@")E,H`B93*`(F4R
M@")E,H`B93*`(F4R@")E,H`B93*`(F4R@")E,H`B91`$1$`1$0!$1`$1$`1$
M0!$1`$1$`1$0!$1`$1$`*H9OVE0_WC_D<KTJBF!])4.G_P`1_P`CEUI]3$^A
M?(B+D;"(B`(B(`B(@"(B`(B(`B(@!7QE>;S=&7RO:VXU@`J9``)WZ>V?BOLT
MKXDO?[>N']YE_P",K]+_`,<BI3J76W\G&MT'INZ]9UG>'^*>F[KUG6=X?XK`
M1?J^7#9'"Y8"]W7K.L[P_P`5SZ:NO6=;WA_BJ\*2<N&R(VS/%ZNO65;WA_BI
M"\W3K*M[P_Q5>%(*<N&R,W98"\W3K*M[P_Q7(O%TZRK>\/\`%8`4@IRX;$NS
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M^_U?;O\`%<^DJ_W^K[=_BL0*2SP1V%S+%RK_`'^K[=_BI"Y5_OU7V[_%8@4@
MIP1V%S+%QK_?JOMW^*F+C7>_57;O\5AA3"CA'879EBXUWOU5V[_%2%QKO?JK
MMW^*Q`I!3@CL+F6+A7>^U7;O\5R+A7>^U7;O\5BA2"G!'879EBX5WOM5V[O%
M2%PK??:KMG>*Q`0!J<+D.;_:;]ZRX1V%S,%PK??:GMG>*D+A6^^5/;.\5B`C
M'$?>I`C&<C'S67".PN98KZWWRI[9WBI"OK??*GMG>*Q<CI'WKD$'@0?D5.".
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MRLF1J#OG1=(4@ED0[Q4U'U\O:'Q4Q4S_`%\O:'Q70%(+/"A<R!4S_7R_OE2%
M1/\`7R_OE=`4@L\*+<[A43_7R_OE2%1/]=+^^5TA2"ED+G<*B;ZZ7]\J0GFQ
M_MI?WRND*0X*60N=PGF^ND_?*D)YOKI/WRND*04LA<[A/-]=)^^5(3S?6R?O
ME=04@LM(7.T3RY_VLG[Y6?8[]5S5-;1/;&8Z7<#'8.\=[).3GX*M"CL]^VKS
M\XOY.7DQ:7`ON=J.IZ"5\27O]O7#^\R_\97VV5\27O\`;UP_O,O_`!E?5_XW
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M_5/$!?.QN&52K"5KYV>NATA*R9O]O$5/MU:89HXY((]E1.]IC;[3P\`NX<<!
M9EBMU'3[97FXSQL=0U7FQHMY@+3RX!P.;0M/V%::-L8V;4,N7HRK=#36'T:`
M'1YEDWLY;[6@^>%&EVSG;9]C;7-0U.+2^*:MF:]F).3C<UK!KDG):==-.*^+
M*CBEE&+SR]3NI0ZE_975[K%M3-;W6ME;'?YHHY;BP<DR,28QS<&\!TK6-I)[
MP^OH8;G=+%-ADDC8K5$&[P]D9>=X\"1CYKBDOMMDV?N]!>;%<*J&Y7>2OY"&
M6)I8TR;[0XEV#PU`RJZJELAF@;8]F:JVDEW+S3R1'V<:`!A)XKOAJ515HN<7
MTZ/;<S-KA=CD*040I!?>9YB04@HA2"@)!2"B%(*,$PIJ`4UD'*F."@IC@L@D
M%(*(4@@)!2"B%(++*2"DWF40I-YE`3"ES*(4N998)!2"B%(+()!2"B%(*`D%
M(*(4@H"04@HA2"@)A2"B%(+()A2"B%(+)204@HA2"A"04AP40I#@H4D%(*(4
M@H"84@HA2"RP2"CL]^VKS\XOY.4@H[/?MJ\_.+^3EY,9^A?<[4=3T$KXDO?[
M>N']YE_XROMM><7GR-[.W*O=4T\,=*'Y+VAKW[SB22[._P#%=>R>T*>"E)U$
MW>VATJ0<M#Y<1?2?J+LOUS.R=^-/479?KF=D[\:^W_D>&^F7I[G/DL^;0I+Z
M1]1EE^NC[%WXT]1EE^NC[%WXT_R/#?3+T]R<EGS>%(+Z.]1EE^NC[%WXT]1M
MF^NC[%WXT_R/#?3+T]R<B6Y\YA2"^B_4=9OKH^Q=^-/4=9_KX^Q=^-3_`"+#
M?3+T]R<B1\[!2"^A_4?9_KX^Q=^-<^H^T?7Q]B[\:?Y%A_IEZ>XY$CYY"D.9
M?0GJ0M'U\?8N_&N?4C:?>&=B[\:G^0X?Z9>GN.1(^?0I!>[5WDCL%M;"ZIJV
MM$TK868IW'+CP&CEE>I.U>\,[%WXU/\`(</]+]/<<B1X`WF4PO??4G:O>6=B
M[\:Y]2EK]Y9V)_&H_P#D&'^E^GN.1(\#"D%[UZE;7[RSL3^-/4M;/>F=B?QJ
M=_X?Z7Z>XY$CP=2"]W]2]L]Z9V)_&GJ8MOO3.Q/XE._\/]+]/<O(D>%!2"]T
M]3%M]Z9V)_$GJ9MWO;>Q/XE._L/]+]/<G(D>'!<KW'U-6[WMG8G\2>INW^^-
M[$_B3OW#_2_3W+R);GB*D%[;ZG*#WQO8'\2>IV@]\;V!_$IW[0^E^GN.1(\4
M"F%[3ZG:'WUO8'\2>IZA]];V!_$IWY0^E^GN.1(\8"DO9O4_1>^M[`_B3U04
M7OS>P/XE._*'TOT]QR);GC84@O8_5#1^_-[`_B3U0T?OS>P/XE.^Z'TOT]QR
M);GCP4PO7O5%2>_M[`_B7/JCI??QV!_$IWW0^E^GN.1+<\B"D%ZYZI*7W\=@
M?Q)ZI:7K`=@?Q)WU0^E^GN.1(\E"D%ZQZIJ;K`=@?Q+GU34_6`[`_B4[YH?2
M_3W'(D>4!2"]5]4]/UB.P/XESZJ(.L1V'YE'VS1^E^GN.1(\L"D%ZCZJ8.L1
MV'YESZJH>LAV'YE.^*/TOT]QR)'EX7(7I_JKBZR'8?F7/JKBZR'8?F4[XH[/
MT]QR)'F0XJ07I?JLBZS_`,#\RY]5L?6?^!^93O>CL_3W'(D>:A2"](]5S.L_
M\#\RY]5[.M/\#\RG>U'9^GN.1(\X"D%Z+ZL&]:?X'YESZL&]:?X'YD[VH[/T
M]QR)'G@4UZ!ZL1UK_@?F7/JR'6O^7_,IWK2V?I[CD2//U,<%OOJS_P#JO^7_
M`#+GU:'K;_+_`)EGO6EL_3W'(D:&%(+>O5J>MO\`+_F3U:NZV_R_YD[TI;/T
M]QR)&CA2"W?U;.ZW/=_S)ZMW];GN_P"93O.EL_3W+R9&E!2;S+=/5P_K<]W_
M`#)ZN9.N#W?\RG>=+9_GF.3(TX*7,MP]7,G7![O^9/5U+UP>[_F4[RI;,<F1
MJ(4@MM]7<O7)[O\`F3U>3=<GN_YE.\:>S')D:H%(+:O5[/UR>[C\2>KZ?KH]
MW'XD[QI[,<F1JX4@MG]7U1UT>[C\2>K^HZ[=W<?B6>\*>S')D:T%(+9/T`J>
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MN!J'U&[DF+=QNY^/Q7"O7C4C9'2G3<7=FRHB+R'4(B(`B(@"(B`(B(`B(@"(
MB`UK;+^CVK_\E#_JME5%M5;ZVOHJ7S")DLT%4R;<<_=!#<\_W+&](;6]24?>
MD!LR+6O2&UO4E'WI/2&UO4E'WI`;*BUKTAM;U)1]Z3TAM;U)1]Z0&RHM:](;
M6]24?>D](;6]24?>D!LJ+6O2&UO4E'WI/2&UO4E'WI`;*BUKTAM;U)1]Z3TA
MM;U)1]Z0&RHM:](;6]24?>D](;6]24?>D!LJ+6O2&UO4E'WI/2&UO4E'WI`;
M*BUKTAM;U)1]Z3TAM;U)1]Z0&RHM:](;6]24?>D](;6]24?>D!LJ+6O2&UO4
ME'WI/2&UO4E'WI`;*BUKTAM;U)1]Z3TAM;U)1]Z0&RHM:](;6]24?>D](;6]
M24?>D!LJ+6O2&UO4E'WI/2&UO4E'WI`;*BUDW#:T#/H2C[TL:W[0;272C;54
MEGI'PN)`)J<:@X.A0&WHM:](;6]24?>D](;6]24?>D!LJ+6O2&UO4E'WI/2&
MUO4E'WI`;*BUKTAM;U)1]Z3TAM;U)1]Z0&RHM:](;6]24?>D](;6]24?>D!L
MJ+6O2&UO4E'WI/2&UO4E'WI`;*BUKTAM;U)1]Z3TAM;U)1]Z0&RHM:](;6]2
M4?>D](;6]24?>D!LJ+6O2&UO4E'WI/2&UO4E'WI`;*BUKTAM;U)1]Z3TAM;U
M)1]Z0&RHM:](;6]24?>D](;6]24?>D!LJ+6O2&UO4E'WI/2&UO4E'WI`;*BU
MKTAM;U)1]Z3TAM;U)1]Z0&RHM:](;6]24?>D](;6]24?>D!LJU7_`.9?_P#.
M_P"9=OI#:WJ2C[TNJUT-YFVK-UN5'#3,\U,.(Y@_7((_U0&U(B(`B(@"(B`(
MB(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(`B(
M@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(#AWT3\EKFPO_NM!_\`<D_XRMC(R".E
M5MAM1LMICHG3"4L<YV^&[O%Q/#[4!9HB(`B(@"(B`(B(`B(@"(B`(B(`B(@"
M(B`(B(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B
M(`B(@"(B`(B(`B(@"(B`(B(`B(@/.MN]N-H+#M=9=G[!;Z"KJ+G&]S15.<WV
M@>&00!H"NO9C;^_3;=/V2VIM%)1USJ;SF*2CEWV;HUP[)/-GGYN&N52>4_9Q
MVT7E3V1I9X*LT$D<D<\T`<W<U)'M@:'@J&R[*U>Q^U&TFS$EODJ)KM03,M-Y
M+'$Y<PAL;W\&YX$Z:CH(0'L-NVZV7NUX=::"^4517#(Y)DF2[''=/!W`\"5&
MNV^V4MEQFH*R_P!##50`F2)TNK<#)!^..;BOGW9.TUL]VV6MCQ=XZZWUO*/@
M;:(XQ2%KP2YTN0Y[2!S\/CIGMN3(=G]GMN+)>MG:J>]5-8Z>"M--O,$6\").
M4Y@-3IQWL=*`^BJ?::RU=?1T,%Q@DJJRF%73QM.LD1X/'PT*U[:7;V"EV==<
MMGZZUU+HJ]M',:J5S6-=KO-R,>UP7FU'72;.;3[`[155OKY[=^C4=-RE+`9#
MRFZ[V<#G]H?>J`VZZ3>2VZM?:ZV*HDVG9.8'0NWVM+3J1CAS9X(#WZKVZV8H
M+FZVU=ZI(:YDC8G0/?[8>X`@8^T+AFW>RTE^]",OE$;COF/D.4UW\XW<\-[.
MF,Y6A6/9R.X^63;>IK;<'_JH31SSPY:UY:WVF$CB"!J.A>54%@N3*:GV;K&7
M>*Y1W+>-+#:HR6N'"85!()'PSCG0'T5M+M_8-GO.Z.:[43+M'3OEBI97ZEP:
M2UIQPSIH2"<Z+OV#VAJ-JMBK;>ZN&*&>J:XO9%G=!#W-TR2>9>,W*`V#:#;^
M@OFSU9<ZV\M<^VSQTO*->';V,$?1P2TZ<-WY+U#R303TODIL\,U/(R9D<H,4
M@+'9Y1^ASP0%I%Y0=DI[H+;%M!0.K'2<DV,2C5^<8!X$YTXJN;MW'0[2[04M
MYJ[936NV\B&2LD<9&E_-*-<9/!>&PTE;:KE!0V:@KYI67,N]`W6V"81?^,38
MQPYQCI^*W>JD%HVT\IE;<;-4UU)4TT$45.('$5+G-`#00.&>)'#'2@/6(MK+
M#-=*6VPW6FDK*N(3P0L?O.?&1D.&.8C53O&TUEV??`R[W*GHC4!YBY9V[O!H
MR['RR%XOY&K95['[4FBOUFGBJ;I21R4=;N.<UC<$\DX\&G_48YPML\IUK=<]
MOM@&OHGU-(VLEY?]67,:,QD;W,.'/T(#9#Y4-B12Q5)VDH>2ED,;?:.<CCEN
M,@:C4C"M;QM;L_8(:>6Z7>DI65`WH3)(/U@Z6XXC4:\%XG+LNPTGE7(LIY03
M#S("F.=W?<[]7IPT!T7#*<[/[1;)[1;0V2KN%F_1^&E&Y3&;S>9K-0YAX'CQ
M_M?`H#VN3:_9Z*RP7E]WI!;9Y!''4\IEA<>`SS'0\>&-5AL\H6RU107&KH[U
M253:"$S3MBDR0T:9^6<#/Q"\*JK!='^3*Z5#;/54U#<-H8ZFCH.3<710X>,[
MO,,%H^Q;K<=G1#Y8ZJ*AM.Y13[-R1`1P8C>_!`;PP3HW[@@.RJ\MCW[&VJ^4
M-+1-GJ+EYI54TLCG>;L.\021C4M`.>"])L>UU@VEDGCLUUIJQ\!_6-B=JT=.
M#Q'Q&B^<12FN\EE@M45GJQ6T-Y`KPZC<,M=OD$G&H`T.>'!>J6JT>CO_`$@Z
M^2EH#34+[,T!T<6Y&YV6:9`QG3^"`W_:2_TNR^SU9>JR.:2GI6ASVP@%YRX#
M3)`Y^E9=MKXKI:Z2O@#VQ54+)F!XP0UP!&?CJM$\JGD\;MA:)ZRC;427B&G$
M5+$VH#(W^V"=X'3@3SJU\GNQ--L;96MC-2*JJAA-5'--RC62-;J&]`R2@*#R
MC>5H;(W&.U6NB\\N#)(_.72L<(H6/&6@D8RX\W-Q^2].!TRO,O+?;Y:G8J#S
M.D?+,ZY0.DY&(N<0`X9.!G`7HE=#+46RHA@?N2R0N8QV<8<6D`_>@//]M_*[
M:;%::EUBN%NK[I3S,C?3.>2,$X=C!&<?`G"V:X[>;,V66*GNUZHZ2J?$V4PO
M?[0!&1D#@OG:J@Y#R7.V6?LI7MVBI+ARE1.*(G#<GVM_&=00W'#GX*^VY=<J
MC::_T3K=-2\K0QQTWF5J$TEQ&XW!?*0=T#&I'#&.(0'O-+M/9*VZLME-<J>6
MLD@%2R)CLE\1`(>WF(P>9=EIO]JOOG)M==%5"FE,,QB.0Q_05X'=XZ[9?8+8
M;;:B8]M=;H'T%0R4%IW7AX:"#KH=[[PO6?)3LZ=G/)];H)6EM54M\ZJ,\=]^
MNOR&!]B`M7;<;,LM$EU=>J44,<_FSYBXX;+_`&3IQ7?4[5V&DK9J.HNU+%40
MTWG4C'OQNQ?VR>&-1]Z\(VJV(O%=Y1+GLM2T\S+-7U#[M'(UAW!)R+M,\/ID
MC"AL_0[0OV$VLVGKK*:ZY/BIJ".EJZ8N_51A@<_<.IP`T_-N4![?1;<[/7J&
ML;9;S0U=53P.FY,2<`!Q//C.,D<%I;O+'%;K3L[)=&V]U5=)W"=]+.3#!"U^
MZ9.<G@1CI!6A;,PUE1M[3U;1<*F"2RSP"HDMGFL?*<D[]6QK1C`T`)U)^Q=#
M;?-;M@_)_<:VT5,L-#<IS6-%,7/#"\.#2TC@0#@'1`>STNW#(]H=H8;G56R&
MTVR.*1D\<I,C0\#60<V<C&%:VW;G9>\7-MNM]\HJFL<,MBCER7:9..G3F^?0
MO&+[05=76^4^:EM]5R-71T;Z8"!PWVYC.&C&N!Q`X85G-LZV@NODGGH;8Z)S
M6XJI8H2"#NL/ZP@<<EW'XH#TZL\H>R-!6U%'5;0T$513YY6,RZM(XC3G^'%7
MHN-(;9Z2%0PT7(\ORV?9Y/=WM[Y8U7R[71&Q>3G:39ZY;.54EV%>)O2?(`Q!
MF\W#^5^\`#CO_->\Q`CR,-!&"-G^'_ZZ`S:+RA;(W&NIZ*DV@H):FHP(HVRZ
MN)X#Y_#BNRY[=;+V:ZLM=QO='3UKB!R3WZMSPWCP;]N%\Z4(AO/D\V=V>M>S
MM4-H#<!.*UM-[+H\N]OE.C4#'-N_)=^T=FN5LV@VLHKKZ1Y2XU7*0MI[4RH%
M8QSR06RG6,C(^C\D!]#7?;;9JPU9I;I>:2DG$8EY.5^"6DX!'3P5=8-L37W'
M:,7"IM<=OMDHY.>&?5L9R<RY.`<`?Q6@6S98S>5>PTUXMTE92T^S44;G5=/E
MID:",.XMW@#TE4=XV;O5QI?*;34%#4%[KI#.R$1D&>)CGDAFGM<0<#H0'MUD
MVRV<VCJ'T]HO%)63,;O.CC?[6.G!UPM5VW\K5GL-FN#K+<;=77>D>QII7/)!
MR\-=PQDC7@=.=:/0L9M9MYLU4;)V&KL[+;1R1UM1)3<BT$L+0W/];!)'2<K4
M*JG\U\EM1LG-LK7_`*24U>999Q1DAC,_2WP-01[/0>*`^IZ*=U50T]0X`.EC
M:\@<!D`KO6':@6VBB!!!$$8(/^Z%F(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`
M(B(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(`B(@"(B`(B(`B(@"U?RC1,F\
MGE]C>,M-*[(S\D1`96Q+&Q[#V-C!AK:*(`?#="OD1`$1$`1$0!$1`$1$`3"(
M@"(B`(B(`B(@"(B`(B(#QSRCV^GNWE2V?H:YLDU(]D;G4[I7",G??KN@XSS9
MZ-%[$UH:T-:``!@`(B`Y1$0!$1`$1$!\R[0V.@A\H-;9(F3,M<]>TRTC:B01
MN)());O8XG[%]!7FGBCV.N%,Q@;"VWR1A@X!O)D8^Y$0%%Y)XF0^3:T1QC#0
MU^!G/]<K=41`$1$`1$0!$1`$1$`1$0!$1`$1$`1$0!$1`$1$`1$0!$1`$1$!
"_]D_
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g378016.jpg
<DESCRIPTION>G378016.JPG
<TEXT>
begin 644 g378016.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+__@`L1$E32S`T,#I;,#)004PQ+C`R
M4$%,,3`Y,2Y/5510551=05)4-4,N15!3_\``$0@!10(Z`P$B``(1`0,1`?_$
M`!P``0`!!0$!```````````````&`0,$!0<""/_$`%(0``$#`@,""0<)!P$%
M!@<!``$``@,$$04&$B$Q$Q07,D%14G&1!R)6866DXA4S-#5R=:&ST2-"9(&4
ML=(6)&+!PO!35'."DJ((&"5#8W3A\?_$`!H!`0`#`0$!```````````````!
M`@,$!0;_Q``T$0$``@(`!`('!P4!`0$``````0(#$002(3%!4043(C)Q@9$4
M8:&QP='P(S-28N%"%7+_V@`,`P$``A$#$0`_`)Y0Y(RUF/',R5N+X/35E2,4
M,8DE!OI$,5AL/K*V7)3D;T:H?!WZK.RM]/S-][N_)A4C00[DIR-Z-4/@[]4Y
M*<C>C5#X._53%$$.Y*<C>C5#X._5.2G(WHU0^#OU4Q4-Q+.E929\I\M4^%QR
M"6`R"6:J$)>;7&@$6<`18V).V]MFT*\E.1O1JA\'?JG)3D;T:H?!WZK"'E$K
MM<T!R^'53)YHF,BK0YDO`QZYBUQ8.:2&6MM<2+@`E;+%L[QT-+0U%%025K:F
M@DQ-S>$$;F4S`PN=8WN[SQ9O3MVA!:Y*<C>C5#X._5.2G(WHU0^#OU61@F<F
M8SBS*9M"Z.DJ!4&CJN%#N&X%X8^[;79M-QON`=VY22HJ8Z6/A)=09TD-)MWV
M01/DIR-Z-4/@[]4Y*<C>C5#X._52SC,0_>_!.,Q=K\$$3Y*<C>C5#X._5.2G
M(WHU0^#OU4LXS%VOP3C,7:_!!$^2G(WHU0^#OU3DIR-Z-4/@[]5+.,Q=K\$X
MS%VOP01/DIR-Z-4/@[]5XE\EV0X8G229;H0QHN3I=^JE_&8NU^"QJ^HC=0S`
M.VZ>KUH(GR;Y`]&:?^GE3DW\G_HS3_T\JG2I=!!N3?R?^C-/_3RIR;^3_P!&
M:?\`IY5L<V^4#`\ES4L6+OJ&NJFN='P4)?L:0#?JWA>\I9\P3.O&_D=\[N*:
M.%X6(LMJO:W7S2K^JOR\^NB-M7R;^3_T9I_Z>5.3?R?^C-/_`$\JG5UHLV9K
MHLH80W$*V.:5KI1$V.%MWN-B20.H-:YQ]0*HEHN3?R?^C-/_`$\J<F_D_P#1
MFG_IY5+*G&L+HX()JK$:2GBJ`#"^:9K!)<7&FYV[PL;#LS83BF(5M#35D1J*
M.IXK)&7M!<_0'^:+W.R_\VNZB@CG)OY/_1FG_IY4Y-_)_P"C-/\`T\JE53CV
M$4<4<M3BM##'(YS&/EJ&-#G--G`$G:0=A'0K6&X]3XGC&+8=%'(U^&R11R/=
M;2\OC$@+;=%G!!&N3?R?^C-/_3RIR;^3_P!&:?\`IY5E4'E`IZ^:FE;A&)1X
M55SO@I\3>UAB<YI<"2`XN8TEK@'.`'79;#"\[9>Q7!:?%H\3IH*6H>Z.,U,S
M(R7--B+$[]QMU$=:#2\F_D_]&:?^GE3DW\G_`*,T_P#3RJ72XKAT%;%135]+
M'5S"\4#YFA[Q_NM)N?Y+"P',M!C^'T=3!(V*2JA,[*:1[>%T!Q:7:0=UQOW(
M(]R;^3_T9I_Z>5.3?R?^C-/_`$\JR:_/S</GQ=[L!Q.?#\)DX*KK8#$YK"&-
M>3H+P\@->"2`MQ-F?#!/!!355/55$LL<9ABJ(P]C7D6<6EP-A<;-^W8$$>Y-
M_)_Z,T_]/*G)OY/_`$9I_P"GE4L9C6%2R5,<>)4;GTH)J&MG:3"!O+Q?S?YJ
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M.,Q=K\%<:X.:'#<4$.Y*LC#;_IJA\'?JN3TQXO2PPQ>;'&P,:T=``L`OHHKY
MT9S&]R#M&5OI^9OO=WY,*D:CF5OI^9OO=WY,*D:`B(@*,8GDJDQ3-5#CE16U
MA%(\2MI.$O$9&VTO`(NVUA<`@&PON-Y.B"+SY&P^3!Z+#X:JLIN)\*(ZB)[>
M%(E#A("2T@ZM1N;7O8BQ"KB&2*'$(8X>.5T$4<3Z9K(7M`%.YK&N@VM/F$1M
M_P!Z][':I.B#089E*BPK%WU\,U0^W"\!3O<W@J?A7A\F@``^<X#>3;<+!;/%
MOJJI^P5F+#Q;ZJJ?L%!CNYQ[U15=SCWJB`B(@(B("LU?T23N']PKRLU?T23N
M']P@W:Y[B?DCPO$\3J:YV.X_`ZHE=*Z.&L`8TN))TC3L&W<NA(KTR6I.ZR:V
M^?L]>1/%GST7^G)J[$V!K^&=B%:PEAN+!M[;]M^Y7,B>1/$V\?\`]25%?AG,
MX#Y/K6#A.=JU6ONV6[RN^HNC[;FY.3:O+&]N;T_D;PRFJ8IVYAS$YT3VO#7U
MH(-C>Q\W=L6VQ[+.(9CS?2RS5$M'A=#1R"*2$QN=+-+=CP6O:X6$8M>W[YMT
MJ9(N>^2U_>E,1IR2ERCF'#61QU."4V.1TU!/A%.VIJ&"\7":HI77W`L(8X#S
MAHV`K)9EK,6%8SQZEP6FJ.+8JVN:V&H9&)F.H^`<UFK:W2X7\[>#UKJ2*B7&
M:K)>:YL,AIW8=$'RTM;')Q:>`.9)-4OD#7R2,<>"TN',`<2-JF&0LOXI@L^*
M28C`V+C,=$(_VC7;8Z6.-^X]#FGO4V1!RF@REC\>8:"H9@E/A=7'6B3$,3H:
M[13UL()+@:8=+QLVC8=MUA85DK'\'HH639<I,3T4%3AH@DJ8PUI=,Z1LPU;-
M+@X-<.<-`V%=C1!RO"<FXY@L[:.;"*#%Q,:!QQ*HE%J?@(V,<-.QYL6%S+=+
MMMMM\SR=Y1Q?*5815TS98JZFU33OD:Z6EE:XVB!Z8BT@@#FD'K72$002'(%-
MB6+Y@J,;95OIZROX6*G972,AEC$4;07QL<`3J:[>-H`Z%BNR96\9J:EE%"VH
MES-%7<*'-U<5;HVW]6D^;^"Z*B#CC\B9@J<JQ8&,#PZFGH*;@C7\.TOKB)F/
MTML#I#PPEQ>#M(V':5,LB8'7X7+C%97TLU,^NF8\,GJ8Y7NTLTZG"-K6-)V#
M9<V`NIBB`B(@(B(-5-]95'V8_P#F1)OK*H^S'_S(@(B("(B`B(@(B("(B`B(
M@(B("(B`B$@"Y-AUE1W"\\Y;QB>LBH\4C)I&&61TC71M,8`O(US@`YHN+D?V
M()"1(M#%G7+<V&SXA'B\#J:"1L<CM+@X.=S0&$:B7=%@;]"VF'8C1XM0QUM!
M4QU%-)?3(P[#8V(V[00000=H092(B`B(@(B("V,'S#.Y:Y;&#YAG<@N%?.C.
M8WN7T65\Z,YC>Y!VC*WT_,WWN[\F%2-1S*WT_,WWN[\F%2-`1$0$1$!$1`6'
MBWU54_8*S%AXM]55/V"@QW<X]ZHJNYQ[U1`1$0$1$!6:OZ))W#^X5Y6:OZ))
MW#^X0;M6C40@D&6,$;P7!75B/PVD>\O=`TN<;DW*QS3FB(]5$3\9F/RB5J\O
M_I;JL4BIG-`'":@>8X;%6DQ.*J+@1P>FW.<-JQZO!VO<WBP9&`#JO?:E)@[&
M%_&6LDO;3:^Q>3&3TI]JURQR?AV\];[_`'.C6#U>]]6RX:/_`+1G_J"T>*9K
MH\'S-1X97S4M+3U-'+4"IJ)Q&`YCV-#!?8;AY._H6T&%T8((@;<;=Y6LQ#+4
M.)9JH\5JF4\]/3T4U/P,T8?=SWQN#A?9L#"/YKUL4Y9WZV(CX3,_I#GMR_\`
MEBX%GC#L8FFA=-#&_C%4RG+'ZF310.:UT@?;3^\#:^[;N58?*)EB>>&%F(.O
M*(7!QII0QHE`,1<XMLW5<6U$740S)DJ:.BIL)H&S"LK<9J)X9J2G(CIJ::[9
MFO=:S1P;C;K(%EDSY4Q;$LPYCPNE;3T6`U$E"U[Y(7:RR*-A(A/-/-#;GFK9
M5*9,^Y>;5U-(RM=)40"7S6P2%LCHFESV,?ITO<`#=K23OV;%HL-\K6#U#HWX
MBV2A@EP^FK&O,4K]/"%X>'69YK6EH&LV!U`JY39%Q1DU!0S8A2'!\.KIZZFT
M0N$[G2<)I:\WTV:977(WV&[:L>D\GF(LRSBF&U5=1NJ*K!(,)BDCC<&M$0D:
M'&^W:'MN!T@H)1-G/`H,7=ACZQW&6R<"XM@D=&)=.K@^$#=/"6W,OJ/5=:'`
M_*=AV*T$>)50CH*+B<M3(9B_6S1,(Q8:`'`W&T&]S8`[5@Q>3*>'-`Q!M11O
MISB3,1<^02F4.%B6!H>(^<W8XBX!Z58IO)=B,6&LI78G2AU-3NBI7B)Q\X5;
M:F,O%]HNW20.O8@E?^O\N&`/;5SND,KX>+-HYC.'-:'.O$&:P`T@W(M8CK5_
M!<SP8[C%734>B2CCHZ:KAJ6./[5LQDZ+;+<'^/J4;Q;)V:<:J(ZFMQ:A<.$D
M+J*-LL,(:6M:TZXW-D>06N)#C8ZK;+!;+(^3:C*C=,]7%/;#Z:C!8TC;$Z4Z
MMO6)!L]108D&?*^JQZJHZ;#Z&6*EKS1RTHKK5P8':3-P);;1^]OVMVK)HO*9
M@511S5%2:BG+:V>DCB%+*^27@R;N:T,N1I%S8>;>QL5KL4R'C&+U8@K*_#)Z
M1E:VIAKY*5W'X&"0/$;)`;;+:0[JZ%=BR;CV'XQ\J4%=AKIH:NMD@9/%)I,5
M2\2.#K'8YKP+$;"-Z#=U.?<LTHI728HQS*F%D[)(HWR-;$YVEKWN:"&-)V7=
M;:#U*UEW.U%C<[:*2T6(/FJFMIX]4EHX971\(X@6:#;9>USL%UH\.R#CF7V%
MF#8Q1M?5TD5/635%*7%KVO>\R1MOI_\`NN&EVS8#MVK)ROD*JROCS\2I:V(B
MMEJ#B,1#K3-=(Y\+F]E[-1:>@@E`Q;.N+TN.X[14%!A3Z?!XHI97UE>Z!T@?
M&7V:-!'01M(Z%=D\IF$/P^-U._3B#Z:GJ74T\<@;$V;00'O:P@&S]G6=BRFY
M$PRJS9C.,XO0X?B#:WB_`-J*9LCH>#9I.UP.\V.SJ5K$\F3UO^HN"JH8_E2:
MCDC!8?V8@T7![]!M;K0;`YZRXW$*BB?B3&20<*)'OC>V*\0O(!(1I+FBY(!)
M%CU+,P7,N%X^Z9N'SR.DA#7/CF@?"\-<+M=I>T$M(!L;6-E$:C(&,56$5N73
MB]+#@<SZI["RG+ISPSG/:UQ)M9KGDW%BX`#9M6PR5DRHR[7UE=5NHN%GACA:
MREX9P`:222Z5[CM)W#8+>LH-_-]95'V8_P#F1)OK*H^S'_S(@(B("(B`B(@(
MB("(B`B(@(B("(B#Q+<PR`1\(=!\PFVK9NOT7W+A5%08M68?F3!L$H,0%+Q<
MAU+70`RTCVMIR(FR$#67!KVZ-Q:QAZ=O>%0`"]@!?:?6@YK0U3H9,4K74V-U
MV$F2F;#B%517K*:0MDUR-:Z/6YL9+;6:=)<ZVRZD/D^IZBFRY.R>.I$;J^HE
M@EJX^#GGC<_4))&G<YQ+N@;`-@4KN;WN;]:H@(BL35+8CI`UR'<T+++FIAKS
MY)U"U:S:=0QZJIEBG+6.`%@=R]4=1+-*6O<"`V^Y>'TD\[N$D<P./1U*[2TK
MX)"YSFD$6V+Y[%7C[\;&2>:,<SXSX?#;LM.&,6NFV6B(OIG"+8P?,,[EKEL8
M/F&=R"X5\Z,YC>Y?197SHSF-[D':,K?3\S?>[OR85(U',K?3\S?>[OR85(T!
M$1`7,LU9NQ?`L^1M-;&,)93NTT\43)>%FT:A')8ZXW$ENDVM8]-S;IJUE1EW
M!ZK&X,9GPVFDQ&!A9'4NC&MH/K\;=5S;>4'-J/.N9:F&"BDJHJ:MEA=6.FGI
M6:6,%-PK6C2\M+7.OTAP:TWVD%;W',V8N,-PZIH7T]&Z3!IL7EX:/6UQC;&[
M@=X(!X0W._8%)WY3R\^BXD[!,/XKP@EX'B[0W6!;5:V^VSNV;E=J\NX+7$&J
MPJCF(FX<&2%I_:6`U;M]FM'<!U((QEK,V+8ECM/QMT7%:\5NBE$6E]+Q>5K!
M=U_.N'&]P+&UE*\8+QA<^AK7#3YUW6L/!5IL&PVCQ"HQ"FH*:&LJ?GIV1@/D
M[STKUBWU54_8*#'=SCWJBJ[G'O5$!$1`1$0%:J6N?32-8W4XC8!T[5=1!>^4
M_P"$J?!O^2?*?\)4^#?\E91!>^4_X2H\&_Y)\I_PE3X-_P`E91!>^4_X2I\&
M_P"2?*?\)4^#?\E91!>^4Q_W2H\&_P"2?*?\)4^#?\E91!>^4_X2I\&_Y)\I
M_P`)4^#?\E91!>^4_P"$J?!O^2?*?\)4^#?\E91!>^4_X2I\&_Y)\I_PE3X-
M_P`E91!>^4_X2I\&_P"2?*?\)4^#?\E91!>^4_X2I\&_Y)\I_P`)4^#?\E91
M!>^4_P"$J?!O^2?*?\)4^#?\E91!>^4_X2I\&_Y)\I_PE3X-_P`E91!XUNFJ
MIIC$^-K@P`/M<VO?<3UKVB("(B`B(@(B("*H:3N"N",#>5CDXC'C[RF(F5I%
MCMD<<0D:UW"0EH(+=H:>JZR%I2W-6+0@1$5@1$0$1$!$1`0D`$DV`Z5;FF9"
MV[SW#I*L".6J(=-=D70P;SWKDS<5%;>JQQS7\O+[YGPC\?)I7'N.:W2!T\D[
MBRGV#ID/1W*]#3LA%QM>=[CO*N-:UC0UH``Z`JJ,7"ZMZW-/-?\`"/A'Z]RV
M3IRUZ0(B+L9B(B`MC!\PSN6N6Q@^89W(+A7SHSF-[E]%E?.C.8WN0=HRM]/S
M-][N_)A4C4<RM]/S-][N_)A4C0$1$!$1`1$0%AXM]55/V"LQ8>+?553]@H,=
MW./>J*KN<>]40$1$!$1`1$06YYHZ:"2>9X9%&TO>X]``N2HA'G;$9*:/$AEN
MH.$2/TMF9*'2D7MJT`;O^KJ48K1G$<(K*)K]#IX7QAW42+!0S#<6S'AV"T>!
MTV7ZAN)0$0\/*W_9]`/.U`]7ZK#+:T3K>H^#U>`PXKX[3-8M;<=)MRZKJ=SW
MC]=>29_*=#KJ&<;B#J9@DG:76,32+@N'1L5B7,.#0-C=-BE)&)(Q*PNE`U,)
ML'#U741Q2+$J3'LR-9A-95?*E&R."2G9=FH,L;D[NGU[/6O.%8!--C^`'$,,
M>^F@P@1R<-%=C)!JL#?9?:JSEOO41_-M:^C^'BGK+WZ:WTF-^[N?QZ)E'CF$
MRU7%8\2I73W<.#$HU7;M.SU+U38SA=:R9]+B%+,V`%TICD!T`=)]7K4-BRW4
MU&%YL(H-%?454O%9)&`.<P]#2=P(N/YK`P3"*R2:2;B.)1OAPN6G=PU-'"TN
M+"!&`!=^W<=_6GKK[B)CNM_\[A9I:U<GNZ\O*)^G74??'R3Z#'L'J9A#!BE)
M)(6<)I;*"=-KW\-JL8!F2BS"RH=2.`,,A9H+@7%O0^PW`[;=RBM#E^6GCR6Y
MN%N9)#(\UAX*Q;?M_P#]6SR+2R4$>)4<^&S4TS*I[N%?$&MD83YH:[IM:_5M
M4TR7FT1,?S4*<1P?"X\-[8[3,QK76/\`*8GZZB?FEZ(BZ'C"(B`B(@(B("(B
M`B(@(B("(B`B(3I%SL'64V"+TP`NL5C5KG05-/*'$1$Z'MZ!?<5C;-6,D8Y[
MRG73:^O4=M6U>45\E>>LU\T0\UM2^EC8YK00YX:7'<V_39>3#PA_:N=*>H[&
M^`61)''41%DC=3';PK?&HQ=D+3(6["&[AWE>9@OR1RQ3=EY>)WMI80]X(;<-
M\T;KKVK4K)*EA9,6MC.]C.G^95QH#6@#<!9>EB]9-?ZG=6=>"J(BT0(B("(O
M+WMC:7/(`]:BUHK&YG4$1OI#TL:6J\[@X&ZY.OH"\%TM7L9>.'I=TN63%$R%
MNEC;#I]:\_UN7BNF'V:?Y>,__F/UGY-N6N/WNL^7[K4-,&NX24ZY>L[AW+(1
M%UX<&/#7EI'_`'X^;.UYM.Y$1%LJ(B("(B`MC!\PSN6N6Q@^89W(+A7SHSF-
M[E]%E?.C.8WN0=HRM]/S-][N_)A4C4<RM]/S-][N_)A4C0$1$!675=,RJ92N
MGB;4/:7-B+P'N`WD#>0KRY5F?!L3D\JE%74&#3S.?$0ZH>UCHVM#+:V/V&*1
MI)%B2#<;-IL'3FUE,]I<VHB<T$-)#P0"=P[U=?(R/3K>UNHZ1<VN>I<2ARQB
M,.'P1NRW6U6#P-=&VCFI*>.=\SJ8L#W".P<&NV!YN1K)N0+K>9CPC%*Z@P^"
MIP:LQ*6EPN;#Q=K2!6NCA+*@.)V-!#QPF\$'KVAU!LL;GN8U[2]MM30=HONN
M%C8M]55/V"H+E+`\1H<UB2HP^6*>$5O'\1<UH;6\),UT-B#=]F@[QYN[I4WQ
MEFO"YSJ<W2V_FFU^]!:=SCWJBJ[G'O5$!$1`18]?7TF%T,U=75$=/2PMU22R
M&S6A:_+N:,'S70NK,'K&U$;7:7M(+7QGH#FG==!N$6E&;LONP>?%QBU/\G03
MFGDJ3?0V0$#3>VW>-HV+*PC',+Q^D=58370UD#'F-TD1)`=8&VT=1'B@V"6/
M45@XU/44N!5\](":B.G>Z,`7\X#_`**YU@];$<4RIQ;':NKGJI==;`^H+PUU
MND='2+=-KK*^6*3$/0X3T?;B,=LD3K6_#?:)GY=OJZG8]12QO:QNN6X:7TV3
M:_'JO%L5X3A9*=C8I[AH+P!;5N-[[>@%8]/B%7#!F2FCKI."9AK96-;7&HT/
MU-%P_KL=MNM9_:8C6X[NR/0MK3:*WWRSKMX[B)^FX=:.P7.P=:L4E93U],VI
MI)FS0.)#9&&X-C8V_F%S^"DJ(<5PND=BF(2LQ3"9'U&N<GSM!(+>S;9X+;>3
M-E.,K1OBJ72RO>>&C,FH1&YL`/W;C;ZU:F6;6Y=?SI^[GS^CJX>'G+S[[:Z>
M?-'YU_FTQL>H^"HXZ6%QOI:"2;=`7():[318[5NQ^LAQ*DKW<4IQ4&SAKZ&_
MO=/J%E(J6GJ,6SAB[JFOK86T<$$X@BF+&ZS&"01U;]GK41Q&YU$?SK^S;)Z'
MG'$VM?I$;[3_`*]O/WHZIIAN(TN+43*RBD,L#R0UV@MO8V.PBZRK;;6VKDV&
MXA/481EJEK\3J*;#ZF6H-14"<L+G-=YK2_H'ZJ_B&)R-HL)H:'&*JLPZ2KEC
MDJ)9C3%Q;:T?"D'S1>]^G^T1Q,:W,?SI^Z^3T+;UO)6WC/AX1-H[](W[/;HZ
MDBC&1JFKJ,%F%55LJFQ5#HX9&R\(0VP\TNL+D=:DZWI;FK%GD<1AG!EMBF=Z
M$1%9B(B("(B`B(@(J%S6R!A<`\BX:=Y"N1@$FX5+Y(I6;^"8AX)`%R;#UKVQ
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M2'@<VW?NNKIA#C>5SI#_`+V[PW*XNC'AO%N>]MS^")F/`1$72@7B5Q9$]PW@
M$A4EFCA%WNMU#I*QW&HJFD-'!1D?O;RN+B>*K2)QTW-]=H[_`#\OFUICF?:G
MI#'X]/UM_P#2LB&$U&F:=VJ^UK1N"L_)\O:9XE9\+#'"QAM=HML7C>C>&XO+
MEF.-B9K$=(F>FW3GOCK7^EK;VB(OIG"(B("(B`B(@(B("V,'S#.Y:Y;&#YAG
M<@N%?.C.8WN7T65\Z,YC>Y!VC*WT_,WWN[\F%2-1S*WT_,WWN[\F%2-`1$0$
M1$"R(B`L/%OJJI^P5F+#Q;ZJJ?L%!CNYQ[U15=SCWJB`L2LQ7#L/>QE;B%)2
MN>+M;/.V,N'6+D766N"?_$%]=X)_^H_\Q;\/A]=DBDRB9U#H>?L8RSB&3*^F
MJL3;/"[0X_)TL<TT9#@1(&:MH:1<^JZYGE/$\T5^2,0PC+^%1UVHPP28A11M
M@FX)P<7M+G6#G@6`.VVI1SR1N:SRGX/K+6@F5OG6%R8G"W\U]/T5%2X=114=
M'`R"FB%HXF"S6B]]G\RK<5P\8+Q6)VBL[AP/!XZ8^3NKPW%8Z_!,)@S&#QJ-
MC:C2;VX-^[2&6%WV()(V%=*\EV(5%?A.+!U0*RA@Q&2*BKN`;$:F(`><0``;
M=?Z*;B*,,<P1L#7<YH:+'O'2O36AK0UH#6C8`!8!<RSQ/%PU/)%PCX];2W7&
M;.;<;P>@J+X=DR2EQ2CJZK%34LHWNDA8VF9&2X]+W#:XJ6(J6I6TQ,NC#Q67
M#6U:3J)[](^'R^2P**D%*ZF%+`*=]]47!C2;[[C<K4>$X;$PLCP^D8PLT%K8
M&@%N^V[=ZEF(K:AEZR\>,K7%J<21R""(21-T1NT"[&]0/0/4O-+14E$7\5I8
M8-;M3^"C#=1ZS;>KZ)J$<]M:VT>%97H<-=.^5D57+)5/J622PMU1EUM@.WJ6
MX;3PMEDE;#&))0!(\-&IX'6>E7$45K%8U"^7/DRVYKSN6*_#:"2D%(^BIG4P
M-Q"8FZ`>NUK*K\/HI:-M')1T[J9NZ%T32P=PM99**=0KZR_G/FMP00TT+88(
MF11,%FLC:&M'<`KB(I5F9F=R(B(@1%YUMX0LU#6T7(Z0HW'8>D)`WKTP7<+J
MM13LJ(C&\>L$;VGK"YLW%1BO%9A:(V\*[';3NVK"BE>R0T]1;A0+M<-SQUA9
M49L[O4\1'K,,S6?O1'27BLIC41AT9TS1F['>OJ[BO-'.)VZK:7CS7M/[IZE6
MHFXK-'([YIYT/]1Z#_P22G<RM941;G>;*WK'05PX\DUQS2W:8Z?%>8ZKC9?]
MK?"=^D/;_8K"C'%L2EAW-E_:L[^D*Y5$QXI1OZ'!S"F*,+8HZE@\Z!VKO;TJ
MV">2]9\+1I$]6=<Z;M%S;8.M8$,\E;%KUF-MR"QF\=Y_19D+P]@(.P[1W+`C
M`@Q.>%NUD@X06Z#TA7X?%2N:U+1\"9Z;9,<;(FZ6-#1ZE<8;."\HO0M6+5FL
MJ*R5!:XMCC<\CIW-\?T5LB63YR72.S'L_'?_`&7M%CCX7'3PVF;2\LC9&+,:
M&]W2O2(NA`B$@"Y-AZUC.JB]Q93LUNZ7=`6&;B,>'7//6>T=YGX0O6EK=E][
MVQMU/<&CK*Q^'EGV4[;-Z9'?\%5E+J=KG=PCNKH"R1L%@N?EXCB/>]BOE'O3
M\9\/EU^];=*=NL_@L14K(SK==[^TY7T1=6'#CPUY<<:A2UIM.Y$1%JJ(B("(
MB`B(@(B("(B`MC!\PSN6N6Q@^89W(+A7SHSF-[E]%E?.C.8WN0=HRM]/S-][
MN_)A4C4<RM]/S-][N_)A4C0:['G8@W+V).PD`XB*60TH-MLNDZ=_KLN+9!K\
MQ39QH::)^:)`RJ<^O^5&$1B)U.W6'D[G"5IT`='>5VC,,-=59<Q.GPR3@Z^6
MEE93/O;3(6D--^C;;:N5Y7I<?J<PY1BCP#&\*&#P/AQ"IKI?V4S"TW:-OGDO
M-P>C9T"Z#LR(M'4YMPBES+!@$LTO'I@+!L+RQI(N&N>!8$C<"?[BX;Q%'I\[
MY>IXIY'8@'M@JGTDG!1/D(E8S6\6:"2&MVN(V#;<K*Q3,^#X/%325M8&LJ6E
M\;F,=("P`$O.D&S!J%W'8+C:@VZP\6^JJG[!6+0YEPK$<5GPVEJ2^JAU:F\&
MX-=I.E^EQ&E^DD`Z2;$[5DXL0,+J`2`2PV]:"P[G'O5%5W./>J("U.+Y7P/'
MY8I<6PNGK)(FEL;I03I!-["QZUMD4Q::SN)'-<V^1_!L4P\29?@BPK$H?.B=
M&7".0]3MIMZG#<M=DORF5F'XD<KYY:ZEQ"(B..LFV:CT"0[MO0_<>GK76U&,
MZ9&PO.N'<#5MX&LC:13U;!YT9ZCVF]8\++IIGBT<F;K'GXPK,>,).BXCE[..
M->37%698SDQ\F&[J6L;=_!LZ"T_O1^K>W\%VFGJ(:NFCJ::9DT$K0^.2-P<U
MP.X@A9Y<-L<^<3VE,3M=1$6*1$1`1$0$1$!$3>@(O8C)W[%YFX..%VJ0,)!`
M<3T^I<UN*QUG43OX)Y9`TNW!6^%;PQA-P\;0"+:AZNM>:&64TK.&#M>XZNGU
MK(DBBJ8]+Q<;P=Q!ZQU*N7/DQ6]J/93$1+U&/-[RM=1'A):J?MRD#N"SG$T]
M&XEQ>6,)U'>5AX<S101=;AJ/\U3A9Y\E\A;MIF1\\+'J)7QXK3M:?-<QP<.M
M9$?/"2PPF9M1)L,8(!)L!=4XBU:YXFT;C7[ICLI44[*J*Q-G#:QXWM/6L>&9
M^LPS`-G;MV;G#K"OBJ:X@1,<\=H"S1_,[_Y*M33-J8Q8Z9&[6/&\']%3#DMA
MGVH]F28V5,(JJ1\1WN;L[^A6\.J#/2,U<]OFN[PJ4M47,D9(VTL9LYK=H/<K
M=/$^.HFEL&,D.H,O<@]*O3AYMS4\.\2;\3%?-%+)V9A^*R)G%T)C#`_4"TW-
MA9>>#89#(6W>>D[?_P#%Z6].&B*16_72-]5JFB,%.V(OU:1:^[8O;6-8W2QH
M:.H!>D75I41$0$1:VM>]M20U[@+#8"N+C^-C@\7K9C?737#BG);EB6R5B2J:
MUVB,&23J:L&F:^HD+'2O#;7.W>ME'$R%MF-`_P"*YN'XO/QU.;%')7SGK/RC
M]9^B]\=<4ZMUE8%/),=50[9T1MW+):UK&Z6@`=0547=AX7'AGFCK:>\SUF?G
M_(96R3;I/81$70H(B("(B`B(@(B("(B`B(@(B("V,'S#.Y:Y;&#YAG<@N%?.
MC.8WN7T65\Z,YC>Y!VC*WT_,WWN[\F%2-1S*WT_,WWN[\F%2-!%L]8-25^`5
M6(2P/GJL.I*F2F8))&@N=$6D$,-S<;.OJ7.O)XW)3\7P:2'!\>I,=+=HF$Y@
M9)H.K:YQ&G?:_J4B\KF,NH),N4$N.U>"4%;5OXW64KBU[6,9<`$;1<D+'\EG
ME#PROP^+`:_,#J[%FU<T%,^9KC)41-)+'DVZ6WWF^Q!U10#,.2\9Q7/-+BM#
M7PX?3B(LEJZ:[*D-T@&,CFO!.T%W-V[-@4_1!R^E\FF+8.V5V&XC22O;43<`
MRICT,$4M.R)Q.AO/!8TVM8VW@DE;+$<F8Q-2T]-15%`UL&'2X.U\VLDTTC(@
M9"`+<('1N\W<01M4^1!#,O90K<(QF!\M13NPZ@%4*,,U&5_&)&O/"7V#3IL+
M7O>^S<I+C#&/PN?6UKK-N+B]BLY8>+?553]@H,=W./>J*KN<>]40$1$!$1!J
MLPY<PS-&%/P[%*<2Q':QPV/B=VFGH/\`?INN/0568_(OBXIJMLF)97J)#H>W
M9I)Z6]A_26[G?B.[+'KZ"DQ2AFHJZGCJ*:9NF2*07#A_UT]"WQ9^2.2T;K/A
M^R)A8P?&</Q_#(<1PRI;44LHV.;O!Z6N'0X=(*SUPS%L`S#Y(L6DQO+CWUN`
M2N'&*>3SM`[,EOPD&[I]?5<J9NPK.&%BLPV6SVV$].\_M(7=1'2.HC8?P4Y<
M'+'/2=U_G<B?"6^1$7.D1$0$1$!78SYJM+W&;.[US\53GQ3KP36>K&=42R5D
MM.7<&&`$%HVN!Z;G<KD<#6G4UOG=+B;GQ*N3"")W&9=+2T:=9ZNI>#42/^:C
MTCM2?IO_`++EPY+<L1BIU\UICS>.&;QIU.00X-#K]!'J5UE]8LK(A!E$TCB^
M0"P.X`>H+(C'G+LO,UPS-N^E?%Z?*R,M#W!NLZ6WZ2L>2E=&XR4UFD[71GFN
M[NHJS7'A,1I(NAMY"LQK[;#M"X,6')6D9,<]?):9C>I6J>9LDA;8LD;SF.WA
M6*\7Q"BON)=L*NO;)+('DM9IOI+1=UN\[E5L3&'4!=QWN)N3_-==<5[9(RVZ
M=$;Z:>U1S0]A8[:T]"JBZ9B)[JJ-:&BS0`!T`65412"(B`B(@(BH2`"2;`;R
MDSH4>]L;"YQL`L-L!K'&:2[&G8T#?9>@#6RZC<0,.P=HK,7E\D<?;FO']*.W
M^T^?P\O/NWW.&-1[WY+$%(R!Y<USB2+;5?1%WX<&/!3DQQJ&5KVM.["(BU5$
M1$!$1`1$0$1$!$1`1$0$1$!$1`6Q@^89W+7+8P?,,[D%PKYT9S&]R^BROG1G
M,;W(.T96^GYF^]W?DPJ1J.96^GYF^]W?DPJ1H-;CKL-IL*J<0Q2FCGIZ*)\[
MM40D+6M%W6!Z;!1ZDS1DAV-X70X6^@J*^N&N`4<#7.8W23J<0/,%NO;MW+,S
MK15\^%&LI<RS8'3T4<DU3)'3,FX1@;?:'=5CWW7,O)_A%+E?,F"34V.XK'!F
M%KJAL4V%1Q1S$!UHW.#CH/[P#=E@/4@[HB(@(B("P\6^JJG[!68L/%OJJI^P
M4&.[G'O5%5W./>J("(B`B(@(B(*/8V1CF/:US'`AS7"X(.\$=(7&\U^3W$\I
M8F<U9$?)%P=W3T+/.TMWNTM_?9UL.[H]7946N+-;%.X[>,>:)C:&9#\HF'9T
MI>"\VEQ6-MYJ0NYP&]S#^\W\1T]:F:Y?GSR7NKJO_4.57<2QN)W"F*)VALSA
MMU-/[K_P/JZ;V0/*>W&IA@68F"AQV-W!_M&Z&SN&RUCS7_[O3T=2UR8:WKZS
M%V\8\8_XB)\)=*1%R;.KY*3R@TV)U6(5C\/@(&O#JNTM`6QM+@^([+.U!Q.T
MEKK6V!<JSK*+G&+U-?@>9J3$J:OK*NBJJBJ9)4FK$D#I>"D+*80`V:&N8//W
MW!!WE7\J2U5-C.7VG$ZRM9B^!.KJH5$[I&B8&,A[0=C`>$<VPL-@V;$'0$1$
M'N:)M33/C.Y[;=RLTD4HIHQ.-+P+';=71(6,-AJ/0+VNK1,\G.DX,=F/?XE>
M=3%GI:U:=(\U]Q/=>>^&#GN`/0#O/\EB4W#1FHT@AKGZHS)T#IV;U=9&R.Y:
MT`G>>D_S7M=%.'UOGG>U9GR6FPCAN&>XOEMIU'98>H*ZB+HB(B-0@1$4@B(@
M(B("(B`B(@+#>XU<G!,-HFGSW#I]2]3R.FDXO$=O[[NH*_'&V*,,8+`+SLDS
MQ=YQ5]R/>GSG_&/N\_IYMH_IQS3W\/W>FM#6AK18#<%5$7H1$1&H8B(BD$1$
M!$1`1$0$1$!$1`1$0$1$!$1`1$0%L8/F&=RURV,'S#.Y!<*^=&<QO<OHLKYT
M9S&]R#M&5OI^9OO=WY,*D:CF5OI^9OO=WY,*D:#78^V@?EW$FXJ;8<:6451O
MNBTG5^%UQO([Z&?->7QBDN;'4[&O^0OE:-C8'D,V$%N]VC=?]`NE^4/'\'P'
M*-:[&XIY:.JB?3%D+"=9<P^;J`\V^T`G9=<HR5BV#5^;LKTS<PXUCIIBYM)1
M34O!LH?V9&I[K?M-(\VX[]VQ!]`J'XAG6:BSW3Y;9A?"-DA,IE=4-C>_83^S
M8X`/`M8V=>YW;"I@-RBV+Y&H\:S)2XO4UU=IISK%*V6T?"``->T\YA%MNDBY
M`/0;AJ8_*5)*R2GCP1S\3BFDC?31UC'-`CB$K_V@%BYH<&EMN<;7MM6SQ?.\
M=#2T,]%02UK:FA?B3FB01N93,#"YUCO=YXLWIV[0L=WDXHGATK\8Q9]<ZS#7
M.DCX4Q\&8N#YFFVDG;;5?;>ZR\0R+15\3(37U\$4<3Z9K(7L`%,YC&N@VM)T
M'@VF_.N39R!@F<F8SB[:9M$^.DJ!.:*JX0.$_`O#)+MM=FT@B][B^[<MUC$C
M687.#J\YMA9I/]MRUV%Y0HL)Q=U?#/4O#>%XO3R.:8Z;A7!\F@``^<X#>3;<
M+!;3%OJJI^P4&.[G'O5%5W./>J("(B`B(@(B("(B`N>>5+(V&8Y@5;CC1Q;%
M*&G=,)XQ\ZU@OI?U[MAWCNV+H:PL7P]N+8+78:Z0Q-JZ=\!>!<MU-(O;IWK3
M%><=XM$HF-OE)N?\W,:UHS)B@:``!QEVY=<RM5Y%S)1X'B..8I228_3P@5(J
MIBPSO!\WA-5@\MV6.W^86-_\OE'Z1S_TC?\`-2!OD4RF[":>EGCJ#51QZ7U<
M,IC=(>T6G4U>CQ.;A,E8B.GPA2L6A+J7+6`?*9QFEH:=]2Z1\W#1O+V:WBSG
MAMRP.(WN`N5[PG+6"X'/+/AF'Q4TDK=#G-<XV;<NTMN3I;<DZ18>I<TE\B59
MALAFRWFRJI']#96N9_[HS_P7G@/+-E[F3T^-0MZ"62DC_P`VEZY/44M[EX^?
M1;<^,.QHN.L\LN.80\1YFR=44]C9TD>N+\'@C\5(<-\M&3:\-$U54T+SLM4P
M&P_\S-05;<+FCKR[^'5/-#H*+78=F#!L7:#AN*T57?HAG:3X7O\`@MB01O!'
M>L)B8Z2D15`)W`GN":7#>TC^2@41$0$1$!$1`1$0$1$!8]1,X$0Q;97?^T=:
M]5$_`M`:+R.V-:J4\'!`N>;R.VN*X,^2V6_V?%.O\I\H\H^^?P[M:1%8Y[?)
MZ@A;!'I&TG:3UE745BJK*:AAX:KJ(H([Z=<KPT7ZKE=>/'3%2*5C40I[5[><
MROHL2DQ7#J^0QT=?35#P+EL4K7$#KL"LM7B8GL6I:DZM&I$1%*HB(@(O+9&/
M<YK7M<YALX`W+3OV]2]("(B`B(@(B("(B`B(@(B("(B`MC!\PSN6N6Q@^89W
M(+A7SHSF-[E]%E?.C.8WN0=HRM]/S-][N_)A4C4<RM]/S-][N_)A4C0<^\IV
M/U&%28#0"OI\.H,0J7MKJN>(2-$3&:C'9VSS]K5#,G9HS')F/+-5/B[7T^/3
M3Z<#$;0*6E:'<&]MMK0-.SK`Z=J[1B6%8?C%+Q7$J*GK*?4'<%41A[;C<;'I
M5N+`L*@Q)N(Q8?3,K&0"G9,V,!S(AN8#T-]00;#H1$0$1$!8>+?553]@K,6'
MBWU54_8*#'=SCWJBJ[G'O5$!$1`1$0$1$!$1`1$0$1$!$1`<`YA8X!S3O:=H
M/\E'<3R)E7%]1K,!H7/=ODCCX)WBRRD2*U;6KUK.ARW$O(3ERI<7X?6U]`_H
M&H2M'C8_BM</)[Y1LO[<OYP%1$W=%+*YG_M?J;^*[&BWCB\O:9W\>JO+#YCS
MWCGE`HZRCAS%/-13MB=P;J601B5NK:X\&ZQ-^Y7/)7C^*U/E&PJ*LQ:ME@=P
MNIDM0]S3^S=:X)MO7:LX>3O"<[5=+48E45D3J:,QL%.]H!!-]MVE:[+WDBR_
MEK'*?%J2IQ"6>#5I9.]A8=32TW`:#N*Z[<7CGAYK$1%M3X=-^"(K[77LGS2'
M"[2".L*JQG43`=43G1N_W3L5+U<6\-F;ZMA7SWVG+C_O8Y^-?:CZ=_P=')6?
M=M]>C*18S:V.^F0.C=U."R&N:X7:01U@K;#Q.'-_;M$_G].ZEJ6KWA5$1;JB
M(B`K<TS88RYW\AUE>I'MC87N-@%C0L=/(*B46'[C>KUKCXG/:)C#B]^?PCSG
M]/.6E*1[UNSU3PNU&>;YQVX=D+)1%M@P5PTY*_.?&9\Y5O>;3N11'RC-+LO4
MP:QKR:Z$!CMSM^P^I2Y8F(8;28I`R&LBX2-DC96C419S=QV*^2LVK-8;\'FK
M@XBF6W:)VY]AS7MSVZ2IP^BPFIPVFDD%+2@CC0TD["-A'_#\/6`YGS!58AAE
M1.ZIFIZV5S9(G4[&0M;_`/B<#<D=-U/*O!Z"NQ&FKZB#55TIO%*'%I;ZMAVC
MU'K*Q*/*>!T&("OIL.CCJ&N+FN#G$,)WEK2;`]P6$8;Q/2>F_P!GK6])\-DI
M/K*;MRQ':)B/>[3,[U,S$[ZS';MI!Y,RX\[+S,=9C4;#45W`<3$+"(VWZ"=M
M[#;ZBMQ38EC%3C>/S28TVFP_"9W_`+-U.'`MLZP)&VPL/65B2Y`KJFO_`&WR
M4V)U2)7U44;FS.:#?3HYHOTV4UBP7#H7U[F4S?\`Z@XNJ0YQ<)";]!W;SN5<
M=,DSU_.?O:<7Q7!4KK'$3,[[5KTB9KT[>6XB>_GI!L'S#C1QB"*:NJIZ>JHI
MYVNJ:9D8):UQ:Z,#;IV#?OZDPW&\P\4R[BE1BHFBQ"KXM)3F!K0!<B]P-^P_
M@I72Y.P&BF9-3T&B1@<UKN%>39PTD;3NL3L]:R69<PJ.CHJ1E+:"AEX:G;PC
MO,?>][WV[^E6C%D\9_&?N_ZIE](<%,^QC[]_9KY6^G>O;79'\AP5,=9F`S5K
MI@VO>QS3&&ZGC?)LZQLMN4T6OI,#PV@Q*IQ"EIA'55-^%>''SKFYV7L-O4M@
MML=9K74O*X[/7/FG)7QUX1'A$>`B(M'((B("(B`B(@(B("(B`B(@+8P?,,[E
MKEL8/F&=R"X5\Z,YC>Y?197SHSF-[D':,K?3\S?>[OR85(U',K?3\S?>[OR8
M5(T!$1`1%SO'<S8QA_E(HL/;B%/#ADK>"8S@FRM=,6W#92#KC));8VTVZ[[`
MZ(BY1#FW-$L;(&8A2.AF=-)!BCZ+1',(8=;PQI=MC+S8/WEK76OL*V^.9MQ8
M8=AM10OIZ-TF#38Q-PT>MKC&V,\#>XL#PAN=^P(.@+#Q;ZJJ?L%1'+6:,5Q/
M':?C;H>*8@*TQ4HCTOI>+RM8+NN=6H.VWM8VLI7C+GC"Y]#-5VV.VUAUH+3N
M<>]457<X]ZH@(B("(B`B(@(B("(B`B(@(B("(B`L;$9*J'#*N6A@$]8R![H(
MG&PDD#26M)]9L%DK'KJ2/$*"HHY72-CJ(G1.=&\M<`X6N"-Q]:"`93Q[,V,T
M>*P1XQ0U.)1O8!#6TAIYJ,E]GET>S4P"^D7WBQ*L29YQ=L45%#5QU3ZC$9J:
MFQ2FPUTO&(XH@YQC@:ZSG:W:+@Z?-)6SC\G#Y*3$8ZW,>(33UC#!QAC&,<V`
MOUEFP;2X@:CTVL-A*V+<F3,IJ(,Q^L;5X>\NH:D4L#>+M+-#HQ&UH:6$=!'0
M+(-GE?$IL7RW1UT\]//-(UP?)3M<QCB'%O-<`6G9M:=QN%MUK\$PB'`L)AP^
M"265K"][Y92"^1[W%SG.MLN7.)V+8(*.:UXLYH(ZB%CNHH[ZHRZ-W^Z5DHL,
MW#8<W]RL3^?U[KUO:O:6+_M<79F;X%5%:P'3*UT9_P!X+)5'-#A9P!'40L/L
MV7'_`&<D_"W6/KW_`!6YZS[U?IT4:]KFZFN!'6"J<+&!?A&>*QYZ2(1O>P%A
M`)\T["M:O-X[TMQ'!VBE\<;G[_\`C?%P],L;B6Q:#62ZW`B%I\T=HK,5JE^B
MQ?95RXN1<7%KCJON7J<#CB,49)ZVOJ9G^>$>##+/M<OA"J)8@7(*$$;P0NQD
M+2YEQ\Y>H:>H;2&J,U0V`1M?I.T'=L]2W2BN?*"HQ'#<.@IXYG'C\9<Z%I<8
MVV(+O5:^]9Y9F*3->[KX"F/)Q-*Y?=\5J3.E31PXK'B.$\7KJ"%L_`MG#FR,
M<X#8X#81<+'?CM=58SE]]?0U.'MJ9W<$R.K&E\>EI#I&VV[]UQTK)ER5-508
MLZNQ=]375\38.,.A#1&QK@0`T';N"V5;E[CF(8'5&I#1A>]FB_"^:!U[-WK6
M7+EGO^GG^STHR^CZ3[,1N8G<^UT]CIK?A-M]_P`F!AF;,0Q6>&>FP&5^$RSF
M%M4V4%XL;%Y9;8U8<7E%@DQ!C321BADJ.+ME%2TRWO8/,>_3ZUE463)Z&>&&
M+'*IN%PU!J&4;6Z3<_NEX-RWU*W39"92U[718A:A94&H;!Q9G"7[/";]/J4?
MU]1_S^:_%;?HOFMO6M=/>^_O_MV_U3$[#9$1=3P!$1`1$0$1$!$1`1$0$1$!
M$1`1$0%L8/F&=RURV,'S#.Y!<*^=&<QO<OHLKYT9S&]R#M&5OI^9OO=WY,*D
M:CF5OI^9OO=WY,*D:`B(@+45N5\#Q'%68G687335K(G0MF?&"[0X6(/7L)'J
MN;;RMNB#0-R1EAM&ZD&!4'%W/;(8C""W4T$`V]0)'<5DU66,#K77JL)HYCP_
M&+R1`_M-(;J[[-:.X#J6V1!@4N"X918C4XA34%/#657S\[(P'R=Y7O%OJJI^
MP5F+#Q;ZJJ?L%!CNYQ[U15=SCWJB`B(@(B("(B`B(@(B("(B`B(@(B("(B`B
M(@(B("(B`B(@H0"""+@[U;XO#_V3/!746=\6._6]8GXPF+3':5`&L:`+-:/`
M+A61W5N&^4NJI\;Q/$6XK6$QPU4,S9Z2J+FO+->VVZQ8!NTD;%W;?O`(ZBH-
MA7DJR_A&/5F)4XF:R5I%-`V1P%*7-<U[F[=Y#MG9Z%>(B(U"$-HIL1PO&,6J
ML!QW%,6IL)PJJ=BE?4RN=!+5:7%C6-)(#FFQV7&SQV.0)J[#\UX-2NQ6NKH<
M8R\,1J65,QE#9]7.;<^:.C_K9*,&\E^6\"G;)1MKRP->TP2U;G1.#VEK@66L
M;@K.R[D;`\KUCZO#HJ@SNA%.U]14.EX.(&^AE^:V_0I$D1$0$1$!$1`1$0$1
M$!$1`1$0$1$!$1`1$0$1$!$1`6Q@^89W+7+8P?,,[D%PKYT9S&]R^BROG1G,
M;W(.T96^GYF^]W?DPJ1J.96^GYF^]W?DPJ1H"(B`B*TZI@;4LIG31B=[2YL9
M<-3@-Y`WD(+J+PZ:-HNZ1H&K3<GIZN]5?(R/3K<UNHZ1<VN>I!Z6'BWU54_8
M*RFR,<]S&O:7-MJ`.T=ZQ<6^JJG[!08[N<>]457<X]ZH@(B("(B`B(@(B("(
MB`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(
MB`B(@(B("(B`B(@(B("V,'S#.Y:Y;&#YAG<@N%?.C.8WN7T65\Z,YC>Y!VC*
MWT_,WWN[\F%2-1S*WT_,WWN[\F%2-`1$0%R_'<)K3Y8\*KZ;!Y9@YK==1,QK
MHFQM`!>QX(=&]MR-)N'7V#:2NH(@Y%7Y4JZ2E,;L&J\1PZ/$,0<*4GA7R&6(
M"*4EYN?.U#43<%U]EEE9BPG%:[#Z"*JP:LQ&6DPJ:@YK76K71PED[7$[!</'
M";P0>O;U-$'.<I8'B-!FICZF@ECJ(A7<?Q!S0&UO"3-=#8@W?9H._FVMTJ;X
MRS7A<YUN;I;?S3O]16>L/%OJJI^P4&.[G'O5%5W./>J("(B`B(@(B("(B`B(
M@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(
M@(B("(B`B(@(B("(B`MC!\PSN6N6Q@^89W(+A7SHSF-[E]%E?.C.8WN0=HRM
M]/S-][N_)A4C4<RM]/S-][N_)A4C0$1$!$1`1$0%AXJ+X55>J,GP68L3%?JF
MK_\`!=_9!C'G'O5%4[SWJB`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("
M(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@+8P?
M,,[EKEL8/F&=R"X5\Z,YC>Y?197SHSF-[D':,K?3\S?>[OR85(U',K?3\S?>
M[OR85(T!$1`5FKJX*"CGJZF01P01NDD>=S6@7)\%>6'BM+)6X35TL/`\)-"Z
M-O#Q\)'<BWG-Z1UA!HH?*'EN:@BK#62QQOD?'IDI9&O9HMK+VZ;M:-3;N-@+
MC:MIB68\*PBKIZ6MJN#FJ!=@#'.`&H-U.(!#&ZG-%W6%R`N=X9Y.LR4^#21.
MJZ)DL\%70\7EDDDCI:>?1\V[:7$%A<&FP\ZUQ9;W&<G8QBE6]\<]#'%-2_)T
MNHO+FT[90]CQLL9-.H$;!<@@[+()/AF8\*QBLJ*6AJN$F@OJ!8YH<`XL+FD@
M![=32V[;BXLLG%?JFK_\%W]E&LK92KL$Q1LM344[Z:DI9*.D$0=K>Q\QDU/N
M-A`#18$[B;[;*72PQ3`"6-KP#<:A>Q0:T[SWHMIH;V1X)H;V1X(-6BVFAO9'
M@FAO9'@@U:+::&]D>":&]D>"#5HMIH;V1X)H;V1X(-6BVFAO9'@FAO9'@@U:
M+::&]D>":&]D>"#5HMIH;V1X)H;V1X(-6BVFAO9'@FAO9'@@U:+::&]D>":&
M]D>"#5HMIH;V1X)H;V1X(-6BVFAO9'@FAO9'@@U:+::&]D>":&]D>"#5HMIH
M;V1X)H;V1X(-6BVFAO9'@FAO9'@@U:+::&]D>":&]D>"#5HMIH;V1X)H;V1X
M(-6BVFAO9'@FAO9'@@U:+::&]D>":&]D>"#5HMIH;V1X)H;V1X(-6BVFAO9'
M@FAO9'@@U:+::&]D>":&]D>"#5HMIH;V1X)H;V1X(-6BVFAO9'@FAO9'@@U:
M+::&]D>":&]D>"#5HMIH;V1X)H;V1X(-6BVFAO9'@FAO9'@@U:+::&]D>":&
M]D>"#5HMIH;V1X)H;V1X(-6BVFAO9'@FAO9'@@U:V,'S#.Y>]#>R/!5M;<@%
M?.C.8WN7T65\Z,YC>Y!VC*WT_,WWN[\F%2-1S*WT_,WWN[\F%2-`1$0$1$!$
M1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`18F)BN=AE2,,?`RN,9
MX!TX)C#[;-0&VW<N:9:S%G_%,R8O15=5@(IL%J&QUA93R!TC2TN\S;ZNE!U9
M%SC#?*MAE/@>$OQ:2>JQ"MHWU8^3Z*1S7L:]S20W>+!I)OT`E;3"O*CEC%ZQ
ML%/4U#&OIWU,<\],^.*1C!=Y:XC;IVW[B@F:*+Y>S]@F9:X4=$:N.9\/&(!5
M4SX1/%>VN,N'G-NI0@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B
M("(B`B(@(B(!7SHSF-[E]%E?.C.8WN0=HRM]/S-][N_)A4C4<RM]/S-][N_)
MA4C0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0#N4/P#
M*=9A..9MKIIX'QXS.V2%K+W8`PM\ZXZST74P1!RW+_DRQ/"7X6Z>KHY.)X'4
M8:[1JVR22.<'"XYMG6Z_4D/DMK)*#+M#55E.(</PFKP^J,6J[C,S2',N!NO?
M;9=21!S'(GDVQ++6-TU;B,V&/91TIIH33"8R27V:G%[K-V?NM%NY=.1$!$1`
M1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`*^=&<QO<OH
MLKYT9S&]R">1YU_T]F+,E'Q#A[XF7Z^&T;X8MEM)ZEE\J7L?WKX$1`Y4O8_O
M7P)RI>Q_>O@1$#E2]C^]?`G*E[']Z^!$0.5+V/[U\"<J7L?WKX$1`Y4O8_O7
MP)RI>Q_>O@1$#E2]C^]?`G*E[']Z^!$0.5+V/[U\"<J7L?WKX$1`Y4O8_O7P
M)RI>Q_>O@1$#E2]C^]?`G*E[']Z^!$0.5+V/[U\"<J7L?WKX$1`Y4O8_O7P)
MRI>Q_>O@1$#E2]C^]?`G*E[']Z^!$0.5+V/[U\"<J7L?WKX$1`Y4O8_O7P)R
MI>Q_>O@1$#E2]C^]?`G*E[']Z^!$0.5+V/[U\"<J7L?WKX$1`Y4O8_O7P)RI
M>Q_>O@1$#E2]C^]?`G*E[']Z^!$0.5+V/[U\"<J7L?WKX$1`Y4O8_O7P)RI>
MQ_>O@1$#E2]C^]?`G*E[']Z^!$0.5+V/[U\"<J7L?WKX$1`Y4O8_O7P)RI>Q
M_>O@1$#E2]C^]?`G*E[']Z^!$0.5+V/[U\"<J7L?WKX$1`Y4O8_O7P)RI>Q_
M>O@1$#E2]C^]?`G*E[']Z^!$0.5+V/[U\"<J7L?WKX$1`Y4O8_O7P)RI>Q_>
MO@1$#E2]C^]?`G*E[']Z^!$0.5+V/[U\"<J7L?WKX$1`Y4O8_O7P)RI>Q_>O
M@1$#E2]C^]?`G*E[']Z^!$0.5+V/[U\"<J7L?WKX$1`Y4O8_O7P)RI>Q_>O@
A1$`>5&[@/D?>?^\_`N<T?^T4-//S>$C:^V^UQ=$0?__9
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g146435.jpg
<DESCRIPTION>G146435.JPG
<TEXT>
begin 644 g146435.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+__@`L1$E32S`T,#I;,#)004PQ+C`R
M4$%,,3`Y,2Y/5510551=05)4-D,N15!3_\``$0@!+0(C`P$B``(1`0,1`?_$
M`!P``0`"`P$!`0`````````````$!@,%!P$""/_$`$X0``$#`P$#!0P(!0,#
M`P('``$``@,$!1$&$B$Q!Q,40906%R(R-E%25&%QD=,50E9R<X&SP2,UD[+1
M,X*A)&*Q1%/A):)#5722I-+Q_\0`&0$!``,!`0````````````````$"`P0%
M_\0`,Q$!``("``0$`P<#!0$```````$"`Q$$$B$Q$T%1805QD2(R@:&QP=$4
M(^$S0F+P\5+_V@`,`P$``A$#$0`_`+IH?0VEKOI*DK[A8:"IJYGS&2:6$.<\
M\\\;S[@%8>]IHK[,6OLX7G)MY!6[[T_ZSU:T%5[VFBOLQ:^SA.]IHK[,6OLX
M5J7/-2ZZO-MUW1V"V6^CE#@QSHZF?FI*D.:\GFB?!&SLXR<Y)`W90;GO::*^
MS%K[.$[VFBOLQ:^SA>2ZPDCUR+"ZVSQ4K:2:H=63#9$ACV,B,=8`?O=Y]PX%
M:,<IU31VQEQNMGC@IZVVON-N;%4[;Y0US`(WY:`UQ$C#D9`R?,@WO>TT5]F+
M7V<)WM-%?9BU]G"DZ>OM?77*XVJ[4,-+<*%L,CNCS&6-\<H.R0XM!R"QP(QU
M>U5^/E)F9%'<ZRULCL=6*LTD\4Y=*[H[7N.VPM`;MMC>1@G&!GB@V_>TT5]F
M+7V<)WM-%?9BU]G":<U/<+C=?HR[VR*BJ9:&.X0"&<R@QN=LEKB6MP]IQG&1
MOW*SOFBC<&OD8UQX`N`)05CO::*^S%K[.$[VFBOLQ:^SA666IA@:'2/`!.!U
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M716/)BU]G"M.VWTA\5Z>"#\Q:PHZ:U:NN=#00,IJ6&8B.&(;+6C`.X>\E%GY
M0/+R\?C_`+!$':^3;R"MWWI_UGJUJJ<FWD%;OO3_`*SU:T!<XUYH>^:JN]-%
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M7_;_`'!!&_\`74OXQ_L<I,UWMM/*Z*:OI8Y&[G,?,T$>\$J-_P"NI?QC_8Y:
M6[<E^C[Y=*BYW&T<]5U#@Z23GY&[1``X!P`W`*U.7?VAYJSE*L&D:6FGJ9'U
MC9Y"P-HG,D+<#.3X0W*'I3E;T[JVOGI*9M31NABYTOK>;C:1D#`.T=^]5O6/
M(5:Z^DI6:6@I;;,V0F9\\TKP]N-P'C=:A:0Y!(J"X3OU0ZBN5*Z+9BC@DE86
MOR-Y\7=C(_-=D4X7PMS,[5^UMU[Z=M/_`.:47:&?Y6'4%_IM/6*:ZS,DG8S9
M$<4."^5SG!K6M\Y)(58[S.@L8^@O_P"5-_\`V4W4FEZR]U]BH::HEH+5;G&I
M=-`]IE$K&AL+6AX<"!EQ)(/`=:Y+Q3_9,_BF-MO#JFROT_1WR>X4U)05;&OC
MEJ96QC+AG9R3C/'=["L-+K.PU=YJ[7'<:?GZ9L+B3,S9DYWQ`PYW\6CWN;YU
M2Z315^L%PI'TT$=WHK555+J.*HG9&^2*I8TN)\'9#F2!W4`6O./,OB31^I(3
M,Z&V6L%S+;4MBI9N9A;)32;3H6M()`()PX[MW#?NHET2LU!9K?%))676BIXX
MI>9>Z6H:P-DP';!R=SL$'''!6.CU!1U]ZDMU,>=V:.*L;.QP=&]DCGM;LD'?
MXA]F\+GDVF-8S5DEQZ'!#)/=*BJ?%35<;9HV/@BC8&S.C.R/`<'[(!.["W7)
M]I6[Z?D@-R9"WFK3#1?PY-H%S)YW?#9D9O\`>@GG79?<ZF.FL=?4VZDK>@5%
M;"6.YN7(:?X0.V6@D`G'MWA3J37&GJJEK:EUSI::"CK'T4DE1.QC><;YCG@<
M$CS@*G7?1]_K;U430VFWQ7%U6)*?4%+5FGD9%M@@21-;_$<&@MWD@[EF9IG4
M%OU$ZZ1VFCKHZ:Y5T\4+ZD-,K*D-(>"1AKF;&R0>(><%!>JC45DI.B])N]!#
MTL`T_.5+&\\#C!;D^$#D</.L5LU+;[D=CG!!.ZKJ*6*&5[0^5T+RUY:,[QNS
M[`=ZY_;M$:@L=*Z%EJL]T-=;Q22,J92(J0\]))L[)&7Q`2C<,$E@X;B-EIC1
MUWT[JV6[EL=1'7SU3*IKI!FGC,KI(G1>8'/A,SQ(._"#>7+6,]'>*^WT6GKA
M<3011RU$E/)"T-#P7``/>"3AIX!??=[8)+;3U-/7TLD]1#%/%1OJ8XIBQ^S@
MEKW#&`[/_C.Y0:C0M->-6WJX7>*5])4PT\<+8JR6(/#6O#P]K'`.&\>-GK6O
MN>A9Y#J7H5%2LZ6^WMH@"&[,4&QM-_[0-EV!UH+HV_6A]QEMS;I1&MB:724X
MJ&\XP#>26YR,;E]VV]6N\QR26NXTE:R,[+W4TS9`T^8X)PN>5VB[]6VZY6%M
MOM3(9JBOJ([O*\OD_C[9;AH`+7^&&.<21LM.,Y&-EH/3%VM-WK+C<XI(B^DA
MI6-EK6U#CL$G=LL8T-&<-W$\>'!!?T1$!$1!IHN,WXTG]Q618XN,WXTG]Q61
M`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0%M/J_D
MM6MI]7\D'YJY0/+R\?C_`+!$Y0/+R\?C_L$0=KY-O(*W?>G_`%GJUJJ<FWD%
M;OO3_K/5K0$1$'/Z/7ESK=<UUJAMM(ZWT4CHJ@=)Q51AI(YXL(`+#@8`WX(.
M_@L;.4]\%MBN-SLXIZ:LMLMQH!%5"5\K6%O@/&R`QQ#V$8+AO(SN7Q4Z+OU?
MRA4]RK*FADH:6<5$%8(=FI:P/<X0#&['A;)=UMQUK7P<DDU0VL;726RF<:.:
MG@DH(7C;>]P(E>QQV6`;(_AL\'+G%!=K#J"LN%TN%JNEOCH;A1LAE+(JCGF/
MCD!P0[9:<@M<TC'5Q.5HF\I)C;'7UEKYFRU+JMM-5MJ`Z1YIVO<=J/9`:'"-
M^SX1X#.,J;:['J.GNM7>ZR:U/N58ZF@DCB$G-1TT9<7;).\O.VXC(P-PWK4#
MDWKJF&&S5M;2_0-$ZK=2<TQPG=S[9&@/^J`P2NQCC@<$&_T[JJLNMR907*U-
MH)YJ!EPI^;J.>#HG'!#CLMV7-);D;QOW%;J[R,%!(PN:''9(!.\^$%7],Z;O
M%%>&W*]U='++36]ENIVTC7`.8';3I'[7!SB&[AN&.)5@O$;'6^1SF-):6X)'
M#P@@P?\`KJ7\8_V.6V6I_P#74OXQ_L<I,HN'.NYIT'-Y\':!RLLN3PXWRS/R
M6K7?FFDX7@(*T5S%9S<?2#&1M''-@^98;8*GGW]'V`[9W\X#C&5Y5OC$UXF,
M'A3^_;T_RZ(X;=.?F61?)>QKFM<X!SMS03O/N4'%T]*F^!51UR+B=5Z*%M=2
MMKNEU/-FI:XQYZ,_.0T@\,_\+U,6;Q-_9F/FY[5UYKXU['.<UK@7-W.`/#WK
MZ7'(+Q>M.7[4UXN$M.6TMWH_I9M)&>;=3OIFLVFAV7#9)8[CU'J7Q4ZIU'#%
M/-<-3QVR>.Q"[Q4KX8?#D?+*6Q':&2`P1L(&\DC?GCLJ[,OG;9MAFT-HC(&=
M^%RD:QO4]=)5R7:.BJ&7:FM[;"Z*,N?'((\OR?#VL2.>"#LX9O!WK1Z9IKG/
M/:FT6I)XZJ&WW5SY^:AD<W9J6?PR"W`R<..1G?@$#&`[HODR,#VL+VASLX&=
MYPN)S<HFI9BRK;514Q@H[?.RG<8&15)FC:]Y?MGG""7%K>;X$;\J+)>*ZQW>
MJJ:>H;7U=/<+Y*QD\3'.C<R$%H&R`X`\2!C(&[`0=X7SMMVPS:&T1D#._"Y/
M6:KK:"&.D@ULV[354M/A]+2T[9(]ICW.:)'$0M!#,C:RX`=>05GT->:N_:BL
ME=73BHG%NN<)E&QX;65<+6D['@DX`WMW'B$'3W3PLE;$Z5C9'>*TN`)]P7V"
M#P*XCK)MI;>=47"5]FKC$]AJJ6XO-/7P%D;=GHDN_<=Q;NWN)&5)I[I7T&J+
MS3MU!+11W&^1133U#(=NDC-()&^,,!SB!&"[(\'@3O0=F7RU[7%P:X$M.#@\
M"N10ZQN]<]M%4:G@ME+!%7/CO',1$5W,RAC2`[+<;)RX-WG&["^M,W^O.O*B
MEDJ136JNN/.],9%@5E1T2`B##]\0+?#&?"/B@C!R'5Y:JG@<&RSQ1N(SA[P#
M_P`K(7M:PO<X!H&22=P"Y=J6TS7?E8J(H;)9;JYEBA.Q=20QF9Y-[<,?O\_#
M=UK6U=%?[!9+C8'WMKJ2T:9=534_1V21SO>:CP,O!=S;0UK0.L-'M0=E!!&0
MBY6S5=RBK:Z>2^Q4\E%6BCI['T9CS5-YEKF\!MASR<AP.R`-X63D\U;>;S>:
M:&NN#*R&KMO3'M+J?,,FTWQ!$20SPB,2>%D>]!=XN,WXTG]Q618XN,WXTG]Q
M61`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!%"J:N2&8L:
M&D8!WKZI:I\\I:X-``SN7G1\4X><_P#3[GFWKLV_I[\G/Y):*C7G6MUI->0:
M>M]MHYFX8Y[9Z@Q2SM<W:+HL^#AN\;\Y((W+[;R@8U1-;):2G93QU513.`J"
M:I@BC,AF=%LX$9`W'/6/.O18KLMI]7\ESS2.M)-45;F"FH&PFG%0#35[9I(<
MD89,S`+7$'.6Y`.03E=#^K^2#\U<H'EY>/Q_V")R@>7EX_'_`&"(.U\FWD%;
MOO3_`*SU:U5.3;R"MWWI_P!9ZM:`B(@(N:TNKK]+RFS6>HJ[?1T[)3'';ZJ)
MT;YX03B6*3@]Y&#LC=C(W$96IM_*Y7R4E=4S1T,SHK=-5"GCBDC-/*V81,C<
M]SB)02X9<S&,'SA!V!%6-/7FZR7^Z6.]&CDJJ2*"HCFI(W1L>R0.!!:YSB"'
M,=U[P1P59[XMTI*.EOU9#1/LE<ZM;!%"QPFCYALCF%SMHAVV(G9PT8R..]!T
MU0KM_+9?]O\`<%7=-Z@O-1>HK9>F43I*JV1W&%](QS!&"X-?&X.<<X+FX<,9
MW[@M]>)HV4+XW/`>[9V0>OP@@P2[;9HI(V!YCDVBTNQD8<./YK/](5'J8_K#
M_"^#XQ]Z\09/I"H]3']8?X3Z0J/4Q_6'^%C1!D^D*CU,?UA_A?#ZI\DD<C[?
M&Y\9)8XR-):2,'!QNW+Q$&JOUJCU!0OHYX)H()I&OJ6T\S&]):WZDA+22TX&
M<8.!C.%]26JDGU`Z]3VQDU3S$<#&RO8YL88Y[FN;EN0[+SOSYELT08G")]>R
MO=:*=U8QNRVH)89&CS!V,@+V-S(9'216F!CW[1<YKF`G:QG)QUX&?<LB(,);
M"Z2"0V>F+X`&PN)9F,#@&G&[\E]-,;:EU2VTTXG<<F0%FT3C&<XSPW+(B"+T
M>DZ,ZF^@J/F'.VW1XCV2[SD8QGVK/%(('!T-KAC<`0"QS01G&>`Z\#X+[1!'
MJ(::KJXJNILE)-4Q?Z<T@8Y[/<XC(7L[(*H3BHLU-*)P&S"38=S@'`.R-^/:
MLZ(,#XZ>6FBIY+-2O@AQS4;M@M9CT1C`_)9'2!YRZUPN/."7>YI\,<'<..[C
MQ7VB#WI3Q.9OH^/G2T,+^<;M%N<XSC@OE]09#(7VV)QD9S;RY[3M-W[CNWC>
M=WM7J(,>8^EMJ_HFGZ0UNRV7:9M@>8.QG"4[HZ1\CZ:TP0OE.9'1N8TO/MP-
MZR(@QPAX:XO:&N=(Y^`<XRXGBLB(@(B("(B`B(@(B("(B`B+T-)X!1-HK&Y'
MB+((O.5@JGQ/@D@:2Y[AC$>\@_LN:>*I-N6D;3ROM%C@$@IV"7&V!@X.5D74
M@1$0$1$!$1`1$0$0G`R>"C/JP7;$##(_V<`L,W$8\,;O/?M'G/RCO*U:6MV2
M"0T$D@`=949U67N+*=A>?2Z@@IGRD.J7[7_8.`4EK6L;AH`'F"Y]\3Q';^W7
MZVG]H_.6GV*>\_D@OHIY7;;Y&EQXK)2TKX)"YSFD$8W*6BIC^$\-CRQFB)YH
MZ[F93;B+S7E\E`UCHR]:DOU+LUU*ZU[1<#-%F6B.RT$Q$8R7%N03XI)/!9.X
M">2X@3U-"Z@;<)Z[GFT[NF2<ZUX,3Y,X+?#._K``PKVB])@I^F](UUHN%OGK
MJNAECMEN=;Z44L#HW2,+FG:E)/'#!N&[)<>M=$^K^2U:VGU?R0?FKE`\O+Q^
M/^P1.4#R\O'X_P"P1!VODV\@K=]Z?]9ZM:JG)MY!6[[T_P"L]6M`1$042;D_
MJJK5PN%7>IJBU,F%5'2R-#I&R!SG!@DXB,%Q(''JX+%%R8,DH66^XWJ>JH:6
M@EH*%C8&1/@C?L^$7#QW`,:`<`;LD$E=`1!5+;I6YT594W&:_FHN=5)3B>H-
M(QK3!%G^$&9.SM;3B79SEV[@H+.3>%\S:>LN<U39H#5.I:`Q-;S1G#FOR_BX
M`2/V=PQM=>`KRB"L:<TE-9J_IU==I+C41T;*&G<Z%L0C@:<X(!.TXG&7;N`W
M!;J[?RV7_;_<%-4*[?RV7_;_`'!!@/C'WKQ>GQC[UX@(B("(B`B(@(B("(B`
MB(@(B("(B`B(@(B("(B`B(@(B("(B`B]#7'@%\.D:QX8\[+CPSNS[E7GKO6^
MH^D65H#F8(]A6OH<Q&:E=QB=X/M:>"RQYHO>U-:TF8\TM9F'+?<L*^XSAV/.
MJ\7CY\<^Q6>J&USYJN>"=Q.P<M:-P+3PW=:ELAV6@`!K?,`O*B>.E9SKVG>0
MW(&\^9?!?/)Q<(F^9N]WQX+GQ9,MZQ&*L1[IF(\V-LV:N6G<W9+,%ISXP/6L
MR^&1,8XN`R\\7$Y)_-?0((R""/8N^N]:GNJ]1$5@1$0$4=];$Q[F':R#@[E\
M].C(Q&Q[G=0PN*WQ'A*S,3DC<-8PY)ZZ2E'DJVAVQ$TR/\PX+XYF:HWSOV&>
M@W]U)CC9$W98T-'L5>?B,_\`IQR5]9[_`(1Y?C]$ZI3OUG\D<4\DYS4/W>@W
M@I#&-C;LL:&CV+Z1;8>%QX9YHZVGO,]9^O\`V%+9+6Z>0B(NE01$0$1$!;3Z
MOY+5K:?5_)!^:N4#R\O'X_[!$Y0/+R\?C_L$0=KY-O(*W?>G_6>K6JIR;>05
MN^]/^L]6M`1$0<TIM6Z@EY3)[//66^C@;(Z.*@JX'1NFB!.S+%)_^(\[G;(W
M8R-Q&5\UFLM46:IOQK)+174UGHVOF=3TTD/_`%,F.:BRZ1V=Q#G>8$#B5LW:
M"JYM8-N53>YY[9'4-K(Z61H=(R4/<\,#SO$8<[(''JX+9C15+)8;[:JFJEE;
M>*F>HFF:`U["\C9QQ\4-:!]U`T]>+K)?[I8[TZCDJJ2&"HCFHXW1L>R3:!!:
MYSB"',=OSO!'!5D\HMTI**EOU9#0OLM<ZM;3PQ->)F<PV1S"Y^2';0B=G`&,
MCCO5CMVE;C15=1<9;^Z>YU,E.)Z@TC`UT$1/\)K,^#M;3LNSG)R.`"@Q\F].
MZ44]7<IJFSPFJ=2T!C:.:,X<U^7\7`"1X;N&-KKP$$C36H+U47F*V7IM$Z2J
MMD=QB?21N8(\N#7QN#G.S@N;AV[._<%O[Q/$RB?$YX#W;.!Y_""U&G-)36:O
MZ=77:6Y5$=&RAIW.A;$(H&G."`?"<3C+MW`;@MW=OY;+_M_N"#`?&/O7B]/C
M'WKQ`1$0$6DU7>I;%89*NG8U]0][880_Q0YQXGW8*BT%+JRBN=)TNOIKC1R@
MBI'-MB,)\[<>-_\`'4J3DU;ETZJ<)-L7BS:(CKK?GKK.NFOK,;\EE15\:PH#
M98[IS-3S$E7T0-V6[6WG&>.,+YEUC1QW6KM[:*OEDI'.;,^.(%C`&EV2<[AN
M/%1XM/5,<#Q$[^Q/3?Y=_P!86)%58=>VV:@-9T*XLB<6MAVH1F=[B1LLW[R,
M'*S2:VML5KJ:V6"LC=2SM@GIWQ@2QN=PR,\-WG3Q:>JT_#N*B=32>^OQ61%4
MJO7$+;?<W4]!6QUM)")1#4P[.6NW!Y`/BC()]BW.G;G)=[%2UDT,D4KV`/#V
M;&T<#+FCT3U*:Y*VG4*9>"SXL?B7C4;U^6_T;1$17<HB(@(B("(B`B(@(B("
M(O0UQ&<*MK5K&[3H>(!G@L<,S)X]MA.,X.1@@J6W&R%CQ&?PJQ,1M,1M&;(P
MRNCVAMMQM#S+.=B)A>[<&C))4&L',5T%2-S7_P`)_P"Q4]N',P1GJ(7+GR6O
MBK>)Z>:T1J=,+*HR[+HXSS9W[3CC(]@7W-$RI@=&[@X?`^=1Z*FE@C=$_P`5
MKSL'/%JSSSLI8LG>[ZK!Q<?8LLM<4:C#]Y,;\T>V3NEI\/.7M)83YR%\5HYB
MM@J>#7?PG_L5[0PN@@\/_4<XO=["5)JX154<D?6X9;[^I=&;^UFKD]>ZL=8T
M\3@O*=DI@C,PV7[(VA[5[4\VR![><V'N:0TYWY]@6UN*QQ/+'7Y(U+ZJ8154
MKXC]9N[V'J7D$+F0L;*X.>&@$C@L5-+.:-FTW9EQOVT,7.?ZSW2>P[F_`+"F
M#-69K6=0MN&4U,326Q@R.\S!GXG@HU)`Z"-S#@-+B6M!SL@]2D````#`'4$7
M5AP1CW.]S*LSL1?$DC(AE[@T>U8.DR2[J>(D>F[<%3-Q>+%/+,[MZ1UGZ0M7
M':W6.R22&C)(`\Y4=]8W.S$TRN]G!>"D,AVJB0O/HC<%(:QK&X:T`>8+'?%9
MNT<D>_6W\1^:W]NOO/Y-7)#.^1SC$[).3@*501OC$FVPM)(QD*8BYN&^#8\&
M>,\6F9Z]]>;2_$VO3DT(B+V',(B("(B`B(@(B("VGU?R6K6T^K^2#\U<H'EY
M>/Q_V")R@>7EX_'_`&"(.U\FWD%;OO3_`*SUYK[555I:U4CZ""FDK:VJ;2PN
MJY-B%A+7.VGGW-QCSE>\FWD%;OO3_K/6OY5*^&EL5MI*NEM\M%7W&*FJ)K@T
MF&!ARXO..!\'`.[&4'QR=:[K=7/J:>OIZ1DT-)2U(DI7DM(E826N!)V7!P.[
M/#"ORYKR95-MAOVIK-9*>UFU4LD4M/56[)#P\.\![\G:<W''/65TI`1<H?>;
MY0<I\T=VNU;1P.D(I*?F&R4=3#EVQ&'#?'(<>,XYV@1O&`M;2:_O\.G7W:IJ
MJWI%9:Y*FFAJJ&)M.Z3;:`87,.ULL#QD2>,-XP$':452TY67.FU3=[!<;E)<
MA34]-4PU$L3&/`DVVN:=@`'PF9&[@[&_"J$FM;];K11:GFKC44MP?<&_1SH&
M-9"(F2NBV7`!V?X.'9)SM'AA!UQ0KM_+9?\`;_<%5-+7&\Q:@IK;<[F;BRLL
M\=Q$CXF1F*3:#7M;L`#8.T",Y(QQ*L]XE#*)["UYVMG!#21XPXGJ0?!\8^]>
M+T^,?>O$!$1!J=261NH++)0\[S,FTV2*3&=E[>!/L6MH+=JBHNU'4WBX4T5/
M29_A41<.D'SOSNPK+--%3PNFGE9%$P9<][@T`>TE1&7NU2,>]ESHWM8SG'%L
MS2&MSC:._<,[LK.U*S;<R[</$9XQ3CK7<=?+>M])U/EM3>XV_-H&VMM5;W4,
M5?TMCG;8D<-K.#NP-V3[UOJ>PU451J:1TD6S='$PX)\'P"WPMV[>>K*V?TW:
M>9?-])T?-,<&N?S[<-)X`G/%??TM;>CQU'TA2\Q([89)SS=ESO,#GBJ5QXX[
M2WR\;Q>2-6KW]O/<3]>D2K%=HZJJM'VBVB2GZ9;W!^'%W-2'?D9&#OSQ44:)
MKW6*KI]FWP5-3512[$3GEK6,)."XY+CO5EN&I[706:>YMJHJJ&(AN*>1KBYY
MX-&_C^RGT]?35%N97MFC%.Z/G#)M@M:,;\GANWY]RCPL4SKV_P`-/Z[CL=-S
M'3FF>WGOFF/KU:"YZ:JZ^[WFJ;-"V*NMHI(\DY:_=O(QPW+;6"EKJ&RTU)<#
M3F:!HC!@)+2P``<>OSK-3W:W5<X@IJ^EFF+=H1QS-<XCSX!4*X:DH::WU$])
M4T=7/$S;;`*IC=H`X._JPKQ%*SS;<]K\3FK&":^GEKRU'5N44&2[T%-'`:RL
MIJ5\S`]K)9F@G(ZLG?[UDJKG043F-JZVF@=)O8)96MVO=D[UIS0X_"R=(Y9Z
MI2)Q&0BEF(B("(B`B\E<(872R;F-&2C7;;&N`(R,[U$6BW:1]`$\`OALC'O>
MUK@7,.'#S*0S<S*C5-.9=FHIW`3`;CU/'F*X_P"LUDFMHZ+<O1D!P05F)`;D
MG=YU#@G;.S(!:X'#FGBT^8J4PAS,'?U$*O'4W6+P5E"JF&DG-4P?PG[IFCJ_
M[E*=X=([8.\L.R1_PL-+)E\U'+X3HMP)^LP\%EI:<T\3HMHN8''8SU-/4N:^
M2?#BEN\=ODMKJQR-%QMF6\9&;3?8[_\`U>6^?GZ=CCXV,.]X6.T.Q3/B/&.1
MP7S&.C7*6+@R7^*SW]:VQTZWP3Y]81/JS5\\D)AV7;,;W[+W`;QYEZR)D;BX
M#PCQ<3DG\U[7<W+2/B>[#GCP1C)S[E\TYD-/'SK2V3'A`^=;<%&J=8U*+,B^
MN<+(SAI<1P&<97RBZ,F.N2.6R(G3X)GD\9XC'FCX_$HR-D>2UH!/$\2?S7VO
M'$-;EQ`'G*5I3''2-'67J+3](F_]U_Q4F!D]1$"^<AF3PXE>/P_QNO$7\/%C
MF9_!TWX6:1NT]$F6IBBW.=EWHC>5CVZJ?Q&B%GG=Q66*GBA\1HSYSO*RKM\#
MB,W^M?ECTK^]N_TTRYJ5^[&_G_"/'1QM.T_,C_.Y2$1=.'!BPQK'72EKVMWD
M1$6RHB(@(B("(B`B(@(B("(B`MI]7\EJUM/J_D@_-7*!Y>7C\?\`8(G*!Y>7
MC\?]@B#M?)MY!6[[T_ZSUIN4*HN])B"6Y6N.VW.K@I*>.LH!/&QQ:XNYW)Q@
MD`@]6%N>3;R"MWWI_P!9ZHO*AJ*HKKC<[2[35!=;188H*VM-5.]CLOSC8V2/
MJD\<]:"Z:%L]TLS:J"LK+%+3.V7116FC;3AKM^2X-XY&/@KBJWI/2NF[#3FM
ML%K91=-B8Y^'.)<W&6@Y)X;15D04X<G5L&J3>.E59@,W2>@&4\SS^T7%^..,
MN)V>&22O:;DVL<$<L$KZZJI#32TD-+45!='312$%S8Q@$<`,DD@``%7!$%:M
M^BZ6W&66.YW62KFFAEFJI:G,LK8O$C<0`-CCD8WY.3O6*#D_LL-Q=4N=5S0`
MSF*BEFS3PF8$2EC<;MH.=Q)QM'&,JU(@K^G](4&GJA]1#45E5,8&4T<E7-SA
MBA:26QMW##03[2>LE;.[?RV7_;_<%-4*[?RV7_;_`'!!@/C'WKQ>GQC[UX@(
MB(*MK^EEJM.-$36R".ICD?"7!O.M&<M&>)Z\>Q5"HCZ=>]1=!L\]%SMH&Q2F
M(->27,W[#>&<?\+IUPMU'=:-])70-F@?@ECL\1P.1P*CVK3]KLKI7V^E$3Y<
M![R]SW$#@,N)W+FR89O??E_Z]K@OB=.&X?DU,VC>O3K-9Z]?;T_%3;A:WT-A
MT^RELC1M!KZN:.B$\L3]@;]@\2=_'S+40V:N?8J6EEME6<7WG)(Y*<@\T6CP
MB`,8XYQN76T4SP\3/<Q_&LE*ZY=SO>]_/^7,;M8:ETFL8:2V/$3S!)2M9#AK
MB#O+-V\X)X><JU2&,\GE0(J22E:V@D;S,D7-N:0T@^#U9.3^:LBQ5-/%5TTM
M-.W;BE86/;G&6D8(5HPQ7<QYL,GQ*V6*5O'W9B?I$1^V_JYAI^E-<[2K:"SS
MT\]))SU56F'98]F>.W];/_PI--I]\?)U=7?1;Q<Y9)&C^">=<WG&X`W9Q@97
M1**C@M]%#1TK-B"%NS&S).![RLZI7AXB.OI^VG1F^-7MDW2NHYHGO.^EIG4_
M/?;R<WK*.2BO%?-<-/5-TAJZ"".F#(B\,<U@!83Q9OZQO4*\V>X,NDLDEJJ6
M03V^.*&&"E;5"+#0#%M.\0@_6&]=513/#Q/FKC^,WI,3RQVUWGRUK4=H[>G5
MK[#32T=@H*:;G!)%`UKA+C:'L.-V1P6P1?0C<?8M+7ICC[4O)O:<EYM/GU?*
M8RLA$<3=J1P`\[C@*%/F>J@E@#L,R'.<,`M/F\ZRIQ,9+<M(_%76DI['MC)8
MT.<.#<XS^:QP2MF.!D.:<.:X8+?>LS7XW'>%Z8HWRMEV1MMX.'F\RPOFRXMQ
MDC>^TIB(GLAW<YIHXAQED#5(QC<."C5^>G4A?NB;D[1X;74%)6W!QK%!;NS,
M_P!-0;0\FA:T\`X@>S>IS/$"CMGAC;S=-'M@'&(QAH_/@N+>[7I%=[G^5O1Y
M54[]OI%/_J@>$WJD'F/M7M+.R9H>PG!W$'B#YBLL4CSGG`T9X!O5^:B58$-1
MST#@9CC;B&_;'G]A]JUQS>(\#)'?LB?6"N_Z>K@JQN&>;?[CP4[;:&;1(`'$
MD\%%J6NJH3$<-8X>$2,N'N7T&@,##X0``W[\J]>%F^.*WZ3'Z(WJ>B/0Y;45
M3F@\VZ3::[J(]BRR0F:=DLCO],DL#1C'O/6LJ+KC%6)BWG"-B+')/%%X[P#Y
MNM8>D2R_Z$)QZ3]P6.3C,..W+O=O2.L_2%ZXK3&_)*6"2KAC.-K:=YF[U\=%
M?)OGF<[_`+6[@L\<,<0\!@"SY^*R_<K%(]9ZS](Z?6?P3K'7O._DP;=5-XC!
M$WSNXKT4;2=J9[I'>T[E)13'`TM.\TS>??M].WY'BS'W>B)]'Q>D_P"*D11-
MACV&DD9SO7VBOAX+A\%N?'2(E%LM[1JTB(BZF8B(@(B("(B`B(@(B("(B`B(
M@(B("VGU?R6K6T^K^2#\U<H'EY>/Q_V")R@>7EX_'_8(@[7R;>05N^]/^L]:
M_4G)78-37JJN5=67.*:L8R.6.GJ1&QX8W`!;LG.X=:V')MY!6[[T_P"L]5GE
M/?JNO'0[58)61TDT5117B*ZQ4Y;-C9P6/XCPBW&=^4%GTGHRUZ0J*IE!<+A4
M231L#HZNJYW8:"<$#`QUC\E:ES#DDMMRHGW62\VI\=U>6-K+A+=&53ZB0$Y8
M6M)YO9!&X^==/0<MBOE]I^5-]'=;O4T,#YRREI9*4/I:J$EVPUKV[VR$#.7$
M>$"W!&`M;'K?4UMM%96WB2Y4]?)133T=%6VZ**$NYP-&'-)>=@.:2'!N0<JY
M#DZH!JDW<UU:ZF,W2OH\R#F>?VB[;X9QEQ=LYQG?[$AY-K0V!]/5U=QKZ44D
ME'3P54X<VFB?C:#,`'.X#:<20`-Z#-IVOND&I[M8+I7_`$@::GIZF*I,+8G8
MDVVN:0W`W%F1NX.QU*HOUS?K?:*/4T]5'4T=P?7M9;^8:T0B)DKXL.&'$_P<
M.R?K;L85VMNCXK:^:<7:Z3UD\L,DU7-*WG)&1>)$<-`V-YR`,G)R<E1X.3ZT
M0USI7S5DU(#4&&@DE',0&<$2E@`!WASA@D@;1QC*"+I>Z7MM_I[;=K@RO;66
MAEQ:\0MC,3]H->P;/%OA`C.\8XE66\2AE$]A:\[6S@AI(\8<3U+7:>T=2:>J
MGU+*VNK9N892Q/K)`\PP-.6QMP!NSUG).!DK:W;^6R_[?[@@P'QC[UXO3XQ]
MZ\0$1<[U9RN6_26H9[/46JJJ)(FL<9(Y6M!VFAW`CVJ^/'?)/+2-RB9TWVM=
M8PZ.M<-0:.6LJ:E[HX(&.#02UI<2YQX``>]>OUI24NBY=2W*BK+?'$'!]+4L
MV9=L'`://M'@>&-_45RW4VO8>4:QU-#0Z3EJHZ.)]3.^28<Y`,;(DCV<;P2,
MC?D=7FVD>AM9W/35M=47!L9H'U,M/0W(&HDV7`B+:(W%X;G&>!/Y)?';';EM
M&I3$[6VHY2:."S6"N9::^IFO<;Y(*2G+72-#/&SG`*MEMK'W"VT]7)25%&^9
MFT:>H;B2/V.'45QZ+2EUATII^*_:.=?704D\+602.CFH]KQ&N9M`'?O+N/P&
M>DZ$MERL^B+3;[N\NKH8<2`NVBS>2UN>O9!`_)4%B1$0$1$!$1!Z#@@KVJ,H
MI)'0'$@;EN[*^5FC.6X\RX>-ITC)Z+5]$*E:R>*.<`O<X9VGG)"D2,>V%[FC
M:>&DAOG7P^JV:@TT;!S@;M9=N;CV>=?)C=)_K2%P]%O@M_\`E32V;)J:Q%8.
MD/*>85%.R4?6&\>8J5$/!SYU@\"-H'@L;G`Z@L^0R+:/4,E.-M_;U'G)7NQQ
MSQ57.QXR&.+'!PW%8702TV^',D7_`+9/A-]QZ_<L%L!Z()#QD<7_`/*FO>]S
M,-?LGT@,E1'#Y,5MXI^IN)[O8IXS`V7;`8>MV[_RH-M:YM*=II&7N(R.I2&P
ML#MHY<_TGG)61;X</):UIGNB9V(B+=`L<[BV"1P."&D@K(3@9/!0WR/JW&.+
M=']9_G]RY.,SQCI-(^];<1$=]_X]?)ICKN=^4(?2I_\`W7*9%'45$;2^8AI'
M!HWE>_1\7I/^*TVMZ9LN@[K2?2<-M$D'--JIW[#&$N&`YPX`^+GVKQ^`^&\5
M%Y_JK3-==N:73FSX]?VXZ_)N:044T(GII(IXR2.=:\/&0<'?PW$$*4"#P(./
M,5^?K!'&W0>I[!3P0VNYSQ1"2:HN`%)*TSEFTPG<P[BW_N`"QU#&6B@N&DC;
M*>AE^F+?#<YJ&JE?%/"\.(&7DEI\_`'\E[^+#CQ5Y<=8B/9R6M-IW,OT,#D9
M&\'K14'DR:VDGU9:J8N%NH+S)%1LVRX1L(WM!)X#`^*N5W<YEDKW-<6N;32$
M$'!!V2KS.HV4KS6BOJFX(X@_!>+B]+6R2VRWLM]9?CJ"9S>;VYB('^$<XR=X
MQ_SE7.[Z[DMMRJZ6*EI96T+6](,M4(WR.(&1&WZV%A7B:S&YZ/8S?!,]+Q3'
M/-/7V[3$;ZSVF9U"ZHJE-K"JJ*^2"SVUE7%!2,JYWR3<V=ES0X!HZS@J.-:W
M"HBL[:&T135-R@?*V,SEH86N(QDCA@9ZE?QJ.6/A?$S$3J/K'3I,]>O3I&^J
MZHJ/=]<UMGK'QU%OHFLC<QKHS6`S/R!DM:.`'M6>Y:PN5/77F&CM,,\5K#7R
MRR3EN6$9X8X_X4>/1-?A7%3$3$1J>O>/:/7WCZKBBI,%]NM=K>WQPQ`4,]O;
M.(738`:[&T\[M[AP`]GM5V5Z7B^].?B>%OP\UB^MS&Q$17<PB(@(B("(B`B(
M@(B("(B`MI]7\EJUM/J_D@_-7*!Y>7C\?]@B<H'EY>/Q_P!@B#M?)MY!6[[T
M_P"L]0>5*VS5=@H:^*2B+;771UKX*Z?F89PT$;+G'<#D@C.[(4[DV\@K=]Z?
M]9ZU?*K;Y+A:;.V$453+#=(I&VZLF$;*X[+@(@3N+CG(!W;D$7DP@GK[OJ'5
M$AM<,=TDB:*:W50J&AS`[:>]PW;1VETE<UY-K?44VI]25=5;[?9):AM/_P#1
MJ2=LAA`#L2/V?!!=G=@#@NE("+EC-27REY49:*[WAUMHS,13TM12CHU1!X6R
M62C>),#:R2-X(POF7E*N+QJ6X4\<'08+=%46N-PR9-J1\8E?C>`2`['HXX90
M=51533EPNL.H[KI^[5S:^2E@IZF*J$+8B6R;;2TAN[<YA(/F._AE5)VO+W06
MREU-43PU%ON+JYL5`(`WF.99*Z,A_C$GF2'9]+=C"#K"A7;^6R_[?[@JKI6Z
MWQM^@MEXKXJ_IEJ9<62-@;$87;0:Z,;/%OA#!._<<JS7B5K:%["U^7;."&$C
MQAQ/4@^#XQ]Z\7I\8^]>("X3RF\GFJ=0ZYJ[C:[9S]))'$ULG/1MR0P`[BX'
MB%W9%M@SVPVYJHF-OS]HVSZPY,KC47FNTO/544D/-3\Q,Q[XV[0=M`-)X8ZQ
MCVA=ETWJ^QZKIN=M-:R5X&7P.\&6/[S>/YC(]JWG`Y5.U)R;V:^U/TC2F2TW
MAIVF5U%X#MKSN:,`^_<?:M,F:N>V\G2?6/X1$:[+CN1<R&K-6:&<(=8T!NEK
M!PV\4#<EOXC=W_./>5?;/?+7J"A%9:JV&K@/%T9WM/F<#O:?80L;XK4C?>/5
M,2V"(BS2(B("(B`OJ,X=[U\HJ7I%ZS6?,A\STIEJH)V.#2S(=GK;YEE<8H6[
M4C@WVN*^)'2/(#9-AO7LC?\`%?#8F,=M`9=Z3CD_%<6/A\TUBMK:A:9ACJ_^
MM@,3(R!D$2/W8(\PXK(]G._ZCG.;C&R#AI_ROM%U4P4I&HA$R\`#6@-``'`!
M>HBV0(B("\<YK&ESB`!UKYEE9"S:><#_`,J,V-]4X23#9C'BL\_O7)GXF:V\
M+%&[SY>4>\^D?KY-*4W'-;I!X=:>MD`^+E+:UK&AK1@#@%Z!@8&X(IX?AHQ3
M-[3S7GO/[1Z1[%[\W2.D"P5M%2W&BFHJV!E133-+)(I!EKAYBLZ+J9JQ:>3[
M3-HL=5:(K9#+359)J.>&TZ4;1+03Q\'.!CAC/'>LM-H33%)9:FSQ6:#H-2X/
MFC>7.,CAP)<3M9'5OW*Q(@@6>R6S3]`*&TT45)3!Q?L1YWN/$DG))X<?,I-9
M3BKH:BF+BT31.CV@,XR",_\`*S+'/,RFIY9Y21'$PO<0,X`&2HGMU6KN+1R]
MU<GT735&EZ*SNJGB6B.U!5M9AS';1.0,^WS]0*PUFB#55D]4R[2P253&"K+*
M=AYQS<`N:3O83CJ4V@UI8[G6P4M-42[=1NB=)"YC7GT03UJ%6:YMLU#5_1E4
M140QEW.34KS&S#@#M8]__(7//@ZW^_H]BD_$XORZF)WOK7_ZGY>L?6.G5J=0
MVJKI;W,^@H[N(IJ)L#I:$MD$X`P&OR,M.X9._<MOIW2\U)!8:NKD,5304LD3
MH``02\D[SGJRIM=JZU6KF8JR=[YW0-F>((7/V&D`[1QXH]Z^JW5]EH##MU+Y
M>=B$[>8B=)B,\'G'`)%<46FTRF^?CLF&N*N.>OGJ9WTF/TG^--57Z!%9)<`R
M[S0P5LW2'Q<PQV'YSXW$CV;NI;%^EFO-^+JQV;O&UC\1C^'ANSD;]ZWM/415
M5/'402-DAE:'L>W@X'@5D6D8J=XC_O\`V7%?XAQ4_9M;M[1Y:]O^,?17(]*F
M"YVNNI[E+%)14K*5[1&")HV]1\V58T17K6*]G/ESY,VO$G>A$168B(B`B(@(
MB("(B`B(@(B("VGU?R6K6T^K^2#\U<H'EY>/Q_V")R@>7EX_'_8(@[7R;>05
MN^]/^L]<]Y3WZ4N&I;E/=+%4U#K#1Q2U57%5<T)7O/\`!IB!G(=M$EPPX`;E
MT+DV\@K=]Z?]9ZA7_DOL^H=3MO554UK-MT3JFDBD`AJ3%XA>,9.`<<>'F0:;
MDF9;*.X7JW1:5[G[I$R"2>,5;Z@21O:2PASB<8WY'M^'456]-Z0I]/7*[7-U
M;55U?<Y@^:>H=DM:,[#&^9K0<*R(*4_DXH9=2R7&:OJY:!\O23;9'!T)FVG.
M)WC.QEQ=L9QDGJW*1)R:Z6=45\L5KIZ<5M%T)[*>)D88W+B7-P,AQVAD_P#:
MWS*VH@K5!H]M#+-4_35TFK9Y8'S54LC-N1D7BQ'#`-@Y.<#)VB<Y4:'D]M4=
M5M2U-;/1M-0Z&@ED;S$)G!$A:`T.WASP,DXVCA6Y$%=L&D*:PU9JNG5M=.VE
M91Q25;VDQ0L.0QNRUO7O).2<#)6UNW\ME_V_W!35"NW\ME_V_P!P08#XQ]Z\
M7I\8^]>("(B`B(@\(#FEK@"UPP01D$>8JA7CDQI>G&[:5K9-/W8;]JG_`-&3
MV.9U`^S=[%?D5Z9+4G=91IS>FY0KKIJICM^OK4ZDVCLQW6D:7T\OO`X?E_\`
MM"Z#1UM+<:2.KHJF*IIY!EDL+PYKOS"^JFF@K*:2FJH(YX)!A\4K`YKA[0=R
MY]6<G%;8JN2Y:"NKK9.XYDM\[B^FE]F_./SS[PM/[>3_`(S^7^#K#HR+GUKY
M3HZ:N;:=96^2P7+JDDR:>7VM?OQ_R/:N@1N$L;9(R'L<,M<PY!'G!'%9WQVI
M]Z")V]0[N.Y:W48K!IJY"BJF4=6:=[8*B5^PV-Y&`2X[AOZUS_2?2:BU7&U.
MNM]H:YDS9)*6HJ&R/>T22C9IYR[C(6;).=Q:2!ORJ)=21<OL===KY<+?IVMN
M5UH7,GN!J0V?%2SFS'S43IAXVRV4.)&X[LYP5<M%7.JO.C+5<*UVU4RPGG'X
MQMEKG-VL#S[.?S0;Y$1`1$0$1$!8IYVPMW[W'@T<2OF>HYLAC!M2G@T=2\@I
MRUW.RG;E/7YO<N'+Q%[WG#P_?SGRK_,^WU:UI$1S7_\`7S%`Z1_/5&]WU6=3
M5*1%O@X>F"NJ]Y[SYS/NK>\VGJ(B+=01$0$1$!0;S_(KC_\`I9?["IR\(#FE
MK@"",$$9!43&XTM2W+:+>CG&G[9>+O;-,,EIJ:*VT,@JFU+9,O>,G#=GJ.>/
MQ4VETU=(N3^ZVET#!6U$[WQL$C<$%S2-_#J*O+&,C8&,:UC`,!K1@#\E]+&N
M"L1UGRT]/+\7RVONM8B.;FB/>)F?7UGK^6E)GL]_MEWJ*^UTE+5]-HHJ>1LT
MH;S3VM`X'<X;N"AW32EY==#6LIX:UU11MAF;#4FE:R0#!W`C:9[/_"Z$BF<%
M9Z*T^*YJ3%HB-ZUY]8Z:WU\M1VU[[0+)0&V62CHG-8UT,8:YL;BYH/$@%V_&
M3UJ>B+6(U&H>=>\WM-[=YZB(BE41$0$1$!$1`1$0$1$!$1`1$0%M/J_DM6MI
M]7\D'YJY0/+R\?C_`+!$Y0/+R\?C_L$0=KY-O(*W?>G_`%GJUJJ<FWD%;OO3
M_K/5K0$1$'(8ZNX47*J^6YW.Y"GFJN;I9J6<34CF.<YK8)8\_P`,@C9SC.T.
M(RH]VO.H-)S7-HNUPJ6S6B26FK*I[)(JF?G(\RPL:2(VL;(?!)P=VXXR;^-`
MV$:G-^Z/)SY=SO,\Z[F>>R29>;SL[>\[\<=_'>ONFT'IND$K66\NCDIWTO-R
MSR2,CA><N8QKG$,:?,W'4@A:8=66W5EYT_)<*RX4M/34U3%+62<Y(QTAD:YI
M=Q(.P"`>&3U*E/U+?+;9*'53+C5U%1<GW%LM#*088Q%',Z/89]4MYEH...79
M72:'2%GMT;FTT52USIHIG2.JY72.='N8"\N+BT`8V2=GV+YI]%V"FN4E='0Y
ME>Z5VP^5[XVF7_4+8R2UI=UD`9W^=!7])2W"AU+36Z>\5EQ@KK+'<'FJ>'ED
MVV&N+#@;+7!WB\!C<K=>)'-H7M$3W-.SEP(P/"''?E1K)I2SZ>EDEMU,]DCX
MF0[<D[Y2V-F=EC2]QV6C)PT8"FW;^6R_[?[@@P'QC[UXO3XQ]Z\0$1$!$1`1
M$0$1$$*Z6BW7NA=17.CAJZ9V_FY6YP?.#Q!]HWK\[\I5JGT#>Z:WV*\7.*AG
M@Y]L'27`1$N((&",C=YL^]?I55_4&B-.ZHJXJJ\6_I,T4?-L=SSV8;DG&&D=
M9*ZN%S^%?[7W?16T;?G#2>J:B/44'T[-<[K:W,D94T?.OEYUKF.&-DNP<9!]
MF,]2Z99]1<E<5!-;Y9JR)TTK97R5[9N=:YKBYFS("2W9VCC!'63DDJ]6?DZT
MK8+I#<[9;#!60YYN3I$CL9!!W%Q'`E;^KMM!7M+:RAI:EIXB:%K_`/R%IQ&?
M!EMN*S^G\D1,*?2Q\G=THH:2DN5"\1RR3,>RXOCGVY!A[B\N#R7#<<G?N\RN
M=!34U+004U!'&RE@8(XF1;VM:-P`PJW6\FFC*_/.Z>I&$]<&U$?_`+2`M*_D
M:L$3MNUW&\VQ_4:>JR/^1G_E8<N&>TS'X)ZNBHN==PVM*`?_`$KE#JW-'".N
M@YP?$EW_`(3/*U;N+=/W9@\W\)Q_M3P:S]V\?I^IMT5%SKN[UE;_`.;<GE:6
MCC)0S<X/@`?_`"JWJ[EHJX*.F%EM]9;ZSG#S[+E2`C9QNQOXY5J<+DO.H_5'
M-#M*C35#B_F8!M2=9ZFK@5@Y7]67;45LMU1/1B&JJHH9"RE:#LN<`<'JXKJ>
MN]05ND[72/MXIX1/*YDM951NDCAPW+<AN-[CN!)P,%<7'<+Q-+1BB>6)[S'?
MY1[^_DUQVIKFGK*VP4[803G:>>+CUK,J7<]1ZBH-/_2W,61M-34'2JBI-0Z2
M&HDVB!'"6G(V@`03G>\`9P5$[X,\VJ&VV%EO@C9514LE/5OD;.YSFM<_#@.;
M:6EV`UV]Y:[&-R8L5,5(I2-1"MK3:=ROZ(BT0(B("(B`B(@(B("(B`B(@(B(
M"(B`B(@(B("(B`B(@(B("(B`B(@+:?5_):M;3ZOY(/S5R@>7EX_'_8(G*!Y>
M7C\?]@B#M?)MY!6[[T_ZSU:U5.3;R"MWWI_UGJUH"(B`BY#'4W&CY57R7*YW
M$03U9CI)Z6H$M(6N<YC()8P?`.1LYQG:'$96&ONEZLE/>:JU7^XW1M#0217"
MMJ,.IQ6.>P,YEIW-+`7EP;EH&`<E!V1%3M,&KMFK+SI^2X5EPI:>FIJF*6LD
MYR1CI"]KF[7$@[`('5D]2I+]27RVV6AU4RXU=147)]Q;+02G,,8B9,Z/89]4
MMYEH)''+LH.SJ%=OY;+_`+?[@J;I*6OH=2TUNFN]7<8*VR1W!YJI-LLFVPUQ
M8?JM<'>+P&-RMUXD<VB>P1/<#LY>,8'A#VY0?!\8^]>+T^,?>O$!$1`1$0$1
M$!$1`1$0$1$!$1`1$0%3>431$NNK=0TK+BRD--,Z0N?&7[66XQN(5R16I>U+
M1:O>"8VXS9.0RIM%]M]R=?X)125,<YC%,X%VRX'&=K=P71M762Y7JW!EKN0I
M9VAS712LVX9VNQEKQD;QC(/5OW;U8$5\N>^68F\[1$1'90'<GMPB=:VTU]I7
M06YKWQT]5;N<BZ0][GNE#!(T`@NPT;]D#=OWJ?-HFIGJZ@/N[.@5U9!7UU.*
M0!TD\>R26/VO`:XL:2""1OP=ZN"+)(3DDGB41$!$1`1$0$1$!$1`1$0$1$!$
M1`1$0$1$!$1`1$0$1$!$1`1$0$1$!;3ZOY+5K:?5_)!^:N4#R\O'X_[!$Y0/
M+R\?C_L$0=KY-O(*W?>G_6>K6JIR;>05N^]/^L]6M`1$05<\G]@=J5]\Z/**
MAYYPQMF>(A,<YE#`<!^\[_/OX[TM_)YIJV4[Z:FI*CHKX7T[J>2MGDB+'>,-
MASRW?Y\9ZU9>=9SG-[;=O&ULYWX\^/,OO*#04>C+'01N;3T\X+IXJATCJN5\
MCGQ8$>7EQ<6@#&R3CV)!HK3]/<Y+A'09G>93LOE>^-IE_P!0MC)+6EW7@#._
MSK?IE!I;)I2SZ>EDEMU,]DCXF0[<D[Y2V-F=EC2]QV6C)PT8"FW;^6R_[?[@
MIN5"NW\ME_V_W!!@/C'WKQ>GQC[UX@(B("(B`B(@(B("(B`B(@(B("(B`B(@
M(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@
M+:?5_):M;3ZOY(/S5R@>7EX_'_8(G*!Y>7C\?]@B#M?)MY!6[[T_ZSU:U5.3
M;R"MWWI_UGJUH"(B#BD4=)0<K1N$KF7!E3<C%'74]2Z.>GD<]S.9D8?'8"-G
M`W;(!PL]V?<[--RD.9=:RIJ6V^BD%0YP:Z)KS(';`:,-#6YQC?NSG.]=-&F+
M(-0F_?1E+]*%FQTGFQM^_/GQNSQQNX*<;=1&6IE-)`9*I@CG?S8S*T`@-=YP
M`3N/G*"FZ4AI+-K&^6FUR!MH934<L<?/%[&32<X#LDD[W-:PXZ^/6J*ZJJJ&
MR4&H+?/-W1U\MU;6GGBYSA''.0TMSC^&61[.X8W>??V&FTW8Z.F;34UGH(8&
MS-G$<=.QK1(W&R_`'C#`P>(PLD%BM--<9KC!;*.*MFSSM2R!HD?GCEP&3G`^
M""C:(@I+;JJEI;5.]]+66"&MJ@9G2!\Q>`)3DG#G`NSY\>Q7B\.E%"\-8TL\
M':<78(\(<!C>OJVV2U6<RFV6VDHN>(,G1X6Q[9'#.!OXE?5V_ELO^W^X(,!\
M8^]>+T^,?>O$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$
M1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!;3ZOY+5K:?5_)!^:N
M4#R\O'X_[!$Y0/+R\?C_`+!$':^3;R"MWWI_UGJUJJ<FWD%;OO3_`*SU:T!$
M1`7@<"2`02./L7DC@R)SG.V0`27>;VK\\4$LFFZ*^O@J'R7"HM\SZ>\458Y\
M=4T,A<^1['>$'AK]H.X`EP'!!^B45&TO#3V76=ZM%OJ9'6ME)1SM9).Z01S2
M&1IPYQ/C-:TXZSOZU2Y*RKH;5;]14=94OO\`75-TBJ8S,XA[8XZ@M;L$X;S9
MCCQ@;OS0=M4*[?RV;V8/_P!P5"T6QENU7;J.@JIYJ2NT]'757.U#I=J;;:!+
MX1."X.?G&`=GV*_7"*>IIWP1,9LO;@O<\C&_S8WH(Y\8^]>*2:-Q).V-Y\R=
M#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"
M",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#
M=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=
M#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"
M",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#
M=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=
M#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"
M",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#=Z8^"=#=Z8^"",BD]#
M=Z8^"=#=Z8^"",MI]7\E$Z&[TQ\%+X-_)!^:N4#R\O'X_P"P1.4#R\O'X_[!
M$':^3;R"MWWI_P!9ZM:JG)MY!6[[T_ZSU:T!$1`6BMVCM/6JMKJNBM-+%+79
M$Y$8P6D`%H'4TXR1P)6]1!IZ72M@HJ)U'2VBCAIW2LF=&R$`%[2"UQ]HP,>;
M"RPZ<LU/=IKK#:Z2.OFR)*AL0#W9QG)]N!GSK9H@UMJT_9[&Z9UKME+1F8@R
M&"(,VL<,XZAD[O:MDB("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("
M(J)>.5"FLM];9Y],ZBDJ997QTQBI6%M3L\3'EXVAC>@O:*O6K5U-<JBIAGH*
MVV]'BAD>ZO:R,9D&0WQCX0X$'KX96V^E;?@'IU-@OYL'GF[W^CQX^Q!+18'U
ME+'4LIGU$39Y-[(W/`<[W#B5G0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!
M$1`1$0$1$!#P1#P0?FGE`\O+Q^/^P1.4#R\O'X_[!$':^3;R"MWWI_UGJUJJ
M<FWD%;OO3_K/5K0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$
M1`1$0$1$!4+5]KKJOE)T-6TU)-+2TDM4:B5C"6Q!T8#=H]62KZB#ANM-,7FX
M7?7YAM59+%7/M@IW1Q$\Z&%NWLD<=G?GS*)J/DV8)=?FWZ:?LMCH_H<0P'&U
MAO.F+'$[M^/:N^X3"#\\ZCTI?JG6=T$UKN<T]94TTU%6TU"V0L8T-QB=SAS.
MR1@CKPOT*,@#/%>H@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B(
M"'@B'@@_-/*!Y>7C\?\`8(G*!Y>7C\?]@B#M?)MY!6[[T_ZSU:US6USWW3E`
MVTT=;;GT\#Y-ATM$\NPY[G;R)@/K>93.Z+4WK5I[!+\Y!?D5![HM3>M6GL$O
MSD[HM3>M6GL$OSD%^14'NBU-ZU:>P2_.3NBU-ZU:>P2_.07Y%0>Z+4WK5I[!
M+\Y.Z+4WK5I[!+\Y!?D5![HM3>M6GL$OSD[HM3>M6GL$OSD%^14'NBU-ZU:>
MP2_.3NBU-ZU:>P2_.07Y%0>Z+4WK5I[!+\Y.Z+4WK5I[!+\Y!?D5![HM3>M6
MGL$OSD[HM3>M6GL$OSD%^14'NBU-ZU:>P2_.3NBU-ZU:>P2_.07Y%0>Z+4WK
M5I[!+\Y.Z+4WK5I[!+\Y!?D5![HM3>M6GL$OSD[HM3>M6GL$OSD%^14'NBU-
MZU:>P2_.3NBU-ZU:>P2_.07Y%0>Z+4WK5I[!+\Y.Z+4WK5I[!+\Y!?D5![HM
M3>M6GL$OSD[HM3>M6GL$OSD%^14'NBU-ZU:>P2_.3NBU-ZU:>P2_.07Y%0>Z
M+4WK5I[!+\Y.Z+4WK5I[!+\Y!?D5![HM3>M6GL$OSD[HM3>M6GL$OSD%^14'
MNBU-ZU:>P2_.3NBU-ZU:>P2_.07Y%0>Z+4WK5I[!+\Y.Z+4WK5I[!+\Y!?D5
M![HM3>M6GL$OSD[HM3>M6GL$OSD%^14'NBU-ZU:>P2_.3NBU-ZU:>P2_.07Y
M%0>Z+4WK5I[!+\Y.Z+4WK5I[!+\Y!?D5![HM3>M6GL$OSD[HM3>M6GL$OSD%
M^14'NBU-ZU:>P2_.3NBU-ZU:>P2_.07Y%0>Z+4WK5I[!+\Y.Z+4WK5I[!+\Y
M!?D5![HM3>M6GL$OSD[HM3>M6GL$OSD%^14'NBU-ZU:>P2_.3NBU-ZU:>P2_
M.07Y%0>Z+4WK5I[!+\Y.Z+4WK5I[!+\Y!?D5![HM3>M6GL$OSD[HM3>M6GL$
MOSD%^14'NBU-ZU:>P2_.3NBU-ZU:>P2_.07Y%0>Z+4WK5I[!+\Y.Z+4WK5I[
M!+\Y!?D5![HM3>M6GL$OSD[HM3>M6GL$OSD%^14'NBU-ZU:>P2_.3NBU-ZU:
M>P2_.07Y#P5![HM3>M6GL$OSD[HM3>M6GL$OSD')^4#R\O'X_P"P16VOT#/J
9"OGNM7=HF3U+R][8J0AHZMV9">KSH@__V3\_
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g37986.jpg
<DESCRIPTION>G37986.JPG
<TEXT>
begin 644 g37986.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+__@`L1$E32S`T,#I;,#)004PQ+C`R
M4$%,,3`Y,2Y/5510551=05)4-T,N15!3_\``$0@"4@(N`P$B``(1`0,1`?_$
M`!P``0`"`P$!`0`````````````%!@,$!P(!"/_$`%P0``$#`P("!`0.#@8)
M!`("`P$"`P0`!1$&(1(Q!Q-!410B87$5%C(U-E9U@9&3E+31TA<C-T)25%5T
ME:&QLK/30T1B<Y+"""0S18*#HL'P)313<J3A8_$X1J/_Q``;`0$``@,!`0``
M`````````````@,!!`4&!__$`#D1``(!`@0#`PL$`@(#`0`````!`@,1!!(A
M,05!411A<1,5(C,T4H&1H;'!,M'A\`9"(V(64_%R_]H`#`,!``(1`Q$`/P#O
M]<]Z7[U/M>EX<2VR51'[I/:@F2GFTA6>(@]AVQGN)KH50>K-+6_6-@=M-QZQ
M+:E!:'6SA;2QR4D]_/WB:`J6GNC6-HG4\658K](9C.,J3+MTA0<,P@;*&XP0
M3G.#CS$U'6GI:N,K6-LLTZWVI"9\A;!;B3P^]'(S@K*04;X[#\%3-IZ+TQ[T
MW=KYJ&XWN6PPN/%,@A(82H%)(QG*L$[^_P!U:EIZ(6[3*LCB=1SG6+-)+T2.
MMEH)`4<J"B`"HG;QCR[*`A8_3%?E6AF^/Z>ABT"Y^A[SB92NL*B>:4X[!WG<
MU.R>D#4DV^7F/IO3;-QA6>2F+(*Y/`\ZO.%=6G&,#?F>SWJ]_8D@^DWTN>BD
MCJ?1/T1Z[JT\7%^#CECRUDNO16Q/NMSD1=07.WP[JZAZ=#CE/"ZM)SD*(RG/
MD_\`U0$)J/IF<M-]ND6+"@*C6I2$2$2IH:D/J/JPT@`@\/;YJJVM);5PN/2'
M-8)+,BR6]U!(P>%2FR/U&NA7/HJ;E7>=+MNH)]JCW`MF9'CI2HN*1L%)</C(
M)[3OG)K8N_1C"NS]^<5<9#8N\-B(H<(5U:6BD@@GF3PCG0%1D=+#VG8L*SP8
MMO6;=9XS\@SIG4ETJ:0H-M#'C*X2#_YO.N])5TO-QAP=*V1F87+6FYR#*?ZO
MA0KDVG`.5YVSRS\-9Y_12V]+$FVW^;;778+4&86FT*,A#:0E)!/J%82-Q].=
MJY]&;,FY1KA;;]<K9*;@BWO.LJ2M4AH?A%0]5_:\W=0&ET).%'1/"<"%'A=D
M*X1S/VQ1Q5,TQHQ'27I^;K2]W>8F\NNN^"+9=X$P@V?%`&.P_J\N]=<T9I:/
MHW3+%DCR7)#3*UJ#C@`)XE%79YZJ,GHAZM^X-675-SM-JN#BER;>P`4$J]4$
MG(X01MV[;<J`@=.]*.I'K#H^(S;X]RN=V\)9+K[I;!4TK`62`=L;G;?!Q6MJ
MKI&U-<-,=5&AHMMSA7M$">EJ0<$YR@)5SX5$$'S=QJ:O_1V\C4VB8%@$N#;K
M6S)'AS'"I4=9`4E2L[$J5G.V^34HKHDAN:9?MCMYFKG2;@FY/W$A/&MY.<'A
MY`;G:@(,ZLCZ4U3KV]S+:?#8L6!UZ&WR4NNK0`$#;Q0"<9WV&:E6.D>_6^XJ
MMNH[%&ARI%L=N$(L2"XE1;0I9;7W'"3RJ2=Z+X$[T>]%+C)F&]1H[,A12E*@
MME(`<&-N(D9Y8]ZL4'HN;1+=F72_W"ZRA;UV^,Y("0([:TE)(`YG!YG]=`1%
MCZ4[Y,D:6>N5ABQ[9?W51V76I)4X%@XXBG&`DGLSG&:\:?Z79][U4S;56VW1
MVW)BHRHSLPMRV@#@**5@)4?[*23Y*L<?HVB1[3I:`+@^4Z?DF0VK@`+QR3@]
MW/LK0'1(P[=H4F=J"XSHT*7X6RS(2VISB!R`I['6*3GL)H#H]*4H!2E*`4I2
M@%*4H!2E*`4I2@%*4H!2E*`4I2@%1]^]CUR_-7?W#4A6";&$V#(BJ44I>;4V
M5#F,@C/ZZ`_)5H8ALV.TM6%C4D75TY2#&>ZQ#41\A9W221Q`#;SUV'4O2[+L
M%ZG6MJ-;'5VF.TJ894OJ5R'%`%2&$X\8@'_SMGI?19;)N@+?I9Z6_FWGCC3D
MI`=;5Q%61\.,>;M%:]RZ+%S+B_.CZFG0GYS#3-R4RTC,DH``6"?]FHXW*?+W
MF@--WI*OMSU$+9IFQQ9B7+4U<VUR9!;PA20<'&03N`!W]M0\75"=7Z[Z-[ZB
M,65/,7`+8XL\*TH((!V[1MYQ6[,T%=YG2;-?@W&XVJ*W9V8S%Q0$N=9C"5(5
MQ>J.-\['(S5@@]%MJMRM/B/+D!JSL264H."7NO20M2CV'<D8H"!M'2W/DZOM
MMGGP+4A$YYQHHB3P^[&*<XZPI'!OCL/T5(:>Z0-2ZC>B7.#IEIW3LJ8J.EY$
MK[>V@'!=4DC'#L=LY_5GS:.B)NTS+(Z-137F+,^78L=;+80`H^,#P@$D_A'>
ML]NZ)XUMG14LW^Z"T1)AFL6P+2&TK.^.(>,4Y[/I)H""B=-XDWE@^"6_T)D7
M'P%`$S,M*2<!Y36/49KS+Z7]0Q6+G<$Z<AO6VVW95N=4)2DN.'BP.$8.^.9/
M>-N=3]OZ*T6R[MN1=0SVK2U-,U%M;2E("R<E)<'C%']G_P#NLSW1;">T]<;0
M;D^$3KL;HISJTY2HD'@`[MN=`13O2M<[(UJ5O4-C89F6=AAY#<:05I<ZT@)2
M5$;$%0R?/[^G#Z9)3D*]H?B6QV=!MPN#"H,LO,K3E(4A1YA0*AD>?W[5>NC6
MVWZY:@E393Y1>8S+"VT`#JBV04K2>_*0=ZTF>C%URUW:+<]3SYSEPB"&%J;0
MVAIL$$$(3L5;#*CN:`T+=TD:CE72UPI.GXC)O=N=EVTIE%65I;*@'-L`''9R
M"ASWK=Z&;Q>[WHGPR\N=<I<ESJI"G.);@XCQ9'9@[`#LJ69T'%9N>EYHFNE6
MGXBXK2>$8="FPC*NXX&=JS:'T:-$VUZW,W61,B*<*V6WD)'4Y))`(YY)[>Z@
M.;6;2K/2U>-17?4<^8DPI[D&#'8<"!&2GDK&#OR\Y!][SI_I+U!:-+0(:V&[
MS.]'';.AUYPH+H2$E!XN_*L9/9BKA<^BU2[W<+E8-37&Q>B1XIC$4`H<5VJ&
MXX2<G?RFJ_JKHT7`M6C[)IQJ868MTZZ3,;(+K?%C+RCRR,=W8!0&IJ_I%U.=
M):IMRH;-LO5I=83)>BR"H!ATX"VR1G.2D>96=B*WF=0HLVNY-WO,$HGQ=)ID
MR2R^5@@.#Q$@C<DD;Y[:G/L419%DO\2XWJ9-GWQ39E3UI2E6&U`H"4C8`8__
M`*K;9Z-8KD]Z5=+G(N"I%H-I?ZQ"4%QOCXN+(Y*&P][-`1=FZ2;XNZ:?;O\`
M88T*#J!),%YF27%(5@%(<!':"GEW^<")MO3!?Y-JM=[E:>B-VB5<1;W'425%
MP*)]4$XY`=YW([*L=EZ+F;;<[5*G7^XW-JSH4FW1Y'"$,9V!V'C$#&,]P[L4
MC]%4*/HV'IM-S?+4:XIN"7BVGB4H$GA(Y8WH"$?Z7IZ-92[.BW6UI$:?X)U,
MR86'W$YP7$E0#>.T#BR<CGSKKE<XO/1(S?9TA4W4%Q=@/RQ*5%=2VXI!SG@0
MZH%:4]F`<8KHP```'(4!]I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`4!YJ\W[I`
MOMN8U)<+9$@1HBVVXJ&B"7`YQ$\:#^`*W_2?>_;W??BHW\NO-B^ZGJ[\SM_[
M'JN5`4_TGWOV]WWXJ-_+IZ3[W[>[[\5&_EU<*4!3_2?>_;W??BHW\NGI/O?M
M[OOQ4;^75PJ$GZOL%KO#%HFW-AFX/J0AJ.K/$HJ("<`#M)H"*])][]O=]^*C
M?RZ>D^]^WN^_%1OY=7"E`4_TGWOV]WWXJ-_+IZ3[W[>[[\5&_EU,WS4]ETVV
MVY>+@S#0YG@+N<'X!4E%DLS8C,J.L+9>0EQM8^^21D'X#0%4])][]O=]^*C?
MRZ>D^]^WN^_%1OY=7"E`4_TGWOV]WWXJ-_+KQIU-TMVM;E9YM\F71A%OCR6U
M2DM@H4IQU)QP)3MA`JYU27;M;K5TI7!5QN$6&ERSQ0@R'DMA1#S^<<1&>8H"
M[4J%]-^F?;%:?EK7UJ>F_3/MBM/RUKZU`35*PQ)D:?&1)AR&I#"\\+K*PM*L
M;;$;&LU`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*HVH#=KETAPK)
M#OLRUQ56IV6LQ4-DJ6EU"1GC2=L*-7FJ8_\`=F@^X$CYPU0'OTGWOV]WWXJ-
M_+IZ3[W[>[[\5&_EU<*4!3_2?>_;W??BHW\NGI/O?M[OOQ4;^75PI0%/])][
M]O=]^*C?RZ>D^]^WN^_%1OY=7"A.*`I_I/O?M[OOQ4;^73TGWOV]WWXJ-_+K
M3U/TG6ZRO.0X#7ATM!PLA6&T'N*NT^0?#5+7TM:C4X2AJ`A)Y)ZE1Q[_`!5U
M</P;&5XYXQLN_0HEB*<7:YT#TGWOV]WWXJ-_+IZ3[W[>[[\5&_EU4[1TP/I=
M2W>+>VIL[%V+D$>7A)W]XUU&VW*'=H+<R"^AYAP92I)_4>X^2M;%8#$85_\`
M+&RZ\B<*L9_I96O2?>_;W??BHW\NGI/O?M[OOQ4;^75PI6F6%/\`2?>_;W??
MBHW\NGI/O?M[OOQ4;^75PI0%/])][]O=]^*C?RZT94&]Z>OVG5+U7<[@Q,N'
M@SS$EMD)*>I=7]Z@'.4#MJ_55=7^N^D/=D?-GZ`M0Y4H.5*`4I2@%*4H!2E*
M`4I2@%*4H!2E*`4I2@*;8ONIZN_,[?\`L>JY53;%]U/5WYG;_P!CU7*@,,M]
MJ/%<<>D(CH`QUJU`!.>1R=JJVD,:>T\6KSJ]B\+7(=4F8\\E(`VRC)4<XW//
M;.-A5FGPXT^$[&F1VI#"TD*;=0%)5YP=J_.L:)&>_P!&"X/.1VENQYJBRM2`
M5-DO(!X3V9&VU`?HE5S@(>995-CAUX9:074A3@[TC._O5S'I<]F'1W[L#]YJ
MM?5NB[%'Z')-P\"0Y=&H+4D7%SQI)<`0<]9SQV8Y`;`#%1.NE.7N!T3JF/.E
MR:ZSUSJ%E*R5I9XB%#<'<[T!VUFXPI$ER,Q+CNOM?[1I#J5*1YP#D4DW"%#<
M;;E2V&%NG#:774I*SY`3O7)]<V"TZ5U9H278;?'MSZ[JB,XN,@(+C:N$$*QZ
MK8G<Y.YK/J2)I6Y.ZE@BU.ZCO?`ZN3)#2<0?%/`CK5$!L)`V2DDG!R"<T!8>
MF%*5=%%^R`<-(._?UB*G],.ML:*LSKJTH;3;V"I2C@`=6G<FN4^&R)_^BLMZ
M4ZIUT12WQK.3PID<*1[P`'O5ZG3)=RU5T?Z8+4=Z`;.W,,:42&7W0T>'C`!X
MN'@R!RR:`[-$GP[@T78<IB2V#@K9<"QGNR#6Q5#CZ/NS6N(.H8YMEN0AM3,Y
MB&%XF((\7B!`&4GD>=7R@%4EVTVZZ]*5P3<8$68ENSQ2@2&4N<)+S^<<0..0
MJ[558OW5+I[C1/XS]`2'I0TS[7;3\B:^K3TH:9]KUI^1-?5J:H:`J?1PVAG1
MZ6FD)0VB=-2E"1@)`E.@`#L%6RJKT>>Q0^Z$[YT[5JH!2E*`4I2@%*4H!2E*
M`4I2@%*4H!2E*`4I2@%*4H!5,?\`NS0?<"1\X:JYU3'_`+LT'W`D?.&J`N=*
M4H!2E*`50^D[4[MEM#<"&X42YO$"M/-#8]41W$YP/?J^5P[I:<6O6+:%'Q41
M$<(\ZE$UU>#8>-?&1C/9:_(HQ$G&F[%&::<>=0TRVIQQ1X4H0DDD]P`KJNA^
MC8!M<[441"N-.&HC@SP_VE>7N'97-[+<C9[U$N(:#IC.=8&RK'%L1C/OUU'0
M.J[IJ?54U<YQ*66XF6X[0PA!XQOY3Y37IN-3Q4:3\EI%*[?/?9&GAU!R]+<Y
MQJR(Q!U9=(L5I+3#3Y2AM/)(P-A4IT?ZG=L%_:9<</@$M8;>1V)4=DK'F.,^
M3S5HZW]F]X_.3^P57R2`2.8&16[&C'$X.-.IK>*^VY6Y.%1M=3]6TK!!6IV!
M'<6"%*:22#WD"L]?.&K.QUQ2E*P!55U?Z[Z0]V1\V?JU55=7^N^D/=D?-GZ`
MM0Y4H.5*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@*;8ONIZN_,[?^QZKE5-L7
MW4]7?F=O_8]5RH#4N:)CEO=1!DL1I!&SK[1<0D=I*0I.=O+7*;9T9RY71W*T
MM!UA!DVF1(ZQ3Z(!4M*@H**00[CF`>5=?<;2ZVIM:0I"@0H'M!K2M5E@66(J
M+;XX994HK*02<D^?S"L:W)K)D=[YN73O*B_IZ=J+H].FF-26]Y*4>!OS&HA4
M2A(``QUNR]MSDCR"H5WHZN5X8T\PC5]O<]+#B0P6K?DE:>'`<^V]@0!@8KI%
MKLT"S-.M6^,EA#JRXL`DY4?/7VWVB!:W)+D..EE4ESK7BDGQE=]86;2Y*2I7
MEE;[MOJ4S5FC[AK2?;%MZC@QG+,^B1P,PRM0?&#E7VW9.VR>?E-:=OZ/KE"N
MU];MVJH[46[KZVX,(B!3K:U`\?5DJ/`#DXX@K`/:1FN@Q+5!@2I4F-&0T]+7
MQOK3G*SWGX34;=)MBTJ95XEAMAZ5PA:DC*WB!L`.T_\`AJ<(3G)1BKMD9>25
MW=VM]=+W[M_H42/T7W=&B9&B_3?',16/$$'*VV^L*^76`Y4KF3D8``[34I<.
MCI=SMEF8>OC;%^LJ4B!<8D?@4EM(``6V5'B&W>!\)!K<WI26+J[.M=EB,NK2
M&U/2"5N+0.0/"0!^NL#/2E<$703W[1;7'^KZHN(2M"RC.>'BR=L^2NM'@6.<
M;Y5\T:[Q-"^[^7/]CI$2V7]^=%%\OT5QN.H.ICP(ZHY?4.1<)6HE(._"G`)Y
MY&U6BJAIC5UCU3+0\AI,>[-ME(;=`X^`G)"%??#8>7R5;ZYE6C4HS<*BLRQ2
MC))Q8JJQ?NJ73W&B?QGZM556+]U2Z>XT3^,_59DM5#2AH"J]'GL4/NA.^=.U
M:JJO1Y[%#[H3OG3M6J@%*CKA?K3:GD,S[C&C.+3Q)2ZX$DC.,UJC6&G#RO<'
MXX5;&C5DKJ+MX$7**W9-TJ%&KM/'E>8/QPKUZ:[`>5XA?'"GD*ONOY,9X]28
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MTI"$!*1@`8`[J^TI7ACIBE*4`JJZO]=](>[(^;/U:JJNK_7?2'NR/FS]`6H<
MJ4'*E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0%-L7W4]7?F=O_8]5RJFV+[J>
MKOS.W_L>JY4`I2E`*4I0&*3(;BQG9#RN%II!6M7<`,FOS?J34$G4MY=GOJ(0
M3PL-GDVWG8>?M/EKN.OW%-:%NZD'!+/#[Q4`?U&OSN:]9_C6'BXSKO>]D:.,
MF[J)T[2FA[*UID:AU(OB96CK4ME92A#?83C<D]WE%2;>D-&:NM3[FGO]7?;/
M#QH*QPJQL%(5V'_PUS'T:O4R$BU&?+?C+X6T1N(J!P?%2!Y\;5UK1UG3H32\
MRYWAP-//`..HR#P!.>%`[U'/PG%9XA#$8=.K*L_*-^C%/2WA_?J8I.,O14=.
M;.-'PFVW`A*U,RHSI'$@[H6DXR#YQ7Z$T9J'TRZ=9FK`$E)+3Z1R"QS(\A!!
M]^OSW.EKGW"3,<&%R'5ND=Q42<?KKJ/0PXHL7AK?@"VE#NR0H']@K9X]AU4P
M:JR7I1M]=&B&%G:IE6S.IU58OW5+I[C1/XS]6JJK%^ZI=/<:)_&?KQ)TBU4-
M*&@*KT>>Q0^Z$[YT[5JJJ]'GL4/NA.^=.U:J`XSTO^R6!^9_YS5#15\Z8/9+
M`_,_\YJAHKZ#PKV&GX?EG)K^L9L-]E;**U6^RME%;4B"-ENME%:S?96RBM:1
M-&RBMA%:R.RME%:TB:-E%;**UD5LHK7D21L-ULHK6;K916M(FC916RCLK6;K
M91V5KS)HV$5LMG!!'.M9%;**UIDT6&'(\(9R?5C95;%0<5XLNA8Y<B.\5-I4
M%I"DG(-<RK#*]"Z+N?:IC_W9H/N!(^<-5<ZIC_W9H/N!(^<-562+G2E*`5B;
MDL/.N-M/-K<:.'$I4"4'N([*]N.(:05N*2E(YJ4<`52-)Z/L.G-37Z]P;NJ2
M_/65O-K>04L@J*B#C^T3N>S:@+S2M=B=$E%P1Y3+I;]6&W`KA\^#M7J/+C2T
ME49]IY*3@EM84`>[:@*">DF?'Z1;?I"X:;,1R:"M#YF)<'!A1"@`G^P1C.U=
M#P#@D"N,:M__`,E])?F7\^NP-SXCDE49$IE3Z?5-)<!4/.,YH#8I7E:T-H*U
MJ"4@9))P`*QQID:8@KC2&GD@X*FEA0!]Z@.?ZGZ2KEI;4]LM,S37VBY2NHCR
MO#DD*3QI25<(22#XP."??KHU<7Z;?9ET?>Z!_B,UV<J"022`!ODT!]I6M%N,
M*=Q>"2V)'#ZKJG4KQY\&MF@%575_KOI#W9'S9^K555U?Z[Z0]V1\V?H"U#E2
M@Y4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`IMB^ZGJ[\SM_['JN54VQ?=3U=
M^9V_]CU7*@%*T[C=K;:&@[<I\6&VHX"Y#R6P3Y"362%/B7*,F3!E,R6%^I=9
M<"TGS$;4!L4I2@(Z^VT7>Q3K>=C(94VD]Q(V/PXK\T/,NQGW&'T%#S2BAQ)Y
MI4#@BOU17/\`771XF_K5<K84-7`C#C:MD/><]BO+V]O?7>X'Q&&%FZ=72,N?
M1FKB:+FKQW1AZ--',P;>S?9C87-D)XF$J'^Q0>1']HC?/<<=]:.KM.:TU3-\
M9B*U!:4>H8$D?XE;;J_9V5`2]9:YL?#$E`Q0V`A(7#3C`V&#C!Y=AK$STBZS
MD.AMB0'7#R2W#2HGW@*Z$<)CG7>+4H-O9MMI+N*G4I9<FI49<5V#-?B/@!YA
MQ3:P#D<0.#O7:NBFSN6[3*YCR2ER>YUB0?\`XP,)/O[GWQ5=TWT<W"[W1=WU
M,CJFW'"\J.<!;RB<GB`]2GR<_-774(2A"4(2$I2,``8`%4<;XG&I36'IN[_V
M:V\%\26&HM/._@?:J<9Q`Z5[D@K2%JLL4I3G<@//YV]\?#5LKF&H=+OZ@Z7V
M)<6XB!(M4&))2Z&BM2P77PI'JA@*&QY]E>8-TZ?0TH:`JO1Y[%#[H3OG3M6J
MJKT>>Q0^Z$[YT[5JH#C/3![)8'YG_G-4-%7SI@]DL#\S_P`YJAHKZ#PKV&GX
M?EG)K^L9G1RJ2EQBQ<8T..P^Z7(Q?4O&0G<#'Z_U5&HY>]4M?7+IZ)69F')?
MCQ2VI;I9'JUIX>%).#M@G;SUS^+XFO0JT51>[>CV>VYOX"A2J4JKJ+:VV^YX
M0A05P%)XLXQC>ML-N-XXT*3GO&*S)?3Z=G(V03Z'I>X>?"KK"G]8Q\%00N[R
M=/7'J3?KA(/$IMUZ"0$+&X``^]R,=M<K_P`A<I1M#32_QZ&[+A$8*5YZZV^'
M7^Z$\TVM0RE*B/(*V$`YQC?NJ+N9N+UQLC,20_$B+:6\\6DC*E@)(020<<SM
MYZW(:+FU+N;DF3&?<*.*/';1PEO8XSN<YV^"CXQ/)*HX++K;771VU7]L1\VQ
MSJFI.^E]--5?1_VY(H!',$5G15<M*Y\723\VYW%]V0N,J0I3J0GJ5<).`,<A
MML>ZL<R?-N,;3#;,ER$;DH./J9QQ`!KC*1GO-4RXI5NH95FNEOIJKF5@*67R
MF9Y;7VUT=BWH4!C)%;*2`,DX'?53==ER=;-1$2W68D6#X2XTC&'5J64@*\F`
M:^,SY!9U(VM]X(B25!I;:.L6V"TE7BI//!)('EK7\ZSRYI1W5U\[%WFR&;+&
M6SL].Z^A=6E)4/%(/F-9T/M<?#UB.+NXJYS"O$R-#MS,./?I+OA#8<?E0U)X
MVRK"^(XV`2203W#>I"8VDWE24SKG&?4E33)"2J,X<;*`*2DGMP2#M5<^(SRI
MY>M_[N9AP^FY-9NEMN?T_<Z$W6RBJ[I1[K+/U2[HY<GH[SC#S[C8;4%I.Z2!
MW9V/=BK$BMO-FBI+F<UQRMIFRBI*$]C[6KD>51J*V&ZUZBNK$HDQ5,?^[-!]
MP)'SAJK>RYUC8)YC8U4'_NS0?<"1\X:K2>A87.E*4!KSH$.YQ%Q)\5F5&<QQ
MLOMA:%8.1D'8[@5Q+HFM%N<UUTA6ER#'<MZ9(:$9QL*;X`\YA/"=L#`^"NUW
M"X1;7"<F3'>JCMXXE\)5C)P-@">9KAW1K?H5HU_K.X7'PF-$N,DNQ77(KH#B
M>M6?P=CA0.#0&IT5:2@7K5.L[?*4Z+1%FA)M[:BAM["W0CC(.2E(!PG."2"<
MXJ4NUNB:`Z;M,ITZ@PHEX`:EQ6U'JUY44YQV<P?(1MSKST-W)F'K+58EMR8Y
MNTP.0^NC.)#@XW3SQ@'"ASK'TBWF+*Z6M*3XR)3\6U/`3'6HKB@WAW?[W?`'
M9F@,G2#!<N?^D'IB&W,?AEZ"$E^.<.)3E[BX3V$C(SV9S7KI<T38]):2C7_3
MT3T-N<*6WP2&5JXE`Y]423DYP<G?X:U=1W^#+Z=]/7U@2G+5"CAI^4F*[P)4
M>M_LY('&G>K!TY7.//T(BV0P](F27&9#333"U$M[GB.!@#S[T!99MJ8U=;K1
M<M0RFTV$0427H:G"VAU]0!"G#D`H2.2<XR=^0KF)E6+3?39I]6B)2!`N2A&F
MLQE$L*)44^*>1Y@[$X([,UKZANR9$S0D^X1Y4K2EOC,LSV"POA:D)3XW6((W
MP.$CF"`<=M9];ZE@3ND#1>HHD28C3T)Y*!-,1:&W,+"B$)QQ$`8[-]\9Q0$]
MTV>S'H^]T#_$9K)K>_NWGI7A:1<@39]IAL>%2X,0I"I2^'B2%<2D@H&4G&=]
M^=0?2?J!J_:AT5*C09Z3`D>$36S%651P5MGA5@8X@$G(&:D=919]NUY:^E#3
ML9ZZ6TI#<QIE"N,)`*%'A(S@I[<;%.^QH#+J^T7&4W"N&C=#7.RWV&\E3<AM
MN,RA;>_$A80YXPY;$'M%=B@.OO6^,[*9ZF0MI*G6LYX%$`E/O'(JH1^E/35Q
MAA5H<D7&>L8;M[$=?7E7X*@1A'E43PCOJWP5RG($=<UIMJ4IM)>;;5Q)0O&X
M![0#VT!L55=7^N^D/=D?-GZM5575_KOI#W9'S9^@+4.5*#E2@%*4H!2E*`4I
M2@%*4H!2E*`4I2@%*4H"FV+[J>KOS.W_`+'JN1Y53;%]U/5WYG;_`-CU7*@.
M)6BS0M>],NK%:D9,QBT<,>)%=)ZM*22,X[>6?^+/=5@9M-DZ)+3JB^VR6\]&
M&%^AG6@MM.9`2D<U`DJ`R>S'/`K/J+HWN+FJW=4:3OZK+<Y"`B4E3(<:>Y;D
M=^PY@\L[&O%CZ)(L6R7V/>[D]<[E?$\,R;C@(WXAPC?DK!WYX&P`Q0%</2)K
MNP6ZRZGU#&M+M@NJT)+,5*DNQTK'$E62>?#D]O+&U9KKKS6S]\UG"L_H2U&L
M"2^7)#:BLMA)/"`#@DX.YQR\M;,?HAO<L6FUZAU5X?I^TN!<>(B-P*7CU(4K
M/(#;MVR!BIUKHX>;N6MI?HD@C4C!:0GJ3]HRE0R=_&]5Y*`IK?2AK5J!IO4D
MZ+:DV6ZRDQ#&:2KK3OPE>2=LD*(&_9G-;EUU[K:1?-9PK/Z$M1M/@O%R0VHK
M+8!/"`#@DX.YQR\M3,OHJ?DZ'TSIX79M*[-+$A3W4$AT`J.`,[>J_56ZUT</
M-W+6TOT2;(U(P6D)ZD_:,I4,G?QO5>2@*:WTG:U;@::U'.B6I-ENLM,0Q6TJ
M+IWX2O).V2%$#?&V<U,2]8ZSU'JV_6G1C-K8CV,\#SLP$J?<!(X1C89*5#WN
M>];LOHJ?DZ'TSIX79M*[-+$A3W4'#H"E'`&=O5?JKY=NC2^,:FNMXTEJ;T*]
M&$XFLN,=8.+M4D]AW)[QD[T!7IG3)>Y.C;!=+5!B(N$JXJM\IAU*E(+@"3XN
MX(!XAWXSVU8M,ZMU4QTE/Z0U3Z&NK7#\+8>A(4D#EXN_,>J&XSMVUB/0XQ&L
M6F[9`N7!Z%7`3WW76LF0OQ<[`^+ZD`<]@.=6-W1;CG2DUK#PU`;;@F)X-U9R
M3OXW%GR\L4!;ZY]<[>Q=.E63$E7!QB,NTQ>.*A24^%X>?(03ZKA&"2$XR.>V
MQZ#7*=70=6R^DV0YI.3;V)$>S,..>%MA96>M>X4H)2<$^-OM0RK<SJU#5'Z+
M]<NZYTX[(F1TL7"&\8\E*/4E6,A0'8#W=X-7@T,%5Z//8H?="=\Z=JU55>CS
MV*'W0G?.G:M5`<9Z8/9+`_,_\YJAHJ^=,'LE@?F?^<U0T5]!X5[#3\/RSDU_
M6,SHK87+O2Y*G&;PIEO@"$-".A24X[3GG6NWV5LHJ6+PE#$I*M&]B=&O5HN]
M.35^AXMD)V'+D3G9KTF?((ZR0H!)P.0`&P`[J^S+=<;L$LW"]ONP@L*4PVRA
MHKQR"E)W(K;;[*V45HSX=A6HIP7H[%BQ5=72D]=SZ^+BMM"(-S5#X=B.H0Z"
M/,KE\-8[19C;ERI+DU^3/EG+TI>`K;D`.0`[JVT=E;**IE@L/G=3(KO<GVFL
MXJ.9V6VI$3-/3KOABYWZ0_`*LKC-L(:ZP=@4I/,5*.V=;]YMLT2NKCP`KJXJ
M6ACB*2G/%G/(C;R5N(K916NL%AZ?Z8VUO\24L36FVY2;OH:4.S.-7^9='9A=
MZ]E+#;75!(:0%%0&0?&W)W->K3I]Z#'N`>N;C\F:]UQD)92V4*"0D83N.P5)
MMULHJB6%HK111+M%6]\SZ_$KT?2$EZZ19EVOLB>W%7UC4=+"64%?85<)\;'=
M6]<--W.7(<7!U&]"9<_HO!&W.$^11P?ASBIQNME'96M+"4;9<NA:L56NY9G=
M]YI::L$;3=I3!C..O$K4ZZ\Z<K=<5ZI1J>16LBME%8:25D5IWU9LHK9925J"
M1S-:R*EH;/`WQJ'C*_4*U:LLJ)Q1L(0$("1V53G_`+LT'W`D?.&JN=4Q_P"[
M-!]P)'SAJM,L+G2E*`&JOIN_7BZ7BXQ;A:U16&">J<X5#/C$8).RMM\BINXW
M>VVAH.W*X18;:N2I#R6P?-DBLD&X0KE&$B!+8E,$X#C#@6DGSC:HM-M.Y;3J
M1C"47&[>SZ$)?;U=K=>K;$@VI4J-(5AUT!1X-\8R-A@;Y-2MYER(%GDRHD54
MJ0TCB0RDG*C[WPUOTI9ZZF74AZ'H+3??77G]M"-L4V5<;-'ES8JHLAQ)*V3G
MQ=SCGON-]^^M:VW6X2[]<84BUN1XL?'4R23AW_SGM[]3=*6>FH\I"\GE6NV^
MFO+[:D1>;A/A/06X5L7-0^]U;R@K`:3MXQ_7\%2,E2FHKCC;1=6A!4EL;%1`
MV`K-2LV(.2:2MM]?[W&A9Y<F?:V)4R&N'(<!*V%JR4'/_AKY'F2W;Q*B.6]Q
MN*TA*FY16"ETGF`.8Q4A2EC+G&\GEWVWT\/MK<T;C)D0T,*BP%RBX\EM80H)
MX$GFLYY@5O4I62#:LE855=7^N^D/=D?-GZM5575_KOI#W9'S9^A@M0Y4H.5*
M`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@*;8ONIZN_,[?^QZKE5-L7W4]7?F=O
M_8]5RH!0G`R:5C?<#,=QQ25*2A)44I&2<#D!VF@.82NF^V-KDR(6G[W.M45P
MMO7%A@=4".T$GEYR*MDC7UA8@V*7X0XXB^.H:@I;;)*RH@;_`(.,C.?UUQ*)
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MT9N.3]3:5A:JZ]NV)BK-D:!X677`X22OO/$#SYD)'+F!^GJ4I0"N6ZK<UBCI
M)FIT@S;W'EV5A+ZIBL<'VU[A4G?GG//(KJ556+]U2Z>XT3^,_0&GT8Z&7H73
MCD65(3(GRGB_)<1GAXL`!(SS`[^TDU=C2AH"J]'GL4/NA.^=.U:JJO1Y[%#[
MH3OG3M6J@.,],'LE@?F?^<U0T5TCI4M-RN&H83D*WRI*$Q>%2F6E+`/&=LBJ
M4C3=]'^YKA\F7]%>]X76IQP5-.2O;KWLY=>+=1Z&FWV5LHK:1IV]C_<\_P"3
MJ^BMA&G[T/\`=$[Y.KZ*V95Z7O+YH@HRZ&LWV5LHK818+P.=JF_$*^BMA%CN
MWY+F?$*^BM>5:G[R^9)1?0UT=E;**S(LEU_)LSXE7T5L(L]S'^[I?Q*OHK7E
M5I^\OF347T,2*V45[1:;D/\`=\KXI7T5L(M5P_$9/Q1K7E4AU1))GANME%?4
M6R>/ZE(^+-;"+=-']3?^+-:TJD.I-)ANME'97Q$"8.<5_P"+-9T0I0_JSW^`
MUKRG'J329Z16RBO"(DG\7=_P&LK#:G'$MI'C$XK7E)=2:1OP(_7.<2AXB>?E
M/=4Q6-EI+#26T]G;WUDKFU)YG<N2L*IC_P!V:#[@2/G#57.J8_\`=F@^X$CY
MPU4#)<Z&E*`X%HZPP^E;7VI[SJ;K)<6`^(\6*7%)0E)*@.1R``D;`[DDFKQI
M3HU9T%J>Y7>WWAQJRO-'-N6@J"0!GB*R=^$@X.,X.,U5EV/6'1EK6\773ED]
M'++=5=:MAM6%M*R5`8&^Q4H#`((/8:E=&6C7&H;_`'F]:J<D6NW38ZF&K7UF
M4C*>$*X"3C`SN<$DT!H(Z6M7WN-<KSIG2C$FP0%D*>?=(=6$C)(`(WQ@X`.,
M]M;]_P"F3P;0=FU/9H3;PFS/!GX[^2ILA)*D@C&3ML>XC:JU9(?2'H33=VTC
M%TH;FAY;G@UP:='`D+'"3CM[\'&.VO%YZ,K]:^B[3MGC0US;@BZ^&2T,>,&N
M))'/MP`D9[Z`FY72MK2TZDCV2YZ0C";<6@J`PU)\;*B0GC5DC;!SRY5):=Z3
MKW+GZGL]]M,2)=[-"<EI2RX5(7PIS@Y)[TG(/(]E9=4:>NDWINTI=V(#KMNB
MQU)?D``I;5]LQGX14,-*WW[*>N[EZ&/^!SK0\Q&>P.%U90V`D>7(/P4!H-],
M^LW=(C4R-,6\VQA[J9+Y>4.)14,!"<Y`W`SON?)4DOI>U'$FV.?<-,L1]/7E
MX(C.==Q/\)('$<'`YYP1N*CX&D-0-_Z.EPL*[5(3=7)/&B*0.,CKD'/P`FMW
M66E;Y/T7T>Q(ML?=D6]<?PMM(&6>%"0>+S$&@)S4O2/>1K56DM'V5FY7)AOK
M)3DAS@;;&`<<QV%.Y/,XQ7BP]*DNXV;4S-QM2(&H;%%=?<BJ45-KX0=P>8&<
M`C/:"#45=K'JK1?2K/U78;(J]6^Z-<#T=MP(6A7BYYY(W3D'!&Y%:MDT;J:>
MWKC5=ZM_@ERO-N?C1;>@@KP4X&=]O4I`SN=SM0&%/3#K9S1R-5-Z7M_H2TYU
M<AXO*'$KBQE"<Y`W"<G.]=DL=V:OMA@79A)0U,CH?2E7-(4`<'S5R&/I*_)_
MT;W[`JUR!=E.DB+@<9'A`5^S>NFZ$A2;;H.QPIC*F9+$)IMUM?-*@G<&@+#5
M5U?Z[Z0]V1\V?JU55=7^N^D/=D?-GZ`M0Y4H.5*`4I2@%*4H!2E*`4I2@%*4
MH!2E*`4I2@*;8ONIZN_,[?\`L>JY54)6G=01M67*]66YVUI,]EAIQJ9$6Z4]
M4%8(*7$\^,UE\%UY^5]/?HU[^=0%JI55\%UY^5]/?HU[^=41I>Z:YU-IV)>&
MY^GXZ9''AI5O>44\*U)Y]</P<^_0&Y.Z)=#W*XNSY-@9,AU?&LH=<0E2N9/"
ME0&_FJ4O.AM-7ZTQ+7<+4RY"A_\`MVFRIL-;8PGA(P,=E:W@NO/ROI[]&O?S
MJ@[-<>DVY.71,R-9[>(CI0PIV"ZKPH>-XR</#`V'^*@)N\=&VD;\F,+C9673
M&:2RTM*UH4$)&$I*DD$@#OS4@O1^GW--C3RK5&-I`P(W#XH[<@\^+._%G/EJ
MK:8G])E\MKDFY,V:S/)=*!'D075J4G`/%D/#;<CWJPZIN?2E88K<BV0K+>D'
M/6HCQ'4+;[O%+I*@?)\%`6*T='>E+%#FQ;=9VFFIS19D96M2G&R,%/$22!Y`
M:S.Z$TT];;;;UVILQ;8OK(:0M8+*LYR%`YY[\ZH>FM3]+E^N28\K3MMM489+
MDF9%=`3YD]8"H^;X:SRM1]*L;6+=E%FMSL%;J$>BC<%TM!"N:R.LVQOD$]E`
M=7I7&KSJ[IAM-U<AMZ5M\YL*PW)BQG5MN#L/^T\7S'E5A?E]*C.F?1%,:P.W
M$)"E6U##G$-]P'.MX20-\>]F@.B5R?7&N6=#ZYN$@1U2[A*M,1F'%2#]M7US
M^<D=@R/*<@"L&F]4]+E^NR(DK3MNM4;&7)4N(Z$I'D'6`J/D'ZJ@[QHC5/2`
M_J*Y7ZWB'=K=';8M#C"5-MO\#BU$@%1.5#`&^V10'9M.R+Q+LK$B^18\2<Z.
M)4=A14&P>223S5W]E2IJMZ%GWFX:3AKU!`?AW1I/5/I>&"X4_?CSC!\^:LAH
M"J]'GL4/NA.^=.U:JJO1Y[%#[H3OG3M6J@%*4H!2E*`4I2@%*4H!2E*`4I2@
M%*4H!6C;XG5%;RQXZR<#N&:WJ5)2:31BPI2E1,BJ8_\`=F@^X$CYPU5SJF/_
M`'9H/N!(^<-4!<Z4I0"E*4!\VK[SK\X](\UMWI>D0M:7*[0=/H9287@6>$^*
MGQL;]O'D@$Y`'*K)T=B7IX7Z;9-1-ZETVS&6['@MNK7+0X,%(ZLI\4GQAMSV
M.*`[52N'=#W2'<IS%\?U%X<\RE;DMVYNC[0PE*$_:]AA)QN$CX*E!T\P<^&G
M3-X%BZWJO1+@'!G..7+WN+-`==Q3:J1JSI/L^FK9;)##;MTD70!4&/$W4\#C
M!SV#<#D3D\N=0[/27'U-:=2V25;)EFO46VONJBRN93U9W!VW&0=P-CD9H#I_
M.E<`Z.>DB%I3H\M4)QB3<[M.FNH9AQU`N8X@`3GED[#OW[C7>8CCST1IR0QU
M#RD`K:XPK@/:,C8X\E`9L4I2@%575_KOI#W9'S9^K555U?Z[Z0]V1\V?H"U#
ME2@Y4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%4SHH^YK:/^=_&75SJI
M-=&VFX[8;8:N++8)(;:NLI"1DDG`#F!N30%MS7S:JO\`8]L'?=?TQ+_F4^Q[
M8.^Z_IB7_,H"T;4JK_8]L'?=?TQ+_F4^Q[8.^Z_IB7_,H"T;=WZJ;=WZJJ_V
M/;!WW7],2_YE/L>V#ONOZ8E_S*`M&W=^JOM5;['M@[[K^F)?\RGV/;!WW7],
M2_YE`6C;NIM57^Q[8.^Z_IB7_,I]CVP=]U_3$O\`F4!:-J$U5_L>V#ONOZ8E
M_P`RGV/;!WW7],2_YE`?.CSV*'W0G?.G:M5:-GL\*Q6QNWV]I3<9LJ4E*G%+
M.5**E$J422223N>VMZ@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%4
MQ_[LT'W`D?.&JN=4Q_[LT'W`D?.&J`N=*9'?3([Z`4ID=],COH#BFKM47*Q:
MWG0M::?]&M*/#,$M04+ZLG!V)&ZAN""0>1%1719:US^E*XW_`$_9I=ITWX.M
MH-OY`42`.$9_M#BP"0GX*[_M3:@/S5H&-*EZ*U=H`PYC-ZDEU]OC;X6\H"/$
M*B=B2G'+&#64:P?7T3CH]3IFZ>C_``^"=5X,>#U?%Q]_%Y,<]\XK](;4VH#\
M]7[3EXT(_P!']_DP7I\>T1DLS41QQEI7$I1_?(!Y93SY5:8FM[CK4:H3;M.J
M8LB+8\!.?:*'G7.J(",;@G/8.0'E`KKFU-J`_*.F]*WO3&G+5T@VUB2[-B7!
M2)$)3)!ZG9.0,9P<J!/]H=U?J2UW!F[6N+<(X6&9#:7$A:2E0!'(@\B.1%;6
MW?3:@/M*9'?3([Z`55=7^N^D/=D?-GZM61WU5=7^N^D/=D?-GZ`M0Y4H.5*`
M4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H
M!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%5V]:21=KY'O
M#-WN-NF,QE1@N&6_&;4H*(/&A7:D58J4!5?2A<?;MJ+X8W\FGI0N/MVU%\,;
M^35JI0%5]*%Q]NVHOAC?R:>E"X^W;47PQOY-6JE`57TH7'V[:B^&-_)IZ4+C
M[=M1?#&_DU:J4!5?2A<?;MJ+X8W\FGI0N/MVU%\,;^35JI0%5]*%Q]NVHOAC
M?R:>E"X^W;47PQOY-6JE`57TH7'V[:B^&-_)IZ4+C[=M1?#&_DU:J4!5?2A<
M?;MJ+X8W\FGI0N/MVU%\,;^35JI0%5]*%Q]NVHOAC?R:,Z+7Z)P)LW4EYN'@
M+_7M,R2SP<?`I&3P-I/)9[:M5*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4
MH!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I
M2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2
ME*`4I2@%*4H!2E*`4I2@%*4H!2E*`5AERX\&*[*EOML1VDE3CKJ@E*0.TD\J
MS5S#IS4L:0MR7>(6U5U8$\IS_L=^?DSCW\4!<[+K'3NHI"X]HO$28\A/$IMI
MSQL=^.>/+4YFN<O.]'476EF5%1$1>$175Q'(`/5MM!!)*PV<8X>+'%V9JCZ>
MU=J)>K]+.B]W6;;KM+>;4Y,0RTU(0-OM;*25(`[R>?+MH#OV12OSE'U1JYG1
M;.JE:GF.+:OO@0B*0@MK;SD\1QD]WD%6*;?[Q=+WJR6[K7TO-62<B-'8+:5-
M%'%CB6GU2N+_`+]W(#M=0TW5=BMST]F7<F&7(#:'925$Y:0H@))V[<CX:XSJ
M'6FJY6H-2/6^XS([=H6RB*EE4=N,0?OWNM4%$+[,9YBM75\AV7+Z0)+[:6W7
M;';W%H2H*"5$M$@$<]Z`_0D>0S*C-26'$N,O(#C:QR4DC((]ZLA(`R3M7YZG
MZIU,N4NVVV=/B1[188CS/@BF$(*U--JXWBZ1E&3C;/TS:M1Z@U)J.%;Y>H_2
M^AFP(N*S'+92^\1N>(Y"D=N`2,`^<`=>M-WM]\MZ)]LE-RHJRI*76SL2#@_K
M%15QUYI6TW)5OGW^!'EI("VEN@%!/8KN]^JOT)%Q71+"+9'6%R04DC;/6*Q^
MNJCT<(TBKHYOBM2"";GU\CT3,SAZ[BWQCB\;S8^^SVT!W5MUMYI#K:TK;6`I
M*DG(4#R(/:*QRYL6`QU\N2U'9X@GC=6$IR3@#)[2=J_.^G+M?VK-T=69%^DV
MF-<3+;6ZDC):"_$]4,9YA)[,BL.H[A>+QIB1!G7]V6BT:F1#:F`)^W)5GA4H
MC8E&"1_]J`_0\>\6^7=)=L8EMN38809#*3XS84,ISYQ6]FN&7K5%WTU<.D*1
M!DB0_!BVYME]322<K2E*G3@;G<G?(R>ZLHO]]T]?D6M&JW;XS/L+\Q3BP@JC
M.H:4I*TE/($@8![Z`[=FF:X1I^_:JC-Z`O,K4DJ8U>Y*HTJ*ZE`;2@$I!&!D
MG8DJ)YXK7LVK]2Q=4VZ1?+W/5#EW0QTR899DP)`*L!M(3@H\^21W4!W^E*4`
MI2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4!J7*YPK/;GKA<)"(\1D`N.
MKY)&<;^^141;->:4O,MN);[_``'Y+A*4,I>`6HXS@`[FHKI@^Y3?_P"Y1_$1
M7*FX$YW6^CK3J2)9;,QQ,S(4VVQ2DRU`)PTI9.RCMG(YD=XH#]&9ID5^>5:Y
MUA(GSKRQ,EIZB]&(B(MR.W##8..J4%J"^L([<?KY;-ROVH7Y72!*;UG(@^@4
MHJAPQP$+'$?%.1DIV"0!VG>@.WMWBWNWEVT(E-JN#+0><8'JDH)P%>:MZN$M
MZB>;U1>]0299MTAW2,60I]#'6EE:^#DC(R<JV!/GK6L^M=46BZ79MZ9<933>
MG%W)ENY*96OK!CA<PV?$2<D\).<<^R@._P!*XI:]07:T6B)>G-;^BDJ797IQ
MM4AM*BMT(*O$*<<(21N#SX3[T=I756K5R[4Z_<ILABYVZ2\^)CL8)"DH6I*V
M$I5QX!&""/>[@.^9'?2OSW:KEK23`T/)5K"<E>H77H[R2VVH--I.`4Y&Z\9.
M3VX[J]R=::J@Z>D6I-VE/R$ZH7:A.`0'^I`!X0582%$\B<=OO`?H'->''6V6
ME.N+2AM`*E*4<``=I-?G^Y:PU?`TE=&C<I+3T.]L,1Y+SK*Y'5K"^)MT-DC(
M*1Y\UMZE7?XR]=:8FZCESHK-F3/;==0D+!R.)&P`"59(QW8H#NC#[,J.W(CN
MH=9<2%H<0H*2I)Y$$<Q4!*U]I.%<U6V3J&WM2T*X%-K>`X5=Q/('SFHK1;,Q
MCH@@)BS7)<LVSC96<$H46\I0,?@D@#MVKG>DD:*5T%SU7/P$S^JD&87^'PCK
M\JX,9\;/J<8^F@.]I4E20I*@01D$'G6&3,BPTMJE2&F4N+2V@N+">)9.`D9Y
MDGD*X#8+GJ%Z3H/3[FHY=H8FV=:G%)*>(@+<+>.,;$H2@`]W*H^X7"\:DL>G
M#/OSREPM4*MK<U`2.L`P4O\`=Q)WQV8/OT!^AX5XM]PF38D24V](A+#<EM)W
M:41D`UO9K@]ZU=>;`G7SMO?0V\FZQ8K<DMI^T)6E65G;<[#<YYUGGZAOVG+I
MJ&QLZH>O+(T\Y<&I:N`N1G4C;"D]AV(']I/G('<<TS7#[)?=46^[Z'ES-1O3
M(]_@O+D-2DI2TT4M<22,`$`;$G.^#WUJZ/U9J1G55C3?[O<U-7&0XREULLR8
M,PY(`;4C!;P>T%79L!F@.]4IV4H!2E*`4I2@%*4H!2E*`4I2@%:\V#%N4)V'
M-CM2(SR>%QIU(4E0[B#6Q3-`5^R:'TSIQYUZTV:+%==24K6E/$HI/,9.<#R<
MJP1.CO2$"8U+B:?@LR&G0\VXVC"D+'(C?;S<JL^:9H"!])6G/0GT+]"(W@/A
M'A748/#UOX7/G7FXZ'TQ=KKZ)S[)"D3?%)><;R3CEGL/OU8,TS0%=NNA-+WN
MZ)N=SLD23,2`.M<3ZK'+B')7OYK8EZ3L,]V<Y*MC#JYS2&9)(/VU",<*3OR&
M!\%36:9H"N7/06EKRN(NX62)(5$;2TR5).4H3R3L=P.XYK/=M&Z<OBHQN=FA
MR3%1U;/&T/$3V)&.SR<JG,TS0&C:;/;[%;T0+9$;BQ4$E+38PD$G)_74+<^C
MK2%XN:KE/L$-Z6H\2W"DCC/>H`@*/G%6C-,T!2=2]'T74>IK!,D-Q%6JVLOL
MNPEM[+2M("0G&PP0#[VU2XT1ID:?38A9HGH8%]9X/P>+Q_A$\R?+G-3^:9H"
M&C:3L$1,I+-JBI3+81'?249#C:$\*4D'8@#:L%LT/IFS(E)MUEAQQ*:++Q0C
M=:#S23SP>ZK!2@(9O2EC:C6V,BVL)9MCG6PT`'#*LYRG?RUJQ]`Z4BW=-U8L
M$%N:ESK4NI:W2O\`"`Y`^]5CI0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E
M`*4I0"E*4!J7.V0[Q;GK?<(Z)$1X<+C2^2AG._O@5JW/35FO,.-$N%N8D,15
M!3"5C_9D#`(/,;5*TH"NNZ$TN]?O1MRR1%W+C#G7J1DE?X6.7%Y<9JOP.BJS
MN7R]W&_0X5R,VX*F1N)LY:2?O5=_FW%="IF@(B3I>QRY,J1(MD9UV7'$5\J1
MGC:'))'+`P/@K4MFA-+6:4)-NLD.,]P*;*T(YI5ZH'O!\M6+-,T!7[5H?3%D
MEN2K;8X49]Q!0I;;8R4GF-^0/<*QVS0&E+-+>E6^Q0X[[R%(6M*3ZE0P0,GQ
M01MMBK)FF:`AF=*6-AJV-M6UA*+6I2H0`/V@GF4[]M8W]&Z=DP9T)ZT1G(\Y
M\R9"%)R''3]_Y%>48J=S3-`5QK0>EF+.+2U9(B8(>#_5!)P7!L%$YR3CO-;\
MC3EGES9DR1;V'9$R/X+(6M.>L:_`/DJ4S3-`:%GLEML$`0;5#;B10HJ#38VR
M>9J%E]&^CI]T5<I6GH3DI:N-:R@@*5WE(/"3YQ5IS3-`434?1Q%U+K>V7:>B
M*]:HL)<5R$X@Y43Q<)!'+&1\%3CVB-,R+''LKMEAJML=?&U'X/%2K?<=N=SD
M]N:G\TH"'3I2Q(8GLBUQBU<`D2T*1D/<(PG(/<*UX.AM,6R%,APK)#88FHZN
M2E"/]JG\$GGCR58*4!$ITS94*MBDVYD&UI*(6Q^T`C!"?>VK2M^@=*6JZ(N4
M&PP8\Q!*D.MMX*2>9`Y#WJL=*`4I2@%*4H!2E*`4I2@%*4H!2E*`'D:YI9--
MQM37O54BXS;KQ1[RY':2Q<7FDI0&FU`!*5`<U&NEGD:IN@_7'67N^[_!9H#U
M]C:R_CE\_3$GZ]/L;67\<OGZ8D_7JX4H"G_8VLOXY?/TQ)^O3[&UE_'+Y^F)
M/UZM4N2F'"?E*0XXEEM3A0VGB4H`9P!VG;E45I/4K&K-/L7>/$E16W5*2&I*
M.%8X3C.VQ&U`17V-K+^.7S],2?KT^QM9?QR^?IB3]>KA7,M57R_V7I5TM;H]
MX<-LNSJP[$4PWA(3@8"N'BWSGG0$[]C:R_CE\_3$GZ]/L;67\<OGZ8D_7JX#
ME2@*?]C:R_CE\_3$GZ]/L;67\<OGZ8D_7J,Z7[I?=.Z1<OEDO#D-<=;:%,AA
MM:7`I7#G*DD@[CMQM5]AN*=A,.+.5*;22>\D"@*K]C:R_CE\_3$GZ]/L;67\
M<OGZ8D_7JX4H"FZ(BBVW?5%M;D2GHT6>TED29"WE)"H[2B.)9)QE1-7*N;QM
M96#36M=6Q[O/\&==FLN(3U+B\I\&:&?%2>T&I7[*^BORU_\`BO?4H"YTJF?9
M7T5^6A\E>^I5LA3(]Q@QYL1P.QY#:76G`"`I*AD'?R&@,]*4H!2E*`4I2@%*
M4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`HVN8WHCJ;2-K<DRV8LN7(2\(TA;
M*EA,=2@.)!!Y@&MG[&UE_'+Y^F)/UZ\ZI]GNAOSR5\U75RH"G_8VLOXY?/TQ
M)^O3[&UE_'+Y^F)/UZN%*`I_V-K+^.7S],2?KT^QM9?QR^?IB3]>MYO5B7-=
MNZ7]#)P4W%$CPPH^TG.-L^_C/>"*L5`4_P"QM9?QR^?IB3]>GV-K+^.7S],2
M?KUL=(;]PA:)N=QMER>@RH3"Y"5MH0KCX0?%(4D[>;!KUT>W*9=]`V6X3WU/
MRWXP6ZXH`%1R=]MJ`U?L;67\<OGZ8D_7I]C:R_CE\_3$GZ]7"M>;'<E1'&69
M3L5Q8P'F0DK1OS'$"/A!H"K_`&-[+^.7S],2?KT^QM9?QR^?IB3]>HOHGO=X
MO$74+=YN"YST*[.16W%(2GQ4@=B0!SR:Z)0%/^QM9?QR^?IB3]>HRX:9BZ:U
M#IB1;YEUXG[GU#J7[B\\A2"PZK!2I1'-(^"NAU2^D&Y1+.]I>X3WNIBL7@*<
M<X2KA!CO#D`3S(H"Z#E2J8.E?16/7K_\5[ZE/LKZ*_+7_P"*]]2@+G2H2P:M
ML>IU2$V><))C\/6CJUH*>+./5`<\'X*FZ`4I2@%*4H!2E*`4I2@%*4H!2E*`
M'D:IN@_7'67N^[_!9JY'D:IN@_7'67N^[_!9H"Y4I2@(O43]RBV*7)M3D5$I
MEM3@\*;4M!"021A*@>SGGWJYA<.DW4['1);-:,-6GK'G%-R&'&'",]8I*2DA
M>VR1D'-=*U7/C6_3-P=DN<"5L.-IPDJ*E%)```!))K@4Z6E[_1U@6!#4DW5J
M7XT3P=?&!UBU9QCE@C>@.DZCUEK33MB;U1)MEJ]"`ILOPN)9DH0L@`\>>#BR
M1L`0,\SSJ'Z29KJNDKH\FV^-X6ZLN+89*PWQ\7!C*CG`WW.#[]2'2==H=QZ&
MW&(:W'WIK;28[;;*RI90M!4,8R,8.<XJMWV]PI>LNCF:R7U1K<R/#'/!G,,$
MA(PKQ=CD'S4!=/3?J;3^M++9=3-6EV+>>-$=^WAQ):<3CQ5!9/$-TC.W/WJR
M7_46MHMLN-]MMNMC5L@\:Q%G)<$E]ILGB7D$!&0"4@@G&">>*KO2=<HR^D+0
MSS9=<:MTHORUMLK6&4*+9!)`[@34$]>57Z%JR'JE-TDZ@)>:M=L;9=+*6^`\
M"T)3XBN\K5V`$<Z`LG2G>F=1=`ZKPPA3;<Q,9T(5S3EQ.1[QR*L%YUPW:KG:
M-.1)-OCS9$42'I4]SA9C-`8!(R.-1(("<CO)KE]UOL>X?Z/D.PQ8\QR>@,-=
M6(R]U)7Q*QMN``,GEE0%3]T4+9KVS:[9ANW+3\B`F#.4TPI:HR@,<101G'J>
MSL(YXR!<+)KQ3NM4Z8FS+7/,EA3\.=;5^(KA]4VM'$KA4`"<YP15]JJ6S4UC
MN=RC,6"*)Q4>)Z0PQP-QD<).5+(&YV`2/&WY``U:Z`JNF?99K+W09^:LU:JJ
MNF?99K+W09^:LU:J`UKAZVRO[E?[IJ'T']SW3?N7&_AIJ8N/K;*_N5_NFH?0
M7W/=-^Y<;^&F@+#2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*5C9>2^WQI
M[R".XBE@9*4I0"E*4!3=4^SW0WYY*^:KJY53=4^SW0WYY*^:KJY4`I2E`<Z@
MZDU.]TEW32;\JV%+-M\*COHAK`"RI('$GK-P`HC8C.QVY5':,U;KK6-ON26&
MK1&=AS'6%376EELD`80AL*R3S)43@`C`)SB/BZEML?IVN%X<5(%M<M0BIE>#
M.<'6!221GA\AWY5FZ&KS&A6W4,68E^,YZ(/STAUA:>)@A/C#*?)RY^2@,[VK
MIFJ>BC6C-TBM1[I:VY$.4E@DMJ4$GQDYWQSV\E:&F;GK2V]$D&[VMNTLP+=!
MZP1Y25N.R4(R5JXDJ`1MR&"=MR,XJ`@WF*WI[I-C+1+2[=I+[D%)B._;TKX@
M.'Q?*.??5HM-YAL_Z/ZX3BGDRT6YR"IDQW./KU(7PHQPYW[^7EH"UQM37O4E
MBLTG3T)B.Y<(WA+TF:E2VHXV'"`D@K63G`R!@$GNK%HO5MUN.H+WIG4#$5-T
MM10KKXF0T\VL9!P22#N/A\E<QMVHI;&GM%09B[G#TVPA;%X,5MUMQ+@*N!"U
M)`4$$<)\7F">ZI/2MWM>G.E2_2F[7/AVJ=%8,3,)Q.6Q@*=((R$[*5E6Y\YQ
M0&UH74L32.F]>WJ:%*:CWY_#:?5.*)`2D><D5-7#7=VL]A3?WKQIV;PA#DFT
M1E8<2@D9#;G6'B6G.^4X.#RJ@6JU.:MT7K.QQFWF;K-NR[E"8?96WUR`0=B0
M!N,C<\\5TW3W2%:EV6,Q<X,R+?&6@V[;C!<+RW$C!ZL!.%`D;'.V=\4!>H$U
MFXV^--CJ*F)#276R1C*5`$?J-5W5_KOI#W9'S9^K#`=D/V]AV5%\%?6@*6QQ
MA?5D_>Y&QQY-JKVK_7?2'NR/FS]`6D<J^T'*E`56U_=+U'[GP/WI%6JJK:_N
MEZC]SX'[TBK50"E*4`I2E`*4I0"E*4`I2E`*4I0`\C5-T'ZXZR]WW?X+-7(\
MC5-T'ZXZR]WW?X+-`7*E*4!@F"083_@A0)/5JZHK]3Q8VSY,U'V07H61(NZF
M%7'QMT>I_LYQ_P!JEZ5BVMR:G:#A9;WOS_\`A$Z?%Y%LQ?%,*F=8K=GU/#V?
M]Z^V/T9,=_T:,?K>N5U749QU?9GRU*THE:Q*57-F]%*_=MX="-M7HL7)GHIX
M-P]<?!NHS_L^SBSVU[@>B?A<[P_P;P?K!X)U6>+@Q]]GMJ"U;KNWZ7'4</A4
M]0RF.A6.$=A6>P?K-<QF=*&IY#Q<:E,14=B&F4D?"K)KJ8/@V*Q45.*LNKYF
MO5QD(MII:]%L=LC^B!N4OP@L>!81X-P9X\X\;B[.?+%>VA.]$GNLZCP+@3U7
M#GK./?BSV8Y8KA\3I0U1'="W);,E':AUE.#[Z<&NFZ1U[`U/_JRD^"W`#)84
MK(6!S*#V^;F*8O@V*PL<\E==48ABH5'9*W+^]Y91X9Z(G_8^!=5MSZSK,_!P
MX]_-;-*5S"UNY5=,^RS67N@S\U9JU55=,^RS67N@S\U9JU4,&M<?6V5_<K_=
M-0^@ON>Z;]RXW\--3%Q];97]RO\`=-0^@ON>Z;]RXW\--`6&E*4!5=4:[A:6
MGLQ),22\MUKK0IKAP!DC&Y'=4*.EVU'_`'=._P"CZU5WI@]DL#\S_P`YJAHK
MUV`X/A:V%A5FG=]_>:%7$3C-I'8ATL6L_P"[YO\`T?360=*=L/\`4)O_`$?3
M7(6^RME%72X)A%R?S(]IJ'6!TGVU7]1F?]'TUD'23;C_`%&7_P!'TURMOLK9
M15,N#X5<G\S*Q$SIPZ1;>?ZE*_Z?IK(.D"`?ZG*_Z?IKFJ.RME%4RX5AER?S
M)^7F=%3KN$K^J2?^GZ:]C6T,_P!5D?\`3]-4!%;**IEPV@N7U)*M(O2=8Q%?
MU9__`*?IKV-613_5W_U?35*;K915,L!17(DJLBX)U/&5_0/?J^FL@U%'/]"[
M^KZ:JC=;*.RJ982DB7E)%E%]85_1.?JK6@2^IDG)^UN*W\GEJ+16RBJG0A%-
M(SF;+32M&WR.L;ZI1\9/+RBMZM"47%V9:G<4I2HF2FZI]GNAOSR5\U75RJFZ
MI]GNAOSR5\U75RH!2E*`A&T7_P!-+JENQ_07JO$0/5\>![_//DQ7M;=[],S:
MTNQ_0;J3Q(Q]LZS_`,Q4Q2HY>\N=;_JMK;?7Q[R*DHO!OT14=R.+4&U>$)5G
MK"KLQ^K]=>IJ;L;I!,-<<005>%AP'C(QMPU)UI76ZPK+;W)T]Y++".9/,GL`
M':3W5*,')Y8ZMD?*VL[+16V\=7WZ[^!XG(N9E0C!<CI8#F90=!*E(QR3CMKU
M<1<"B/Z'+CI4'D]=UP)RW]]C'WW=7);UTM724ZM%H8;AL<DK=2%N'R_@CS;U
M"CI)U7D?^J@X["PW]%=NG_CN,G',[+N;_9,U7CH)K2]N[[G=K@F<6$>AZF$N
M]8GB+X)'!GQL8[<<J]S1+,17@)9$C(X>N!*,9&<XWY9KF>G.EHN/HC7]EM"5
M'`E,@@)_^R=]O*/@KJ33K;S2'6EI6VL!25).00>1!KG8O!5L+++55K_+X%M.
MM&:67E_=3W55U?Z[Z0]V1\V?JU55=7^N^D/=D?-GZU3):ARI0<J4!5;7]TO4
M?N?`_>D5:JJMK^Z7J/W/@?O2*M5`*4I0"E*4`I2E`*4I0"E*4`I2E`#R-4W0
M?KCK+W?=_@LU<CR-4W0?KCK+W?=_@LT!<J4I0"E*4`J*U)>$V'3\RY*2%%E'
MB))]4L[)'PD5*U1>EHJ&C`$YP9385YM_^^*V<'25;$0IRV;1"I)Q@VCB4J4_
M-E.RI+BGI#JBM:U'=2C786;)IO06EV9]V@HF2U\*5J4T%J4XH9X4A6P`W^"N
M,U)6JW7*_P`YJW0^L>6H\7"I9X$#M4>X#OKW>/POE813GDA'>VEUX\CF4IY6
M]+MG5G;)IO7FEW9]I@HARD<00I#00I+@&>%03LH';X=JXY&D/Q)+4F.XIE]I
M06A:3NE0KM$QV%T;:&\";>#L]Y*N`=KCJA@JQV)'_8#F:XE6GP7-*-2S;IW]
M&_3G\">(LFNO,_2FE[T-0:=AW'`2MQ&'$C[U8.%#X1^NIBJ!T0E1TB^"/%$Q
M?#_A3G]=7^O(XVE&CB9TX[)LZ%*3E!-E5TS[+-9>Z#/S5FK555TS[+-9>Z#/
MS5FK56J3-:X^MLK^Y7^Z:A]!?<]TW[EQOX::F+CZVRO[E?[IJ'T%]SW3?N7&
M_AIH"PTI2@.,],'LE@?F?^<U0T5?.F#V2P/S/_.:H:*^@\*]AI^'Y9R:_K&9
MV^RME%:R.53DZ"ZNX0RVN)'AJC\)*U!*EO$C`'?MFJ\=CZ6$E"-7:5]>EB_#
M82IB(R=/>-M/$U6^RME%>41'1,,7"2Z,$@'D.^M@Q^K;4X'F7$)5P**%@\)[
MCY:JGCL-FC'.KRVUW,K"5[.61V6YZ1V5LHK&AGA0A;CC306>%'6+`XCW"LZ&
MU=:6\>,GF.ZM=XS#MRBIJZW)]EKI)Y7KL9D5LHK6;*"E2DN-K"3A12H'![C6
M93K;"`MUQ#:<@96H`9/(;UK2QN'<<^=6+%@Z^;+D=]S;;K916CX0TTM"%K2E
M:\A*2H`JQSP.VMAN4R6RM+B5!*BD\)S@CF#W8JAXNA)-J:T)/"5XM)P>IOMU
MLH[*C8D^-*0E33R%)5ZDA0(5YB.?(T3?(`F")UZ.OQQ=7QIX\=_#G.*UYXJC
M92S*S)QPE=MQ47=$TBME%:D=Q#S:7&UI6A7)23D&MM%1EJ5)6-IE:D+"DG!%
M3C3@=;"QV_JJ"16]$=ZM6#ZE7.M.M&ZN3BR2I2E:I84W5/L]T-^>2OFJZN54
MW5/L]T-^>2OFJZN5`*4I0"E*4`K@G2/J)V\ZD>B(6?`X*BTVD'92QLI7GSMY
MAY:[T:_+4PJ5.D%>>,NK*L]_$<UZ/_&Z,9UIU'O%:?$U,9)J*74OG1II&%>_
M";G<VP]'86&VV5>I4K&25=X&1M5GM=ZT3J6ZKL;-E9'$%!I:XJ$I<P-^$C<;
M9(Y5QEMYUG_9NN-__19'[*ZQT>Z/59$G4=Z4(ZDM$M-K/#U2"-UK[CCL[!Y:
MW^*X=0SUZM1W?Z$M+/\`/>4T)7M&*\2C:UT^WIK4CL)A2C&6A+S/%N0DYVSV
MX(.]7;HDU$ZX'[#(65);1UT8D\DY\9/FW!'OU1]9W].H]2R)K0(CI`:8SS*$
MYW]\DGWZW>C0J&O8'".:70KS<!__`%6SBJ$JO#/^?]2C?XI?VY&$E&MZ.USO
M]575_KOI#W9'S9^K555U?Z[Z0]V1\V?KPATRU#E2@Y4H"JVO[I>H_<^!^](J
MU55;7]TO4?N?`_>D5:J`4I2@%*4H!2E*`4I2@%*4H!2E*`'D:IN@_7'67N^[
M_!9JY'D:IN@_7'67N^[_``6:`N5*56-0=(>E-+3!$N]X98DX!+*4J<6D'ED)
M!Q[]`6>E:-IO%NOMN;N%KEM2HCGJ76E9'E'D/D.];U`*@]764W_3$RWHQURT
M\31/X:3D?LQ[]3F:5.G4E3FIQW6IB235F?E933B7BRIM0="N`H(P0K.,>?.U
M?H32>EVM,6(,L)0J>ZCB>=6/5+QL-OO0=JB=8='K=ZE>BEK>3$N8(42?4.D<
MB<<E;#?X:HLQOI(@O=6ZY>E'L4RLN)/OIS7JL1B%Q6E&%.HH=4^OY1HPCY"3
M;5R?N_1G?[U/<GW"^Q77E#_XE`)'8E(SL*Y6$*4L(2DJ43PA*1DDYQ@5=(C?
M2/.=ZII=[!/,NK+:1YRK%7?1?1PU8GTW&YN-R;@G=M*?4,GO&?5*\O9V=]7Q
MQ_8*35>I&3TRJ/\`!%TO*R]%-=;E@T99%:?TO$@N@!_!<>Q^&HY(][E[U3]!
M2O'5:DJLW4ENW<Z$4HJR*=IF;%&NM8PC(:$HS&'0SQCC*/!FAQ8YXR,9JXUR
MUG2B[QTIW:^)N0B&TW-I02E@%3H5%9XDE?$,)(VQCO-=2J!DUKCZVRO[E?[I
MJ'T%]SW3?N7&_AIJ8N/K;*_N5_NFH?07W/=-^Y<;^&F@+#2E*`XSTP>R6!^9
M_P"<U0T5?.F#V2P/S/\`SFJ&BOH/"O8:?A^6<FOZQF='+WJF;S85W:ZVA_A:
M=1&95EM9W23P\*P.WD1\%0R*QN6F#)?6^]'"W7!PJ45*SC;R[<NRM7BF!J8F
M5.=)I.#>^JU-O!XJ%&,X33:E;9VV)YFXLOZ^E,-.I4EFWI:=5GQ0YUA4`3WX
M)J'GQYUGTQ/;=AV*TL2`6_%==XE*.P4"`<GM'.L\"WQ(#!9BQT--J.5`#U1\
MN>=&=/VE$I$E,%OK4'B225$)/>`3@?!7!?\`CTXY;37?OUY'0?&,RE>/6WQZ
MDG-LIO-PLTQU#3[45E86A6X#A"<*P>?(_JKS;$VQ-UO<:#,>7-4D"0ZMU2TH
M4>+A`).`1D[#E7B7:H-S"!,CI=X?4GB*2/?!!K:@6N#;XIBQ(K33"LE2`,A6
M>><\_?J3X1.SIYEDUMIKKWD5Q*.=55#TM+ZZ:*VQH")!T=HA],E#++IBE#I2
M?&?=*2.?WQ)/O"O,N,J:-&1;HWUI6KB?0X,A2TL$[CMWK>CZ6L;4M,I%M9ZY
M)XDE14H)/D!)`^"I15JA/71FY.1PJ8RDI;=*CE(.>S..T]E5+AE3.ISDMT]-
MK)6$L?'(Z<(V5FM]=7<BE16I72$7'VTK\$M:5L\0SP+4Z05#RX&*^1&7)!U6
MPEIM[BF<*67E%*%$LH\4D;@'E4[$M$"+<),]F.$2I0P\YQ*)6/,3@>]62WV"
MU6^$_#C0FT1Y"N)UM1*PLXQOQ$]E:\N%/*HYN5OK=%RXGZ3EEW=_I:Q476[C
M;T6BWN"QVU)F-*9:84[Q$I4"0D<.Y(R"3W\ZGID`29SA?ML%^(L*;Z\G#S2,
M'(.1OW92H>:I&UZ2L%JFB;"MC+<E((2Z2I:D^;B)Q[U9I^CM/7>4J3.M;3KR
M_5J"EIXO.$D`U5+AT\MKJ_Q)1XC%2NXZ:<UR^%OH-!2[=)L#C=JB(CPXTMUA
M`;45(<X2/'!.^^?AJW(J/M\*+;H;42&PVQ':'"AMM.$I%2"*VU%QBDSG-J4F
MT;**V$5KHK;C-EU8'9VFJ9NR,HD(Y4IH<7O&LM?````.0K[6D]RTINJ?9[H;
M\\E?-5U<JINJ?9[H;\\E?-5U<JP!2H^\WNV:?MRY]VFLQ(J#@N.JQD]P',GR
M"HK3O2!I?5<I<6S7=F3(0.(M%*D+([2`H#(\U`66E*4`K\]:]L3ECU5*'!B-
M*49#"@-L*.2/.#G]5?H7-1.H=/0-26TPIR#@'B;<3LIM7>/HY&NGPK']CKYI
M?I>C*:]+RD;+<YGT5Z58N#KE\FH"VX[G!'0H9!6-RH^;(QY?-5OUEI>^:G4(
MS%TCQK<G!+)0HEQ7>HCF.X>_5(FZ7USIELL6J9+?@))4DPG,<]SE'//FS4:)
M'2&I0`5J#)Y>*OZ*[52C/$8CM=*M#NOR7@]F:RDH0R2BR*U1II_2US;@OR&W
MUK9#H4VD@`$D8W\U7/HBL3CDV1?'48:;26&"?OE'U1'F&WOFO-KZ/+_J&:U-
MU1+>;:2`GA<<XWE)YXSR2-_/Y*ZS#AQ[?$:B1&DM,-)"4(3R`JOB?%5V;LT9
M*4W^IK;X$J-#T\[5ER,]4_74R-`FZ4E3)#4>.W>05NO+"$IS'?&Y.PW(JX53
M=?1U2Y&EXZ`P2[=^`B0WUC9!C/Y"DY&1C/;7EC=+@A:5H2M"@I*@""#D$5ZJ
MN:'TT_I'3+-F>N1GI86LM.%LHX$$Y",%1V&_;5CH"JVO[I>H_<^!^](JU55;
M7]TO4?N?`_>D5:J`4I2@%*4H!2E*`4I2@%*4H!2E*`'D:IN@_7'67N^[_!9J
MY'D:IN@_7'67N^[_``6:`N1KBO0U;(%\D:LN=XB1YET7<EM.F0D.%*#OPX.<
M`G(\N/)7:JYU?NB*W7.^2KO;+O<[)*F@B7X"[PH>SS)'E[=\>2@*]>KY8.CK
MH^NDC0+[+C[]P#"R'2ZF.ZKBR2D[#`00.PX'/%?1<]8Z#UKIB%>=1"^0K\L,
MNMK9""RX2D91C?`*QY",[#:K>QT5Z98T.[I01W50W5=8X\5CKE.]CG%C&1@#
MEC&V.=:>G^B>#:+[$N]PO%RO,B"CJX0FN`ICI'+`[QV=GDY4!S1W5.N)6C]2
M:C1JIUENS7/J6XZ8Z"7`5I'C*QR`4,#![<U8;?J#6-IUMHU=TOHG1M2,]8]#
M#"4-L92"`C&^W$G?MP<U;D=%%J;TI>]/B?,\'N\OPIUSQ.-"N)*L)VQCQ1SJ
M0E='\"5=-,3URY(<T^V&XZ1PX<`"1X^W]D<L4!R!S5.N)>C]2:C;U4ZRW9KG
MU+<9,=&7`5I&%*QR`4,#![<U8;?J#6-IUMHU5TOHG1M2,EQZ&&$H;8RD$!&-
M]N)._;@YJVM]%%J;TG>]/"?-\'N\OPIUP\'&A7$E6$[8QXHYU(RNC^!*NFF)
MZY<D.:?;#<=(X<.``#Q]O[(Y8H#F46_ZYUA8M1:PM^I1:XMJ><\&MR6$E*DM
MI"B%D]O"1SSOGE623KO5>IKAH1JTW/T*7>XS@D\#*7$A:5J2I82KR))`SW5:
M;CT+6R5-GF%>KK;;?<7.LF6^,Z`TZ<YY$;#/8<U/'HYL[=]T]<XJWHR;$RIF
M-';(*"D@CQLC).Y.<\Z`K_1O>K\C6FI]*7NZKN@MA;5'D.-A*RE7/./(4]_;
M74*K=JT;#M.L;QJ5J2^N3=$H2ZTO'`CA``X=L]G;5DH#G5NM\*?TBZB3/G.E
M(N++C%OXPEMU:(K2N-0`ROAVV)X00#C.]=%KBNHK%J*3J+7%]L6IY%L5;7&G
M!%0G*'E)BMK45'/:G`Y'EO5\Z--5R-9:'A766A*)9*FGN`82I23CB`[,C!QY
M:&7;D66X^MLK^Y7^Z:A]!?<]TW[EQOX::F+CZVRO[E?[IJ'T%]SW3?N7&_AI
MH8+#2E*`XSTP>R6!^9_YS5#15\Z8/9+`_,_\YJAHKZ#PKV&GX?EG)K^L9G;[
M*V45K-]E;**VI$$;+?96RBM9OLK916M(FC81V5LHK61V5LHK6D31LHK916LB
MME%:\B2-ANME%:S=;**UI$T;+=;*.RM9NME'96O,FC816RBM9%;**UIDT;+8
MR0!SJ:C,]2T`?5'<UI6V/G[<H;#U/TU)USZT[O*BZ*YBE*502*;JGV>Z&_/)
M7S5=7*J;JGV>Z&_/)7S5=7*@..])++5TZ8M$6BYI#EJ6%N%E9\1;F3L1V^I0
M/+G';5LGV'1$37-HF/B+"OP0?`VVE]27>SU*<!1W(`/9D;U(ZRT/:=;P&8]R
MZYMV.OK(\EA?"XRKR'EV#8]PJ'TQT66^PZ@%^G72XWJZ(1P,OSW.+JAC&WEP
M2-SVG`H"@Q;_`*YUA8]1:PM^I1:XMJ><$:W)824J2VD*(63V\)'/.^>59W-=
M:HU/<M"LVRZ"TF]Q'A)X&4N)"T*4DK"5?_0D#/:*LUQZ%K9*FSU0KU=;;;[B
MYUDRWQG0&G3G/(C89[#FIX]'-G;ONGKG%6]&38F5,QH[9!04D$>,2,D[DYS0
M'*(UXU[*M.L4C5[J&]+NN8=\'1UDHA2ME'L&$$]OJL;BI5[6.J[Y<M!0X-Y%
MN<O<!2I3B6$K3QC.5A)'/"3@<LFK]&Z-[=&B:JCIFRBG4:UKD$\.6BKBSP;?
MVCSS6.#T8VV#<=,S$39:EV!E3+"5<.'`K.ZMN?C=E`<PC7C7LJTZQ2-7NH;T
MNZYAWP='62B%*V4>P803V^JQN*F7]<:HU*YHG3]MN"+7,O,'PJ9/2R%';B!"
M0=AGJU'`[2-P*O4;HWMT:)JJ.F;**=1K6N03PY:*N+/!M_://-:4_HEM,RR6
M2&S/G1)MF1P0[BPL)>`SG!VP=]^S]9H"EJUEJO3Z-;Z8GW?PZ;:((EP[D&TI
M6`2C90W&<.#GD['<[5JG4.N+):M&ZIFZF7+8N\AIE^"J.A*`VK<;CFHIR<[;
MXJ_P.B6TP['>H3T^=+FWE'!,N+ZPIY0SG`VP-]^W]0K;N71M;KGIJP61R;*0
MQ97&W&5IX>)90,#BVQ\%`76J;KYJ0_)TLW$EB(^;P.%\MAS@_P!7>R>$[';-
M7*J)TFV^7=6M-08-Q=MTEZ\)2B6T,J:^T/$D;C?`(Y]M`673T&-#MO''G.7`
MR5%YV8XX%J?4=N+(V`P``$@``8`J6KD.@KY?;!TCS]`7FX"Z,-,=?$E%`2M(
MP%<)\A"NW."-C@UUZAEVOH56U_=+U'[GP/WI%6JJK:_NEZC]SX'[TBK50P*4
MI0"E*4`I2E`*4I0"E*4`I2E`#R-4W0?KCK+W?=_@LU<CR-4W0?KCK+W?=_@L
MT!<J4I0&I<[@S:;5,N,GBZB*RM]SA&3PI!)QY=JY,GI@U.+2UJ1>B2=-NN<(
M?;EA;N.+ASP@=XQN`,]M=0U))$335RD*MZKBAN,M2XB3@O)QNGWQFOS/(D:9
MM.FO3'HS5UQLUS)!-E4Z7#Q<6"G(`R`-\JR"*`[S-Z2;-$U99K`%I4Y<FNN4
M^MU*$,)*"I(5G?B5MA.WJA5EEWJUP'TL3+E#C/*&4MO/I0H^8$YKA-Z3;7>E
M31%VU-%C13/M:)-P+PX4E_@4$D]Q!"`!YJC8HTH]-Z0%Z\4CT>3(=Z@2%*"P
MG"N#JAVG/#CR</9F@/T=*G1(,<R)<IF.P,`N/.!"1GEN=JKNKM9Q[!HB=J.W
M>#W)$8H`2V^"A1*TI(XDYY<5<**GE6+HQ&K^M]`.L>ZSKLA/#Q_:^/R<.,?V
M<U,ZB5H[TA:^;T@F5U8<C&0I)_U0GKDXZGL[_>\F*`[=;=109D*V*D2HL>9/
MC-OHBJ?3QGC3G"0=SV]G94Q7Y_Z)T*L^OVV=5LAR\7&V,O6J8XOB`9X/]FCL
M!X=MOP2.W?\`0%`*4I0'';MI;4^J-6:RAVG4;=LM3\EAF6P6.-3F8S62#S&4
MD#`(SBNDZ5TW#TEIR)98)4IF.D^.OU2U$Y4H^4DFH[3/LLUE[H,_-6:M5`:U
MQ];97]RO]TU#Z"^Y[IOW+C?PTU,7'UME?W*_W34/H+[GNF_<N-_#30%AI2E`
M<^UYHBYZGO$67">BMMM,=6H/*4#GB)VP#WU6D]$U^']:M_QB_JUV:E=2AQC%
M4::I0:LNXHEAX2=V<>3T57P<Y4#_`!K^K65/1?>A_68/^-7U:ZY2IOCF+?-?
M(QV:F<I3T:7D?UF#_C5]6LJ>CF[C^L0O\:OJUU&E0?&,4^:^1GL\#FB>CZ[#
M^GA_XU?165.@KH/Z>)_B5]%=&I47Q7$OFOD9\A`Y^G0]S']-%_Q*^BLJ=&7$
M?TT;_$KZ*O=*@^)5WS7R,^1B4E.D9Z>;L?\`Q'Z*S)TM.']*Q_B/T5<*5!X^
MLS/DHE43IJ8.;C'^(_169.GY8_I&?A/T59:5%XRJS/DXE?39)(YK:^$_17B)
M&4_(ZKL!\8CL%6.M>)&$9"NU:U$J-8[1)IWW&1&=*0A(2D8`&`*^TI6L3%*4
MH"FZI]GNAOSR5\U75RJFZI]GNAOSR5\U75RH!2E*`YQJ+I$O+>LI&EM*Z=3=
M9\1E+TE3T@-)0"`<`'&=E)WSVTM?2U$<T;=;U>;8_;I5K=ZA^$5`J6YV!!.,
MYP=NS!YU3=<IT=>>DB?#OKLW3%UC-(+%U;>\24G`P2,;$#8'(Y8SMBH!NX3M
M0=%NMHEQG.7R!9GVE6VY/I/$3Q\)()W]3OOG`5Y:`[]9M30+KI>'?5R(T>.^
MRAQ94^DI:40"4%6PR"<=E24.X0[BR7H4MB2T#PE;#@6G/=D&OSA<E6$VKHW9
MD+;]*N?_`%+J5'J_"^%!6',=N^_D*L5LL=4UJS7*>C\GT(%B47/!"2T'L)]0
M>_U>,?VL4!W^/>[5+EF)'N<-Z2,Y9;?0I8QS\4'.U5G3&OV[U<=3L3VH]OCV
M2;X+U[C^$K'$H9).`GU(^&N5:05T;-V31BBF0K41D@$6X_;^NS_2]O!G&/)Y
M,U5KM$N"M2ZMN+K*I>FX&H>LN<1MPIZT%U8!V[`,C.=N(4!^KH\EB9'1(C/-
MO,N#*'&U!25#O!&QK+6G:9$&5:(C]M+9@N,H5'ZH`)X,>+@#D,=E;E`*HG29
M&N4QO33%GFI@W!=X3U$A:`L-D,/$D@\]@1[]7NJKJ_UWTA[LCYL_0$3HCHZD
MV&_S]2WZ[&ZWV8GJU/!'`A"-M@._8#L``P!70*#E2@*K:_NEZC]SX'[TBK55
M5M?W2]1^Y\#]Z15JH!2E*`4I2@%*4H!2E*`4I2@%*4H`>1JFZ#]<=9>[[O\`
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MZVO3&J!/8*<+;E,1VW$J[P>`)(^`^>FE+)TK3)#B]3ZG$".E/B(BLQW'5*\_
M`4@?":`Z0NTVUUV,XY`BK<B@".I3*26<<N`X\7D.5;E<GMMHZ6EZK=B7'4);
ML@4X$366HQ61@\!X"C.^V1COJ+?M?3HW<U1V;Y!=C<>$RN!A*>'O*2CB'FP?
M?H#ME*YQ?M/=(\>R-.6/62Y=S3CKFI,6.AM>V_`0WL<\N(\NVH[3%FZ6ICLA
M6I-1B`RAL]4B.U&<<<7V;\!`3^O]M`0^H=<7:R](=YTSIQEDWJZ7..4NR<=6
MVCP9I/:=R2#[P[2179K<U+8MS#4Z2F5*2@!UY+8;"U=I"1R'DKBLGHIU-?=,
M7"Y7AR/Z=#/;DQY;:TCB0A"4A!*0`GD3RYI%=CL*[FY8X9O3+;5RZL"0EI84
MDK&Q(([#SQV9Q0&Q<?6V5_<K_=-0^@ON>Z;]RXW\--3%Q];97]RO]TU#Z"^Y
M[IOW+C?PTT!8:4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4!
M3=4^SW0WYY*^:KJY5`:BTR;[*MLMFYR;?+MSJW6'HZ$*(*D%!R%I(Y$]E:GI
M9O\`[>;M\DB?RJ`M5*JOI9O_`+>;M\DB?RJ@;5&U+<-5Z@M"]:7)+5L\&ZM:
M8D7B7UC94>+[5C8C;%`7>Y6&SWE2%7.UPII;V09+"7"GS9&U96K3;6+:JW-0
M(K<%22DQDLI#9!YCAQC!J!]+-_\`;S=ODD3^54*[8>D$:L98;U9(-@+.7)*F
M8O7AS!V">KQC/#V=IH"XMZ=LC5L5;&[3!3`4HJ5&$=`;)[RG&,^6L]NM5NM#
M!8ML&-#9)XBW':2VDGOP!SJBP[%TB+U5-8EZK?;L249BR&V8Q>6KQ=E)ZO`'
MJNSL%;]VTUK(6QXV?7$M4\#+29<2-U2CW$I:R//0%DBZ<LD*>J?%M$!B8HDJ
M?:CH2LYY^,!G>LR;1;$HE(3;X@3+.9(#*</'O7MXW,\ZXY$M_3P_,0R_=H<=
MDJPI]8CJ"1WX2DD_!4]JRR]*,),16E]3.7'B!$A,IF,V4G;!3X@&#OMG(VH#
MID:+'A1T1XK#3#"-D-M("4I\P&PK-7);]9NEV-%A/6/4B):ULI\*COLQT*;=
MQXW"K@"5)S[_`)ZD=,Z?Z2)-O==U)J]<.4K_`&3,.-'7P^59+>#OC8?#W`=)
MJ@=*M^8TQ"T_>I#:W6HEUXRVCFH^#O`#R;D;U4?0SIV]$_!C>H7@_'P^%<+'
M!P_A</!Q>]BIJY:'U1>-7VN)?+DF]Z48/7OIE-LMK+W5K3ZE"0<94.WM[<4!
M,=&-UU/J.R>CU^D1!'F95#BQV@.!&?5*5DDGLQV8WWY7NN<]&.EM0Z*>NEDF
MEM^QAY3MO?#H*TY.X*>S(P?(0>^NC4!5;7]TO4?N?`_>D5:JJMK^Z7J/W/@?
MO2*M5`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"H75_L*OON=(_AJJ:KP\RW(9
M<9>;2XTXDH6A8R%`C!!':*`@-)3XB-&6)*I3`4+?'!!<&WVM/EJ9]$87XVQ\
M:GZ:A_2%I#VK67Y`U]6GI"TA[5K+\@:^K0$QZ(POQMCXU/TT]$87XVQ\:GZ:
MA_2%I#VK67Y`U]6GI"TA[5K+\@:^K0$QZ(POQMCXU/TT]$87XVQ\:GZ:A_2%
MI#VK67Y`U]6GI"TA[5K+\@:^K0$QZ(POQMCXU/TT]$87XVQ\:GZ:A_2%I#VK
M67Y`U]6GI"TA[5K+\@:^K0$QZ(POQMCXU/TT]$87XVQ\:GZ:A_2%I#VK67Y`
MU]6GI"TA[5K+\@:^K0$QZ(POQMCXU/TT]$87XVQ\:GZ:A_2%I#VK67Y`U]6G
MI"TA[5K+\@:^K0&_<+A#-NE`2V">I7_2)_!/EK0T']SW3?N7&_AIIZ0M(>U:
MR_(&OJU.QX[,6.W'CM(:9:2$-MH2`E*1L``.0%`9*4I0"E*4`I2E`*4I0"E*
M4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*H]@D,,=)>M>N>;;SX!CC4!G[2>^
MKQ4//TGIVZRU2[A8K;+DJ`"G9$5"UD`8&Y&:`W_1&%^-L?&I^FGHC"_&V/C4
M_34/Z0M(>U:R_(&OJT](6D/:M9?D#7U:`F/1&%^-L?&I^FGHC"_&V/C4_34/
MZ0M(>U:R_(&OJT](6D/:M9?D#7U:`F/1&%^-L?&I^FGHC"_&V/C4_34/Z0M(
M>U:R_(&OJT](6D/:M9?D#7U:`F/1&%^-L?&I^FGHC"_&V/C4_34/Z0M(>U:R
M_(&OJT](6D/:M9?D#7U:`F/1&%^-L?&I^FGHC"_&V/C4_34/Z0M(>U:R_(&O
MJT](6D/:M9?D#7U:`F/1&%^-L?&I^FGHC"_&V/C4_34/Z0M(>U:R_(&OJT](
M6D/:M9?D#7U:`T[,ZV]TDZC4TXE:?0^`,I4"/52*MM1UKL-GLG6^A5KA0>MQ
MUG@S"6^/&<9X0,XR?AJ1H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H
M!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2
M@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%<VZ4]=WW1\ZP0['%A/O
M71Q;6)25'Q@4!."%#&Z^VNDUP_I[8=E:AT/'8D*CO.RG$(>3S;45M`*'E!WH
M#+>ND?I)T8B-/U/IRU"V./!I:HSA*LXS@$+5@X!QD8VKK,C4%IA6^/.G7"-#
MCR$I4VN4ZEL*R,@;GGBOSMJFS3[#KJU6SI#OMSN^FWE\;,CKBE.<X)4DYQC/
MC`'/"<@U*Z_;D7/IOMUM\`@SXS4%'@,*8^6X[F4D\QSW!V[>$#R4!WAJ]6M^
MV+N;5QB.0$)*E24/)+:0.9*LXVK3&K]-%;"!J"U\3X!93X6WEP$X'#OODC%<
M-LEMEVK3W2.PE^UMP7(+JS;X,X/^"NC(QCF-LC/DQV5$QM/Z0<_T?9%X6&/1
MU+IR]UGVT.]:`$`9Y%'9Y<T!V76.M;EI_7.D[)$9C+C7=\MOJ=2HK2.)(\4@
M@#U1Y@U:+AJ:PVF0(]QO5OAO\/%U<B2A"L=^"<XKALN3+EW?H;?G*6N0M*2I
M2_5*\=O!/G&*P7A-NU)J363UDTU`D*BASPZY7J8HA!'$"II`W3ND@;]@Y<J`
M_0J;A"5`$],M@PRCK/"`X.KX?PN+.,>6M6W:CL=X>4S;;Q`F.I'$41Y"'%`=
M^`:_,LJ7+1_H^6>.''$PG;RXB04G[T94!YLY/G`KJ/H!T9V36NFGH$M4*YK2
M/`6H3A4B1D@)+A`//)&21D$YY4!T>=J:PVR7X)/O5OBR<`]4_)0A>_+8G-9Y
MMYM=M,<3KC$C&2K@8#SR4=:K;9.3N=QR[Z_+MAM\O4,'5LR?:K3,EEY9ES+E
M-+3L3GXR1W`]O;C'+:M_5D20YH#H^M]QFQYJ1,?CA^*^'4*:XT``*'<-O)B@
M/T4SJO3T@2"S?;:X(R2M_@E(/5I!P2K?89[:VK;>+9>&ENVRX19K:#PJ5&>2
MX$GN."<&N$WW0FG6.GW3]C8MS35KDPP\[&3GA64AWGOOG@3GOK3AH7IN]]*\
M:QH,9N/#/5-M;!L<6Y'=@*5CNH#O+.J+!)N'@#%[MSLSB*/!T2D%SB',<(.<
MUEE7^SP9AAR[K"8DALO%EU]*5A`SE6"<XV._DK\N1M/.2>CFV2V8>G[>3(RW
M>';B6WRX%'Q%`[`[#;LP#VU<K[:V-1=/6EX5Z0W)0]:FG)"4JRAQ26W%\QS2
M5#WQ0':V]4V)^W2Y\:\0)$:(DJ?<:DH4EL8^^(.![]5SHZZ1XNO(DUXI8AOM
M2%):B%X*=+("?'4/.K&PQV5SVPZ>ML'IGUMI]F*@6IRU*48@SP;AI6,>0J..
M[-;G^CM;[6=-SK@MICT3,I;/6D_;.IX6SCS<5`=PI5=U/KK3FCPV+W<VX[CH
MRAH)*W%#OX4@D#RG:OFF-=Z<U@'!9;DW(=;&5LJ24.)'?PJ`./*-J`L=*4H!
M2E*`4I2@%*QOOM1F%OONH::;!4MQ:@E*0.TD\A6*WW")=8#,Z"^A^*\.)MU'
M)0SC(^"@-FE1E]U#:=-6Y4^\3FHD8''$X=U'N2!NH^0"JQ:>F'1%YN#<&->0
MA]TA+8?96TE1/(<2AC/G-`7JE*4`I2E`*5HW2\VZRQT/W*8S&;6L-H+BL%:B
M<!*1S)\@K>H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%
M*4H!2E*`4I2@%*4H!2E*`4I2@%0-_P!'V;4TZVS+I'6Z];7.MC*2ZI/"K*3D
M@'?=(YU/4H"%U-I2SZNMJ8%YB>$,)<#B<**5)4.T$;C8D5&7/HUTM>;3`MUP
MMZGVX"`W&<4\OK4(')/&#DCR&K;2@*'<M`VVQ]'-_LVE[8$/38KB0D+*EO+*
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MYJ(/9Y>55'1_2M'U9J&^VT+A14QSP6T%W*Y.`LJ7W$82#L-@>9H"5O71-HR_
MW1VY3;3_`*T\>)U3+RVPX>\A)`SY>VI"YZ`TY=HMIBR('#'M2N*&VRXIM+9V
M[`=_4CG6GH"_3[AI)VXZ@NEJD.-O+"I,)Y)92@!)W4-@1DY]ZI*U:XTQ?)W@
M5LOL&3)WPTVZ.)6.>!V^]0&63I.T2]61-3/,+-TB-%EET.*`"3Q;<.<'U:J\
M0='66WWRZ7=B*?"[H.&65K*DN#NX3L!7NX:PT[:I;\6?>H,:0PV''6G7@E24
MG&#CWQ\-;%EU%9]1QER+/<8\UIM7"LLKSPGN(YB@*LUT-Z%9N:9R;(DK2YU@
M:4\M36?_`*$XQY.53SVCK+(U=&U0Y'6;K&:ZIIT.J"0G"ACASCDHU/4H"$C:
M2M$35<S4K4=8NDQH,O.%Q1"D@)&.'D/4)J-L71MI?35VD7.TP7(TE]"FUE,A
M93PE040`3@;@5;:4!PS15OAZIZ;M83;W'1*=@+ZN,S(3QI0`K@!`.VP2,?\`
MVSSWKH,7H^TU!UUZ8H251KD&]X[#@0W@@I*BV!V]O9D9YU7-2]'6HH>M7=6Z
M&N46+-E)X9<:4/M;G+)&QSG`)!QN,@TT=T=ZA&N%ZQUG<8\FXH041V8I/`@8
MQGD```3@`<SDG-`8>CK65_OD+6KERG]>JVNJ3%/5(3U8`<(Y`9]2.>>558=)
M.K/L(>F$W8^BGHQX-U_4-_[/@SP\/#P\^W&:FH71QKK3]TU'$L4^TIM-Z<45
M/OA1>:2>+=*0/5`*(YD=NU:WV)-2?8>]*W'!]$/17PO/7'J^#@QSX>>?)0'V
M^WSI&TWT=R]1W._QNNE*BJB-1XZ#X.%DE8.4;[<([>W>OL[5VO-):$=U1?;I
M#EKN;;"+=%;92`PMP%94K"1G"!RR1D^2KCK_`$;=-2]&K%@@*CB:CJ,EU92C
MQ!@[X/[*V-9:".KNCQBP+?0Q+C(:6RY@E`=0GAP>W!!(]_/DH#G%CZ3KY;-5
M6"/<M56[4$*YJ2S);C,I0J(M1`&X2,[J&_;@[#8U+-W_`%]J+I*U/IRS7R-"
MBPE\:'7XJ5EI(P`A.V_$3N3G`&U;]@T;KQ5[M2[S)L42WP``Z($=*G)>.7%Q
M(V)P-QC&^!FIK2VC;I9^DK5%_E*CF%<RGJ`A9*]B#XPQM\-`<X<U-JO5W0WJ
M=%PN#*95JE=7*<#*<R&<;HV&`>+'C#&PKH?0Q%NS'1]!<N%P;DQG6TJAM);"
M2PWOXI('C'.^3418NC.\Q-'ZTL\MZ(AZ\O+<C+0LJ2`<D<6VW9WU9>C.RZFT
M]IT6G4*H!;BA+</P514>#<GC)`WR10%$UXRUJ3I]TWI^ZY7:FV`X&%'Q7%$+
M4<^<H2GS"O'29=>CABXFQWC3EQ:<MZT$2+9&::204`A`5D93N-L<QM5SZ1^C
MI_5DBWWFS3TV^_6XYCOJ!X5`'(!(W&#N#@\R"-ZJ-YT'TIZUC,VO45[M#-M"
M@MSJ$9*B.1P$C)\F0*`^:NUMJ8:DTA:](3BQ'O%N:6VB6VA9RLD!:R03D)P3
M@\QVU):BG:[T]9[/&N.L;)`<6MU4VY/A'$H<7BI;:*1Q83C.!G)[`,G<G]&]
MR3KK1EP@O,KMMBB-QG5.KX7%<'$,A(&.1';3I`T#?[QK:TZGLAMDI4-CJ50[
MF"6L@J.<`;YXO(00#0$#H7I'OMT.KX$J\,W3T/@.RH5P;C!KBX01GAP-LD'!
M'8>=0T35W27/Z,G]8(U%%:8A.%"FO!&RX^.,`J)X<#!4```,@'W[-I[HXU5;
M]0:HN-S=MKRKU;'6`J.HH2AU8&!P\.R1N,^3-;-LZ.+Y$Z$I^D7%1/1-]:E(
M*73U>[B5;JQGDD]E`47I/N5WU);M`7PRFF6YR$]6P&Q]JD\2>->>U)\7`\E?
MH>T,SH]HBLW.4F5.0T$OOH0$AQ?:H`<L]U<GU!T7:@N&@](6^&]"3=+&K*TN
M+/5JS@Y"L=A2.SMKJMC%T%EB^C1CFY<'^L>#YZOB_LY[*`D*4I0"E*4`I2E`
M*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0'A;B6^'B..)7"//7N
MHZ];04D<^L%9K?*\*C`D^.G97G[ZGD>3,8OK8VZ4I4#(I2E`*4I0"E*I9Z6-
M$)4I)OJ,I)!Q'=.X.#]Y0%TI5+^RSHC\N)^3/?4I]EG1'Y<3\F>^I0Q=%TKA
M_2D^G3?3%I+5,YI9M:&PRXX$Y""%+R?.`X%>]M5\^RSHC\N)^3/?4K2NO2%T
M<7NWN0+G<8\N*YZIIV(Z0?+ZC8^4;T%T0?2]KS3<CHXF6^#=8DZ5<`A#+49T
M.$#C2HJ5CD`!V]M4#6%K9M4/HMM^H06XZ&O]=2X<<"%.(4H''+`./>J\6J1T
M*66X(G04Q424*XD+<9D.<![P%)(!J"Z1-2Z9U/KG2,MJ6S+M<-U7AW6,+X0@
MJ3D%)3DY`/+-+"Z,EQB6%CI]TW'TJW#ZEZ.4S6H7"6BDI6#D)VW1C/O&L/1+
M!LS6KM;)=9AHF1I#B+>E7"%H3]N"@V.>.$`''95JT[>NB#2LMV79GF(TAQ/"
MIWJ9"U!/<"I)P/-7QJ]=$#&I7-0M/LHNCA65O):DC)6"E1X>'AR03DX[:6%T
M<J2Y-1_HXA,<J$9=]*97#^!P`@'R<03[^*G>DB+HZ#IO2TC1:HJ;QU[9CJAK
M!>4GASE>-^+CX>>^<BNA6_5711:[$]9(DB,BV/E2G(RXSZT+)QG/$D]P^"HZ
MS3.A>P7--QMW@S4M!RAQ3,AS@/>D*20#Y1071$/VF'>O])=V/=XC,IM,%#JF
M74\2"L,IY@['!)YUN=$\=FW]+>NX$-M+,1MW"&4#"4@.'``\F35@3K'HN3J5
M6HA.:%V4WU2I/4R,E.`,8X<<@.ROMNUCT7VF\3KM!G-,SIYS)>#,@EPYSN"G
M`W[J"Z.ETJE_99T1^7$_)GOJ4^RSHC\N)^3/?4H+HNE*JEOZ2M(W2X1X$.\(
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M>G4E[_*TSXTUE&H[UM_ZK+^--1?`ZOO+ZF>TQZ':Z5QA.H;S^5)?QIK(G4%X
M_*<OXPU%\%JK_9?4SVF/0['2N0B_7?\`*<KXPUD3?;M^4I7QAJ+X15]Y#M"Z
M'6J5RE-[NI_WC)^,-9!>KI^4)/QAJ#X547^R,^770ZE2N8IO-S/]?D?XS65-
MWN7X](_QFHOAE3WD9\LNATFE<Z%VN/X\_P#XZR"ZW#\=?_QU%\.GU0\LCH-*
MH:;G//\`7'_\=9$W*=^-O?XJB\!-<T9\JB\4JEBX3?QI[_%61,^8?ZR[_BJ/
M8I]3/E$3]Z_]B/[P?]ZBX,DQ9`5]X=E#R5K*DOO)"7'EK3G.%'-!SJZ%++#)
M(BY7=T6T$$`@Y!K[4;:I7&WU"CXR?4^45)5SYQ<79EJ=Q2E*B9%*4H!7'-"*
M5Z2[?XQ_I>W_`/E778ZXWH3V%V__`)O\5=;F"]8_`XO'/9X^/X98^)7X1^&G
M$K\(_#7RE=4\J?>)7X1^&G$K\(_#7RE`?>)7X1^&G$K\(_#7RE`?>)7X1^&G
M$K\(_#7RE`?>)7X1^&G$K\(_#7RE`?>)7X1^&G$K\(_#7RE`?>)7X1^&G$K\
M(_#7RE`1MS43=]-9)]>6>W^PY74QR%<KN7KQIGW99_<<KJ@Y"N1C/6GKN"^R
M_%G);'ZYZG]W97[$5,U#6/USU/[NROV(J9KHX?U43SO$/:I^(I2E7&F*4I0"
ME*4`I2E`*4I0"E*4`J$U=[&W_P"^C_QVZFZA-7>QM_\`OH_\=NJZOJY>!L83
MVB'BON==%*"E<(]X*4I0'&.F'V20/S/_`#FN?IKH'3#[)('YG_G-<_37T/A/
ML-/P_+.37]8S*FLJ:Q)K*FMUE9E365-8DUE35+,F5/965-8D]E94U6S)N0F/
M"9*6R<#F?-6D_?[>BVRI?@4UEMITM,++:B)!':G&=MCN=N52=I4E,P!7WR<5
MHI>NL+3U\F7B4H+3UJV04@):`R$!..8/B_#7DN*XJM3QEE)J*2>CMSZ<_`]!
M@</3GA;V3;;U:O:RZ\O$VVOMG#P;\6,=G.MM,5X`GJS@5I6QY4AF(^M/"IQ"
M%E/<2`<5AMB%2->WE]UUQ7@_51VD<9X4I+84=N6236UQ''UJ$U&DD_1;UOR-
M;!82E6C>HW^I+3O);J7$H"E(('EK(VVM?J4DU5K0E3VE-03W7'7'I?A2E<;A
M4`$\:4@#LQBMJ3"EWNR:=2'7A&4$.32TX4*4.JR,D;XXN?GK1?%J_P"AQ5[K
M76UFKZFRN'T6L\6VK-VTOH[="QI20<$;UE"58Y&H2=-5%U)8;>TXHK=0]UR"
M2H]6$;*/_$!OYZQV9CK]77R:ZZZMQE]$9I)6>%".K2H@)Y;DU6^*UI?H2T3;
MWY=":X=0B[2;UDDMN:OKIR)R2Z\U#>=C,>$/I02VR%!/6*[!D\LUAESI+3,9
M<2.F0MR0VTXE*LA"2<+5D?@[U78PE2M`W9J/UCDCCF-LA!/%LXK`'_:O=[MK
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M9=2^TEQ/(CX*K2>52-MD=6YU:CXJ^7D-:E>%U=%D78F*4I6D6"E*4`KC>A/8
M7;_^;_%779*XWH3V%V__`)O\5=;F!]8_`XO'/9X^/X98J4K;C")'@S;G/SX+
M#:+BP!DG`).W;RY=I-=&K5C2@YR/.8>A.O45.&[-2E;EIN"[HZEJX66-"0]_
MLPV]Q.-[;!?B@9\Q.#WUC8ANR9$UEK"EQ'"A8W!)YC'G!'PU3'%1O::R\]38
MJ8":2=)J:O;3J:]*V7X3C$7PE3C*F@O@*D.!6%9Q@^7.U>VK:^XTVX5--ATX
M;#BPDK/D%6=HI9<V96*>QXC/DR.^^QITKTM"FW%MJ&%H5PJ&>1KV_'5'C,/K
M4G@?5PHP<[X)P>[8'X*FZD5:[WV*E2F[I+;?N,5*R/,J8DPXRB#(F)4MEI.2
MHI3C).V`/&'PUG?MSS#3KBELJ#..M"7`2CSCLJ'EZ7O(M[)7LWD>G<:E*VFX
M#JV$O*6TTVM7"A3JPGB/<,T3;WU3U0O$#R4\1!5MCLK/EZ5VLRT,=DKY5+([
M/8U:5DFL^A[L=F0XVEZ1Q=6V#E1X0"KX`1\(K'4H3C-7B[E=2E.E++-69&7+
MUXTS[LL_N.5U0<A7*[EZ\:9]V6?W'*ZH.0KEXSUIZK@OLOQ9R6Q^N>I_=V5^
MQ%3-0UC]<]3^[LK]B*F:Z.']5$\[Q#VJ?B*4I5QIBE*4`I2E`*4I0"E*4`I2
ME`*A-7>QM_\`OH_\=NINH35WL;?_`+Z/_';JNKZN7@;&$]HAXK[G712@I7"/
M>"E*4!QCIA]DD#\S_P`YKGZ:Z!TP^R2!^9_YS7/TU]#X3[#3\/RSDU_6,RIK
M*FM)YR0EU!:;XF&@%RE__&A2@A)_QJ3^NMQM:7$)6@@I4`01VBMB-:$YR@GJ
MM_E<@XM)/J9DUE36)-94UA@RI[*RIK$GLK*FJV9,R:CY5B9N#B3-ESY+(7QB
M,[)*FL]FW=[]2":RK`96RVM:`XZ@K0CBW*1C)Q[XK1Q%.A.4552;Y7_!?3=5
M1DX7MS_DRMGA((VQRQ6M#M:8AFK;ERR],5Q./*=RL'&!PG&V!R\U;*>=99RA
M;+/+GOI4KP=I3O5I."0!6KC:N&I6E7MT7QW_`)+\-2KU;JE?34T$6-E%C-I;
ME3&V%%7$M#N'%<1)4"K&X.3G:MI=K;7"9BMR9<8,H"$.1WRA>``-R-CR[16P
MVKC;0L#'$`?AKY<+E`M+<94Q;P,A12VEII3A)`R=D@GE5&*EA:$5GCI+3:^V
MQ/#TZU9O)*V775VL:]JT_"M<IZ6VI]^8\,+DR72XX1W9[!6Q;K,U;F):&Y4Q
MQ<M96X\Z[Q.<7#PY"L=@`K.W,BN1V)#3N67U!"%%)3XQS@$$9!V(W[:VT\A5
M=)X6I!3@E;;I\#-2&(ISRRO??37XD=&L#$:S>AC$N<VCC4YUZ'\.\15Q$\0'
M:3W5Y1I2&&(;)ESUHBR3*`6_GK'.+BRO;QL'EYS4PGG65&^W;4G1H7O9%:G5
MM:[--^RQY-[B75QZ1UL4'JF@Y]JR005%..>#C.>ZM6=I&+<%N<=RN[3+@PIA
MJ80WCM`!!P/)FIM-94\ZA/#TI;Q056HMI,QVV!&MD!F%#:#4=E/"A`[!_P!S
MY:WD\JQ)K*GE1I+1&#*GLK*GE6)/965/*JF91E3V5E3SK$GLK*GG53)&5/*L
MB>RL:>59$]E5LD3L-_KV=SXZ=C]-;%0D9XLO!79R(\E30((!&X-<^I#*RV+N
M?:4I59D5QO0GL+M__-_BKKLE<;T)["[?_P`W^*NMS`^L?@<7CGL\?'\,L5;K
M#3%PM%PM+[H:\*1PH43VG_\`>*TJ^$!0(4`0>8-="O2\K!P/.X7$/#U542O8
MF&+:Y!>,V>XS'C,9<6ZMP!(`[23R'E-0UON#DRS:LO3/&A$EMY^,3D'JTM<*
M%=XSP<7?@BM)=EMKKB%NPVW.#="7"5I2?(DDI'P5LRHD><R693276B<E"B<'
MS]_.M2>%J5+N;5[6^MSI4>(4,/EC2B[7N[[[6/JHK-OZ-IC$5I#2&^I"0VD)
M&>)O?S^6INZ1')MQM\Z%9H,]3+92A^1)4@QR2"0E(2K!V&_/;%0,F#&E]7X0
MRET-G*`K.`=CRY=@^"ODJ!$FD&2PEPC8$DC]AK%3!.4G)/G^#-#BL80C"46]
M+/;K?F?42W9MXNKKJXQ4E]+2TQG5.(2M*`%#B*4Y/+.,X(QS%34..+I;7;>5
MA"T.(?:41G!"@3_W'OU$1X[$2.B/&9;99;&$-MI"4I'D`K.N[2K>RI-LM8>F
MJ;*4R'I"4M(43S*=U$#8X`WY5.M2<<.H1U:M:W4JPV(C4QKJR:47>]^G0RVV
M8U-UW/N"R!'C_P#IT8GD`C=P^^LE/_`*QRFY-BMMZDBRVB!$6'EOR79SF7>(
MJ\96&R23GEG.^!6G;X2;?;V(@67.K3A2U<UJ.ZE'RDDGWZQFSVXR$OJA-*=2
MOC2I0*N%7>`=@?+54L`VE9\K,V8<8C&<G*-];K;I;F;KED6JVVB4Q:HUSF\`
MZR1.>4&HYX`"KJ^\\N0(WR14PRE7V07UG="X#'"1R.%.YQ\(JNR[;"G[2XR'
MA@IPO."#S!&=_?H+;"!>(CI!>2$N$$CB`.0.>PSW4E@9N3=^OU,1XM2C3C'*
M],O3D[FM:(K'`Y-ZE'A3K\@N/$>.HEY6<GG]ZGX!W5)UC8CLQ6$,,-I;:0,)
M0GD*R5T*<,D%$XU>IY6I*?5D9<O7C3/NRS^XY75!R%<KN7KQIGW99_<<KJ@Y
M"N7C/6GJ>"^R_%G);'ZYZG]W97[$5,U#6/USU/[NROV(J9KHX?U43SO$/:I^
M(I6Q#B.39`90<=I4>P5]BO6*?-7"B7%YUY"RV7$L*+16-BD+QPD@[;'GMSK%
M3$TZ<LLMS%#!5JT<\%IXI&M2LKK"VI+D<@J6V<'A!\^?-7@MK".,H4$?A8./
MAJU3BTFGN:\J<XMIK5'FE>D-K<SP(4K'/A!->>W!YUFZV(V=KBE?>%7#Q<)X
M>_&U.%7#Q<*N'OQM2Z%F?*5Z+;@1QE"PC\+A./AHE"UG"$J4>Y(S3,C.5WM8
M\TKT4+"^`H4%?@D;_!0MN!)46UA(."2DXI=#*^AYJ$U=[&W_`.^C_P`=NINH
M35WL;?\`[Z/_`!VZA5]7+P+L)[1#Q7W.NBE!2N$>\%*4H#C'3#[)('YG_G-<
M_370.F'V20/S/_.:YV\]X/'<>QG@25`=Y[!7T'A<E'`4V^2?W9RJZO5:.BZ!
MTHW?]&ZH6^@9N85!84>Q+:3N/^8H_P"&N8Z9>6Y:$L/`AZ,M3#B3S!!_\^"O
MTSI"S&P:1M=K5_M6&$AT][A\99_Q$UP#55M]+W2Q>X(3PQ[@!.8VP#Q;J_ZN
M/X*\UPW&-\0<Y?[W_C]C<K4_^*RY'I-94UB365->N9SS*GLK*FL2>RLJ:K9D
MS)D&,VZZF()2PGQ6BL)XCYSL*^7:ZF/(MJ46),B<_%6M`+R4]2D</$GB(P=R
M.7=7U-8TP(WHAX?U0\**.KZSB.>'NQG%<7'<,6)JQJ*35M]?MT9T<-CY4:4J
M:2U[E_69H!DJ@L&8E*910"Z$<@KMQ6O=(:8VE-2O]:ZZY):6XLN*SCQ=@.X"
MI!-:]UAOW*U/0&9G@R'P4NJ#065)(P1OR\]1XE@W7H98*\E:U_J8P6(5&I>6
MS3^S-Z/_`.W:_P#HG]@K5O#:U7G3:DH40E]XJ('+[21O6XTG@;0G.>$`9\U:
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M+!7&]">PNW_\W^*NNR5QO0GL+M__`#?XJZW,#ZQ^!Q>.>SQ\?PRQ4I2NJ>5%
M>FVUNK"&TE2CR`%>:VX$5V4XXEJ6_%*4%1<8`*\=PR"/U576GY.FY]"_#TO+
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M=LB27``MYE#B@GD"4@G'PU*O+MT"?%M\IJ4[(=9,AUQK'!';S@%6_:<@8R3@
M]U0ED]8+;^:M?N"K5,<NB]1V]<591;2QQ.\#:5=:HJQA2CN`$Y(QC<\]L5=B
MZDXJ"B][]W(UN'T*4I5'-7M:VE]WT*^Q+CS.M<BJ6MA+BD(6M!1Q@=H!`.*R
MU\>DI?O5V:;(4W'E=4".6>K0I0]XJ(K[6Y1EGIQD<W%4_)UI0M:S%*4JTUR,
MN7KQIGW99_<<KJ@Y"N5W+UXTS[LL_N.5U0<A7(QGK3UW!?9?BSDMC]<]3^[L
MK]B*F:AK'ZYZG]W97[$5,UT</ZJ)YWB'M4_$E++E2I33:N!Y;)#:NX_^8J'L
MMN>BQ($`,J;=9:;;*,8X2`,_KR<UF0M;:@I"U(4.2DG!%>9$Z_.I4VW>NI0=
MN),-LN#S*.W_`$U14IU8U'.FKW7R-BC6H5*$:5:3CE=]%>]_R2T*0A_I"N:&
ML%+,5AMPC_Y/'41YPE2/A%1=EN$^?I*[2YDMQU3T5R0VDI2D,@A7"E``V``3
MSR<[UK0&%VF,INW2%LO*)4J0X.N6M2CE2E%7JE'O-8VHK\:Q^A<6:ME!9ZA;
MG5)4I2>$@['8'>M9X&:C;G96\;F^N+4G-/9.3NNZUD2LJ5X/I^RNIN4J`E\A
MUTQ(:GUO'@XN'(!X1G<[;@8&*UYUP3-O:BRQ*0R8Z5*5(C.,Y7Q$;!8&=L':
MOC<B?%AM1H<P-(;``#C(=&PQR)&/AK58BNIEOS9DQV9-?"4K><`2`E.>%"$C
M9*1DG',DDDFK*.&J0KYWMK]2C$8ZA4PGDUO9*UMK<^GYZDNTA<ZRS8+>[Z4]
M>P.]:2"!\('PFM>=PR=26*RG(8AH\.DI/:XK*&TG_P#Z''D%>XMPMEI6F;<;
MG'B)3Q80XKQEC'8.9Y\@*B;<X]*?F7=YMQIZ>^7DH6,+;:2`EI)'80D`D=A4
M:C*DZF(<8O3?XVM_)93K^1P4:DUZ7Z5WQO=_L3INS<;4=P1*GW&2V,-"$S;'
M%-,IX0=E)2>)6^2K.-\8&*B429K&F&9DBZ/VJ,X\&U!J$7)3I"B$I2-RDJ`'
MWI(WY5EF2[U)2MMN\*CH6,%;<9'6@?V5GEY^$XKRP9=OM;-OMDE$9AD!*0XP
M'L#'E(W[<U7'!U5%JW3^[?<OGQ/#2J1E=\^3TOR_^$J])6YJ73^%/<#L-Q:@
M\GA62%-X*AV'QC\-1%P>F72]S$R)BQ#@SP&8J$)"24-C=2L<1RI9.,XV%?$^
MB)EQI+UT<?=CM*;;4MAL'*L942`,[@''+:O,6.XR7UO2%2'GWE/..*0$Y40!
MR&P&$BK:&$E&<7-;+\FMC.(TY4YJB]9-<N5K,V*A-7>QM_\`OH_\=NINH35W
ML;?_`+Z/_';K?J^KEX')PGM$/%?<ZZ*5Y6HH;4H)4H@$\*>9\@JIQ.D&'.4^
MB+9KXZN.YU3R$PO&;7SX5`JR#O7"/>%NI595K((25*T]?TI`R28.P'^*N<7:
MZZCOZ'[E$AW*<@.E#,6$O@2V,9RI1Y;=N"2>ZJYU,K22NV;>&PJJQE4G++&-
MKO??9)&;IA]DD#\S_P`YJIZ6M@O6L+/;U#+:I`D/#_\`C:\<_"H)'OU(2;'J
M6ZVQ,J5:;D930X&HRU=8YC.2!OC&Y.=JWNCV0S8-1R)<N.\^ZZTB*R&D@]7E
M>5E6>6X0/>->DCQBC'A2HWM/56^.OT9JRX75EB6Z7IQ5G=?F^S.ZCE7%>GNV
M&,YI_4[:?_;/F*^1^`O<9\V%?XJO$CI&MS;SX9@S9##*N%3[:!P?K/[:B>DZ
M?;[[T=JB);6X+HV515X`"'$$*'%VC?8XSVUYV&)C"6>+VU-J7#\3I%P?I?M?
M['+T]F.594UB@VRY,QHL-R,Z_-X$IZMI)*E[<P#C.U;Z(<IU#K$6"[(F!0PV
MD8.V<C?M[@>9&*]G+CV"62TKYG;P\317!<7:;E&V57UYKN_O(Q)[*RIK*+-?
MQ_\`ZU>/DX^M7I5MO;+:G'=.W="$`J4I3"0$@<R3Q;"MEX_"_P#L7S.=Y*?0
M^)K*GD*T;?,1/C!]IMY#9/BEU'#Q>4>3RUO)Y"K5)25UL8M9V,J>=94UB3SK
M*FJV2,H[*RIYUB'965/.JV9,J:RIY5B365/*J691D2,\ZS)K$GG4!J364+39
M;CEIR9/=P6XC)\8@]I.^/)VFJ*DXP6:3)I-[$C*U58X%T3;9=R89ED`\"R0!
MGEE6,`^<U.IK\\Q+K99.K;I,U3`E+9D*6I+:20MI95L#N.0V_P"U76Q=(%AL
M)\"3<9LNU\/VCKH_VV/_`&,Y\9/=VCS5SH8Q2?I6L6NGIH=63RKS$FQ)@48L
MIA\(.%=4XE?"?+@[5S/4G2A8IFFKA$MLB4)CS);;*F2D;X!WSMMFJ-IZ;8[1
M"CW*->[A`OS145)$?K&%ISLDX(.",9YU&IBXJ5HZHRJ;MJ?I%/965/*N6Q^F
MNS*C-=;;9YE%(XVV@DI"NWA)5DCWJ3>F9,5AMUO3,X(=44MJDN!M*L=QX3WB
MCQ%.VYC*T['5T]E94\ZP,E2FD*6D)64@J2#D`XW&>VLZ>=99DRIY5D3V5C3R
MK(GLJMDC,GG61/*L:>=9$\JI9E&Y$=X%\).ROVUOU%)J08<XV]^8YUK5(\R:
M9EKC>A/87;_^;_%779*XWH3V%V__`)O\5=7X'UC\#C\<]GCX_AEBI2E=4\J*
M^A3B`>J><:41CC;5A0H$J(R$J(SC(';7WJU\7#P*XN[A.:C+*U9DXYHM2CN:
M+D%QYMY#]SN;W7$=85RCXP').```-SR`K,J/UD],QU^0XXA"D-I6Z2AL'&>%
M/(9X168@@X((/EKTI"T@%2%`'M((J"I4X[)%LL37G?-)OXFNVP6YSLQ4B2[(
M<2$E;KQ44I!)`3W#*C7E<>0Z\IURZW12BDH3_K1`0#SP``,[8R<G%;/`H@'A
M5@G`..=>DM+6ZEH)(6H@`$8K#I4K:I:$HXC$IWC)W?>]>A@CL-Q8S4=H$-M(
M"$`G.`!@5]?\*=;#;5RG1D8(X8[H3^T''O8K=;B%5Z7;E]8.K*`7>'"5%2>+
MQ>_'*M-M76JD\#:^!B0ZQQ'?/`LIS[^*CY2C5M#?F3\EB</>HKIIV>O.US%#
MAL08R8\=!2VDD[J*B23DDD[DDDDD[FL]?4I4KU*2?,,U\((.""#W$5>K+1&I
M+,_2?,4I2LD2,N7KQIGW99_<<KJ@Y"N5W+UXTS[LL_N.5U0<A7(QGK3UW!?9
M?BSDMC]<]3^[LK]B*F:AK'ZYZG]W97[$5,UT</ZJ)YWB'M4_$4I7U*BE04.8
M.15QJ'RE3"XWA5\A2$)_U60SQ*`'BH6@\CW9XO\`IJ,LTM<^!>]0I<C86M:H
M"9:^!AII(X4*4>P*QQD]RJT'CXI7R[;]VMK'7CPB;=LRLWIWJU[F*F?+7N9=
MX!B6Y+UTM,N>N2AET07$CC2K(R$\1.VW;WU*%QV5+?-KF6F2REKA1`6WP+"N
M]2P20,_V?IK#XA%13RF5P>;FXN?)/;KW$2O[3!DS5GA8C(XW%]P\U?#L2#6R
MU<)ENTC=7GFX3LB*A1*`DELKXCD')R0-AW[&OH1)M6FXSIN-K;F/R"'9EQ\5
M`25*)"4E6YQL!Q<M]\8K#QKC*69::6^)F/"HU(0R2U=[Z=';3[&K6S!B*G2.
MI0M*3PDY.]96Y=LN.IX<:+*A24NQU.NIBNI6$J04\\'D>+_IK-IRZ2[C=)2I
M#$5IA+KJ(R&VB%H2A91XRL[DXS@`8VYTGCFX?\:UM?P,TN$Y:B\M+2]N>NE_
M@0T:0W*CH?:SU:\\/$,'8D?]JRU'V/UEB_\`U5^\JI"MZ#<HILY%:*C4E%<F
MQ4)J[V-O_P!]'_CMU-U":N]C;_\`?1_X[=8J^KEX%F$]HAXK[G7!5?OVF!<9
M:+K;92K=>V4<#<MM/$EQ&<]6ZCDXCR'<<P15A%*X1[PJUKU'X=(78;]$%MO*
MFU#J>/B:DIQ@K87]^.\>J3VCMJHVR8G2*;G8K[$D&+)R$.LISQ`CAR/(1\!K
MHMZL5OU!`,2XQPX@*"VU@E*VECDM"ANE0["*K?HK.THM,352A.M!4$L7HMC[
M7GDF2D;)/9U@\4]O":JJ4\S33LT;N%Q:HQE3G&\96YV=ULTRKZ2BL.ZUCR+5
M$DI@-Y\=[<CQ2,DC;WJF^C=H=1=W0V%.![`!]\XJ_L)9ZI*F`@-J&04`8([]
MJ^H:;;*BA"4E6Y(&,U"GAU!IWVO]38Q7%'7C.+CNHK>_Z6WKUO<XK)N;\^+<
M1<9LMN:5X$%EK@;..?%CL&_/>MV<I#NE=*`$*`?<2H>7B&U=<+#)<ZPM(*_P
MN$9^&OG@L?@X.H;X<YX>`8S4.S/6\O[>_4O?&(^CEIVL[[_]6NG?<HNHDI3T
MD:?`2`.`#E_:56M8[@S;>D:\,2DK2J6\4->+L259&?)CMKHJFFUJ2I:$J4GU
M)(!(\U4/I#Z2[%H=HH<;;FWE2<M14XRGN4L_>C]9[.^K'1]+,GSO]+&JL>O)
M>2E'3+EW[\R>WT^I:-1:DM&E;4NXW>4W'83L`=U+5^"E/-1\@K\RZTZ1[_TE
MW#T+MK*XMJXLIBH5NL#[YU7+WN0\IWJ'ER-1])5Z-RNTE74`D)5C#;2?P&T_
M^>4U=+5:HEIC!B(WPIYJ4=U+/>37;P/#*F(].6D?OX'&JUU#1;F&P615K9XI
M$MZ5*4,*4MQ12GR)!_;S\U3J>0K$FLJ>0KU,*<:<5&.QHN3D[LRIYUE36)/.
MLJ:BR1E'965/.L0[*RIYU6S)E365/*L2:RIY52S*(_4%\8T]97[@^`HH'"VW
MG'&L\A]/D!J!T':%KBJU)<OMMTN)+@<4-T-GD$]V?V8%5SI<DR%R;?$2ASP=
M#:GE*"3PE1/#S\@'ZZGM`#5VOHSK-IE0+1;[>AMDNJ8+BB>'``SS.!D\N8KC
MUL5"-=Y]H[>/4JQF&K5J*IT=+[^'0P:]M*84^)JB-!;EN-K#4J.XWQH<200%
M*'?V9\W=4_:]/6>;;HTV3IJ%%D.MA:F5,`E!/9R_[5-O]&,6.H>F'I`N_&4Y
M/5+3&1_W%?8O1%H>X$I;U/<IRR<Y3=&UG]0K7[934W)1NGRT*?-E>5&-.52S
M7-7VZ;HC7M*6)YE;2K-"2E:2DE,=*2,]Q`V/EJ@7BRS]%03X);[;<X:G0&I$
MB&%OLDG9*N\'D#^RNL_8*M++?^HZEU#'<'J5"2D@>\$C]M:KW17K&!E5JULF
M4!R:N$7(/G4"H_JI/%T:G^MGU1BEP[$T7I-371W_`)->VM,MVZ/(7"8A.J92
MMU"&PGJSC)&P[-ZX_JUU_45O=U0X\OP<SC"AL$9PVA'$I7PE/OD]U7/56I;W
MI,O635-K93)DQ%EJ1!>RA05Q)!P>6X\_DKG<6_AS2Z[&IKQPV6XY&^5N/-K6
MH]WBMI33%XB%2,8P>@X;@:M&I*I56O+GH?H+0.HT:FTG#F<0,AI(8DI[G$@`
MGWQ@^_5J3SJ'TY9(VG;%$MD9"4AE`"U`8*UX\91[R34PGG5L4U%7.J]S*GE6
M1/96-/*LB>RHLD9D\ZR)Y5C3SK(GE5+,HS)W(J1:;ZM`';VUK1&LGK#R'*MV
MM6I+6Q8D*XWH3V%V_P#YO\5==DKC>A/87;_^;_%76Q@?6/P.-QSV>/C^&6*E
M*5U3RILSY<J)I1/@;W4/O3FV$O<(46@M0!4D$$<6,XSWU[N]PGMN:?8CRULJ
MD)6[(>2A)6XEL)\7)&`"I8)P.S;%1LM$B4U'CB0EN*T^E]38:!*U).1XV=A[
MU?74R7[A&D/24J:BM*;99#0'#Q<.259W]0.P<ZYDL&Y5')KG]#NPXE&%%0C+
M51M\;_L3S:4KUU,:7XR41&7D)/+B)6DX]Y(K3TS)N=SBOF\2"LR&RXIHMI2F
M,2=D)VSL.U1)R,U'LKG)NK]R?FAR0XA#:2AD-A"4E1`QDY]6>=8K@;M=([D2
M5=R(;NSS<>,EI;B.U)7DD`]N`#Y1579*N5)J[M;?;4V/..&SNSLKW>GZM-OF
M;"KK+7H.T2(CW@S\Y]I'7)0%*;"LE12%`C)`(&0<9K?GS)(GZ<*7E!;Z'4N+
M(&58"=\<N_X:B9#3[[<*,E]#4*(XEU+"&1NI(('C9V&_+'97IY,E^?#?<DCJ
M8:%)9:2T`05``DJSOR[JL['*[;6MW\F4^<J6513T45I_V3_NI)%R1+Z0EAV0
MOJ('"EAD!(2"XWE2B<9)V[\5[T_+F3;[=1(D9BF0^RW%2A*4(2A?#G89*E'B
M))/;Y*CGI5V?N34M4YE(82OJD(C8\90P"L\7C8[!@5C@^&V]IY3$Q'A;KCCJ
MGU,`CB6OB/B9\N.=5K!3<;./*WQN73XI24[QGHY)[<K;?,SVBX(<T;#,N;-@
M+>"%KF1FLY/<3PJQGS>^*]W%,@7".^]=6Y<>2R?!D(9"<I3PY45`GB.X[AOR
MK7@+G6NUQH,26C@82$_;F`L*P.>,C'O&L(8ER+@)]RG*E2$MEII*6PTTRDD%
M7"D$[D@9)).P&U74\/4C7SVT_OQ->MC:$\(Z5]>2MW_+\FS2E*Z1PB,N7KQI
MGW99_<<KJ@Y"N5W+UXTS[LL_N.5U0<A7(QGK3UW!?9?BSDMC]<]3^[LK]B*F
M:AK'ZYZG]W97[$5,UT</ZJ)YWB'M4_$4I2KC3/DZ7<EV5^VP5L-"0E;:GW"K
MB:2H8)0`-SC.,XWKW&=5`A*BQF6%L%L-=0\"4%(&`#CR5YI5#P]-YM-]S:6-
MKK):7Z=C74[<Y,N(IP0846*HN!F$E1+J]\<:E`>*,YX0-SC)VQ6U)NEQ,GPE
MBVVA<I.S<EXK!0,8]2`?U*%>:5%X2DU:WU+5Q+$*6:Z^2MH8[>N1;;4_%4AB
MXN25*<D^$^(EU:E%2CL#@$J.!@X&*],S;DFUI8DL6Z6[UBG"AT*#:,J)`20,
M[`XSC?WZ]4K+PM)N]OZC"XAB$K7Z\ESW^!CBO7+T65<I3T="DI#;,6,DAIM(
MYDYW4H]^V`,`<R=E-YN[4Q;K$&TMH()5XSG$ZH]I./%&<D^J)K%2L/!TFDK;
M&8\2Q,9.2>_<OH:MMC+AVYB.ZI*G$)PHHS@DDG;/9O6U2E;"22LC2E)RDY/=
MBH35WL;?_OH_\=NINH35WL;?_OH_\=NH5?5R\"[">T0\5]SHFI[V-/V-V:$!
M;F0AI)Y%1Y9\G,^]7(G^DF[,WQNW"[NO7!1"E1F8H6AO/WJB!Y1GGC.YKI/2
M'`?G:64IA!6J.Z'E)'/A`()QY,YKG6A;I!TNC5-S=;"[E-EA4?BWZQ!3G&1N
M`%%6?,*\O5:SM3=E;0^KX.G)8:,J%-3DY6=U>RTLNY/74Z!:ND6R2(;@G3&6
M9\9*?"8Z%<9!)('#C.>1VYCMJ6MNIK)J!;D2,^EU2D'B:<;(XD\CL1N.^N93
M[GIY3YD0[/;&+]-<#MP4LE99S@I41V9]5R\^2:K%PGNV^#<9]MN<E<AJ.MU$
MLA;:^/(W`5OCW@,=F*.NU-16JT^O]Z$H\-A.A.K)-22DU9W6CVV?U?S.A6;4
M%FTWJ*9%@W%T:>+"5-15-J6&9!6KB2UME*.$`E/(%0QCE5]]'K9Z$"ZF6V(1
M&0Z>7/&,<\Y[.=<VT1&8F:>O[\AEMUP,$A2D@X)0H[=V]1RTO+Z.HJQQ*8;N
M*BX.[*=OUY^&HK$34<SZ-ELN%8=U/)Q;5I).]M;J^FF_(Z?:]7V6\2_!8DO+
MQ&4H6@H*O-GG6.=K2PVZ<J'(FX>0<+X$*4$GN)`JO^B6DWKO:6XL0R)82D-.
M1ACJCMCBW'+GY*I\)3C$>[M294".YQ*#S<MDJ=4=\\'ES]-9E7E%))I_W^\R
M-'AE&HW*2E%)+1[ZMJ^B>FG3<ONM[S*C0K6[;)JFVY3W"7&B#Q)(["0>^OSO
M%MULE6&;=[JP[+?;4ZZXZ727'"',#B)._/>NM3T]5I"P)Z_KFTS5%"N$I\7G
MC!]^N>R[:JQ66^6V7OX*\ZA9QZI/7I.??!!]^L1JR4U+OCH6+"4HTG"R=HU-
M;=)))^*^A(1NK$9H-(#;?`"E`&.$8Y8K:X@G<[5KN.MN.16%29;;>5.88;RT
M?[P@[[<A7D2G&[G.2E+P6PA"F@^U@%1:\4@'.05`&N[3_P`EQ#IRO!7TMT6M
MM=?V-6K_`(]AHU8Q4I;N_5V5]-$KOIJ;#LMN*Q(DN!2VF&''5)1S/"DFL\*0
MF9"8DH24I>;2X`>8!&:K49,Y.CYZKE(=>EN0WW'"Z<J3E)\4Y_\`-ZF[%ZP6
M[\V;_=%;W!,96Q%2KY1WU^'+;N.9QK#TZ*HJ$<OHK??=[Z+7O)5/.LJ:Q)YU
ME37=9Q3*.RLJ>=8AV5DXDH25*4$I`R23@`54S)Z>D-18[DA]Q+;+:2I:U'9(
M';7-Q?\`4NK=2@Z=6Y%@QSPAQ0PC':ISF"3V)WQ\)JQS;5*U;(0B6IV+9&U!
M261XKLI0^^/X*>X<^WNQKW;5,.R-M6'3,5$FXJ/5M,1T<26U'S>J5Y/AKEXF
M;EK)Y8+YLO@K;:L:YOCK%H;TXPH2[Q<`EI26D8V)'WN3@J.P'OUU+3\6W=#W
M1<ER[*'6-?;I758*G7ED>*G)&2!A(\B<U%]&71>NP/+U/JE:9%^=RL!:N(1@
M1N<\N/',\@-AWU3^E/6ESN\YIRUQ(-ZTB`&_%1UR%O=O&4X6TL<DD%)(R02#
M7$Q%=UIYC9A'*K'0[5>+;K-EU[3&O9\9[8K86EE:F\G&Z'49QDXR#CRU7=2]
M&.MKB%*;O]BN9/X]9F&E_P")*%?]JY[=K#IN):4V-B[)T_>)9;ES(EQXW4M;
M9;9+R$^+C)60I/-0R<IJP/0>DK1VD+9`L*YDN1UCDJ8]$6)00E6`VVD')QPI
M*MACQQ5!(J]PZ/>DZQJXX\&8E"?OK7()!_X4*R/@KL/0?Z8G--7%[4;]R<D>
M&%MM$]2RM"4H&<!>X&5'X*J>H.D?I%TZ8-L1:U3)C4=*IDMRW+*%O*\8I1P8
M&$`A)/:0:MO11J_6&K)%Q<U#;VHL1A"$M*3&4T5+).1XQ.<`?K%`5;IRM;5R
MUYHN,[G@F.&.L_V2ZC/[QJ@Z)Z/4:DE7&:S<3&;@30VP>JZP.8/%ON.P#X:O
M?3VS(NNL=)6B&\6Y+H6$**B`@K6E(5MN/4GX*C.A"6@6N\6U)07FI"70K.R@
MH<.?-E/ZZNH14II,A)M;'7`<G/?O61/.HZTW!%S@I?2G@<2I33S1.2VXDX4D
M^8_",'MJ13SKHWNM"HRIY5D3V5C3RK(GLJ#)&9/.L[*"XL(',U@34K"9X&^-
M0\97[*UZDLJ))&RA(0@)'(5]I2M,L%<;T)["[?\`\W^*NNR5QO0GL+M__-_B
MKK<P/K'X'%XY[/'Q_#+%2E*ZIY44K(PX&9#;A2%!*@2DC.14BIEF%>)TR40+
M>U'\,"RGQ4IX<*'=MPDX\M:U?$JB[27+^HW<+@I8E7@]4TGX/F15*]6UZ8UI
M!5W=<@,W&6]QA5Q5PLQDK7D)[,\*2`!D9(YUE>NMI>NUK;$^WR%O!0D(B.I4
M`I(XN+`)(!W'P54L='-ER_\`TVI<)FJ?E%)?Q?>_U\#!7UT=3$$EP\+2G4LI
M/>M1P!4D\)\IB:NW.V:X-*/VAH`MEE/]I2>(J/DPGWJTY=PDM:-86TB$M]R2
MTPA:FRI"2H@<>,@D@DD<NRJWCG*-X1UND6+A,85,M26EF]GR,&:5NONKLL.S
MM"9:&@XCBE/W%P)6[@)V0,C<D[G.!W'->H$FUS=0SDQ'F)<:,PA\>#K2XG*N
M(%.Q.XX2<?VA4EQ"%WIL0?!ZMHM26MOA?[FLTQUD65(*PE$9HNKVR2`"3CX*
MUVW`ZTAQ.>%:0H9[B,ULVZYR[KI&ZRIK$5IUV"MU"(Z".!"D*(0HD^,1VG;M
MVK1A?^PC?W*/W15N'K3J5)*2M:VA3C,+2HT:<H.[=[OP9GI2E;9S2,N7KQIG
MW99_<<KJ@Y"N5W+UXTS[LL_N.5U0<A7(QGK3UW!?9?BSDMC]<]3^[LK]B*F:
MAK'ZYZG]W97[$5,UT</ZJ)YWB'M4_$4I2KC3%*4H!2E*`4I2@%*4H!2E*`5"
M:N]C;_\`?1_X[=3=0FKO8V__`'T?^.W5=7U<O`V,)[1#Q7W.N=E<ZU-T9SKE
M<7)MBU!Z%ET\2V5PVWDI5WH.RD^;??EBNC"E<%I/<]]&<H?I=CG.E.B.W:?@
M7'PZ8Y<[I<$X=FNH&4'F"@'.^=\G.<#LVJK:AZ-[Y#LCS4W5HE>$NHAQ6&[<
MTV5EUQ*<*5N<!)4=L8P37;ZK%RS<M=VF#N6;<RY<'>[C5EIH?K=/_#3*KWL9
M52:65-V):#8[=;8RV(D1IMMQ`0L`>K`&-^_:JIK/5^ENCNR.1WF&7'7TDMVU
MK&7<]JAR2GRGWLFJQTD]-T.P=;:=-K:F7,90Y(]4U'/D[%J\G(=N>5</BVFX
M:@GN76]R'G%/JXU*<5EQT^7N'_@K8PV$J8F>2E&[^Q"==Q5Y2))K56J-07-Q
MVW/(M4;K`L"&@-I:P<@!7JE<N1._;77--ZRM-TEL0M:0HOARB$,W3@"6WSV!
MS'J%^?Q3V8Y5S^.RW'92TRA*&TC`2D8`K,IM#K:FW$)6A0PI*AD$>6O2_P#C
ME'R&1OTNO+Y=/J:GG"MY3/=_/7YGZ1D6FWRX[3#T-EQIHY;2I.R3Y.ZN%=-<
M"='UA$CLS%1[;?&.!W[6E0ZU&`1GGN.K[:W-)ZZN.DN")*#UQL@V",\3\0?V
M,^K0/P3N.SNJ=Z86X>JNC!K4-G?:E"WO(ELO-'.49X5#R8R"0=QPUYVMA986
MJHUH_P`FU&LYQ]&1S]YFY".PB!<A&6T@)RJ.AP'`Y^,,@^_7FT6N1!5)>E7%
M^9+DDJ6ZYN`3VA)R,UL0Y"9<1F2CU+J`L>^*VTUZY8#"N3JQ@M?K\-C0>)K:
M)R>FW=X$._:;[,9DL2-1$LO-EH(3$;2`D\QMRVSRQ4W`C>!V^-%X^/J6TM\6
M,9P,9KVFLJ>0K%#!T,.VZ4;7,5*]2K^MW,J>=9`I*4Y4H`=Y.*QIYT=C,2F2
MU(9;>;/-#B0H'WC5DKVT(H^KN$)E)+DR,@)YE3R1C]=1DC6-L0[X/`2_=99V
M#$%LN$^^-OVU$Z@L&CV&>*>TF"2-G&$J3^H`IJHPM<7;2+QCZ4OTQ,'BXN%Y
ME`!/;XIR#Y]JXF,QE:EHK?._T-BG3C(Z&-*=)6LUACP`6"V.>K4^OA61Y0/'
M/FP!74]"]&-BT%'\(:_UFXE&'9SP`(':$CDA/Z^\FN+6C_2&U5"6!<8L"X-]
MN6RTOWBG;]5=%A=*^@^D&W>@M_2Y`\(P%L2G"AM1[@Z@C]>*X=2K.H\TW<VE
M%+1$+K_I4LNIG9>C[?='(,1Y/5JNZ1EI2P?]FH<^J/(K'P%.<T6);;WT0+5>
MI^6[F^E;,!AEWB:6,;O.%)PI(SXJ#N3N0`-^L?8-T_;R]<;"LKN'#Q0TW%77
MQFE]BN$`%6.SB*AVD&JA;?L@:2N4MK6JF96F5+ZZ>]<<265I)_HM\\:CL$8Y
MG)`&]5F2!LDZP:F9FZMUC8NH1;WFUO38+A0)[Y((:4RK*2HC*E%)3@<^=2MC
MM=DFW^XZ\9UFS(6RXIP"X1UQ0B6YGJ0L[@I!&<)SLD;8K1N^H.CK6EOB6TOW
M32S,/CZAE#"78N5$GC4E'C<1[_>K<OG1TVW8X.E+=K#3[2XCBI4UN7(+#CKZ
MP.$E)!P$M\(`Y[J[Z`K,JW:L2PI7V0+=(:4<$(U&/&_X2H;><5W+H7T](L>C
M%OS)34J1/?+_`%S3W6I4V`$I`5V\C\-<79Z#[Z_.:CLWO3[Q6<?:IO$KRX3P
MY)`!-?IQAF!I?3:&APL0+=&P3C9+:$[GX!F@/S[TLO)OG2I<FA+6P+-9UJ"T
M*Q]L""O&?*7`/U57>A666-;/1R?%D1'$X[RDA0_8:CA%E:PU=#NKW$#?KPMO
MJ\_T84@J]X!6/^&M[HM0@]*J"P/M*/"".0PG"@/VBK:6DT5MWN='=O";!KFW
MSF^-5FU.A"5<(SU<D`!*L>4%(/P]E=%'.J%T=&+?-&VXR4)><M<UT-*/WBDJ
M5PD?\*ZOJ:WH7M?J09E3RK(GLK&GE65`*B`!DGD*2,FY#8ZYW<>(G<U,5AC,
MAAD([>9/EK-7/J3S,M2L*4I4#(KC>A/87;_^;_%779*XWH3V%V__`)O\5=;F
M!]8_`XO'/9X^/X98J4I75/*BL=V>G7.UHM&8Z8"R@2%DJZQ:`KB*`,8P<`9)
MY9K)2JZE*%1)26Q?0Q%2@VZ;M=6,OAKK<-;`BQI3:EA?52"0G(WR"`<'..RM
M5F1<G+LW-?$2*Q'04,0XH*D$GFIQ1`*CV```#<[D[9:5!X:FY9FBV..KQI^3
M3T^OS/#]PN:7)#MNMUIB2W@4F<5K6L`\SP<(R>W'%C-&'';=86+7&AQIC;/#
MPF6ZI&"D#"LA)R<C/97NE0['2LU;Z]"Q\2Q#:=UI?DN>]SZF=-1!AM/PK?<'
MF&PDK?4IO"L#."$JV)'+`[*\6R3<HLV1<)3K"Y#Y'VAE)2RTD#9*>T]Y4=R>
MP``5ZI4NRTKMVW(/B&(RJ-]K<E?38QOW&[NPIL5B!:8K+[*FDI2XXHY4""HG
MA'('9('OT8;ZF.TUG/`A*,]^`!62E2I4(4FW'F0Q&+JUTE/9=UMQ2E*N-4C+
MEZ\:9]V6?W'*ZH.0KE=R]>-,^[+/[CE=4'(5R,9ZT]=P7V7XLY+8_7/4_N[*
M_8BIFH:Q^N>I_=V5^Q%3-='#^JB>=XA[5/Q%*4JXTQ2E*`4I2@%*4H!2E*`4
MI2@%0FKO8V__`'T?^.W4W4)J[V-O_P!]'_CMU75]7+P-C">T0\5]SKHI04KA
M'O!7%.D&)J@1+_)84[&7=YK4&!%B[R)24CA'$?O6\!U>!N>+<@;'M=>2A*E!
M12"4\B1RH#\HR^C=[1[T+T84T].?9ZXM(W0SXQ`&?OCMSY=V>=;*:Z!TP^R2
M!^9_YS7/TU]`X/3C'!0<5J]_F<K$-NH[F5-94UB365-=!E1E3V5Z9<F6]N:+
M<XE+4YI;4R&Y_L9*5)*3Q#[U>#LL;]^17E-94UIXC#TZ\,E171.$W!W1#:25
M(:MBX$MM3;\1PH*5?@G<'S<ZL::Q)`SG&^,9K*FJZ-+R5-4[WL9E+,VS,FLJ
M>0K$FLJ>0HP94\ZRIK$GG65-5,F9,!2>%0!2>8.X-477=JTS;[8J0Y$2S.=R
M&$QCP%:N\CE@=NU7L<JYQJK0]_N4]R<W,;GDC"4*PVI([$@>IQ[]<WB";I6C
M#,_L6TK9M78H=O-NZW%Q3*ZLGU4<IR!YE#?X14ZC3=FNB$^@VHV1)(_]K<F_
M!E$]P7DH/PBH=Z+<-/S0B9!#;I3LB2R%!0[P#M[XJ8AWG3,P]7>M/%GB.\BV
M/*;(\[:R4GWL5YI*VDB^KFWC?X6_/X)G3>OM7]&5P$"0AU<1."JWRR>`I[VU
M?>Y["G(/<:_1VDM;:=Z1+0X(W5K648E0)*05H!YY2=E)\HV\QVK\\*T@=06<
MLZ6U&U=H[7C(@3!U;[/?PYY9\F`:I4>1>=)7U#S2I-NN45>1L4J2?*.T'NY$
M5B<''7D*->-32^JY;?1ZGZ-O'038U:EA7FUJ5%C-2$O2;?P\2'$I/$0CM3G&
M,<M]L5^<M2W"7=M3W.?-:<:DR)3CCC3@PILE1\4@\L<O>K]5=&72;"UW;>I>
MX(]Y81_K$<'98_#1WI[QV?`3)WGHWTW?=50=0S(05+BG*DIP$/D>I+@^^X>S
MOY'(VJ!>43H*Z.W;)"5J:ZLE$Z6WPQ6E#=ID[\1'8I6WF'GKUT\:P\'M3.D+
M<KCN%R4DO)0=T-9V3YU*`]X'OJZ](/2%;-!V<O/J2_<74GP6&%>,X?PCW)':
M?>&]?G6VRY;#DOI'U">NEO.J]#6W!_[B3V+`_P#C;'O9"0*RE<C*65%ILL!J
MT:GD%"TF-H^RK2\M.Z52UI45X/?Q*4/^$57NAM@HO%YNA]1$MZ\G^THY_8DU
M,7N*]HOH7,:8I0O&H9(<D\1\<#U1!\P`SY5FO>BX7H'T.7Z[.^*Y.9=*21]Z
M`6T?"HJJ^FO27=J:]+5-_#^_&YO]!,E3ECNT8\FY2'`?_LG!_=KK:>=<=Z!O
M_87S^]9_8NNQ)YUM4?5HLEN94\JE+7'R>O4-ALGZ:CXS*GWDMI[3N>X58T(2
MVA*$C"0,"J<1.RRHE!<SU2E*TRP4I2@%<;T)["[?_P`W^*NNR5Q73:;Q9;!&
MMTG2U]6\R7`I349"DG+BE#!XQV$5M82<83;D['*XO1J5:*C35W?\,M%*C/1.
MX^U347R5'UZ>B=Q]JFHODJ/KUT>T4O>/.>;\5[C).E1GHG<?:IJ+Y*CZ]/1.
MX^U347R5'UZ=HI>\/-^*]QDG2HST3N/M4U%\E1]>GHG<?:IJ+Y*CZ].T4O>'
MF_%>XR3I49Z)W'VJ:B^2H^O3T3N/M4U%\E1]>G:*7O#S?BO<9)TJ,]$[C[5-
M1?)4?7IZ)W'VJ:B^2H^O3M%+WAYOQ7N,DZ5&>B=Q]JFHODJ/KT]$[C[5-1?)
M4?7IVBE[P\WXKW&2=*C/1.X^U347R5'UZ>B=Q]JFHODJ/KT[12]X>;\5[C%R
M]>-,^[+/[CE=4'(5R=*;I=;Y84IT[>(R(]R;D.NR6$H0E"4K!)(4?PA76!R%
M<S%2C*I>+/3<*I3I8?+-6=V<7C7B%9[WJ1B>I]IQ=YD.I`BNK!2>'!!2DCL-
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MX:Y#LAUYC@1X&\,X>03N4`<@:[ABF*Q+&3DFFD3I\&H4YJ:D]'?E^P%*4K4.
MN*4I0'-^D31UXU'>8DFW-LJ::C]6HN.\)SQ$]WEJICHOU./Z&)\H'T5W2E=?
M#\:Q-"DJ4+67=_)KSPT)2S,X<.C'4P_H8OR@?160=&>I1_0Q?E`^BNVTJSS_
M`(OHOE_)CLL#BHZ-M1C^AB_'CZ*R#HXU$/Z&-\>/HKLU*QY]Q71?+^1V6!QP
M='6H1_11OCQ]%9!T>Z@']%&^/'T5U^E1?&\3T7R_DSV:!R,:`OX_HH_QP^BL
M@T%?A_11_CA]%=8I4?/.)[OE_([-`Y4-"WP?T4?XX?161.A[V/Z-CXX?174:
M5'SOB.[Y?R9[/`YB-$WK_P"-CXW_`/58)^A=3/QRB#)BQ'3_`$BP'/U'%=5I
M49<4KR5G;^_$RJ$4?EZ[]!.NI$EV4N5"GNJWXE2"%J\GC#`^'%4VX:5NVD@?
M3'I64&>+AZ\K4E&3V!:<HS7[1<2I32TH7P+*2$JQGA/?BN2:UZ(;_J]8<DZU
M>>2@Y1&?BA+2?,$$#/EP37/<KNY:U=6.&P8VEYKK:[?>9]BG@Y09F'&@KR.H
MP4^<IJQW>5<$06H6O+;X?`(Q%OD+"UMYY$+&RQ_9.":TKWT(:VLR5N-P&[@T
MG[Z$YQG_``'"O@!JKVZ^W[2LAV*A3K*3XK\*4WEM8[0MM6WZJG&HMG_?@:M3
M#MNZ=[==_@]_G<\-29FD=0L3K1<D+<95UD:7'.RT^4'<9W!2KRBNL7G_`$B;
MI-M\>+8K2B-/<0D.O._;,.'F&T=N_(JSYJX_=I%NFJ3+A1S#<6?ML4$J;2>]
M!.X3_9.<=Y[/%JN\JSNK?@E+4LCA1(QE;6>90?O2?PN8["*K=KFQ%O+WETF1
M$PYJK]TA2WIMV=PMNT=9]N<[B\1_LD?V1OCL%6W15@G:NOD+56JNK:@I(;M-
MO">%"^'=(0CL;2!GRXR=N<#8M*VW3D9O4.N`Y)G2/ML.S`\;SYY\;@YX[<'W
M\\JLD?5\N'IZ;T@7E*6YLI*H5B@CU#2.U21YP"5=H3Y0*LBDMS5JRE)6COM?
M\+\LKW2A,DZTZ38FG+;]L\&6F&WOL75'*U>]L#_]35LZ7XXTIT<PK(CA2E];
M<=M*5;EML<1/PA/PUCZ`-(.2ILK6=Q"EGB6U$4O<K6?]HY^OA]]7=6MKNW7C
MI>Z13;["V#:;0#&7.63U*5DY<.>TYP`!DGASRWK"J-7MS-F%-1BH]#>Z#K2Z
MQHR;<U)`1)F\"3VD(2!^TJKIPK[:M-L:1T1`LD=PNHC'"G2GA*U$E2E8[,DF
MMNV1?"9'$H?:T;GRGL%;=&=J5WR,27I$I;(O4L=8H>.O?S"MZE*TI2<G=EB5
MA2E*B9%*4H!7S`[A7VE`?,#N%,#N%?:4!\P.X4P.X5]I0'S`[A3`[A7VE`?,
M#N%,#N%?:4!\P.X4P.X5]I0'S`[A3`[A7VE`?,#N%,#N%?:4!\P.ZOM*4`I2
ME`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E
M*4`I2E`*4I0"E*4!0>E&\:OL5N@W#2L0R@VZKPMH1^NRC`P2!XP&<\JH,/I0
MT5KYM%KUW9&8<G'`F4K)0E7D6,+;W[]N\UWRJMJ?H[TQJU*E72UM&21M*9^U
MO#_B'/W\B@.(:QZ!ID.,NYZ3E&ZPE#C3&."Z$GM2H;.#S8/GKE5J>DVJ^,K2
MTRF6TYPI$M`X6W.0*@K;Q3OOL,;BOTA;=#:RZ.I!7I6Y)O5F*N)RTS5!M>.W
MJU>I"O+XH[P:VM6:!LG2A:7+A&C.VJ_M#A47V2VL+`V0\G[X=RAG;<$C:@>I
MR!4VV.)D,(N;LDNC-\U$Z"5+3VL1P=_&Y=A5Y$@UH-"Z=+.MX-KB-"+":2&F
M&4[HAQDXR?*<8R>TX'=59O-EO-DNRK#<6'VY++N$Q]U`J5C!2!SXML$<]J_4
MG1+T>IT1IWK9:$F[S0%R3SZH=C8/D[>\^85ENY7&FD[EJ1IR+&TTQ8(2W8D)
MII+/VE7"LM@;@*&X)[5#?<XP=ZW[=;H=I@,P8$9J-%93PMM-)X4I%;5*P6$?
M>$J7$0E(RHN``5LQ(PBQTMC<\U'O-9BD*()`.#D>2OM3SO+E,6UN*4I4#(I2
ME`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E
M*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*
M4I0"E*4`KX.VE*`HNKX45WI$T,^Y&96Z)4@=8IL%6$LE0&?(K<>7>KV.5*4`
MI2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0
#'__9
`
end

</TEXT>
</DOCUMENT>
</SUBMISSION>
